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 Abstract 
EBV is a lymphotropic herpesvirus that establishes lifelong persistence in the 
memory B cell compartment of the human host.  It is still unclear, however, 
whether the virus infects memory B cells directly, or first targets naive B cells, 
driving them to differentiate into memory B cells via germinal centre (GC) 
transit.  Using ex vivo analysis of sorted B cell subsets, we have found that 
whilst EBV preferentially colonises isotype-switched memory B cells, the virus 
was excluded from tonsillar GC B cells.  Furthermore we found substantial viral 
loads in non-switched memory B cell populations, whose origins are likely to be 
germinal centre-independent.  Using in vitro infection experiments, we showed 
that enzymes AID, UNG and pol-η, which are associated with the GC processes 
somatic hypermutation (SHM) and class switch recombination (CSR) were 
upregulated in EBV-infected B cells.  Indeed following in vitro transformation, 
SHM of immunoglobulin (Ig) genes was induced in a proportion naive B cells.  
Whilst these cells did not undergo CSR following EBV infection alone, additional 
cytokine stimulation together with CD40L was able to induce isotype switching.  
EBV infection in vitro together with the provision of appropriate signals was 
therefore able to induce genotypic and phenotypic memory B cell characteristics 
in naive B cells, in a non-GC environment.  Taken together our findings suggest 
that GC transit is not an essential requirement for EBV colonisation of the 
memory B cell population. 
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1 Introduction 
1.1 Introduction to Epstein Barr Virus 
Epstein Barr virus (EBV) is a gamma subfamily member of the herpes virus 
family.  Within the human host population, infection with EBV is widespread, 
with >90% of individuals carrying the virus.  EBV is a lymphotropic virus, 
targeting B cells for colonisation, whereby it has the capacity to establish latent 
infection and persist within the host indefinitely.  As is the case with typical 
herpes viruses, the life cycle of EBV can be broadly divided into two stages; the 
dormant or latent stage of infection characterised by downregulation of most 
viral genes, and a reactivation or lytic stage which enables the production of 
new infectious virus and is required to maintain B cell infection within the host, 
and spread within the host population (Rickinson and Kieff, 2007, White and 
Fenner, 1994). 
Infectious virus is manufactured and released within the oropharynx, and is 
spread through saliva.  In the developing world, most infants acquire subclinical 
EBV infections via interactions with family members.  Conversely, in developed 
countries it is often the case that such contact is delayed until adolescence 
when amorous encounters lead to contraction of the virus.  In such instances 
infection may manifest as the self-limiting lymphoproliferative disease, infectious 
mononucleosis (IM), otherwise known as glandular fever (Rickinson and Kieff, 
2007, White and Fenner, 1994). 
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Although in most instances EBV is a harmless passenger within the host, the 
virus is associated with a number of diseases in addition to IM.  When infection 
is left unchecked by the immune response in immunosuppressed individuals, 
severe lymphoproliterative diseases can ensue which may prove fatal.  
Furthermore, EBV is associated with a number of malignancies, the most 
notorious of which are Burkitt’s lymphoma, Hodgkin’s lymphoma, and 
nasopharyngeal carcinoma (Rowe et al., 2009, Kuppers, 2009, Kapatai and 
Murray, 2007, Shah and Young, 2009). 
1.1.1 EBV is a Member of the Herpesvirus Family 
Although EBV is classified as a unique virus species with individual properties, it 
is ultimately a member of the Herpesviridae family, sharing many characteristics 
with other family members, and therefore it is important to consider the virus 
within this setting (White and Fenner, 1994, Davis-Poynter and Farrell, 1996, 
Davison et al., 2009). 
The name of this virus family herpes derives from the Greek word meaning 
“creeping”.  All herpes viruses have the capacity to persist within their hosts 
indefinitely.  Most vertebrate species examined have been found to support at 
least one species of herpes virus which has co-evolved with its host for 
millennia.  Additionally, different subfamilies can co-exist within a single host 
non-competitively since each occupies a distinct ecological niche (cell type).  
Structurally, the virion consists of several concentric layers ( Figure 1).  The 
double-stranded (ds) DNA genome is at the centre of the particle, and is 
associated with a protein core.  This inner core is surrounded by an icosohedral 
capsid of approximately 100nm in diameter.  The capsid is encased in an 
Figure 1.  Structure of the Herpesvirus
A. Schematic representation of the composition and structure of a typical herpesvirus. 
Taken from The Big Picture Book of Viruses
(http://www.virology.net/Big_Virology/BVDNAherpes.html). B. Electron micrograph of 
the EBV virion. Taken from Young and Rickinson, 2004.
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amorphous tegument composed of globular material, and an outer lipoprotein 
envelope, which is obtained via budding through the nuclear envelope of the 
host cell.  The virion ranges from 120-200nm, but is typically around 150nm in 
diameter (White and Fenner, 1994, Davison et al., 2009). 
Latent genomes persist within the virus-specific target cell (typically neurons or 
lymphocytes) until reactivation triggers lytic replication, usually within the 
process of continuous virus shedding or due to a disruption in the host 
immunity.  Reactivation of herpes viruses are almost always seen in cases of 
severe immunosuppression, for example in AIDS patients.  Viral replication 
takes place in the cell nucleus and usually involves sequential expression of 
immediate early (IE), early (E) and late (L) genes, the earlier of which regulate 
transcription of the later genes (White and Fenner, 1994). 
The herpesvirus family is subdivided into three subfamilies based on biological 
properties, Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae.  
The Alphaherpesvirinae includes herpes simplex virus types 1 and 2, and 
Varicella-Zoster Virus, which persist latently within sensory nerve ganglia.  The 
Betaherpesvirinae includes cytomegalovirus and human herpesvirus 6, whose 
infection produces characteristic large, multinucleate cells (cytomeglia), and 
which establish latency in lymphoreticular tissue.  Finally, the 
Gammaherpesvirinae include Kaposi’s sarcoma-associated herpesvirus 
(KSHV), and EBV, which is the only human member of the genus 
Lymphocryptovirus (LCV).  Non-human LCVs, however, are known to infect 
both old world primates such as chimpanzees, gorillas and orang-utans, and 
new world primates such as black spider monkeys, black-pencilled marmosets 
and common marmosets.  Gammaherpesviruses are distinguished from other 
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herpesvirus members by their ability to establish persistence in lymphoid cells 
(White and Fenner, 1994, Ehlers et al., 2010). 
1.1.2 EBV Subtypes 
EBV is divided into two subtypes; type1 and type 2, distinguishable by allelic 
polymorphisms within the latent antigen genes EBNA2, 3A, 3B and 3C 
(Dambaugh et al., 1984, Sample et al., 1990).  Within types 1 and 2, numerous 
further strains are identifiable predominantly by small sequence variations within 
latent genes EBNA1, EBNA2 and LMP1 (Aitken et al., 1994, Habeshaw et al., 
1999, Miller et al., 1994, Schuster et al., 1996, Sung et al., 1998, Wrightham et 
al., 1995). 
In order to study the prevalence of different types and strains within the human 
population, both in vitro and ex vivo techniques have been employed; the 
results of which have lead to conflicting conclusions regarding the number of 
strains present within individuals.  In vitro assays generating LCLs from throat 
washings have suggested that within European populations, individual 
immunocompetent hosts have a tendency to carry a single dominant strain, 
which in 90% of cases is type 1 (Gratama et al., 1994, Yao et al., 1991).  By 
contrast, examination of viral DNA sequences in ex vivo blood and throat 
samples using polymerase chain reaction (PCR) assays, has revealed co-
infection with types 1 and 2 within healthy individuals (Apolloni and Sculley, 
1994), and multiple strains in IM patients (Plaza et al., 2003).  Furthermore 
heteroduplex tracking assays (HTAs) mapping co-resident LMP1 sequences 
have demonstrated the presence of multiple strains in both asymptomatic 
carriers and IM patients (Sitki-Green et al., 2003, Sitki-Green et al., 2004).  
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These findings were supported by a study using HTAs mapping both LMP1 and 
EBNA2 in IM patients, which also found multiple strains in both blood and throat 
within ex vivo samples from these individuals.  Possible explanations for these 
contradictory findings are firstly that one strain may have dominant transforming 
properties in vitro, producing an outgrowth of infected cells, or secondly that 
particular strains may harbour transformation deficiencies.  The latter possibility 
is particularly significant since if this were the case, it would suggest that 
transformation is not a prerequisite for virus colonisation and persistence in vivo 
(Tierney et al., 2006). 
1.1.3 EBV Genome 
During latent infection, the EBV genome exists as an extrachromosomal circular 
plasmid, or episome, within the nucleus of the infected cell.  The genome is 
replicated once during S phase (Adams, 1987) along with the host DNA, and is 
partitioned equally into the two daughter cells at the end of mitosis (Kirchmaier 
and Sugden, 1995).  This maintenance of the viral genome appears to require 
only the cis element, OriP, and EBV nuclear antigen (EBNA) 1 (Yates et al., 
1984, Yates et al., 1985).  The EBV genome, which is approximately 172 
kilobase pairs (kbp) long, has been fully sequenced (Baer et al., 1984) (Figure 
2).  Since initial mapping was carried out by digesting the genome into smaller 
fragments using the BamHI enzyme, open reading frames encoding the various 
genes were designated BamHI regions and named in order of size, with A being 
the largest and Z the smallest (Young and Murray, 2003).  The EBV genome 
also contains a series of 0.5kbp terminal repeats (TRs) of variable number, 
together with internal repeats (IRs), which serve to divide the genome into short 
and long domains (Young and Murray, 2003). 
Figure 2.  Schematic diagram of the EBV genome
Location and transcription of the EBV latent genes on the dsDNA episome. The large blue 
solid arrows represent exons encoding each of the latent proteins and the direction in 
which they are transcribed. The long outer red arrow represents EBV transcription in the 
latency III program, where all the EBV nuclear antigens (EBNAs) are transcribed from 
either the Cp or Wp promoter. The inner shorter blue arrow represents the EBNA1 
transcript originating from the Qp promoter during Latencies I and II. Taken from Murray 
and Young, 2001.
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1.1.4 Alternative Forms of EBV Latent Infection 
Latent infection is the term used to describe the stage in the virus life cycle 
where a limited number of viral genes are expressed, but no infectious virus is 
actively produced.  Since an assortment of different viral gene expression 
patterns have been observed during latent EBV infections, latency has been 
divided into four separate types; Latency I, Latency II, Latency III and Latency 0 
(Figure 3). 
Latency III  
The most readily available in vitro model to study EBV latent infection is 
lymphoblastoid cell lines (LCLs).  Lymphoblastoid cells lines are produced by 
the infection of resting B cells using supernatant containing EBV, which has 
been harvested from virus-infected cell lines.  In contrast to resting B cells, 
LCLs are transformed, activated, continuously proliferating cells, in which each 
cell contains multiple copies of the EBV genome.  LCLs characteristically 
express six nuclear antigens (EBNAs1, 2, 3A, 3B, 3C and –LP), and three latent 
membrane proteins (LMP1, 2A and 2B), the coordinate expression of which 
facilitates cell growth and transformation.  In addition these cells also express a 
number of non-coding transcripts including those derived from the BamHI A 
region (BART) transcripts, and EBV-encoded RNAs (EBERs) 1 and 2 
(Rickinson and Kieff, 2007).  This form of latent infection established in resting 
B cells in vitro is known as Latency III (see Figure 3). 
Events during B cell Infection in Vitro  
The process of EBV infection of resting B cells in vitro is defined by a specific 
series of events.  Initial attachment and internalisation of the EBV particle into 
Figure 3.  Patterns of EBV latent gene expression in different forms of latency
The top panel is a schematic illustration of the linear EBV genome, showing the location of the 
BamHI W internal repeat (IR1) and indicating the genomic location of latent cycle genes. Note 
that the genome is circularised in latently infected cells through the terminal repeats (TR). 
Shown below are the transcripts expressed in each form of latency with promoters 
(arrowheads) and splicing patterns as shown; coding exons (EBNA and LMP mRNAs) are 
shaded solid, while non-coding exons (EBER RNAs, BART RNAs, BamH miRNAs and BART 
miRNAs) are unfilled.  Adapted from Kelly et al. 2009.
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the cell is facilitated by interaction between the viral protein gp350 and the B 
cell surface receptor CD21 (otherwise known as complement receptor 1 (CR1)), 
and by interaction of the viral coreceptor gp42 with HLA II on the B cell surface 
(Nemerow et al., 1987, Tanner et al., 1987).  The first detectable viral 
transcripts are initiated from Wp promoters situated within the BamHI W repeat 
regions (Alfieri et al., 1991, Sample et al., 1986, Woisetschlaeger et al., 1990). 
Whilst Wp-derived transcripts have the capacity to encode each EBNA protein, 
during the early stage of infection only EBNA2 and EBNA-LP are expressed 
(Alfieri et al., 1991).  Subsequently EBNA2 alone or EBNA2 together with 
EBNA-LP go on to activate both viral and cellular promoters that are involved in 
the transformation process.  These include the viral promoters Cp, located 
upstream in the BamHI C region (Rooney et al., 1992, Sung et al., 1991, 
Woisetschlaeger et al., 1991), and the LMP promoters (Abbot et al., 1990, 
Fahraeus et al., 1990, Nitsche et al., 1997, Wang et al., 1990, Zimber-Strobl et 
al., 1991), and promoters for cellular genes CD21, CD23 and cyclin D2 (Cordier 
et al., 1990, Sinclair et al., 1994, Wang et al., 1987).  At the same time as Cp is 
activated, expression of all six EBNA proteins begins and transcription from Wp 
declines (Woisetschlaeger et al., 1991).  The different EBNA proteins are 
translated from distinct mRNA splice products derived from a single long 
primary transcript (Woisetschlaeger et al., 1989).  The LMPs are expressed 
from separate promoters in the BamHI N region.  Whereas transcription of both 
LMP 1 and 2B is initiated at the same promoter, the process occurs in a 
bidirectional fashion, with LMP1 transcribed leftward and LMP2B transcribed 
rightward (Rickinson and Kieff, 2007) (see Figure 3). 
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Although Latency III is the classic gene expression program exhibited following 
infection of resting B cells in vitro, B cells expressing this profile are seldom 
seen in vivo in the context of non-malignant infection.  In circumstances where 
rare latency III infected cells have been detected during primary infection 
(Tierney et al., 1994), it has been proposed that this programme drives host cell 
proliferation in the initial stages of infection, but viral gene expression is 
downregulated to a more restricted pattern thereafter.  In the context of EBV-
driven lymphoproliferations in immunocompromised individuals, latency III 
expression can be readily detected in infected cells (Young et al., 1989).  This 
may be due to the absence of an efficient CD8+ T cell response, which under 
normal conditions would facilitate the removal of B cells expressing the full 
complement of EBV antigens (see PTLD section later). 
Latency I and II 
Other forms of latent infection, in which there is a more restricted pattern of 
gene expression, have also been described.  The latency I form of infection is 
typically found in Burkitt’s lymphoma (BL) tumours cells, and BL-derived cell 
lines.  In these cells EBNA1 transcripts are driven by the Qp promoter located in 
the BamHI Q region of the genome (Schaefer et al., 1995, Nonkwelo et al., 
1996).  No other viral proteins are expressed as Cp/Wp and LMP promoters are 
all silent, however the non-coding EBERs and BART transcripts can be 
detected (Rowe et al., 2009). 
The Latency II programme was originally identified in undifferentiated 
nasopharyngeal carcinoma (NPC) (Fahraeus et al., 1988, Young et al., 1988, 
Gilligan et al., 1990), and has since been found in EBV-associated gastric 
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carcinomas (Imai et al., 1994, Sugiura et al., 1996), Hodgkin’s lymphoma 
(Niedobitek et al., 1991, Pallesen et al., 1991b) and T-cell lymphomas (Chiang 
et al., 1996).  Similarly to Latency I, in Latency II EBNA1 transcription is driven 
by the Qp promoter in the absence of the other EBNAs.  In addition LMP1, 
LMP2A and LMP2B are also expressed (Fahraeus et al., 1988, Young et al., 
1988, Gilligan et al., 1990, Niedobitek et al., 1991, Pallesen et al., 1991a, 
Pallesen et al., 1991b).  As with Latency I, EBERs and BARTs can also be 
detected in Latency II (Rowe et al., 2009). 
A further form of latency where expression of all viral proteins is switched off 
has also been described.  It has been proposed that the virus uses this 
program, termed Latency 0, in order to avoid detection by the host immune 
system, thereby achieving long term persistence within resting memory B cells.  
In this scenario EBV infection is identified by the presence of EBER transcripts 
(Miyashita et al., 1995).   
Individual transcripts and proteins expressed during EBV latent infection are 
discussed in further detail below. 
EBNA1 
EBNA1 is a DNA-binding phosphoprotein that is expressed in all EBV-
associated tumours.  It localises to the nucleus of the host cell where it is able 
to interact with host chromosomes (Shire et al., 1999), and plays an essential 
role in viral genome replication and maintenance (Lee et al., 1999).  EBNA1 
binds to specific sequences with the plasmid origin of replication (OriP), 
including those from within the OriP dyad symmetry (DS) element, and the 
family of repeats (FR) (Rawlins et al., 1985).  EBNA1 tethers the replicated EBV 
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genome to metaphase host cell chromosomes via the amino (N) terminal of the 
protein, ensuring equal numbers of EBV genomes are acquired by the daughter 
cells (Reedman and Klein, 1973, Ohno et al., 1977, Petti et al., 1990, Mackey et 
al., 1995, Mackey and Sugden, 1999).  In addition to its role in genome 
maintenance, EBNA1 also acts as a transcriptional regulator, mediating 
expression of other viral genes.  EBNA1 binds specific sites immediately 
downstream of the Qp promoter, and is able to negatively regulate its own 
expression (Sample et al., 1992, Nonkwelo et al., 1996).  The protein can also 
functional as a transcriptional activator of the Cp promoter (Yates et al., 1984, 
Altmann et al., 2006), and the LMP1 promoter (Gahn and Sugden, 1995).  
Furthermore, the use of chromatin immunoprecipitation and microassays has 
revealed that EBNA1 can bind to and regulate various cellular genes and 
promoters, and has identified several binding sites within the human genome 
(Dresang et al., 2009, Canaan et al., 2009, Lu et al., 2010). 
Although EBNA1’s primary function still appears to be the propagation of the 
EBV genome, EBNA1 expression may also be necessary for B cell 
transformation (Lee et al., 1999), and the resultant development of B cell 
lymphomas within transgenic mice following EBNA expression suggests the 
protein plays a role in tumourigenesis (Wilson et al., 1996). 
EBNA2 
EBNA2 is a transcriptional activator protein which is the first viral antigen to be 
expressed following B cell infection (Young and Rickinson, 2004, Thompson 
and Kurzrock, 2004).  EBNA2 transactivates the Cp promoter during the early 
stages of infection, producing a switch from Wp to Cp transcription 
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(Woisetschlaeger et al., 1991).  The protein upregulates expression of viral 
genes including LMPs, and various cellular genes including CD21, CD23 and c-
myc (Wang et al., 1987, Wang et al., 1990, Kaiser et al., 1999).  Although it 
contains a transcription activation domain, it does not bind DNA directly, but 
rather binds cellular proteins including RBP-Jκ, PU.1 and AP2, which mediate 
interactions with other promoter regions (Grossman et al., 1994, Hsieh and 
Hayward, 1995). 
EBNA2 has a key function in growth transformation of the host cell since the 
P3HR-1 EBV strain, which carries an EBNA2 deletion, is unable to transform B 
cells in vitro (Cohen et al., 1989).  Indeed EBNA2 expression has been linked to 
transformation of non-B cells; specifically the rat fibroblast cell line F2408 
(Shimakage et al., 1995).  In vitro studies have demonstrated that EBNA2 is 
important for the continuous proliferation characteristic of LCLs since the 
EREB2.5 LCL, which has been engineered to express an oestrogen receptor-
EBNA2 fusion protein, requires oestrogen in order for cell survival and 
proliferation to occur (Kempkes et al., 1995).  EBNA2 may also have a role in 
tumorigenicity since transgenic mice carrying the EBNA2 gene have been 
shown to develop multiple tumour foci (Tornell et al., 1996). 
EBNA3 Family 
The EBNA3 latent protein family comprises three related nuclear proteins, 3A, 
3B and 3C.  All three have activation and repression functions on viral 
promoters (Cludts and Farrell, 1998, Lin et al., 2002, Marshall and Sample, 
1995, Radkov et al., 1997, Zhao and Sample, 2000), and interact with cellular 
corepressor proteins (Cotter and Robertson, 2000, Hickabottom et al., 2002, 
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Knight et al., 2003, Radkov et al., 1999, Touitou et al., 2001).  They associate 
with RBP-Jκ, disrupting its binding to cognate Jκ sequences and to EBNA2, 
resulting in repression of EBNA2-mediated transactivation.  This mechanism 
enables the EBNA3 proteins, together with EBNA2, to control RBP-Jκ activity 
and consequently to regulate expression of viral and cellular proteins that 
contain Jκ sequences (Young and Murray, 2003).  In addition to their 
transcriptional regulatory functions, further studies have revealed the EBNA3 
family of proteins are involved in disruption of the host cell cycle; specifically at 
the G2/M checkpoint (Krauer et al., 2004). 
Whereas EBNA3A and 3C have been shown to be essential for in vitro growth 
transformation of B cells, EBNA3B is dispensable (Tomkinson et al., 1993, 
Tomkinson and Kieff, 1992, Chen et al., 2005).  Since 3B is, however, 
conserved in lymphocryptoviruses infecting Old World primates (Jiang et al., 
2000), it is likely to be an important component of infection in vivo. 
EBNA-LP 
EBNA-leader protein (LP) is encoded by the leader of each of the EBNA 
mRNAs, and varies in size according to the number of BamHI W repeats 
contained within the specific EBV isolate (Rickinson and Kieff, 2007).  In 
recently infected B cells, a range of EBNA-LP isoforms are expressed, but this 
number decreases over time spent in culture (Finke et al., 1987, Dillner et al., 
1986).  EBNA-LP appears to be required (but is not essential) for effective 
outgrowth of LCLs since infection with mutant viruses expressing defective 
EBNA-LP results in reduced transformation efficiencies (Hammerschmidt and 
Sugden, 1989, Mannick et al., 1991, Allan et al., 1992).  The protein also 
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functions as a coactivator of EBNA2, preferentially enhancing expression of 
LMP1 (Fahraeus et al., 1990, Harada and Kieff, 1997, Nitsche et al., 1997, 
Peng et al., 2005). 
LMP1 
Latent membrane protein 1 (LMP1) is expressed in all EBV-positive tumours 
except BL, and due to its critical role in B cell transformation is considered to be 
a classical viral oncogene (Kaye et al., 1993, Izumi and Kieff, 1997, Middeldorp 
and Pegtel, 2008).  The LMP1 protein contains a transmembrane domain 
containing six loops, an amino (N) terminal cytoplasmic portion which fixes the 
protein to the membrane of the infected cell, and a long cytoplasmic tail which is 
able to interact with cellular signalling molecules.  The cytoplasmic portion 
contains carboxy (C) terminal activation regions (CTARs) which are functionally 
homologous to the cytoplasmic tail of human CD40 as they interact with tumour 
necrosis factor (TNF) receptor associated factors (TRAFs) and TNF receptor-1 
associated death domain protein (TRADD) (Luftig et al., 2003, Devergne et al., 
1998, Schneider et al., 2008).  Interactions between CTARs and 
TRAFs/TRADDs lead to activation of various intracellular signalling molecules 
including MAP kinases.  Indeed CTARs 1 and 2 were identified based on their 
capacity to activate the NF-κB signalling pathway (Huen et al., 1995).  Deletion 
of the LMP1 C-terminal signalling domain was shown not to ablate B-cell 
transforming capabilities (Kaye et al., 1999), indicating that the transmembrane 
domains of the protein are also important for activation of signalling pathways 
and other critical roles of LMP1.  Further studies have revealed the lipid 
microdomains or “rafts” within this section of the protein to be involved in 
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intracellular signalling processes which ultimately lead to NF-κB activation 
(Kaykas et al., 2001, Kaykas et al., 2002, Soni et al., 2006, Yasui et al., 2004). 
The homology of LMP1 with CD40 is an important consideration within the 
context of in vivo B cell infection.  One of the most widely believed models of 
EBV colonisation of the B cell compartment is based in part on the ability of 
LMP1 to mimic the CD40-CD40 ligand (L) interaction usually provided by T cell 
help (Uchida et al., 1999).  The infected cell subsequently participates in a 
germinal centre (GC) reaction, resulting in differentiation to a memory B cell. 
LMP1 expression in healthy tissue is rarely seen; approximately 20% of EBER-
positive cells in healthy tonsil tissue were found to express low levels by 
immunohistochemistry in one study (Hudnall et al., 2005).  By comparison, 
LMP1 expression in EBV-positive tumours including post-transplant 
lymphoproliferative disease (PTLD) (Liebowitz, 1998), Hodgkin’s Lymphoma 
(HL) (Dukers et al., 2000) and subsets of nasopharyngeal carcinoma (NPC) 
(Khabir et al., 2005) is relatively high, and in immunocompromised individuals 
evidence of abundant LMP1 expression has been observed in healthy tonsils 
preceding the onset of PTLD (Mowry et al., 2008). 
LMP2 
The LMPs 2A and 2B share a similar structure, comprising a transmembrane 
domain made up of 12 membrane-spanning loops, with a C-terminal 
cytoplasmic tail.  Additionally, LMP2A has an N-terminal cytoplasmic portion 
that comprises eight tyrosine residues, two of which form an immunoreceptor 
tyrosine-based activation motif (ITAM) (Longnecker, 2000).  Upon 
phosphorylation, the ITAM is able to recruit various cellular tyrosine kinase 
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proteins, ultimately leading to the disruption of B cell receptor (BCR) signalling 
(Longnecker, 2000, Dykstra et al., 2001). 
LMP1 and LMP2A together have the potential to mimic antigen-driven activation 
of B cells, and provide survival signals.  BCR-negative pre-cursor cells 
observed in the periphery of LMP2A transgenic mice first lead to the suggestion 
that the protein promotes survival of defective B cells, which would otherwise be 
selected for apoptosis (Caldwell et al., 1998).  The ability of EBV infection to 
rescue BCR- B cells was further highlighted by subsequent in vitro infection 
studies using GC B cells.  In one study, infection of human tonsillar GC B cells 
yielded a small proportion of LCL cultures containing BCR- cells (Chaganti et 
al., 2005), and in a second, BCR- GC B cells were selected based on lack of Ig 
expression, and successfully transformed by EBV (Mancao et al., 2005).  The 
link between LMP2A expression and cell survival was firmly established when a 
recombinant EBV encoding a conditional, floxed LMP2A allele was able to 
transform both BCR+ and BCR- GC B cells effectively in vitro.  The same study 
confirmed that cell survival and proliferation were absolutely dependent on 
LMP2A (Mancao and Hammerschmidt, 2007). 
Within the context of B cell colonisation during primary infection in vivo, it has 
been proposed that LMP2A’s capacity to imitate BCR signalling may act in 
conjunction with LMP1’s surrogate T cell help in order to drive infected cells 
through GC reactions.  When considering this hypothesis however, the 
prevailing BCR+ phenotype of the EBV-infected memory B cell reservoir is an 
important counter-argument. 
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EBERs 
EBV also encodes a pair of non-coding RNAs, EBERs1 and 2, which can be 
detected in all forms of latent infection.  Neither of the two gene products 
appear to be essential for B cell transformation, however EBER2 may increase 
the efficiently of this process (Wu et al., 2007).  A contribution to malignancy 
has been suggested by various studies in which EBERS have been shown to 
increase tumourigenicity, promote cell survival and induce the upregulation of 
cytokines such as IL-10 (Ruf et al., 2000, Takada and Nanbo, 2001).  EBERs 
can bind directly to the ds RNA-activated protein kinase, PKR, which 
contributes to the antiviral effects of interferon (IFN), suggesting that EBER-
mediated inhibition of this molecule could promote viral resistance (Clarke et al., 
1991, Nanbo et al., 2002).  In addition, EBERs also interact with the autoantigen 
La (Lerner et al., 1981) and the ribosomal protein L22 (Fok et al., 2006, 
Toczyski et al., 1994, Houmani et al., 2009), and have been shown to induce 
expression of IL-10 in BL (Takada and Nanbo, 2001, Ruf et al., 2000, Kitagawa 
et al., 2000), IL-9 in EBV-infected T cells (Yang et al., 2004) and insulin-like 
growth factor in epithelial cells (Iwakiri et al., 2003, Iwakiri et al., 2005).  Stable 
expression of EBERs in immortalized nasopharyngeal epithelial cells confers 
resistance to apoptosis (Wong et al., 2005). 
BHRF1 
BamHI fragment H rightward open reading frame 1 (BHRF1), which encodes a 
gene homologous to cellular Bcl2 (Vaux et al., 1988), was initially classified as 
an early lytic cycle protein since it was never detected in tightly latent LCLs and 
is expressed from its own lytic cycle promoter (Pearson et al., 1987, Austin et 
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al., 1988).  Recent studies, however, have highlighted an anti-apoptotic role for 
BHRF1 during latent infection in a subset of BL and growth transformation of B 
cells (Altmann and Hammerschmidt, 2005, Kelly et al., 2009).  An investigation 
into the anti-apoptotic activity of EBV in BL focussing on EBNA2-deleted Wp-
restricted BL cell lines revealed that deletions within certain tumours had placed 
a copy of the Wp promoter immediately upstream from BHRF1 (Kelly et al., 
2009).  Expression of BHRF1 was also detected in these lines at both the 
mRNA and protein levels.  Furthermore, the study used a dox-inducible vector 
expressing BHRF1 in BL lines to show that BHRF1 conveyed anti-apoptotic 
properties on the infected cells even at low levels of expression.  In addition to 
the role of BHRF1 in BL, BHRF1 was also found to be constitutively expressed 
in long term LCL cultures; a finding which was consistent with the observed 
burst of BHRF1 expression correlating with resistance from apoptosis 
immediately following B cell EBV infection (Altmann and Hammerschmidt, 
2005). 
1.1.5 EBV Lytic Infection 
EBV lytic infection occurs in vivo during primary infection, where the virus 
replicates in epithelial cells that have acquired the virus either directly, or, as 
suggested by in vitro experiments (Shannon-Lowe et al., 2006), indirectly from 
the surface of adjacent B cells.  Reactivation of the lytic cycle also occurs 
sporadically during persistent infection, probably when memory B cells are 
induced to differentiate into plasma cells (Laichalk and Thorley-Lawson, 2005).  
Lytic infection in the oropharynx leads to high levels of infectious virus shed into 
the throat, which ensures transmission to new hosts and maintains infection of 
the current host (Fafi-Kremer et al., 2005, Balfour et al., 2005).  In vitro, 
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approximately 5% of cells in LCL cultures undergo spontaneous lytic replication, 
and Akata-BL cell lines stably transfected with reporter plasmids can be induced 
into lytic cycle by cross-linking of the BCR with anti-Ig (Binne et al., 2002, 
Ressing et al., 2005). 
Lytic replication involves the sequential expression of lytic viral antigens.  The 
process is initiated by immediate early genes BZLF1 and BRLF1, which 
transactivate expression of early genes such as BALF2, BHRF1 and BMRF1.  
Whilst the latter antigens are involved in viral DNA synthesis, further late lytic 
antigens are involved in synthesis of viral structural proteins.  Specifically, late 
antigen BLLF1 encodes the envelope glycoproteins gp350 and gp220, BCRF1 
encodes a viral protein that closely resembles IL-10, and BALF4 encodes the 
glycoprotein gp110 (Rickinson and Kieff, 2007). 
The process of viral replication imposes significant nuclear and cytoplasmic 
changes within the infected cell, which ultimately leads to cell lysis.  The initial 
stages take part in the nucleus and involve synthesis of viral DNA, which is 
subsequently packaged into the capsid.  Capsids bud through the nuclear 
membrane, forming cytoplasmic vesicles which contain the enveloped virus.  
The vesicles fuse with the plasma membrane of the host cell, and the new virus 
particle is released via exocytosis, followed by death of the host cell (Rickinson 
and Kieff, 2007). 
1.2 B cell Development 
Before discussing what is known about EBV persistence in the B cell system, it 
is first necessary to provide an introduction to the normal pathways of B cell 
development.  The main purpose of a B cell is to produce immunoglobulin (Ig).  
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Immunoglobulin when expressed on the B cell surface is the essential 
component of the B cell receptor (BCR) complex and is also termed “antibody” 
when in secreted form.  The primary role of Ig is to recognize and bind to 
specific pathogenic antigens, which it has been primed to do via a series of 
diversification processes starting with VDJ recombination in the immature B cell, 
and finishing with somatic hypermutation in the activated mature B cell.  As a 
result of these mechanisms the B cell pool is collectively capable of recognizing 
almost infinite numbers of unique antigens.  Different effector functions are 
determined by both the class of Ig expressed by the individual B cell, and the B 
cell sub-type (see below).  As a result of Ig production, B cells function within 
the immune system to bind pathogens such as bacteria and viruses.  This can 
result in neutralization, when sites on the pathogen necessary for replication are 
blocked by antibodies, and opsonisation, which promotes complement-driven 
phagocytosis by other immune cells.  B cells also function as antigen-presenting 
cells, presenting MHC class II-restricted antigens to T cells, and can produce 
immunomodulatory cytokines that influence different components of the immune 
response, for example T cell differentiation, dendritic cell regulation, transplant 
rejection, tumour immunity and lymphoid organogenesis. 
Importantly, B cells not only carry out these effector functions during the first 
encounter of pathogenic antigen within the context of a primary response, but 
subsequently confer lifelong protection against that pathogen via production of 
highly specific, rapidly-responding memory cells that can persist within the 
individual for life (LeBien and Tedder, 2008, Parham, 2000). 
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1.2.1 Antibody Structure 
The function of antibodies in host defence is to recognise and bind to specific 
antigens in order to facilitate clearance of that antigen from the body either by 
direct neutralization or targeting to other components of the immune system.  
Antigen and/or immune system constituents interact with different parts of the 
antibody molecule (Figure 4).  The antigen-binding portion is highly variable 
between each molecule, accounting for the vast diversification in antibody 
specificities.  The remaining parts of the antibody molecule are more conserved 
and as such are used to distinguish the five different classes of antibody, which 
have distinct effector functions; IgD, IgM, IgG, IgA and IgE.  Since IgG is the 
most abundant antibody found in human beings, it usually serves as the 
example to describe antibody structure (LeBien and Tedder, 2008, Litman et al., 
1993, Parham, 2000, Market and Papavasiliou, 2003). 
Antibodies are glycoproteins comprised of two identical heavy chains and two 
identical light chains.  Each heavy chain is covalently linked to a light chain via a 
disulphide bond, and together the two heavy and light chain pairs resemble a Y-
shaped structure with two arms and a stem.  Most of the antibody molecule 
consists of amino acid sequences of limited diversity known as the constant 
regions (CH in the heavy chain, CL in the light chain).  The light chains contain 
a single C domain, whereas the heavy chains consist of three or four, 
depending on isotype.  The configuration of the CH domains determines 
whether the antibody is IgM, IgD, IgG, IgA or IgE.  The amino terminal at the 
end of each chain is made up of a single variable domain (VH in the heavy 
chain, VL in the light chain) containing highly variable amino acid sequences.  
Two different classes of light chain are found in humans, κ and λ.  Both types 
Figure 4.  Structure of an antibody molecule
The diagram shows the structure and locations of functional domains within an IgG
molecule.  The constant (C) regions are shown in blue and the variable (V) regions are in 
yellow.  Both the heavy (H) and light (L) chains are highlighted.  The basic positions of 
the V, D and J segments within the variable region are shown on the left arm of the H 
chain.  Adapted from Janeway et. al. 2001.
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are associated with each class of antibody, although the κ chain is more 
abundant, being present in two thirds of antibody molecules.  The pairing of the 
VH and VL segments produces the antigen binding site at the amino-terminal of 
the molecule.  Within each V domain, three regions of highly diverse amino acid 
sequences known as complementarity-determining regions (CDRs) together 
form the hypervariable regions of the binding site.  The less diverse regions, 
known as the framework regions provide structural stability for the V domain 
(LeBien and Tedder, 2008, Litman et al., 1993, Parham, 2000, Market and 
Papavasiliou, 2003). 
1.2.2 B cell Receptor 
Antibodies that are membrane-bound to the B cell surface are referred to as 
Immunoglobulin (Ig) molecules (Figure 5).  Although surface Ig is able to bind 
specific antigen, this interaction alone is not sufficient to stimulate the B cell, but 
requires two transmembrane proteins, Igα and Igβ (CD79).  These possess long 
cytoplasmic tails containing intracellular tyrosine-based activation motifs 
(ITAMs), which can interact with signalling molecules such as Src family 
kinases following antigen-binding (Reth, 1989).  This complex of Ig, Igα and Igβ 
forms the functional B cell receptor (BCR). 
B cell activation is achieved by binding of the BCR to protein or carbohydrate 
epitopes.  Following specific binding in a naive B cell, IgM molecules become 
cross-linked with each other on the cell surface and cluster in a localised area.  
This assemblage provides a signal to the cell nucleus from the BCR complex, 
which is communicated via Igα and Igβ.  In addition to Ig cross-linking, other 
signals are required to activate the B cell.  In particular the B cell co-receptor 
Figure 5.  B cell receptor complex
Binding of CD21 (CR2) to C3d bound antigen enables the co-receptor complex to cluster 
with the BCR complex.  This allows receptor-associated kinases to phosphorylate CD19, 
which in turn binds the Src-family tyrosine kinases and PI3 Kinase, thus activating 
downstream signalling pathway.  Adapted from Janeway et al., 2001.
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complex which is made of several proteins including; complement receptor CR2 
(also known as CD21), CD19 and CD81.  CR2 binds complement 3d-bound 
antigen, enabling the co-receptor complex to cluster to the BCR complex.  
Receptor-associated kinases are then able to phosporylate CD19, which then 
binds Src family tyrosine kinases and P13 kinases, in order to activate the 
downstream signalling pathway (Figure 5).  This simultaneous ligation of the 
BCR and B cell co-receptor is able to increase the activation signal 1000-
10,000-fold.  When the B cell is stimulated by T-dependent antigens, CD4 T cell 
help is also required for proliferation and differentiation of the B cell (see later) 
(LeBien and Tedder, 2008, Parham, 2000, Litman et al., 1993). 
1.2.3 Organisation of Immunoglobulin Genes 
In humans the organisation of Ig loci differs to that of other genes elsewhere in 
the genome.  In non-B cells, the germline Ig genes are in a fragmented form 
that cannot be expressed (Figure 6a).  Rather than containing a single gene, Ig 
heavy and light chain loci contain different sets of gene segments 
corresponding to the major components of the variable domain.  In humans, Ig 
genes are found at three separate chromosomal locations; chromosome 14 
(heavy chain locus), chromosome 2 (κ light chain locus) and chromosome 22 (λ 
light chain locus).  In both the light and heavy chains, different gene segments 
encode the leader peptide (L), the variable region (V) and the constant region 
(C).  In order to express the V region genes, rearrangements to form functional 
sequences are first necessary.  The light chain variable domain is encoded by 
two gene segments; one variable (V) region segment and one joining (J) region 
segment.  The heavy chain variable domain is also encoded by one V segment 
and one J region segment, and an additional diversity (D) segment encoding an 
Figure 6.  Ig gene rearrangement
A. Germline distribution of genes on the heavy chain locus situated on chromosome 14.  
B. Sequence of the gene rearrangement for the heavy chain and assembly of both heavy 
and light chains to form a functional polypeptide.  Disulphide bonds are shown as solid 
black bars.  Adapted from Janeway et al., 2001.
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extra region situated between the V and J regions.  Approximately 65 V, 27 D 
and 6 J regions are available for Heavy chain rearrangement.  CDR1 and CDR2 
represent regions of diversity with the V gene in both heavy and light chains.  
The CDR3 region is determined by the junction between the V and J segments 
in the light chains, but in the heavy chain includes the junctions between the V, 
D and J regions (Market and Papavasiliou, 2003, Parham, 2000). 
1.2.4 B cell Maturation 
B cells develop in the bone marrow throughout adult life, from hematopoietic 
stems carrying germline Ig genes.  B cell development occurs in successive 
stages (Figure 7) distinguished by molecular changes accompanying Ig gene 
rearrangements, where V, D and J segments are recombined to form functional 
BCRs (Figure 6b) (Li et al., 1993, Rajewsky, 1996).  The heavy chain is the first 
to be rearranged in the earliest identifiable B cell, known as the progenitor B cell 
(pro-B cell).  In order to generate the heavy chain, two recombination events 
take place.  The first brings together a D and a J segment in the early pro-B cell, 
and the second event adds a V segment to the recombined DJ segment in the 
late pro-B cell.  The multiple V, D and J segments that are available ensure that 
thousands of different VDJ combinations are possible; hence the rearrangement 
mechanism is very important for the generation of a diverse repertoire of Ig 
variable regions.  Once the cell is able to express a functional heavy chain, it is 
known as a large pre-B cell.  In the early phase of the pre-B cell stage, a μ 
heavy chain is transiently expressed on the cell surface.  The chain is joined by 
two surrogate light chains to form the pre-B-cell receptor which, upon 
stimulation, induces cell division mechanisms to yield small pre-B cells.  In 
these cells, most μ heavy chains remain in the cell cytoplasm, whereas a small 
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proportion is expressed on the cell surface.  Small pre-B cells then initiate 
rearrangement of the light chain during which another recombination event is 
needed to bring together a V and a J segment (Wang et al., 1998).  The cutting 
and joining together of the gene segments is carried out by enzymes encoded 
by recombination activating genes 1 and 2 (RAG 1 and 2) (Schatz et al., 1989), 
and during this process further V region diversity is provided to the antibody 
molecule via the introduction of additional N nucleotides at V, D and J junctions 
(since the accumulation of these nucleotides is specific to each individual B cell, 
distinct junction CDR3 sequence provide a means to identify clonally related B 
cells). 
B cell development can only continue to the next phase following a productive 
VDJ rearrangement.  Since every cell carries two copies of each Ig loci ( one 
inherited from each parent) rearrangements can take place on either of the 
homologous chromosomes, affording the cell two attempts to make a productive 
rearrangement.  If this is successful, subsequent rearrangements are 
prevented, ensuring that the cell carries a heavy or light chain of single 
specificity whereas B cells unable to generate productive rearrangements are 
eliminated by apoptosis.  This process is known as allelic exclusion 
(Mostoslavsky et al., 2004). 
After the heavy and light chains have been successfully rearranged and 
expressed, they are able to assemble with the μ heavy chains into functional 
IgM molecules.  In this final stage, however, the immature B cells are not yet 
fully released into the periphery.  Due to the random nature of the 
rearrangement process, some B cell receptors may be reactive towards self 
antigen.  In order to prevent potential targeting of the body’s own constituents, 
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which may lead to autoimmune disorders, the immature B cells are therefore 
selected for self-tolerance (Nemazee et al., 1991). 
Release from the bone marrow into the peripheral blood coincides with 
alternative mRNA splicing of the heavy chain to yield IgD as well as IgM 
transcripts.  The assembled VDJ sequence lies upstream from the C region 
genes.  The closest C region gene on the 3' side of the VDJ sequence is Cμ 
(encoding IgM), followed by Cδ (encoding IgD).  In mature, naive B cells 
transcription of the complete Ig heavy chain begins at the V gene segment and 
continues through the μ and δ genes before terminating.  The primary transcript 
is processed to remove introns between the C region genes, and alternatively 
spliced to yield either IgM or IgD mRNA.  The resultant naive B cell is therefore 
identifiable by co-expression of IgM and IgD on the cell surface (Geisberger et 
al., 2006). 
Immature B cells exiting the bone marrow are referred to as transitional B cells.  
They express the B cell marker CD21, with IgD and CD22 (LeBien and Tedder, 
2008), and are associated with TI responses (Coutinho and Moller, 1975).  
Following entrance to the periphery, B cells circulate between the blood and 
lymphoid tissues, including the lymph nodes, spleen and mucosa-associated 
lymphoid tissue.  B cells are also particularly enriched in areas of gut-associate 
lymphoid tissue (GALT), including Peyer’s patches, the appendix and the 
tonsils, where high numbers of IgA-secreting B cells congregate.  Within 
lymphoid tissue, B cells gather in organised structures known as follicles.  As 
billions of mature B cells leave the bone marrow every day however, 
competition exists for a limited number of follicular sites.  B cells which are 
unable to gain access to lymphoid follicles only survive for a few days, whereas 
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those that are able to enter and receive survival signals survive between three 
and eight weeks, or until they encounter antigen (LeBien and Tedder, 2008). 
Mature B cells circulating in the peripheral blood can be divided into three main 
subsets (Klein et al., 1998); (i) antigen-inexperienced IgD+CD27- naive B cells 
carrying germline IgH genes, which make up ~60% of the peripheral blood B 
cell population, (ii) antigen-selected IgD-CD27+ switched memory B cells that 
have differentiated via a germinal centre reaction, where clonal B cell expansion 
occurs alongside IgH mutation and isotype switching and (iii) IgD+CD27+ non-
switched memory B cells whose origins are controversial.  Although these cells 
carry mutated IgH genes, their presence in GC-deficient individuals suggests 
SHM arises in a GC-independent manner (Weller et al., 2001, Weller et al., 
2005, Agematsu et al., 1998).  The switched memory and non-switched 
memory subsets each comprise ~15-20% of the peripheral blood B cell 
population. 
In addition to the three largest circulating B cell subpopulations described 
above, CD27+IgM+IgD- B cells, also known as IgM-only B cells, represent a 
small fraction (~1%) of the B cell pool.  The origins of IgM-only B cells are not 
fully understood, but there is evidence to suggest that these cells are products 
of a GC reaction since they can be detected in elevated numbers in individuals 
who are able to form GCs, but are unable to carry out CSR or SHM, due to a 
deficiency of the enzyme vital to these processes, activation-induced cytidine 
deaminase (AID) (Weill et al., 2009). 
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1.2.5 T cell-Dependent B cell Activation 
Naive B cells pass through the T cell zone of secondary lymphoid tissue until 
they encounter their specific antigen.  Upon binding antigen, the B cell receptor 
complex not only sends signals to the cell nucleus (as described previously), 
but internalises the antigen via receptor-mediated endocytosis before 
processing the fragments that will be presented to a specific CD4 T cell.  The B 
cell presents the antigenic peptide to a CD4 T cell via a complex with the MHC 
class II molecule on its surface.  This contact prompts binding between CD40 
ligand (CD40L) on the T cell surface with CD40 on the B cell.  The CD40L-
CD40 interaction induces increased expression of the adhesion molecule ICAM-
1 on the cell surface, which in turn strengthens the interaction between the B 
cell and T cell, and also induces the CD4 T cell to express cytokines such as IL-
4, further inciting B cell proliferation (Parker, 1993). 
Upon activation with specific antigen, clonal expansion of the activated B cell 
occurs, leading either to the transient production of plasmablasts and short-lived 
extrafollicular plasma cells, which secrete unmutated antibodies, or to germinal 
centre (GC) formation in nearby lymphoid follicles (Figure 8) (McHeyzer-
Williams and McHeyzer-Williams, 2005).  Upregulation of Bcl6 and AID 
expression is a hallmark of GC B cells (Allman et al., 1996, Muramatsu et al., 
1999), which can broadly be divided into two cell types; centroblasts and 
centrocytes.  Centroblasts are highly proliferating GC B cells that are present 
within the dark zone of the GC and are identifiable by surface expression of 
CD38 and CD77.  Centroblasts give rise to centrocytes, which undergo lower 
rates of proliferation, also express CD38, but lack CD77 expression (Ma and 
Staudt, 2001).  The purpose of the GC reaction is to enable BCR affinity 
Figure 8.  T-dependent B cell activation and differentiation
Upon encounter with antigen in lymphoid tissues, naïve B cells proliferate to form a germinal 
centre,  undergoing SHM and CSR in order to differentiate into memory B cells or antibody 
secreting plasma cells.   GC cells that acquire deleterious mutations or fail to achieve affinity 
maturation are eliminated by apoptosis. Adapted from Kuppers, 2003.
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maturation via somatic hypermutation (SHM) and class switch recombination 
(CSR).  Following the successful completion of these processes B cells are able 
to leave the secondary lymphoid organ and differentiate into either antibody-
secreting terminally differentiated plasma cells, or long-lived resting memory B 
cells, both of which express highly specific isotype-switched antibodies.  
Memory B cells are also capable of terminally differentiating into plasma cells 
upon re-encounter with antigen in secondary immune responses.  Antigen-
specific antibody titres, which persist within individuals for sustained periods, 
typically derive from long-lived plasma cells which reside within the bone 
marrow (McHeyzer-Williams and McHeyzer-Williams, 2005, LeBien and Tedder, 
2008, Parker, 1993). 
Somatic Hypermutation 
Somatic hypermutation (SHM) in humans is a hallmark of the GC affinity 
maturity process, occurring at the centroblast stage.  SHM is dependent on the 
enzyme, activation-induced cytidine deaminase (AID), which is expressed by 
centroblasts and initiates mutation by targeting cytidine nucleotide residues for 
deamination (Muramatsu et al., 1999, Muramatsu et al., 2000).  Point mutations 
introduced during SHM may ultimately lead to amino acid replacements within 
the heavy and light chain variable regions of the Ig molecule, which in turn 
impacts on the affinity of the BCR for binding specific antigen.  Favourable 
changes resulting in an increased capacity to bind antigen are subsequently 
positively selected for, whilst cells bearing unfavourable mutations are 
eliminated (Peled et al., 2008, McHeyzer-Williams and McHeyzer-Williams, 
2005). 
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Most mutations are single nucleotide changes starting 100-200bp from the 
transcription initiation site and ending 1.5-2.0 kb downstream.  The highest 
frequency of SHM is found primarily within the V, D and J coding regions of the 
rearranged Ig locus, with a much lower frequency in unrearranged Ig VDJ 
segments or the Ig constant region.  Compared to the basal rate of mutation in 
the eukaryotic genome, the rates of IgV region mutation during SHM are 
estimated to be 10,000 – 1,000,000 times higher (Peled et al., 2008). 
At the molecular level, the first step of SHM involves an AID-mediated 
deamination event converting a cytosine residue to a uracil residue.  This base 
change may be interpreted as a thymidine residue during DNA replication, 
resulting in a C-T transition mutation in the daughter cell.  Alternatively, uracil 
DNA glycosylase, UNG, may remove the uracil residue to yield an abasic site, 
which is subsequently subject to DNA repair mechanisms (Schrader et al., 
2005).  Under normal circumstances, point mutations introduced into the 
genome are repaired efficiently by high fidelity repair enzymes, such as Pol β 
(Beard and Wilson, 2006).  Within the context of a germinal centre reaction, 
however, normal repair mechanisms are replaced with error-prone enzymes, 
such as Pol η and θ, which have the capacity to incorporate further mutations 
into the afflicted segment during their attempts to repair the AID-induced 
damage (Delbos et al., 2007, Masuda et al., 2005).  Specifically, the processes 
of base excision repair (BER) and mismatch repair (MMR), normally employed 
to maintain genome integrity, induce significant diversification of the Ig locus 
during SHM.  Whereas short-patch BER involves repair of the abasic site using 
any of the four available nucleotides, long-patch BER and MMR ultimately lead 
to excision of a section of the uracil-bearing strand comprising several 
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nucleotides, which is then “repaired” by error-prone polymerases which add a 
mixture of bases to the site, forming a sequence of DNA containing multiple 
mutations (Di Noia and Neuberger, 2007). 
The classic SHM scenario occurs within the context of a germinal centre 
reaction where antigen-activated naive B cells acquire Ig mutations in a T cell-
dependent manner.  Various studies have found instances of SHM outside of 
this familiar setting; both in terms of SHM in non-Ig genes following EBV 
infection (Epeldegui et al., 2007), and in the absence of germinal centres in 
non-switched memory cells (Weller et al., 2001) (see below). 
Class-Switch Recombination 
Whereas SHM of the Ig variable region is important for generating antibody 
diversity, class-switch recombination (CSR) involves the Ig constant (C) region 
and determines the effector function of the molecule (Figure 9).  This portion of 
the Ig not only interacts and is bound by other immune cells, epithelial cells and 
complement, but determines whether antibodies are able to pass through 
epithelial membranes at mucosal surfaces, tissues, or polymerise for increased 
avidity.  In naive B cells, constant heavy region Cμ and Cδ genes are 
transcribed resulting in expression of IgM and IgD.  During CSR, double-
stranded breaks (DSB) are introduced into switch (S) regions, and the 
intervening DNA strands removed by an intrachromosmal deletional 
recombination event (Stavnezer et al., 2008). 
S regions are located downstream of each of the CH regions except Cδ and 
consist of tandem repeats of short G-rich sequences (20-80bp).  In order for 
CSR to occur, DSBs must be created in two S regions; the Sμ region upstream 
Figure 9.  Events during class switch recombination
A B cell expressing IgM and IgD undergoes CSR to IgA.   A. AID deaminates dC residues in 
transcriptionally active S regions (Sμ and Sα in the diagram).   B. Double-strand breaks in each region 
enable CSR by intrachromosomal deletion.  C. The IgH locus after CSR to IgA.  Adapted from Stavnezer
et al. 2008.
A
B
C
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of the Cμ gene and any other S region further downstream (denoted Sx).  The 
overall length of S regions varies with each isotype (~1kb-12kb), and CSR can 
occur anywhere within or near to these regions (Dunnick et al., 1993, Min et al., 
2005).  As with SHM, the enzyme AID is essential for the process of CSR 
(Muramatsu et al., 2000).  AID deaminates dC nucleotides to uracil within 
transcriptionally active S regions, which subsequently leads to an abasic site 
following removal of the uracil residue by UNG.  Error-prone DNA repair 
mechanisms generate DSBs at the AID-targeted sites (Schrader et al., 2005).  
Overhanging strands at the DSBs are either repaired by translesion 
polymerases, or removed by exonucleases to produce blunt ends, which are 
then joined by end-joining recombination (Stavnezer et al., 2008).  IgG1-4, IgA 
or IgE isotypes are then expressed. 
Every naive B cell has the potential to switch to any of these classes (Jefferis 
and Kumararatne, 1990, Smith, 1992); however, isotype switching in vivo 
largely depends on the infection instigating the response.  Factors involved in 
isotype switching to particular classes include various cytokines expressed by T 
cells and dendritic cells (Banchereau and Rousset, 1992, Geha et al., 2003, 
Toellner et al., 1996).  Class switching has been demonstrated in in vitro 
systems using mouse splenic B cells and human naive B cells in numerous 
studies.  In these techniques, CD40 ligation is typically used, together with the 
addition of cytokines such as IL-4, IL-10, IL-13, IL-21 and TGFβ, each of which 
has been shown to induce CSR (Gascan et al., 1991, Pene et al., 1988, Jabara 
et al., 1990, Punnonen et al., 1993, Briere et al., 1994, Defrance et al., 1992, 
Kitani and Strober, 1994, Fayette et al., 1997, Pene et al., 2004, Nagumo et al., 
2002, Servet-Delprat et al., 1995).  Controversy still remains, however, as to 
32 
 
which isotype expression results from particular cytokines.  A recent study 
exploring stimulation of peripheral blood naive B cells with different cytokine 
combinations demonstrated that CD40L/IL-4/IL-21 upregulated IgG1 
expression, whereas treatment with CD40L and IL-21 alone yielded IgG3 or IgA 
expression (Avery et al., 2008). 
As with somatic hypermutation, CSR is predominantly found in centroblast cells 
during a germinal centre reaction.  However, recent evidence suggests the 
process may occur at low levels prior to germinal centre formation (Cunningham 
et al., 2007), or outside the context of the germinal centre.  Thus in one study 
almost normal levels of gut IgA were detected in CD40-/- mice lacking germinal 
centres (Bergqvist et al., 2006), whilst other studies found evidence of switching 
in pre-B and immature B cells isolated from bone marrow (Han et al., 2007, 
Ueda et al., 2007). 
1.2.6 T cell-Independent (TI) B cell Activation 
In addition to the classical T cell-dependent mechanism, distinct subtypes of B 
cells, B-1 cells and marginal zone B cells may be activated independently of 
interaction with T cells (Martin et al., 2001, Zandvoort and Timens, 2002).  
Relatively little is known about the function and origins of B-1 cells in humans, 
and whether they derive from the same progenitors as conventional B cells or 
have a distinct lineage remains controversial (Martin and Kearney, 2001, 
Dorshkind and Montecino-Rodriguez, 2007, LeBien and Tedder, 2008).  B-1 
cells can be further subdivided based on CD5 expression into B-1a (CD5+) and 
B-1b (CD5-).  While it is believed that both are involved in T-independent (TI) 
responses, B-1a cells may contribute towards innate immunity, whilst B-1b cells 
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may be associated with the adaptive response (Haas et al., 2005).  Marginal 
zone B cells, which may be synonymous with circulating IgD+IgM+CD27+ non-
switched memory B cells (Weller et al., 2004), have similarly controversial 
origins and diversification methods (discussed in further detail below).  These B 
cell types may become activated upon contact with pathogens without the 
necessity for T cell help.  TI responses involve recognition of conserved 
pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide 
on gram-negative bacteria, and bacterial or viral unmethylated CpG DNA 
(Ademokun et al., 2010, Janeway and Medzhitov, 2002).  In TI type I 
responses, non-BCR receptors are utilised, whereas TI type II responses 
involve direct BCR engagement of pathogen-derived antigens (Ademokun et al., 
2010).  T-independent B cell activation results in the rapid differentiation into 
low affinity IgM-secreting polyclonal plasmablasts of a collectively broad 
specificity for antigen.  Although these cells are short-lived and offer no 
immunological memory upon re-infection, the speed at which they are 
generated ensures an effective first line of defence against pathogens such as 
encapsulated bacteria, and as such the TI-independent response is deemed 
part of innate immunity.  TI-independent immunity is not present in humans at 
birth, but rather develops later in childhood (Ademokun et al., 2010, Parham, 
2000). 
1.2.7 Non-Switched Memory B cells 
Memory B cells (both switched and non-switched) are identifiable on the basis 
on several criteria; larger cell size with abundant cytoplasm, the ability to induce 
Ig secretion following appropriate stimulation in vitro, mutated Ig genes and, 
crucially, expression of the TNF-receptor superfamily molecule CD27 (Klein et 
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al., 1998).  Indeed since the majority of B cells displaying these characteristics 
were all found to express CD27, this molecule is now universally used as the 
definitive memory B cell marker by most researchers.  Subsequently, however, 
the acceptance that CD27 is an unequivocal marker for memory B cells has 
been challenged by several findings including; the identification of a subset of 
CD27+ precursor B cells in the bone marrow (Vaskova et al., 2008), and the 
isolation of CD27- class-switched B cells within the peripheral blood (Fecteau et 
al., 2006, Wei et al., 2007).  Furthermore the ongoing debate as to the origins of 
NS memory B cells also brings into question the validity of CD27 as a marker of 
memory, as it has been suggested that these CD27-expressing cells undergo 
prediversification independently of antigen-driven activation, and therefore 
should not be classified as memory B cells at all. 
The NS memory subset is identifiable by its IgM+IgD+CD27+ phenotype and 
mutated Ig genotype, which is highly similar to that of marginal zone B cells.  
Indeed NS memory B cells are often referred to as marginal zone B cells, 
regardless of their anatomical location.  Since the cells express a mutated BCR, 
which would normally be indicative of GC-associated SHM, yet appear not to 
have completed a typical GC reaction since CSR has not taken place; their 
method of diversification is unclear. 
Three main theories have been proposed describing the development of 
IgM+IgD+CD27+ subset; (i) the cells are products of abortive germinal centre 
reactions following TD antigen stimulation, (ii) the cells have a role in TI 
responses and diversify their BCR in extrafollicular sites and (iii) the cells are 
neither the products of TD nor TI antigen-driven activation and are instead 
prediversified prior to participating in an immune response. 
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T-dependent Diversification 
NS memory B cells may be activated in a T-dependent manner yet only go 
through a partial GC reaction, exiting the GC before CSR is initiated.  This 
hypothesis was initially put forward due to the morphological and genotypic 
similarities between non-switched and conventional memory B cell types (Klein 
et al., 1998).  Recent work to support this view found mutations within the Bcl6 
locus of IgM+IgD+CD27+ B cells, an event restricted to the confines of a GC 
reaction where Bcl6 is predominantly expressed, together with evidence for 
clonally related NS and S memory B cells sharing the same Ig mutations, 
presumably acquired by a common ancestor GC B cell within the reaction 
(Seifert and Kuppers, 2009).  Fascinatingly, although this study provides solid 
evidence to support the hypothesis of a TD route for the development of NS 
memory B cells, recent, equally compelling findings from a separate 
investigation, directly contradict the work carried out by Seifert and Kuppers.  
Comparisons of IgVH gene usage from different B cell subsets concluded not 
only that switched and non-switched memory B cells carry significantly distinct 
IgVH repertoires, indicating separate diversification pathways for each, but that 
within this pool of >1500 IgG and IgM memory B cell Ig genes studied, no 
clonally related cells were isolated (Wu et al., 2010). 
T-independent Diversification 
The original argument for T-independent (TI) IgM+IgD+CD27+ B cell 
development comes from studies of X-linked hyper-IgM (HIGM) patients 
(Agematsu et al., 1998, Weller et al., 2001).  Defects within CD40 or CD40L 
prevent the interaction between the two molecules which normally follows 
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antigen activation, leading to a lack of T-B collaboration in these patients.  As 
such, germinal centre reactions cannot occur, resulting in a lack of isotype-
switched memory B cells.  Intriguingly these patients have high levels of 
circulating IgM+IgD+CD27+ memory B cells, which express BCRs carrying 
mutations, albeit at lower rates than age-matched donor controls (Agematsu et 
al., 1998, Weller et al., 2001).  The presence of an IgM+IgD+CD27+ subset in 
HIGM patients suggests an alternative role for these cells, leading to the 
proposal that NS memory B cells may be involved in TI responses.  The theory 
that peripheral blood IgM+IgD+CD27+ B cells are essentially circulating 
marginal zone B cells supports this argument (Weller et al., 2004).  Studies of B 
cell subsets in asplenic individuals revealed little or no NS memory B cells 
within the peripheral blood, a finding which correlated with increased 
occurrence of infections with encapsulated bacteria such as Streptococcus 
pneumoniae (Kruetzmann et al., 2003).  Regarding the diversification of these 
cells during TI responses, Kruetzmann et al. suggested possible SHM within 
extrafollicular sites of the spleen.  Alternatively, evidence of low levels of 
hypermutation within GCs of transgenic mice formed in response to TI antigens 
such as NP-ficoll, suggests that GC-dependent SHM is possible in the absence 
of a classical TD response (de Vinuesa et al., 2000, Toellner et al., 2002). 
Prediversification Prior to an Immune Response 
In the scenarios described above, the involvement of IgM+IgD+CD27+ NS 
memory B cells in either TD responses or TI responses, assume that these cells 
are true memory B cells that are derived from antigen-activated 
IgM+IgD+CD27- naive B cells.  There are, however, several convincing studies 
indicating that the NS memory B cell subset is not formed as a result of a typical 
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immune response, but rather represents a prediversified cell population that is 
formed via a separate developmental route to conventional mature B cells.  
Several factors support this notion, primarily the existence of a somatically 
mutated IgM+IgD+CD27+ memory B cell population in the blood and spleen of 
young infants and in cord blood and foetal tissues.  Such evidence indicates 
that these cells are already diversified prior to pathogenic contact, although their 
number and IgH mutation frequency increases with age (Weller et al., 2008, 
Weller et al., 2001, Scheeren et al., 2008, Weller et al., 2004).  In addition, an 
examination of B cell subsets in children under the age of two years was carried 
out by Weller et al. to look for evidence of antigen-driven clonal expansion 
within the different populations.  This investigation took advantage of the fact 
that children of this age group have not yet fully developed TI responses, yet 
undergo childhood vaccinations which engage TD responses.  IgH 
spectratyping was carried out to analyse lengths of CDR3 regions within B cell 
populations; a technique based on the premise that clonally unrelated B cells 
bear unique CDR3 sequences and therefore a collection of diverse cells will 
present a range of different CDR3 lengths.  As expected naive B cell 
populations revealed an extremely diverse CDR3 repertoire, whereas 
conventional memory B cell populations displayed a very restricted repertoire of 
CDR3 lengths, indicative of antigen-driven clonal expansion as a result of TD 
responses generated by the vaccinations.  By contrast, the IgM+IgD+CD27+ 
NS memory B cells examined showed a diverse repertoire similar to that of 
naive B cells, indicating a lack of clonal expansion.  Furthermore, these diverse 
IgM+IgD+CD27+ B cells, which were isolated from individuals who were 
incapable of mounting TI immune responses, carried mutated Ig genes, strongly 
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suggesting the process of SHM occurred in these cells in the absence of either 
a TD or a TI response (Weller et al., 2008). 
Although the debate concerning the development and diversification processes 
of the IgM+IgD+CD27+ memory B cell subset remains ongoing, with convincing 
arguments presented from each viewpoint, a fourth possibility may be that these 
cells do indeed undergo pre-diversification, but then go on to participate in TD 
or TI responses, which may account for the increase in cell number and 
mutations with age. 
1.2.8 Activation-Induced Cytidine Deaminase (AID) 
The enzyme activation-induced cytidine deaminase (AID) is a 24kDa protein 
which shuttles back and forth between the cytoplasm and nucleus.  Structurally 
the carboxy (C) terminal of the protein is involved in CSR, whereas the amino 
(N) terminal facilitates SHM (Bransteitter et al., 2004).  AID is highly expressed 
in centroblast B cells; however, lower expression has been detected elsewhere 
in immature and transitional B cells from human cord blood and foetal tissues 
(Kuraoka et al., 2009), plasmablast-like cells in mouse spleens during TI 
responses (Han et al., 2007), in small numbers of peripheral blood memory B 
cells (Wu et al., 2008), and in B cells stimulated with IL-4 in vitro (Zhou et al., 
2003). 
Five separate AID variants have been identified (Figure 10).  The most 
prevalent transcript in healthy cells is known as AID full-length (AID-FL) (Revy 
et al., 2000, Greeve et al., 2003), and contains five exons.  The second variant, 
AID-ΔE4a carries a 30bp deletion in exon 4 (Noguchi et al., 2001, Oppezzo et 
al., 2005, Oppezzo et al., 2003, Greeve et al., 2003), whilst a third variant, AID-
Figure 10.  Functional domains of AID isoforms
The upper diagram highlights the functional domains of the full-length molecule, including the somatic 
hypermutation (SHM) and class switch recombination (CSR) domains.  The lengths of the corresponding 
exons are given below.  Exon arrangements of five distinct AID variants; AID-FL, AID-ΔE4a, AID-ΔE4, AID-
ΔE3E4 and AID-ivs3 are shown.  Adapted from (Wu et al., 2008).
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ΔE4, is missing all of exon 4 (Noguchi et al., 2001, Oppezzo et al., 2003).  The 
fourth AID-ΔE3E4 transcript lacks both exon 3 and exon 4 (Greeve et al., 2003), 
whereas in the AID-ivs3 transcript the intronic sequence between exons 3 and 4 
is retained (Greeve et al., 2003, McCarthy et al., 2003, Albesiano et al., 2003).  
Alternative transcript expression has been reported in asthmatic patients 
(Noguchi et al., 2001), cases of non-Hodgkin’s lymphoma (Greeve et al., 2003), 
chronic lymphocytic leukaemia (McCarthy et al., 2003), and in B cells stimulated 
with CD40L and IL-4 (Oppezzo et al., 2003). 
Recent work examining AID variant transcripts in detail suggests not only that 
expression by single B cell chronic lymphocytic leukemia (B-CLL) cells is 
restricted to one variant type, but that splicing results in specific impairment of 
the AID function, depending on which exon is missing.  Specifically, in relation 
to SHM activity the authors suggest the variant AID-ΔE3E4 does not support 
SHM, whereas the variants AID-ΔE4a and AID-ΔE4 showed increased levels of 
SHM.  Class-switch recombination was defective in all splice variants (Wu et al., 
2008). 
In vitro studies have revealed that within cell-free systems AID only targets 
single-stranded (ss) DNA, however C in double-stranded (ds) DNA is 
deaminated in vivo.  Strong evidence suggests that this is due to the availability 
of ssDNA within transcription bubbles of genes that are being actively 
transcribed (Bransteitter et al., 2003), and therefore transcription itself is 
essential for AID activity.  As hypermutation occurs at the highest rates within Ig 
genes, much speculation exists as to the mechanisms employed in AID 
targeting.  It is clear that gene transcription is not the only factor required for 
AID action since not all genes undergoing transcription in centroblasts are 
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mutated (Shen et al., 2000).  Possible explanations include targeting of AID to 
the Ig locus either via increased accessibility to this part of the genome, or by 
active recruitment of the enzyme by additional proteins or cis-acting sequences.  
Alternatively, error-prone repair mechanisms may be selectively employed to 
deal with AID-induced deaminations within the Ig, whereas those inflicted 
elsewhere in the genome may be repaired in an error-free fashion (Peled et al., 
2008).  Another aspect to this puzzle is that SHM has been discovered within 
non-Ig genes in normal individuals (Bcl6, CD79 and CD95) (Shen et al., 1998, 
Muschen et al., 2000, Gordon et al., 2003), as well as in malignant B cells (Bcl6, 
Pim1, Myc, RhoH/TTF and Pax5) (Pasqualucci et al., 2001, Pasqualucci et al., 
1998), albeit at much lower levels than within the Ig locus.  Of particular 
relevance to this study are the reports not only of AID upregulation following 
EBV infection of B cells in vitro (He et al., 2003), but also the discovery that this 
EBV-induced AID expression, together with an upregulation of pol-η 
corresponds to SHM within the proto-oncogenes, Bcl6 and p53 (Epeldegui et 
al., 2007).  Work published by others has shown that whilst splenic naive B cells 
induced to express AID in short-term culture undergo CSR, no SHM was seen 
(Petersen et al., 2001).  However, at the time of writing no other studies have 
focussed on SHM in naive B cells induced to express AID following EBV 
infection in vitro. 
1.3 EBV Colonisation in Vivo 
1.3.1 Primary Infection 
EBV is transmitted orally during exchange of saliva.  Typically individuals 
become infected in an asymptomatic manner during infancy via close familial 
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contacts.  In some instances however, usually in societies of the developed 
world, when the virus is acquired later in life during adolescence or adulthood, 
infection can produce the the self-limiting disease known as infectious 
mononucleosis (IM) (Gratama et al., 1990, Crawford et al., 2006).  Although it is 
known that EBV enters the host via the oropharynx, the initial target cell infected 
by EBV is still a matter of debate.  The two principal candidates include (i) 
epithelial cells and (ii) B cells. 
Epithelial cells in Primary EBV Infection  
Early studies of EBV primary infection described high titres of virus recorded 
from the saliva and throat washings of IM patients (Gerber et al., 1972).  More 
specifically, EBV DNA and lytic transcripts were detected in epithelial cells that 
had been shed into throat washings, suggesting that they were not only 
permissive for EBV infection, but also for the lytic production of new infectious 
virus (Sixbey et al., 1984).  Although both these investigations point to the 
oropharyngeal epithelium as an important reservoir for EBV infection during IM, 
subsequent studies using post-mortem tongue biopsies from a range of non-IM 
patients only found evidence of epithelial cell lytic infection in a very small 
proportion (1.3%) of tongue mucosal samples (Frangou et al., 2005), or in 
conjunction with an impaired immune response either as a result of 
immunosuppressive therapy or terminal cancer (Herrmann et al., 2002). 
B cells in Primary EBV Infection  
In contrast several separate studies provide evidence that B cells are the 
principal target for EBV during primary infection.  More than one investigation 
failed to find evidence of EBV replication within the epithelium, but instead 
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found that infection was confined to B cells, with lytic antigens identified within 
plasmacytoid B cells located proximally to epithelial crypts (Anagnostopoulos et 
al., 1995, Niedobitek et al., 1997).  These observations are supported by in vitro 
epithelial cell infection experiments.  While infection with cell-free virus is 
extremely difficult to achieve in vitro, co-culture of epithelial cells with infected B 
cells increases the efficiency of epithelial cell infection up to 1000-fold 
(Shannon-Lowe et al., 2006), suggesting that B cell-mediated delivery of the 
virus is a prerequisite for epithelial cell infection.  Examination of patients with 
the rare hereditary disorder XLA also favours the hypothesis that B cells are the 
initial target for EBV colonisation.  Since this disease is characterised by a lack 
of circulating mature B cells, it is reasonable to assume that these individuals 
are unlikely to support persistent long term EBV infection.  Indeed no evidence 
of the virus was detected either in throat washings or peripheral blood.  More 
importantly no EBV-specific T cells could be found in these patients, suggesting 
not only a lack of persistent infection, but also an inhibition of primary infection 
in the absence of mature B cells (Faulkner et al., 1999), supporting the 
hypothesis that B cells are required for epithelial cell infection.  Considering all 
the evidence described above, it is likely that that EBV first infects B cells, not 
least since the virus ultimately establishes stable persistence within the B cell 
population. 
1.3.2 Establishment of Persistent Infection 
Assuming EBV primarily targets oropharyngeal B cells for infection, there is 
further dispute as to the exact order of events and B cell subtypes involved in 
early stages of infection leading to persistent colonisation.  In order to identify 
the predominant B cell types infected with EBV, investigators have focussed on 
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phenotypic expression of B cell markers, and genotypic differences in Ig 
sequences.  Such investigations have revealed that latent EBV infection is 
largely restricted to the IgD-CD27+ switched memory B cell population within 
the peripheral blood of both healthy carriers and IM patients, and is excluded 
from the IgD+CD27- naive B cell population (Babcock et al., 1998, Hochberg et 
al., 2004).  This finding has been further substantiated by Ig analysis of 
individual EBV-infected cells, which were found to contain mutated IgV regions, 
consistent with a memory B cell genotype (Souza et al., 2005).  Although the 
outcome of primary EBV infection is the persistent infection of the switched 
memory B cell compartment, the mechanisms the virus employs to achieve this 
goal remain controversial.  More than one model has been proposed to 
describe these events, with the key disparity between the hypotheses resting on 
whether or not the process is dependent on germinal transit (Figure 11). 
Germinal Centre-Dependent Colonisation of Memory B cells  
Perhaps the most popular explanation for memory B cell colonisation, put 
forward by Thorley-Lawson and colleagues, suggests that the virus uses a 
Latency III pattern of gene expression to mimic physiological antigen-driven 
naive B cell activation, followed by subsequent germinal centre-mediated 
differentiation into a memory cell (Thorley-Lawson and Gross, 2004).  This 
hypothesis is based on the findings that EBV expresses different forms of 
latency in different B cell types in vivo.  In this model, initial infection is proposed 
to occur in naive B cells since these are the only cell type within the oropharynx 
where Latency III infection has been detected (Babcock et al., 2000, Joseph et 
al., 2000a).  A subsequent switch from Latency III to Latency II then pushes the 
infected naive B cell to become a GC B blast (Thorley-Lawson, 2001, Babcock 
Figure 11.   Selective colonization of the memory B cell compartment during primary EBV 
infection
Two theories describing EBV colonisation of the memory B cell population.  One hypothesis proposes 
that the virus preferentially infects IgM+IgD+ naïve B cells, transiently expressing latency III genes, of 
which LMP1 and LMP2 are able to mimic antigen stimulation and drive the cell through a germinal 
centre (GC) reaction. Thereafter the physiological processes of SHM and CSR take place and deliver 
latently infected IgG+CD27+ or IgA+CD27+ progeny cells into the long-lived memory compartment.
An alternative hypothesis, based on histochemmical studies of individual cells micro-dissected from IM 
tonsillar tissue, questions the involvement of GC transit and instead proposes the preferential infection 
and/or survival of memory cells post-infection, compared to their naïve counterparts.  Taken from 
Rowe et al. 2009.
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and Thorley-Lawson, 2000) via the expression of LMP1 and LMP2, which are 
able to substitute for the T cell help and BCR signals normally required following 
antigen activation (Kilger et al., 1998, Caldwell et al., 1998).  The infected cell is 
then presumed to transit through the GC processes of SHM and CSR, 
simultaneously carrying the virus, until completion of the differentiation process 
yields an infected memory B cell (Thorley-Lawson and Gross, 2004).  All viral 
gene expression is then switched off by the time the infected cell has acquired 
its memory characteristics. 
Germinal Centre-Independent Colonisation of Memory B cells  
Alternative models have also been suggested to explain the selective 
colonisation of memory B cells.  One of the principal arguments against the GC 
model is the difficulty to detect EBV-positive GC B cells.  The virus has been 
detected within tonsillar CD10+ B cells (Babcock et al., 2000), and although the 
reliability of this phenotypic molecule as a GC marker is debatable since 
immature B cells also express CD10 (Kalled et al., 1995), a very recent study 
attempted to validate these EBV-infected CD10+ B cells as GC derived since 
they co-express the characteristic GC proteins AID and Bcl6 (Roughan and 
Thorley-Lawson, 2009).  Immunohistochemical evidence for the presence of 
EBV within tonsillar GCs is, however, unconvincing and is more consistent with 
the second model of EBV persistence; the direct infection of memory B cells 
(Kurth et al., 2000, Kuppers, 2003).  Thus, in immunohistochemical 
examinations of IM tonsillar tissue, EBV-positive cells have been consistently 
identified in extrafollicular areas, but only rarely in follicles or germinal centres 
(Anagnostopoulos et al., 1995, Niedobitek et al., 1997, Kurth et al., 2000, Kurth 
et al., 2003).  In these studies, significant variation has been found regarding 
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both the type of infected cell, and the viral proteins expressed therein.  The 
following is a summary of morphological descriptions of infected cells, together 
with viral expression: (a) small cells expressing EBNA2 but not LMP1, which 
may reflect recent infection, (b) slightly larger lymphoblastoid cells expressing 
EBNA2 and LMP1, possibly reflecting a Latency III type infection, (c) large 
blast-like cells, which morphologically resemble HRS cells and express LMP1 in 
the absence of EBNA2, (d) a small population of small cells expressing neither 
EBNA2 nor LMP1, which resemble peripheral blood memory B cells. 
Interestingly, morphologically distinct EBV-infected cells belonging to the same 
clone have been isolated in these investigations (Kurth et al., 2000), suggesting 
that the cell morphology and EBNA1/LMP1 expression patterns described 
above may represent sequential stages of virus infection.  Based on these 
findings, it has been suggested that the Latency III program is expressed 
immediately upon infection of the host B cell, as evidenced by the 
EBNA2+/LMP1+ lymphoblastoid cells, followed either by downregulation of 
EBNA2 as seen in the blast-like cells, or by downregulation of both proteins, as 
seen in the small resting cells.  Taken together, the studies by Anagnostopoulos 
et al., Niedobitek et al. and Kurth et al. provide convincing evidence that 
infection occurs within tonsillar extrafollicular areas, and argue against 
obligatory GC transit of infected cells.  Instead, the direct infection and 
preferential expansion of memory B cells within the tonsil is a more likely 
explanation for these observations.  This is further supported by studies 
analysing the mutational status of the Ig V region of individual EBV-infected B 
cell clones from IM tonsils (Kurth et al., 2003).  While the virus was detected in 
both unmutated, genotypically naive B cells and mutated B cell clones, there 
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was no evidence of EBV infection within cell clones that were actively 
undergoing SHM (identifiable by intraclonally diverse IgV sequences), i.e. cells 
that were, by definition, true GC B cells.  Instead, infection was confined to 
memory B cell clones with identical IgV mutations, suggesting expansion of 
infected cells occurred following completion of the GC reaction. 
Susceptibility of B cell Subsets to EBV Infection  
The susceptibility of different B cell subsets to EBV infection in vitro have 
yielded results that collectively suggest no significant difference exists between 
naive or switched memory tonsillar B cells.  In one experiment where total 
tonsilllar B cells were infected, the relative proportions of IgM+, IgA+ or IgG+ 
transformed cells were comparable to the starting population (Ehlin-Henriksson 
et al., 2003).  A separate examination of tonsillar B cell populations that were 
separated based on expression of CD19 and CD27, found that whilst both 
CD27- naive and CD27+ memory B cells were equally susceptible to infection in 
vitro, when CD19+CD27+ B cells were further separated into IgA or IgM 
switched, or IgM non-switched tonsillar memory B cells, the switched population 
produced a higher frequency of infection (Dorner et al., 2008).  A more recent 
study has compared infectibility of B cells from nasopharyngeal-associated 
tissue (NALT) with B cells from peripheral blood or other lymphoid locations 
(Dorner et al., 2010).  This investigation concluded that whilst naive and 
memory B cells from NALT are equally susceptible to EBV infection, memory B 
cells from NALT are significantly more infectable than those from remote 
lymphatic organs.  In addition the investigators have proposed that the surface 
molecule beta-1 (β1) integrin expressed by NALT B cells, is a marker for 
increased susceptibility to EBV infection (Dorner et al., 2010).  When non-NALT 
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peripheral blood memory B cells were stimulated with CD40, together with BCR 
cross-linking in the same study, an increased susceptibility to EBV infection was 
observed.  Based on their results, this group has suggested that EBV may take 
advantage of the activation status of NALT memory B cells in order to establish 
persistence directly via the colonisation of memory B cells (Dorner et al., 2010). 
1.3.3 Persistent Infection 
In the weeks following IM presentation, the EBV DNA load within peripheral 
blood mononuclear cells (PBMCs) falls significantly, whereas high viral loads 
persist in saliva for up to 34 weeks (Balfour et al., 2005, Fafi-Kremer et al., 
2005).  It appears from these studies that IM patients remain highly infectious 
during convalescence and the length of time it takes for them to acquire viral 
loads comparable to long-term carriers remains unknown.  The majority of 
healthy EBV carriers shed virus intermittently (Balfour et al., 2005, Yao et al., 
1985) as a result of viral replication with the oropharyngeal epithelium.  
Detection of lytic cycle transcripts within plasmacytoid cells located close to the 
crypt epithelium suggests the virus lytic cycle may be reactivated in B cells 
during their terminal differentiation to plasma B cells (Anagnostopoulos et al., 
1995, Thorley-Lawson and Babcock, 1999).  It has thus been suggested that 
following reactivation in infected B cells virus is transferred to oropharyngeal 
epithelial cells, where lytic replication occurs (Rickinson and Kieff, 2007). 
In chronic EBV carriers, the frequency of infected B cells within the peripheral 
blood is approximately 1-50 per 106; a value which is around 1000-fold lower 
than that estimated for IM patients (Miyashita et al., 1995, Khan et al., 1996).  
Within the B cell population, persistent infection is reportedly limited to the 
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switched memory subgroup (Babcock et al., 1998), and in such cells, all viral 
gene expression in silenced with the exception of EBERs and BARTs (Tierney 
et al., 1994, Chen et al., 1999).  Indeed it is likely that restricted pattern of 
latency, characterised by downregulation of immunogenic viral proteins, 
facilitates evasion of cytotoxic T cell-mediated clearance of infected cells, 
thereby ensuring long term persistence of the virus. 
The frequency of EBV-infected cells estimated within tonsils is comparable to 
peripheral blood values.  In lymph nodes located elsewhere such as the spleen 
and mesenteric lymphoid tissue, the frequency of infected B cells is 
approximately 20-fold lower than in the tonsils (Laichalk et al., 2002).  It has 
been suggested that these cells are oropharyngeal-derived circulating B cells 
performing surveillance of more distal lymphoid tissue before returning to the 
oropharynx (Laichalk et al., 2002). 
Histological examination of chronic carrier tonsils revealed the presence of low 
numbers of EBER-positive cells which do not express either EBNA2 or LMP1.  
The cells, which morphologically resemble small lymphocytes consistent with 
memory B cells, are located in extrafollicular regions (Niedobitek et al., 1992).  
Some studies have also isolated low numbers of EBV-positive naive B cells 
(Babcock et al., 2000, Joseph et al., 2000a, Laichalk et al., 2002), and the 
detection of lytic replication in these cases could indicate they are examples of 
de novo infection (Babcock et al., 1998, Babcock et al., 2000, Joseph et al., 
2000a).  In addition, investigations employing RT-PCR techniques to examine 
viral load in tonsillar B cell subsets have found Latency III transcripts within the 
naive B cell subset (Babcock et al., 2000, Joseph et al., 2000a).  In parallel, GC 
and memory B cells populations were found to express LMP1, LMP2A and Qp-
49 
 
initiated EBNA1 transcripts, characteristic of a Latency II gene expression 
pattern. 
1.4 Immune Response to EBV Infection 
Herpesviruses have co-evolved with their hosts and ancestors for millions of 
years, and as such a fine balance has been struck between viral infection and 
persistence, and the ability to mount an effective immune response.  Although 
EBV is widespread within the human population with up to 90% of individuals 
infected, virus-associated disease is relatively rare.  The virus is never fully 
cleared from the host due to adaptive mechanisms employed to evade 
detection from immunity.  One such strategy is the ability to downregulate 
expression of viral antigens and exist in a silent state within resting memory B 
cells, which effectively function in the same way as their uninfected 
counterparts. 
1.4.1 Antibody Response against EBV Infection 
The presentation of IM is typically characterised by increased levels of 
heterophile antibodies within the serum, which may persist for up to one year 
(Blake et al., 1976).  Consequently one of the most established diagnostic tools 
for the detected of IM, the monospot test, is designed to detect the presence of 
these antibodies via their ability to agglutinate sheep and horse erythrocytes.  
Although the monospot test is arguably the most traditional assay used for IM 
diagnosis, its tendency to yield false positive results has ultimately led to the 
development of more specific methods (Sumaya and Ench, 1985).  Enzyme 
immunoassays are commonly used to detect IgG and IgM antibodies that are 
reactive against viral capsid antigen (VCA) and EBNA1.  EBV-specific proteins 
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can also be used to estimate the stage of infection.  For example IgG reactivity 
against early antigen (EA) can be detected at all stages of infection, whereas 
IgG anti-p23 is prevalent early on, and EBNA1 antibodies which are detectable 
between four to eight weeks during illness are reportedly an indicator of past 
infection (Bauer, 2001).  In addition, EBV infections are generally characterised 
by a transition from an increase in IgG avidity over time; in one particular study, 
anti-VCA IgG was found to be low in patients with recent infections, but higher 
in patients with past infections (Gray, 1995, Robertson et al., 2003).  This 
persistent antibody response against a lytic cycle antigen is consistent with the 
suggestion that EBV infection undergoes intermittent lytic reactivation 
throughout the host’s lifetime. 
1.4.2 Cell-Mediated Responses to EBV Infection 
The most extensively studied and possibly most important component of the 
cellular immune response against EBV is the CD8+ T cell response.  Acute IM 
is marked by an expansion of CD8+ T cell populations of oligoclonal T cell 
receptor (TCR) usage (Annels et al., 2000).  Remarkably, during IM individual 
epitope responses are accountable for 1%-40% of the total CD8+ T cell 
population, with reactivities to immediate early (IE) or early (E) lytic proteins 
being dominant.  Responses to latent proteins are smaller, accounting for 0.1%-
5% of CD8+ T cells, and are usually reactive against the EBNA3 family of 
proteins (Hislop et al., 2007).  Antigen-stimulation of EBV-specific CD8+ T cells 
isolated from IM blood is required to prolong survival in vitro (Callan et al., 2000, 
Dunne et al., 2002, Tamaru et al., 1993), perhaps explaining why EBV-specific 
CD8+ populations decline rapidly in vivo, following the limited availability of viral 
antigen upon entrance into latency (Hislop et al., 2007).  In the months following 
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IM, the surviving low numbers of EBV epitope-specific CD8+ T cells lose 
expression of activation markers such as CD38 and Ki-67, indicating that they 
are no longer in an activated state (Catalina et al., 2001, Hislop et al., 2005). 
Investigations focussing on long-term virus carriers with no history of IM have 
revealed that memory CD8+ T cells are maintained in the presence of low level 
antigenic stimulation, most of which display a resting phenotype and lack 
activation markers such as CD38 and CD69 (Catalina et al., 2002, Hislop et al., 
2001).  Individual epitope-specific populations account for 0.2%-2% of the 
CD8+ T cell population in the case of lytic epitopes (Benninger-Doring et al., 
1999, Saulquin et al., 2000, Bihl et al., 2006), and 0.05%-1% in the case of 
latent epitopes (Bihl et al., 2006).  Although fluctuations in the frequency of 
memory CD8+ T cells can be seen over time, levels remain more or less stable 
(Crough et al., 2005) until later on in life when an increase is observed; 60+ 
year old individuals may harbour up to 14% CD8+ T cells against individual 
EBV epitopes (Ouyang et al., 2003, Khan et al., 2004). 
Significantly less is known about the CD4+ T cell response during primary EBV 
infection.  The CD4+ T cell pool does undergo an expansion such as that seen 
in the CD8+ T cell population, but no marked oligoclonality can be observed 
(Maini et al., 2000).  The frequencies of EBV-specific CD4+ T cells are very low 
relative to their CD8+ counterparts, but are nonetheless comparable to CD4+ 
responses to other pathogens (Gamadia et al., 2003).  Responses to several 
latent and lytic antigens have been studied, with the most common CD4+ T cell 
response being to the immediate early (IE) protein BZLF1, less common 
responses observed against BMFL1 or the latent protein EBNA3A, and the least 
frequent against EBNA1 (Woodberry et al., 2005, Precopio et al., 2003).  As 
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with the CD8 response, EBV-specific CD4+ T cell numbers peak during acute 
IM and decline rapidly thereafter (Precopio et al., 2003). 
There is conflicting evidence for and against the involvement of the natural killer 
(NK) cell response during EBV infection.  The NK response is an important 
component of the early innate immune response, and has been shown to play a 
role in the early response against CMV infections in mice and humans (Braud et 
al., 2002, Vidal and Lanier, 2006).  Expansions of NK cells have been observed 
in the blood of acute IM patients (Williams et al., 2005), and NK cells have been 
found to inhibit resting B cell transformation by EBV in vitro via IFNγ production 
(Lotz et al., 1985).  Clinical evidence, however, conflicts with these studies 
since, in recipients of T-depleted stem cell transplants, EBV-driven 
lymphoproliferative disease (LPD) is most common during the 3-6 months 
following transplantation, the time period in which the NK cell, but not the T cell 
population has recovered (O'Reilly et al., 1997). 
1.5 EBV-Associated Diseases 
1.5.1 Infectious Mononucleosis 
Infectious mononucleosis (IM) most commonly affects individuals within the 
second decade of life, and is the result of primary EBV infection that has been 
delayed until adolescence as a result of the improved economic and sanitation 
standards of the developed world (Takeuchi et al., 2006, Luzuriaga and 
Sullivan, 2010).  Studies carried out in the U.S. using cohorts of university 
students have revealed the incidence of I.M. to be approximately 500 cases per 
100,000 individuals per year.  The highest incidence occurs in the 15 to 24 year 
age group, with between 30 to 50% of primary infections manifesting as IM 
53 
 
(Crawford et al., 2006).  The virus is transmitted through saliva, and in IM cases 
predominantly via kissing (Thorley-Lawson, 2001).  Although the delay between 
infection and the onset of symptoms means many of the initial events in 
infection have already taken place by the time patients present at clinic, the 
incubation period has been estimated to be between 30 and 50 days (Luzuriaga 
and Sullivan, 2010). 
During IM, lytic replication at oropharyngeal sites results in high levels of virus 
being shed into saliva (Balfour et al., 2005, Hadinoto et al., 2008).  Such 
shedding decreases over the first year following IM presentation, but thereafter 
persists at lower levels for life(Hadinoto et al., 2009).  In addition to high virus 
loads in saliva, levels of detectable virus are also significantly increased within 
the B cell reservoir of both the peripheral blood and tonsils.  IM is also 
characterized by lymphocytosis, including a large expansion of T cells (Callan et 
al., 1998, Catalina et al., 2001, Precopio et al., 2003), with evidence to suggest 
that this response not only limits primary infection and controls chronic infection, 
but that it may also contribute to the symptoms of IM (Hadinoto et al., 2008, 
Clute et al., 2005).  Although the vast majority of IM cases make full recoveries, 
a history of IM is associated with an increase risk of developing both multiple 
sclerosis (Thacker et al., 2006) and HL (Hjalgrim et al., 2003, Lunemann and 
Munz, 2009). 
Various risk factors have been suggested for the development of IM during 
primary EBV infection.  These include; (i) age-related alterations in host 
immunity, for example the exaggerated CD8+ T cell response observed in IM 
may be a result of cross-reactivity of the memory T cell repertoire with earlier 
infection (Clute et al., 2005), (ii) polymorphisms in the HLA class I locus 
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(McAulay et al., 2007), (iii) sexual behavior (Crawford et al., 2006), and (iv) 
infection with EBV type 1 (Crawford et al., 2006). 
1.5.2 X-Linked Lymphoproliferative Disease 
X-linked lymphoproliferative disease (XLP) in an extremely rare disorder 
inherited on the X chromosome.  It was first identified in 1975 when three 
maternally related boys succumbed to fatal IM (Purtilo et al., 1975), and is 
characterized by extreme sensitivity to EBV infection (Seemayer et al., 1995, 
Nagy and Klein, 2010).  Primary EBV infection in these patients leads to 
fulminant, often fatal IM in approximately 50% of cases, the development of 
malignant tumours in 30%, and dys-gammaglobulinemia in 30%.  Around 53% 
of XLP patients develop lymphomas (which are not always EBV-associated), 
and the risk of lymphoma development has been estimated to be 200-fold 
(Nagy et al., 2009). 
The causative factor of this disease is the inheritance of mutations within the 
SH2D1A gene, which encodes the signaling lymphocytic activation molecule 
(SLAM)-associated protein (SAP) (Coffey et al., 1998, Nichols et al., 1998, 
Sayos et al., 1998, Veillette, 2006).  Expression of SAP has been detected in 
NK cells, T cells and thymocytes (Nichols et al., 1998, Liu et al., 2002, Sayos et 
al., 2000), and is upregulated in activated T cells in vitro (Nagy et al., 2009), and 
elevated numbers of SAP-expressing T cells have been observed at the time of 
IM presentation in non-XLP patients (Williams et al., 2004).  SAP deficiency 
interferes with the CD4+ T cell help required by B cells in order to produce 
competent GCs and GC activities (Crotty et al., 2003, Ma et al., 2005, Cannons 
et al., 2006).  XLP patients can therefore present with hypogammaglobulinemia 
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even in the absence of EBV infection, together with an impaired IgG or IgA 
antibody response, which is mostly likely a result of the poor GC formation 
observed in these cases (Ma et al., 2006). 
Recent studies have described pro-apoptotic function for the SAP protein in BL 
cell lines (Nagy et al., 2004, Nagy et al., 2009).  Since the marked reduction of 
white cells occuring 3 to 16 days following IM presentation is reportedly a result 
of T-cell-mediated apoptosis, a link has been suggested between the clearance 
of EBV-infected B cells and the role of SAP, whose expression is upregulated in 
the T cells of IM patients (Nagy and Klein, 2010, Nagy et al., 2009).  This 
hypothesis is indeed consistent with the extreme sensitivity to EBV infection 
observed in SAP-deficient XLP patients, who are unable to eliminate 
lymphocyte expansions.  Furthermore, these investigators suggest that in XLP, 
which is also characterized by increased levels of lymphoma, DNA-damaged B 
cells that would be removed by apoptosis in healthy individuals, are able to 
survive in and go on to acquire mutations which ultimately result in lymphoma 
development (Nagy and Klein, 2010). 
1.5.3 Post-Transplant Lymphoproliferative Disease 
Immunocompromised individuals with depleted T cell numbers are at high risk 
of developing B cell lymphomas.  Perhaps the most extensively studied 
example of these EBV-associated lymphomas is the condition known as post-
transplant lymphoproliferative diseases (PTLD), which arises in transplant 
recipients who are undergoing immunosuppressive therapy.  PTLD 
encompasses a range of morphologically distinct tumours, which are usually B 
cell-derived, and mostly EBV-positive (Krams and Martinez, 2008).  According 
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to the World Health Organization (WHO), PTLD tumours can be divided into 
three main subtypes (Harris et al., 2000): (i) early lesions, which arise during the 
first year after graft transplantation and are polyclonal, IM-like proliferations 
which regress following the withdrawal of immune suppression, (ii) polymorphic 
PTLD, which is the most commonly occurring, can manifest at any time 
following transplantation, includes tumours derived from B cells at various 
stages of differentiation, and can be either polyclonal or monoclonal ,and (iii) 
monomorphic PTLD lesions, which arise later following transplantation, are 
mostly monoclonal and comprise a range of different subtypes including diffuse 
large B cell lymphomas, BL-like lesions and plasma cell myeloma (Harris et al., 
2000, Krams and Martinez, 2008). 
Early-onset tumours are almost exclusively EBV-positive, and express both 
EBNA2 and LMP1, indicative of a Latency III gene expression program.  
Consequently, these lesions have been identified as virus-transformed B cells 
that have been able to grow out in the absence of T cell control (Young et al., 
1989).  EBV-positive PTLD tumours arising later on have been found to exhibit 
a range of viral gene expression profiles, including latency III expression similar 
to early lesions, lack of EBNA2 and LMP1, and LMP1 expression in the 
absence of EBNA2 (Young et al., 1989, Timms et al., 2003, Capello et al., 
2003). 
Although the pathogenesis of PTLD has traditionally been attributed to 
diminished EBV-specific CD8+ T cell responses, recent studies have shown 
that these circulating cells are both readily detectable in transplant recipients, 
and comparable to those present in healthy individuals (Macedo et al., 2005, 
Guppy et al., 2007).  Interestingly, these investigations have further shown that 
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the functional activity of EBV-specific CD8+ T cells (defined by IFN-γ 
production) is impaired in these cases, suggesting that T cell functional 
capacity, rather than absolute numbers, may be more important in the 
pathogenesis of PTLD.  The observation that the proportion of function EBV-
specific CD8+ T cells increases following withdrawal of immune suppression, 
supports this hypothesis (Guppy et al., 2007). 
1.5.4 Hodgkin’s Lymphoma  
The first cases of Hodgkin’s Lymphoma (HL) were originally identified by 
Thomas Hodgkin in 1832 (Hodgkin, 1832).  The trademark mononucleated 
Hodgkin’s cell and multinucleated Reed-Sternberg, collectively known as HRS 
cells, were subsequently described in 1900 (Kuppers, 2009).  Distinct subtypes 
of HL are distinguished on the basis of cell morphology and phenotype, and the 
composition of the cellular infiltrate of the tumour tissue; the two main types are 
classified as classical HL and nodular lymphocyte-predominant HL (NLPHL) 
(Kapatai and Murray, 2007, Kuppers, 2009).  Since NLPHL only accounts for 
5% of HL cases, with EBV-association rarely seen (Anagnostopoulos et al., 
2000, Chang et al., 2005), this HL type will not be discussed in any further 
detail.  Classical HL is further subdivided into nodular sclerosis (60%), mixed 
cellularity (30%) and the rarer lymphocyte depletion and lymphocyte-rich forms 
(Kapatai and Murray, 2007, Kuppers, 2009). 
The HRS cells in classical HL comprise roughly 1% of the tumour, with the 
remaining portion made up of an infiltrate of mixed immune cells including T 
cells, B cells, plasma cells, neutrophils, eosinophils and mast cells.  
Remarkably, there is evidence to suggest the HRS cells themselves actively 
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attract many of these cells via secretion of a range of chemokines such as 
CCL5, CCL17, CCL22 and IL-8 (Skinnider and Mak, 2002, Aldinucci et al., 
2008, Fischer et al., 2003).  Although HRS cells exhibit a very unique 
phenotype which has proven difficult to assign to any particular cell type, most 
researchers have concluded they are derived from mature B cells of germinal 
centre origin (Kapatai and Murray, 2007, Kuppers, 2009).  The Ig genes in HRS 
cells are both rearranged and somatically hypermutated, consistent with 
antigen-driven germinal centre activity and up to a quarter of cases carry 
disruptive mutations that confer a non-functional BCR (Kuppers et al., 1994, 
Kanzler et al., 1996, Brauninger et al., 2003).  Whereas other lymphomas retain 
phenotypic and functional features of the original cell type (Kuppers, 2005), 
HRS cells display a dramatic loss in B cell phenotype (Schwering et al., 2003), 
which has been attributed to a complex deregulation of multiple signalling 
pathways and transcription factor networks, for example NF-κB, Jak-Stat, P13K-
Akt, Notch 1 and receptor tyrosine kinases (Kuppers, 2009).  In addition, HRS 
cells often express markers associated with cells of other haematopoietic 
lineages (Mathas et al., 2006, Takahashi et al., 1995, Drexler, 1992, van den 
Berg et al., 1999). 
Approximately 40% of cases of classical HL reported in the developed world are 
EBV-associated.  Most instances of EBV-positive HL are of the mixed cellularity 
or lymphocyte-depleted subtype, with fewer being nodular sclerosis HL or 
lymphocyte rich HL (Anagnostopoulos et al., 2000, Chang et al., 2005).  In 
cases of paediatric HL in Central and South America, up to 90% of cases are 
EBV-associated, and HL in AIDS patients is almost always EBV-positive 
(Dolcetti et al., 2001, Kutok and Wang, 2006).  HRS cells infected with EBV 
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express three viral proteins, EBNA1, LMP1 and LMP2A, along with the EBERs 
and BARTs.  In addition to its role in viral genome maintenance, EBNA1 has 
also been shown to have a direct role in HL pathogenesis by facilitating 
downregulation of the putative tumour suppressor gene, protein tyrosine kinase 
–κ (Flavell et al., 2008).  LMP1 and LMP2A can mimic physiologic CD40 and 
BCR signalling respectively (Kilger et al., 1998, Alber et al., 1993), both of which 
are instrumental in instigating the GC reaction following antigen-activation of B 
cells (Liu et al., 1989).  It has therefore been suggested that via expression of 
LMP1 and LMP2A EBV is able to promote survival of infected B cells within the 
GC.  Interestingly, both of these viral proteins have been linked to the 
downregulation of the B cell phenotype in EBV+ HRS cells (Portis et al., 2003, 
Vockerodt et al., 2008). 
Despite the significant association of EBV with many cases of HL, the 
pathogenic contribution of the virus is still questioned by some investigators 
since approximately 60% of tumours do not harbour EBV-infected HRS cells.  
More recent studies have, however, provided evidence to support the role of 
EBV in the pathogenesis of HL.  For example, a number of in vitro 
investigations have unequivocally demonstrated the ability of the virus to rescue 
B cells harbouring crippled BCRs (Bechtel et al., 2005, Mancao et al., 2005, 
Chaganti et al., 2005, Mancao and Hammerschmidt, 2007); findings which are 
consistent with the observation that the majority of HRS cells with non-
functional BCRs are EBV-infected (Brauninger et al., 2006). 
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1.5.5 Burkitt’s Lymphoma  
Burkitt’s lymphoma (BL) was first described by Dennis Burkitt in 1956 as a 
tumour affecting children in equatorial Africa.  Following its discovery, a 
transmissible pathogen such as an insect-borne vector was initially proposed to 
be the causative agent of BL (Burkitt, 1958, Burkitt, 1962).  Research carried 
out by Epstein and colleagues later revealed that cells in a BL-derived line were 
infected with a hitherto unidentified herpesvirus, which was subsequently 
named EBV (Epstein et al., 1964).   The three distinct forms of BL which are 
now recognised (endemic BL, sporadic BL and HIV-associated BL) are 
distinguished on the basis of geographical and anthropological distribution 
(Rickinson and Kieff, 2007), rather than on discrepancies within the tumours 
themselves.  Endemic BL arises in children within equatorial Africa and Papua 
New Guinea, where the incidence of the disease is high.  In these areas, where 
malaria is holoendemic, there is a 100%-association between BL and EBV.  
Sporadic BL cases occur in the rest of the world, with incidence and EBV 
association correlating with certain areas.  The lowest incidence is recorded in 
developed countries, where EBV association is also lowest (15-20% of 
tumours), whereas some developing countries such as equatorial Brazil and 
north Africa present an intermediate incidence of BL, with up to 85% of tumours 
being EBV+ (Kelly and Rickinson, 2007).  Unlike endemic and sporadic BL 
which primarily afflicts children, HIV-associated BL, which displays a 30-40% 
association with EBV, arises in adults infected with HIV.  Development of the 
lymphoma commonly precedes the onset of AIDs, arising in HIV+ individuals 
who are often still relatively immunocompetent up until that point (Carbone, 
2003, Kelly and Rickinson, 2007). 
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The BL tumour itself usually affects the jaw or abdomen.  Histological 
characteristics include collections of malignant, round, monomorphic cells that 
are interspersed with macrophages (Rickinson and Kieff, 2007).  The highly 
proliferative malignant cells phenotypically resemble GC B cells (Gregory et al., 
1988), expressing GC markers such as Bcl6, CD10 and CD38 (Dogan et al., 
2000, Pajic et al., 2001).  The primary tumourigenic event in the pathogenesis 
of all cases of BL is the deregulation of the cellular oncogene c-myc, which 
occurs as a result of chromosomal translocation of the c-myc gene located on 
chromosome (c) 8, onto an Ig locus on either c14, c22 or c2 (Dalla-Favera et 
al., 1982, Lenoir et al., 1982, Taub et al., 1982).  All BL tumours carry the c-myc 
translocation, regardless of whether they are EBV+ or EBV-. 
The c-myc protein is a transcription factor that has been estimated to bind 
around 15% of cellular gene promoters (Li et al., 2003).  It influences various 
cellular functions including proliferation and apoptosis, and its expression is 
usually very tightly regulated.  For example, promotion of cellular proliferation is 
counterbalanced by c-myc-induced apoptotic checkpoints which include the p53 
pathway (Adhikary and Eilers, 2005).  The translocation of the c-myc gene that 
occurs in BL places the c-myc under the control of promoters within Ig gene 
loci, resulting in a deregulation of expression and therefore of c-myc-mediated 
control of growth and apoptosis.  Although over-expression of c-myc is also a 
common feature in many other lymphomas, precisely how it drives 
tumourigenesis is still an unresolved issue. 
In EBV-associated BL, the viral expression program is more restricted than that 
seen elsewhere, for example in LCLs (Rowe et al., 1986, Rowe et al., 1987, 
Masucci et al., 1987).  Most BL tumours only express EBNA1, reflecting a 
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latency I type of infection, in which the Qp, rather than the Wp or Cp promoter is 
used to generate the EBNA transcript (Rowe et al., 2009, Schaefer et al., 1995, 
Nonkwelo et al., 1996).  In addition, 15% of endemic BL cases also display a 
unique type of latency in which expression of the EBNAs is activated from Wp, 
rather than Qp for reasons that are still not fully understood.  In this program, 
termed Wp-restricted latency, all EBNAs except for EBNA2 are expressed, 
together with LMP1 and LMP2A (Kelly et al., 2002, Kelly et al., 2006).  The 
absence of EBNA2 is attributable to a deleted sequence within the viral genome 
which has removed the EBNA2 gene (Kelly et al., 2005).  Interestingly, the viral 
protein BHRF1, which was not previously associated with latent infection, has 
recently been identified in Wp-restricted latency and shown to provide a survival 
advantage to infected BL cells (Kelly et al., 2009). 
Although c-myc translocation is the key event in the pathogenesis of BL, the 
association of EBV is also believed to be an important contributing factor.  The 
exact involvement of the virus in tumourigenesis is still an issue of extensive 
research, however, one intriguing hypothesis has been put forward, based on 
the link between the GC-like characteristics of the BL cells, and the malarial co-
factor in endemic BL cases (Rowe et al., 2009).  Immunosupression of EBV-
specific CD8+ T cells has been described in individuals suffering from acute 
malarial infections (Moss et al., 1983, Whittle et al., 1984, Njie et al., 2009, 
Moormann et al., 2007), a phenomenon which may lead to the increase in viral 
load which has been observed in the peripheral blood in such cases (Moormann 
et al., 2005, Rasti et al., 2005, Yone et al., 2006).  In addition, it has been found 
that malaria infection produces a mitogenic effect on B cells (Greenwood and 
Vick, 1975, Chene et al., 2007), and based on these findings, it has been 
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suggested that the two factors together may lead to elevated activation of B 
cells, producing increased GC activity.  Since the GC environment is conducive 
to AID-mediated mutations and DNA-breaks, it is reasonable to assume that 
increased GC activity may lead to an increase in the likelihood of c-myc 
translocations taking place.  DNA damaged cells, which would usually be 
eliminated via apoptosis may be rescued by EBV infection (Rowe et al., 2009).  
Although only 30-40% of cases are EBV-associated, a similar theory has been 
suggested for EBV+ cases of HIV-associated BL, since HIV infection also 
activates the B cell system (Ioachim et al., 1990). 
1.6 Aims of Current Work 
It is widely acknowledged that EBV selectively colonises switched memory B 
cells in vivo.  The mechanisms involved in this process, however, are 
controversial and the involvement of the GC reaction is at the heart of this 
debate.  The aim of the present study is, therefore, to improve our 
understanding of how the virus establishes persistence in the memory B cell 
compartment via a combination of ex vivo, and in vitro investigations. 
Both the ex vivo and in vitro sections of this PhD project involved ongoing work 
carried out within the B cell group.  The focus of both chapters was a 
continuation of the PhD project previously carried out by Dr Sridhar Chaganti, 
and as such the initial part of the ex vivo investigation was carried out in 
collaboration between myself and Dr Chaganti, and was subsequently 
published (Chaganti et al., 2009). 
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The following questions were the primary focus of this project: 
(i) Examination of EBV colonisation in distinct B cell subpopulations 
isolated ex vivo from the peripheral blood and tonsil on the basis of 
phenotypic markers.  Of particular interest is the colonisation firstly of 
non-switched memory B cells, whose origins are likely GC-
independent, and secondly on GC cells themselves (chapter 3). 
(ii) Examination of EBV transformation of IgD+CD27- naive B cells in 
vitro, focusing on EBV-induced alterations to cell IgH genotype, and 
Ig phenotype.  The aim of these experiments is to ask whether EBV 
infection alone is capable of conferring memory characteristics on an 
infected naive B cell, thus colonising a “memory” cell (Chapter 4). 
(iii) Analysis of expression of AID, UNG and pol-η (molecules involved in 
the SHM and CSR) in EBV-infected B cells (Chapter 4). 
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2 Materials and Methods 
2.1 Standard Cell Culture 
All cell lines were grown in cell culture medium (RPMI1640 medium (Gibco or 
Sigma) supplemented with 10% v/v selected foetal calf serum (FCS), 6mM 
glutamine (Gibco) and 8μg/mL gentamycin) at 37˚C, 5% CO2, in 25cm flasks. 
Cells were passaged twice weekly by replacement of 80% or 50% (LCLs and 
CD40 blasts) of cell culture medium/cell mix with fresh cell culture medium.  
Human fibroblast cells and mouse L cell fibroblasts were grown in DMEM 
medium (Gibco) supplemented with 10% v/v FCS, 6mM glutamine (Gibco) and 
8μg/mL gentamycin at 37˚C, 5% CO 2, in 75cm flasks. In order to passage 
fibroblasts, medium was removed and cells washed in 1x PBS to remove 
serum. Adherent cells were dislodged by the addition of 5mL 0.5% w/v trypsin 
(Gibco) and 5 minutes incubation at 37˚C. Any remaining cells were washed off 
with warm medium and cells were pelleted by centrifugation at 1,400 RPM for 4 
minutes in a large benchtop centrifuge before resuspension in supplemented 
DMEM medium. 
2.2 Biological Samples 
The following biological samples were included in this study; peripheral blood 
from healthy adult EBV carriers, umbilical cord blood from healthy neonates, 
tonsillar tissue from chronic EBV carriers, and tonsillar tissue from IM patients. 
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Adult peripheral blood was supplied by the National Blood Service (Birmingham, 
UK) as either plasma-depleted buffy coats (between 45-65ml), or plasma-
depleted leukocyte cones (approximately 15ml). 
Tonsillar tissue was obtained following informed consent from patients 
undergoing tonsillectomy at the Queen Elizabeth Hospital, Birmingham, or the 
Birmingham Children’s Hospital.  This material was supplied via collaboration 
between Dr Michael Kuo (consultant ENT Surgeon, University Hospital 
Birmingham and Birmingham Children’s Hospital) and Dr Sridhar Chaganti.  
Tonsil lymphocyte suspensions were processed by Dr Sridhar Chaganti and 
stored in liquid nitrogen prior to being used in this project.   
The B cell group was able to acquire a rare collection of frozen tonsillar cell 
suspensions from adult IM patients undergoing tonsillectomy.  This material was 
donated by Professor WF Berglar (Pathology Institute, University of Heidelberg, 
Germany) 
Umbilical cord blood samples (10-75ml) were obtained from healthy neonates 
following delivery by women undergoing elective caesarean section at the 
Birmingham Women’s Hospital and were kindly collected after informed consent 
by Dr David Lissauer (Clinical Research Fellow, Birmingham Women's 
Foundation Trust and School of Clinical and Experimental Medicine). 
All investigations using the above samples were approved by the South 
Birmingham Research Ethics Committee, UK. 
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2.3 Isolation of Blood B cell Subsets 
2.3.1 Isolation of Peripheral Blood Mononuclear cells (PBMCs) 
Adult peripheral blood samples from buffy coats or leukocyte cones were diluted 
1:1 in 1x phosphate buffered saline (PBS).  45ml diluted blood was then 
carefully overlaid onto 15ml Lymphoprep TM (Axis-Shield) in 50ml Falcon tubes 
(CorningTM).  To fractionate the different leukocytes, the samples were 
centrifuged at 1800rpm (without brake) for 30 minutes at room temperature.  
The top layer containing serum and platelets was first removed with a 25ml 
pipette and discarded, in order to provide easier access to the lymphocyte-rich 
interface.  Lymphocytes were carefully collected using a 5ml plastic Pasteur 
pipette, and deposited into two 50ml tubes.  In order to remove any residual 
Lymphoprep, the cells were washed in PBS, by increasing the cell suspension 
total volume to 50ml, and then centrifuged at 1600rpm (with brake) for 10 
minutes at room temperature.  The cells were washed twice more by removing 
the supernatant, resuspending the cells in 50ml PBS and centrifuging at 
1200rpm for the second wash, followed by 1000rpm for the third wash.  The 
PBMC pellet was then resuspended in wash buffer (RPMI supplemented with 
1% foetal calf serum (FCS, PAA Laboratories), 2mM glutamine (Gibco), and 
50units/ml penicillin and 50µg/ml streptomycin (PS) (Gibco)) prior to being 
counted. 
2.3.2 Isolation of B cells from PBMCs 
CD19-expressing B cells were positively selected from the PBMC suspension 
using M-450 CD19 Dynabeads® (Dynal).  The pan-B cell marker CD19 is 
expressed on the cell surface of most members of the B cell lineage, with 
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exception of terminally differentiated plasma cells, and as such is an excellent 
target to distinguish B cells from other lymphocytes.  The beads themselves are 
coated with monoclonal antibody (mAb) specific for the CD19 antigen.  The 
amount of Dynabeads® used in each B cell preparation was calculated as per 
the manufacturer’s instructions; at a ratio of four beads to every B cell, 
assuming B cells comprise 5% of PBMCs.  The Dynabeads were first washed in 
2ml cold wash buffer (supplemented RPMI described above) to remove residual 
preservatives, before addition to the PBMC sample.  The total volume of the 
PBMC/bead suspension was adjusted to give a concentration of 1 x 107 
beads/ml, before being transferred to appropriate number of 15ml tubes and 
incubated in a laboratory cold room (4°C) for 30 minutes whilst undergoing 
gentle rotation on a sample mixer (DYNAL® sample-mixer) to ensure maximum 
contact between the beads and the cells.  Bead-bound cells were then collected 
by allowing Dynabeads® to attach to a Dynal MPC magnet (Dynal) for two 
minutes.  A high purity of isolated CD19+ B cells was achieved by washing the 
bead-bound cells in 10ml wash buffer a further five times.   
The Dynabeads® were detached from the CD19+ cells using DETACHaBEAD® 
CD19 (Dynal).  Since DETACHaBEAD® CD19 contains polyclonal anti-Fab 
antibodies targeting the CD19 mAb on the Dynabeads®, detachment of the 
latter from the B cell surface is accomplished by successful competition 
between the DETACHaBEAD® abs and the CD19 antigen for Dynabead CD19 
mAb binding sites.  The DETACHaBEAD® reagent was added according to the 
manufacturer’s instructions; using 10µl for every 25µl of Dynabeads® used with 
the bead-bound cell/DETACHaBEAD mixture resuspended in 1000µl wash 
buffer in a 15ml tube.  The tube was then placed on a sample mixer and gently 
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mixed for 45 minutes at room temperature.  Upon completion of the incubation 
period, the mixture was made up to 10ml with wash buffer and the detached 
beads allowed to adhere to the magnet for 2 minutes.  At this stage the CD19+ 
B cells were free in the supernatant, which was removed and placed in a fresh 
50ml tube.  The Dynabeads®/ DETACHaBEAD® complexes were washed and 
added to the magnet twice more in wash buffer in order to achieve maximal 
recovery of CD19+ cells.  Approximately 100µl of the remaining bead mixture 
was placed on a haemocytometer and viewed under the microscope in order to 
ascertain that all cells had been detached and collected from the beads.  The 
CD19+ B cells were then centrifuged at 1400rpm for 4 minutes, resuspended in 
B cell complete medium (RPMI supplemented with 10% FCS, glutamine and 
PS), and stored at 4°C until required (no longer than 24 hours). 
2.3.3 FACS Sorting of Healthy Adult B cell Subsets 
Cell surface antigens IgD and CD27 were used as targets for FACS sorting the 
purified B cells into 3 different subsets; IgD+CD27- naïve B cells, IgD-CD27+ 
switched memory B cells and IgD+CD27+ non-switched memory B cells. 
Purified B cells were centrifuged at 1400rpm for 4 minutes at room temperature, 
washed once in 10ml FACS wash buffer (1x PBS supplemented with 2% FCS, 
PS), and the pellet resuspended in 4ml FACS wash buffer.  The resuspended 
cells were added directly into a 5ml polypropylene FACS tube (BD Biosciences) 
via a sterile 50micron filter to eliminate cell clumps or other material that may 
cause blockages in the FACS apparatus during sorting.  50µl of cell suspension 
was then added to each of four control FACS tubes, and the remaining cells 
were pelleted, the supernatant poured off and the pellet resuspended in 50µl 
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FACS wash buffer for every 5 x 106 cells.  During the course of the study, 
several combinations of dual staining were employed with the ultimate goal to 
produce the purest sorted B cells populations possible.  Three different 
strategies were eventually explored before the conclusion of the project (see 
Table 1 for antibody details). 
(1) B cells were costained with FITC-labelled anti-IgD and PE-labelled anti-
CD27. 
(2) B cells were costained with FITC-labelled anti-IgD and APC-labelled anti-
CD27. 
(3) B cells were costained with PE-labelled anti-IgD and FITC-labelled anti-
CD27. 
No antibody was added to the unstained control tube.  The isotype control was 
dual stained with appropriate antibodies, 2 of either; FITC control (1:20, Dako), 
PE control (1:20, Dako) or APC control (1:20, SEROTEC).  Two samples were 
included for compensation controls using anti-IgD and anti-CD27 single stains 
with the same fluorescence-labelled antibodies used to stain the sorting sample.  
The sorting sample was dual stained with both anti-IgD and anti-CD27, with 
volume of antibody calculated according to cell number.  All 5 tubes were 
incubated at 4°C for 15-30 minutes before being washed once with FACS wash 
buffer and resuspended in 500µl FACS wash buffer.  Collection tubes were 
prepared prior to cell sorting, each containing 500µl FACS wash buffer.  As 
described above, three B cell fractions were collected during a single FACS 
sorting session on a MoFlo cell sorter (Dako Cytomation); (1) IgD+CD27- naïve 
B cells, (2) IgD-CD27+ switched memory B cells and (3) IgD+CD27+ non-
antibody conjugate dilution manufacturer
anti-CD20 RPE 1:40 Dako
anti-IgD FITC 1:40 Dako
anti-IgD RPE 1:40 Dako
anti-CD27 FITC 1:20 BD Pharmingen
anti-CD27 RPE 1:20 BD Pharmingen
anti-CD27 APC 1:20 BD Pharmingen
anti-CD38 PE-Cy5 1:40 BD Pharmingen
anti-IgG FITC 1:20 Dako
anti-IgA FITC 1:20 Dako
anti-M FITC 1:20 Dako
Table 1 – List of antibodies used to isolate B cell subsets and for phenoytpe
analysis
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switched memory B cells.  Small volumes of the three sorted subsets were used 
to analyse population purity. 
2.4 Isolation of Tonsillar B cell Subsets 
All tonsillar tissue used in this study was provided in the form of unfractionated 
mononuclear cells (UMs).  UMs used for virus load studies were either 
recovered from liquid nitrogen storage (previously prepared by Dr Sridhar 
Chaganti, or Professor WF Berglar), or provided as fresh Ums by Dr Martina 
Vockerdodt (University of Birmingham).  In some cases, tonsillar B cells were 
provided by Dr Claire Shannon-Lowe (for the generation of BTN-LCL1), and by 
Dr Christopher Fox (for frequency of infected cell assays). 
2.4.1 Isolation of B cells by CD3-Depletion of Tonsillar UMs 
Since tonsillar UM cells comprise a high proportion (30-80%) of B cells, with the 
remainder being mostly T cells, it can be more desirable to deplete the T cells 
using CD3 Dynabeads, rather than to positively select B cells.  This strategy 
has the added benefit of skipping.  Starting numbers of tonsillar UMs varied as 
cells were inevitably lost upon recovery from liquid nitrogen, but the majority of 
aliquots were stored at 200 x 106 UM cells per vial.  The vials were transferred 
from liquid nitrogen to the tissue culture lab on ice before being thawed briefly at 
37°C, and added to complete B cell medium.  The cells were then pelleted by 
centrifugation and resuspended in wash buffer.  The UMs were counted in order 
to calculate the number of magnetic beads to use.  A total count of 200 x 106 
will be used in the following example calculation.  It was assumed that B cells 
represented 50% of the UM sample; therefore 100 x 106 T cells would be 
contained in one frozen vial.  The manufacturer advises 4 beads per target cell, 
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therefore with the beads at a concentration of 4 x 108/ml, 1ml of beads is 
required to deplete 100 x 106 T cells.  The Dynabeads were washed once with 
1ml wash buffer before being added to the cell suspension.  The final volume 
was then adjusted according to number of beads used, aiming for 1ml for every 
50µl beads, which in this example is 20ml.  The mixture was then divided 
between two 15ml tubes and incubated with gentle rotation on a sample mixer 
for 30 minutes at 4οC.  The tubes were then placed on a Dynal MPC for 2 
minutes in order for the bead-bound T cells to adhere to the magnet, and the 
supernatant removed to a fresh 50ml container.  The beads were washed once 
more with 10ml wash buffer to ensure all B cells were collected.  The B cells 
were then pelleted and resuspended in 20ml complete B cell medium and 
stored at 4οC until used (no longer than 24 hours). 
2.4.2 FACS Sorting of Tonsillar B cell Subsets 
The purified B cells were counted in order to determine what quantity of 
antibodies to use during staining.  A triple staining procedure was employed in 
order to isolate four distinct B cell subsets; CD38+ germinal centre B cells, and 
three CD38- non-germinal centre populations, namely IgD+CD27- naïve B cells, 
IgD-CD27+ switched memory B cells and IgD+CD27+ non-switched B cells.  As 
with the blood B cell staining procedure, two slightly different protocols were 
used at various times during the study (see Table 1 for antibody details): 
1. B cells were costained with PE-Cy5-labelled anti-CD38, FITC-labelled 
anti-IgD and PE-labelled anti-CD27. 
2. B cells were costained with PE-Cy5-labelled anti-CD38 (, PE-labelled 
anti-IgD and FITC-labelled anti-CD27. 
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Steps involving FACS staining were as described above in the blood B cell 
FACS staining procedure.  Five control tubes were set up; (1) unstained, no 
antibody added, (2) isotype control, triple staining for PE-Cy5, FITC and PE 
antibodies, (3) CD38-PE-Cy5 only, (4) IgD-FITC or IgD-PE only, and (5) CD27-
PE or CD27-FITC only.  B cells to be sorted were triple stained in accordance 
with one of the above protocols, and the subsets were isolated to high purity 
using a MoFlo cell sorter.  Small volumes of sorted subsets were used to 
analyse the purity of each population.  The cells were stored at 4°C prior to use. 
2.5 Isolation of Lymphocytes from Umbilical Cord Blood 
Cord blood was diluted 1:1 with sterile 1x PBS.  35ml diluted blood was gently 
overlaid onto 15ml Lymphoprep in 50ml Falcon tubes.  The tubes were then 
centrifuged at 1800rpm for 30 minutes with no brake at room temperature in 
order to fractionate the blood.  The lymphocyte-rich interface was carefully 
removed with a transfer pipette and transferred to a new 50ml tube.  1x PBS 
was added to the cells to a volume of 50ml.  The suspension was then 
centrifuged at 1600rpm to remove any residual Lymphoprep.  The pellet was 
then washed twice more in 50ml 1x PBS before being resuspended in 20ml B 
cell complete medium.  The suspended cord blood lymphocytes were stored at 
4°C until used. 
2.6 B cell Transformation 
2.6.1 Preparation of B95.8 Virus Supernatant 
B95.8 virus supernatant was harvested from B95.8 cell cultures typically 
containing 5-10% cells in lytic cycle.  The supernatant was filtered (using a 
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0.45µm Supor® membrane filter) before being stored at -80οC in 1ml aliquots.  A 
small aliquot was reserved for genome quantitation by qPCR.  20µl of the 
filtered supernatant was incubated with 20µl 2x lysis buffer (2x PCR buffer, 2% 
TWEEN® 20, and 0.2mg/ml Proteinase K) in an Eppendorf Thermocycler at 55 
οC for 1 hour, followed by 95οC for 5 minutes in order to inactivate the 
Proteinase K.  Small aliquots of the lysate were then used in an EBV load qPCR 
assay (see qPCR for EBV load section below).  The 2089 supernatant used in 
this study contained 3x108 virus genomes/ ml, and the B95.8 supernatant 
contained 2.5 x 108 virus genomes/ml. 
2.6.2 Establishment of Bulk LCLs from Purified B cells  
Freshly isolated B cells were used to generate LCLs.  Cell types used to 
generate bulk infections included; unsorted CD19+ peripheral blood B cells, 
purified IgD+CD27- peripheral blood naive B cells, purified CD38-IgD+CD27- 
tonsillar naive B cells, and umbilical cord B cells (see establishment of bulk 
LCLs from umbilical cord lymphocytes section below).  Between 0.5 x 106 and 3 
x 106 B cells were incubated with virus supernatant at 50 MOI (multiplicity of 
infection = the ratio of virus particles to target cells) for a minimum of 1 hour at 
37οC.  The cells were then centrifuged in a microcentrifuge at 8000rpm for 3 
minutes or until a cell pellet was visible, resuspended in 200µl complete B cell 
medium, and added to a single well of round-bottomed 96-well plate.  When 
higher cell numbers were used, the volume of media and well size was adjusted 
appropriately.  Cultures were expanded until enough cells were present to seed 
a T25 tissue culture flask (usually around 4 weeks after infection), at which point 
cell pellets were collected every week and stored at -80°C for DNA and/or RNA.  
The cultures were routinely split 1:1 every 3-4 days. 
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2.6.3 Establishment of Limiting Dilution LCL Cultures from Naive 
Peripheral Blood B cells 
In order to establish clonal LCLs from purified naive peripheral blood cells, a 
limiting dilution technique was employed whereby cells were seeded in 96-well 
plates in decreasingly low numbers.  Irradiated human fibroblasts were used as 
a feeder layer to support transformation of low cell numbers.  To allow time to 
adhere to the plates, these feeder cells were seeded into round-bottomed 96-
well plates, typically at 1000-2000 cells in 100µl complete B cell medium per 
well, 24 hours before the addition of naive B cells.  In order to eventually seed 
three 96-well plates, at 1000 cells/well, 500 cells/well and 200 cells/well, 
appropriate numbers of naive B cells were divided into three 1.5ml microfuge 
tubes.  Each sample was incubated in 200µl of complete B cell medium plus 
virus supernatant, and incubated at 37°C overnight.  The following day, the cells 
were mixed thoroughly by pipetting up and down, and added to 5ml RPMI 10%.  
The 5ml containing the cells was mixed thoroughly and added to a 10cm dish.  
A multichannel pipette was used to seed 100µl of the cell mixture per well into 
48 wells.  The cells were then expanded separately, and pellets collected for 
DNA and RNA at 14 weeks. 
Other naive LCL clones were generated from transformation assays (see 
Transformation Assays section below). 
2.6.4 Establishment of Bulk LCLs from Purified Cord Blood 
Lymphocytes 
Umbilical cord blood lymphocytes were counted (average yield 30-50 x 106 from 
one cord bleed), and number of B cells estimated by assuming they accounted 
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for 5% of the lymphocyte pool.  10 x 106 lymphocytes (or 0.5 x 106 estimated B 
cells) were set aside for bulk infections.  The quantity of virus supernatant was 
calculated based on estimated number of B cells, aiming for an MOI of 50.  The 
cells were pelleted and resuspended in 2ml complete B cell complete medium 
plus B95.8 supernatant in a 15ml tube, then incubated at 37°C for 1 hour.  
Following incubation, the lymphocytes were centrifuged again at 1400rpm, 
resuspended in 3ml B cell complete medium supplemented with 1ug/ml 
cyclosporin A (CSA) and added to 1 well of 6-well plate.  The cells were 
cultured in CSA-supplemented media for 2 weeks in order to prevent T-cell 
killing of B cells, after which time standard B cell complete medium was used.  
The LCLs were expanded and pellets collected when enough cells were 
available to seed a T25 flask.  Thereafter the cultures were split 1:1 every 3-4 
days. 
2.7 Transformation Assays 
In order to compare the transformation efficiency of different peripheral blood B 
cell subsets (IgD+CD27- naïve, IgD-CD27+ switched memory and IgD+CD27+ 
non-switched memory), cells were infected with B95.8 supernatant at a range of 
different MOIs, typically either 50, 25, 12.5 and 6.25, or 25, 12.5, 5 and 1.  The 
cells were collected by FACS to high purity (as described above), and counted 
using a haemocytometer.  Since the number of sorted non-switched memory 
cells collected was usually the lowest of the3 subsets, this population 
determined the number of cells used in the assay; typically four 96-well plates 
were set up (containing 800-1000 B cells per well), each plate being infected at 
a different MOI.  On occasions where non-switched memory numbers were 
extremely limited, 48 wells of a 96-well plate were used at each MOI. 
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Four infections were set up using different MOIs for each of the three B cell 
populations.  Aliquots containing 80,000-100,000 cells were added to four 
tubes, centrifuged and resuspended in the correct volume of B95.8 supernatant.  
Each infection was then incubated at 37°C for a minimum of 1 hour.  The 
supernatant and cells were then diluted in 10ml complete B cell medium and 
100µl of the mixture was pipetted onto human fibroblast feeders (see 
establishment of clonal LCLs from PB naive B cells above).  The plates were 
scored at 5-6 weeks post-infection, and in one experiment wells established 
from the naive subset were selected for expansion to clonal LCLs cultures. 
2.8 Generation of CD40 Blasts 
Activated CD40 blasts were generated from primary CD19+ B cells or FACS 
sorted IgD+CD27+ naive B cells by culturing with irradiated CD40 ligand-
expressing mouse L cells in the presence of interleukin-4 (IL-4) (Fecteau and 
Neron, 2003).  For primary B cell stimulation, irradiated L cells were plated into 
6-well tissue culture plates at 0.5 x 106 per well, and allowed to adhere over 
night before the addition of 2-4 x 106 B cells in 3ml CD40 blast medium 
(Iscove’s Medium supplemented with 10% human serum and 100 U/ml IL-4) 
(Fecteau and Neron, 2003).  In the case of sorted naive B cells, irradiated L 
cells were plated into 24-well plates at 0.2 x 106 per well and allowed to adhere 
overnight before the addition of 0.5-1.5 x 106 naive B cells.  Cultures were 
maintained for 8-10 weeks or until the CD40 blasts stopped proliferating.  Cell 
pellets were collected for DNA every 7 days from approximately 6 weeks in 
culture. 
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2.9 Induction of Lytic Replication in AKBM cells 
2 x 106 AKBM cells were pelleted by centrifugation and washed once in 1ml 
Optimem media.  The cells were then resuspended in 100ul of Optimem, 
containing F(ab’)2 goat anti-human IgG antibody (Cappel: 55049) at 1% of 
sterile stock solution.  The mixture was incubated for 30 minutes to 1 hr at 37°C 
in a CO2 gassed incubator.  Following incubation, the cell suspension was 
transferred to fresh cell culture media and grown for 3 days before GFP-positive 
and GFP-negative cells were sorted by FACS. 
2.10 Induction of Ig Isotype Switching 
Naive B cell-derived LCLs were cultured with irradiated CD40 ligand-expressing 
mouse L cells in IL-4/IL-21-supplemented complete B cell medium.  L cells were 
added to 12-well tissue culture plates at 0.2 x 106 per well prior to addition of 2 x 
106 LCLs in 1.5ml CD40 blast medium supplemented with either 100 U/ml IL-4 
alone, or IL-4 plus 50ng/ml IL-21 (Avery et al., 2008).  The cells were split after 
3-4 days in culture, and harvested after 7 days for Ig phenotype staining. 
2.11 Analysis of Ig Phenotype by Flow Cytometry 
Surface immunoglobulin (sIg) expression was determined by flow cytometry.  
Briefly, between 0.2 x 106 and 1 x 106 cells were added to a FACS tube and 
pelleted by centrifugation at 1400rpm for 4 minutes.  The cells were washed 
once in FACS wash buffer before being resuspended in 100ul FACS wash 
buffer containing fluorochrome-conjugated antibodies (against IgD, IgM, IgG 
and IgA) diluted to the appropriate concentration; isotype controls were set up in 
parallel for each antibody.  The samples were then incubated at 4°C for 30 
minutes, in the dark.  Following incubation the cells were pelleted and 
79 
 
resuspended in 1ml FACS washing buffer (or fixed in 1ml 1% 
formaldehyde/PBS solution).  The samples were stored at 4°C in the dark until 
analysed on a Coulter® Epics® XL-MCL flow cytometer.  FACS data were 
analysed using FloJo software. 
Cells were also analysed for intra-cytoplasmic immunoglobulin (Ig) using 
fluorochrome-labelled isotype-specific mAbs to IgD, IgM, IgG and IgA (Dako), 
together with commercial fixing and permeabilisation kit (Caltag).  The staining 
protocol was followed as per the manufacturer’s instructions, and FACS 
analysis was performed as detailed above. 
2.12 Analysis of IgVH Genotype 
2.12.1 DNA Extraction 
Genomic DNA was extracted from cell pellets (typically 1-2 x 106 cells) using a 
Qiagen® DNeasy Blood and Tissue Kit.  The procedure was carried out 
according to the manufacturer’s instructions, and the DNA eluted in 50-100µl 
PCR grade water (Ambion), depending on initial cell input.  DNA quality and 
concentration was determined using a NanoDrop™ spectrophotometer, and the 
DNA stored at -20°C. 
2.12.2 IgH PCR 
PCR amplification of the Ig heavy chain variable region (IgH PCR) was 
performed using published primers (Aubin et al., 1995, Timms et al., 2003), and 
a high fidelity Taq polymerase.  Note that the Expand High Fidelity System 
includes a 3'5' exonuclease proofreading activity, and is reported to be 3-fold 
more accurate compared to standard Taq DNA polymerase (estimated error 
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rate 8 x 10-6 per bp/doubling (Cline et al., 1996)).  The forward primer 
corresponded to a consensus sequence for the framework 1 (FR1c) region (5'–
AGG TGC AGC TGS WGS AGT CDG G-3'), and the reverse primer consisted 
of a combination of a consensus primer for JH1, 2, 4 and 5 (5'–ACC TGA GGA 
GAC GGT GAC CAG GGT-3'), plus JH3 (5'–TAC CTG AAG AGA CGG TGA 
CCA TTG T-3') and JH6 (5'–ACC TGA GGA GAC GGT GAC CGT GGT-3') 
specific primers.  Each PCR assay contained a water-only negative control, and 
a Namalwa DNA positive control.  The DNA and PCR reagents were added to 
thin-walled 0.5ml PCR tubes in a PCR set-up room.  Every PCR reaction 
contained a final concentration of 1x Expand High Fidelity reaction buffer (with 
1.5mM MgCl2), (Roche), 3.5 units of Expand High Fedility enzyme mix (Roche), 
200µM each of dATP, dGTP, dTTP and dCTP, 0.8µM FRIc primer and 0.26µM 
each of JH primer (JH1245, JH3 and JH6).  The assembled PCR reactions 
were placed in an Eppendorf™ Thermocycler and amplified using the following 
conditions; initial denaturation at 94C° for 5 minutes, followed by 29 cycles of 
94°C for 30 seconds (denaturation), 61°C for 1 minute (annealing) and 72°C for 
1 minute (extension), plus a final 10 minute extension at 72°C.  Completed PCR 
reactions were stored at 8°C until analysis. 
The Expand High Fidelity enzyme mix contains thermostable Taq DNA 
polymerase together with a polymerase with a 3'-5' exonuclease proofreading 
activity.  The polymerase mixture provides a higher fidelity of DNA synthesis (3-
fold compared to Taq DNA polymerase alone), and generates a mixture of 
blunt-ended products and 3' overhang products suitable for TA cloning. 
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2.12.3 Identification and Recovery of the PCR Product  
Since analysis of the PCR products demanded better resolution than that 
provided by an agarose gel, non-denaturing polyacrylamide gels were used.  
13µl of gel loading dye (1.25 mg/ml bromophenol blue, 1.25 mg/ml xylene 
cyanol, 30% v/v glycerol) was added to 50µl of PCR product.  Aliquots of 5µl 
and 50µl of sample were loaded in adjacent wells of a gel comprised of 8% 
acrylamide solution (BioRad), 5x TBE buffer (50mM Tris base, 50mM boric acid, 
2mM EDTA), 0.07% w/v ammonium persulphate and 0.02% v/v N, N, N, N 
tetramethylenediamine (TEMED, Sigma) in 1x TBE running buffer.  The 5µl 
aliquot was used to improve discrimination of the bands of interest.  The size of 
the expected PCR products (~360bp) was determined by comparison to a 1kb 
DNA ladder (Invitrogen), which was run in parallel to the samples.  
Electrophoresis was carried out at 180V for ~2 hours.  The gel was stained with 
ethidium bromide, and the bands were visualised by UV light using a 
transilluminator. 
The desired bands were sliced from the gel using a scalpel blade and placed in 
a 1.5ml microfuge tube.  The gel fragments were mashed using a 1000µl filter 
tip, and 350µl 2.5M ammonium acetate added.  The mixture was left shaking 
overnight at 37°C.  The following day, the eluate was transferred to a fresh 
1.5ml tube and the DNA precipitated by addition of 2.5 volumes of 99% ethanol 
together with 2μg glycogen DNA carrier (Roche) in order to help visualise the 
pellet.  The sample was incubated for 30 minutes at -70°C, and then pelleted by 
centrifugation at 13000 rpm for 30 minutes at 4°C.  The DNA pellet was washed 
twice more in 70% v/v ethanol, air-dried and resuspended in 25µl PCR grade 
water.  To estimate the quantity of the PCR product, a 3µl aliquot of DNA was 
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analysed on a 2% agarose gel (1x TBE as running buffer), with comparison 
against a 1kb DNA ladder. 
2.12.4 Cloning the IgH PCR Product 
For sequencing purposes, the IgH PCR product was ligated into a plasmid 
vector and transformed into competent E.coli.  To achieve this, the TA cloning 
system chosen was the pGEM® Easy Vector System I (Promega). 
During IgH PCR, Expand High Fidelity Taq polymerase adds a non-template 
directed nucleotide, invariably deoxyadenosine, to the 3' end of the PCR 
product.  Since the linearised pGEM-T vector contains a single deoxythymidine 
at each 3' end, the PCR product can be cloned directly into the vector without 
prior enzymatic manipulation.   
The pGEMT plasmid harbours an ampicillin resistance gene, enabling 
transformed bacteria to be selected on agar plates or in broth containing 
ampicillin.  The plasmid also carries an α-peptide coding region for β-
galactosidase (lacZ gene), which complements a deletion in the α region of the 
LacZ gene in the host DH5α cells.  Transformed cells containing the empty 
plasmid vector are therefore able to produce β-galactosidase and can be 
screened on X-gal indicator plates.  Successful insertion of the PCR product, 
within the a-peptide region results in insertional inactivation of the β-
galactosidase enzyme.  Recognition sites for the restriction enzyme EcoRI 
flanking the pGEM-T vector cloning site provide a means by which clones 
containing the insert can be readily identified.  EcoRI digestion followed by 
agarose gel electrophoresis allows both confirmation of the insertion of a PCR 
product insertion and estimation of insert size (see below).  The pGEM-T vector 
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also contains an M13 primer sequence adjacent to the cloning site, which is 
used to sequence the IgH inserts. 
PCR product ligation 
For each IgH PCR product, 3.5µl DNA was added to 0.5µl pGEM®-T Easy 
vector, 5µl 2x Rapid Ligation Buffer and 1µl T4 DNA Ligase (all supplied in the 
Promega kit) in a 1.5ml microfuge tube and incubated for 1 hour at room 
temperature.  A positive control using control insert DNA (supplied) and a 
background vector-only control were set up in parallel. 
E.coli transformation 
Ligation reactions were transformed into DH5α competent cells and plated out 
onto X-Gal/IPTG/ampicillin L-broth agar plates, enabling blue/white colony 
screening.  100µl of DH5α competent cells (for preparation of competent cells 
see below) were added to the ligation products and left on ice for at least 5 
minutes.  The cells were then heat shocked at 42°C for 2 minutes, and returned 
to ice for 1 minute.  1ml L-broth (no ampicillin) was added to the tubes, and the 
mixture incubated in a shaker for 1 hour at 37°C.  The cells were then pelleted 
by centrifugation at 6000rpm for 3 minutes in a microcentrifuge.  All but 
approximately 150µl of supernatant was discarded, and the cells resuspended 
by gentle pipetting up and down.  Each suspension was spread on a freshly 
prepared indicator plate containing; LB agar, 100µg/ml ampicillin , 80µl 2% X-
gal (Calbiochem®) and 20µl 100mM IPTG (Promega).  The plates were 
incubated overnight at 37°C.  IPTG induces β-galactosidase production, which 
breaks down the X-gal on the plates, giving a blue colour to those colonies 
containing DH5α transformed with plasmid alone (no DNA inserts).  Those cells 
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which are transformed with the recombination plasmid carrying PCR products 
cannot synthesise β-galactosidase and therefore produce white colonies. 
The plates were inspected the next day and up to 24 colonies picked for 
analysis.  The selected colonies were inoculated into 2ml L-broth containing 
100µg/ml ampicillin in 15ml tubes, and incubated overnight in a shaker at 37°C. 
Analysis of recombinant plasmids 
Plasmid DNA was extracted using a QIAgen® Spin Miniprep Kit, following the 
manufacturer’s instructions.  DNA was eluted from the column in 50µl PCR-
grade water.  In order to determine whether the DNA contained a PCR product 
of expected size, an aliquot was digested with the restriction endonuclease 
EcoRI (Roche).  3µl DNA was added to 2µl 10x Buffer H (supplied with the 
enzyme), 14.5µl PCR-grade water, and 0.5µl EcoRI enzyme.  The mixture was 
incubated at 37°C for 1 hour and the digested fragments were separated using 
electrophoresis on a 2% agarose gel.  The samples were mixed with 5µl 5x gel 
loading dye and loaded on the gel, which was then run in 1x TBE buffer.  The 
gel was stained in a solution of 1x TBE containing 0.5mg/ml ethidium bromide, 
and was visualised under UV.  Plasmid clones containing DNA inserts of the 
predicted size (300-360bp) were analysed by DNA sequencing. 
2.12.5 Preparation of Competent Cells 
Competent DH5α cells were prepared using the following protocol (Inoue et al., 
1990); 250ml SOB medium (containing per 1 litre; 20 g bacto-tryptone, 5 g 
yeast extract, 10 ml 250 mM KCl, 0.5 g NaCl, pH 7, plus 20mM Mg+ salts), was 
added to a sterile 2 litre flask.  Approximately 10-12 DH5α colonies were added 
to the broth.  The cells were grown at room temperature with gentle shaking, 
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until the culture reached a density of A600 = 0.6.  The flask was then incubated 
on ice for 10 minutes.  The culture was then divided and centrifuged at 2500xg 
(3000rpm in Beckmann J-6B) for 10 minutes at 4°C.  The supernatant was 
discarded and the DH5α pellet resuspended in 80ml ice-cold TB (containing 
10mM Pipes, 15mM CaCl2, 260mM KCl adjusted to pH 6.7 with KOH, before 
addition of 55mM MnCl2).  The resuspended cells were incubated on ice for 10 
minutes before being centrifuged again for 10 minutes at 2500xg.  The pellet 
was resuspended in 20ml ice-cold TB, and 1.5ml DMSO added and gently 
mixed in.  The cells were incubated on ice for a further 10 minutes before being 
aliquoted in volumes of 200ul into sterile 1.5ml microcentrifuge tubes.  The 
aliquots were flash-frozen by dunking in liquid nitrogen and stored at -80°C. 
2.12.6 Sequencing IgH Products 
For each PCR product derived from bulk LCL time points, at least 20 plasmid 
clones were sequenced, whereas in the case of clonal LCLs cultures, 3-5 
samples were analysed.  200-500ng plasmid DNA was added to a thin-walled 
0.5ml PCR tubes together with 3.2 pmol M13 forward primer, and the volume 
adjusted to 10µl with PCR-grade water.  The sequencing reaction was prepared 
and performed using the plasmid to profile DNA sequencing service at the 
Functional Genomics Laboratory, University of Birmgham, UK. 
2.12.7 Analysis of IgH Sequences 
Raw sequence data were interpreted using the Chromas Lite (version 2.01) 
software package and corrected if required by manual checking of each 
chromatogram trace.  Corrected sequences were further characterised using 
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BioEdit software version 7.0.5 (created by Tom Hall, Ibis Therapeutics, A 
division of Isis Pharmaceuticals, 1891 Rutherford Road, Carlsbad, CA, USA). 
The EcoRI restriction sites (GAATTC) flanking the inserted DNA sequence was 
identified first, allowing the intervening sequence to be copied into a new 
datafile.  The trimmed sequence was then analysed using V-BASE (MRC 
Centre for Protein Engineering, The University of Cambridge, UK) to confirm the 
IgV status (in some cases it was necessary to reverse and complement the 
sequence as the insert may be ligated in the opposite direction relative to the 
M13 primer site).  V-BASE is a comprehensive database of >1000 published Ig 
variable germline sequences.  Each IgVH sequence was aligned with the 
nearest germline sequence and identified by V-BASE.  The number of 
mutations (single nucleotide changes compared to corresponding germline 
sequence), together with the matched V, D and J region alignments, and the 
first 10 amino acids of the junction translation were noted and added to an 
Excel spreadsheet.  Confirmation of the V-BASE alignments was carried out 
using a separate database, IMGT/V-QUEST (Brochet et al., 2008) in a selection 
of sequences.  Sequence alignment figures highlighting differences to germline 
were produced with GeneDoc (Karl Nicholas, Pittsburgh Supercomputing 
Center, USA). 
2.13 Taqman qPCR to Estimate EBV DNA Load 
2.13.1 Introduction 
Real-time quantitative PCR (qPCR) is an invaluable tool to measure quantities 
of both DNA and RNA (Heid et al., 1996).  Unlike standard PCR assays, which 
provide a measurement of endpoint PCR products, qPCR measurements are 
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made at the optimal phase of DNA amplification, before the reaction reaches 
plateau (ref).  In this study, dual-labelled TaqMan probes specific for the gene of 
interest (DNA or RNA) were used (ref).  TaqMan probes are labelled at the 5' 
end with a fluorescent reporter (usually FAM or VIC), and at the 3' end with a 
fluorescent quencher (TAMRA or BHQ).  Close proximity of the quencher to the 
reporter ensures that an intact probe emits minimal fluorescence.  During the 
PCR reaction, primer extension during amplification of the target sequence 
leads to displacement and cleavage of the probe by the 5'-3' exonuclease 
activity of Taq polymerase.  Resultant release of the reporter produces an 
increase of fluorescence intensity during the reaction, levels of which are 
continuously monitored and the data collected throughout the PCR reaction.  
Accumulation of the PCR product is therefore measured in real-time.  An 
additional advantage of using real-time PCR is the ability to simultaneously 
detect more than one PCR product (multiplex PCR) using separate probes 
labelled with dyes emitting fluorescence on different spectra.  In much of this 
study, PCR amplification of the gene of interest (DNA POL, encoded by BALF5) 
was multiplexed with PCR amplification of the cellular gene beta-2-
microglobulin (β2M).  BALF5/POL values were normalised against β2M values 
(serving as an internal control) in order to compensate for variations in the 
quality and quantity of the starting sample.  Multiplex PCR was not carried out 
for quantification of EBV genome copies in viral supernatants. 
2.13.2 Preparation of Namalwa Standards  
DNA was extracted from test samples and controls using a Qiagen DNeasy® 
Blood and Tissue Kit as described above.  DNA from the Namalwa-BL line 
known to contain two integrated copies of the EBV genome (Lawrence et al., 
88 
 
1988) was used to generate qPCR standards containing known EBV copy 
numbers.  Namalwa cells were washed, counted, and DNA extracted from 
pellets containing 3-5 x 106 cells.  The DNA concentration was measured and 
adjusted to 132ng/µl (4 x 104 copies/µl), and serially diluted in PCR-grade water 
to generate a set of 8 standards ranging from 4 x 104 copies/µl to 1 copy/µl.  
The standards were divided into single-use aliquots and stored at -20°C. 
2.13.3 Setting up qPCR Reactions 
qPCR reactions were performed essentially as described (Gallagher et al., 
1999, Murray et al., 2003).  Each 25µl reaction contained 1x TaqMan Universal 
PCR Master Mix (ABI Applied Biosystems), 200nM 5' FAM-labelled POL probe 
specific for the EBV polymerase (POL) BALF5 gene, 200μM forward and 
reverse POL primers, 100nM 5' VIC-labelled β2M probe, 60nM β2M forward 
and 80nM β2M reverse primers; note the β2M reaction is primer-limited so that 
amplification does not interfere with detection of the weaker POL signal.  Primer 
sequences (Alta Bioscience University of Birmingham) were as follows:- POL 
forward (5'-AGT CCT TCT TGG CTA GTC TGT TGA C-3'), POL reverse (5'-
CTT TGG CGC GGA TCC TC-3'), β2M forward (5'-GGA ATT GAT TTG GGA 
GAG CAT C-3') and β2M reverse (5'CAG GTC CTG GCT CTA CAA TTT ACT 
AA-3').  Probes (Eurogentec) were as follows:- POL (5'-FAM-CAT CAA GAA 
GCT GCT GGC GGC C-TAMRA-3') and β2M (5'-VIC- AGT GTG ACT GGG 
CAG ATC ATC CAC CTT C-TAMRA-3').  The TaqMan Universal PCR Master 
Mix contains PCR buffer, AmpliTaq Gold (a modified version of the recombinant 
AmpliTaq DNA polymerase), MgCl2, dNTPs (dUTP replacing dTTP), UNG 
(uracil N glycosylase, an enzyme that destroys uracil-containing DNA, thereby 
acting as a carryover prevention step) and ROX (a passive reference dye).  
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After adding 20µl reaction mix to wells of a 96-well PCR plate, 5µl of test or 
standard DNA was added to each well.  Namalwa standards were loaded in 
duplicate, and test samples were loaded in triplicate.  No template controls were 
included as negative controls.  The wells were sealed with Microamp Optical 
Caps (Applied Biosystems), and the plate centrifuged at 1000rpm for 1 minute 
to mix the reagents.  The plate was then loaded onto an ABI Prism 7700 
Sequence Detection System (Applied Biosystems) machine.  The thermal 
cycling conditions comprised an initial 50°C incubation to activate the UNG, a 
step 95°C to activate the AmpliTaq Gold and deactivate the UNG, followed by 
40 cycles of 95°C for 15 seconds (denaturation) and 60°C for 10 minutes 
(annealing and extension of primers). 
2.13.4 qPCR Data Analysis 
Fluorescent signals produced during the qPCR were analysed using SDS 
software version 1.7 (Applied Biosystems).  FAM and VIC fluorescent intensities 
were plotted against cycle number and amplification curves used to determine 
Ct values where the fluorescence reaches an arbitrary threshold level.  Because 
the Ct value is inversely proportional to the amount of target DNA in the initial 
sample, the Namalwa standards could be used to generate POL and β2M 
calibration curves, from which test sample POL and β2M copy numbers could 
be deduced.  Data are expressed as EBV genome copies (POL) per 106 cells 
(half of β2M copy number, assuming 2 β2M copies per diploid cell). 
2.13.5 Limiting Dilution EBV POL qPCR Assays  
Although the quantitative EBV POL assay described above measures the total 
number of EBV genomes within a sample, it cannot be used to calculate the 
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number of EBV-positive cells present.  In order to estimate the number of 
infected cells within a population (frequency), limiting dilution PCR assays have 
been described (Khan et al., 1996).  The current protocol was adapted from a 
published method (Babcock et al., 1998) and was used primarily to examine the 
frequency of virus-infected cells in both unsorted and sorted tonsillar B cells 
from IM patients. 
The number of cells used in each limiting dilution assay depended upon how 
many cells were available (if sorted, cell number was often limited), and how 
many positive cells were expected in the sample based on a previous total EBV 
load assay carried out on B cells from the same tonsil.  For example when 
analysing B cells from IM donors with high EBV loads, only small numbers of 
cells are required for a positive signal; in this case the maximum number of cells 
added per well was 250.  In other cases, such as chronic virus carriers, much 
higher numbers of cells are needed and here the maximum input was 10, 000 – 
50, 000 cells per well.  The cells to be tested were counted and resuspended in 
160μl PBS.  Eight replicates of 10μl were added to wells of a 96-well PCR plate.  
A further 80μl PBS was then added to the remaining cells (two-fold dilution) and 
the process repeated another 6-7 times.   In this way, several 2-fold dilutions 
were generated with 8 replicates of each dilution.  10ul of 2x lysis buffer(2x PCR 
buffer, 2% TWEEN® 20, and 0.2mg/ml Proteinase K) was added to each well 
and the plate was covered with a film lid and centrifuged for 1 minute at 
1000rpm.  The cells were then lysed by incubation at 55°C for 2 hours, followed 
by 10 minutes at 95°C to inactivate the proteinase K within the lysis buffer.  The 
plates were then stored at -20°C until required. 
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As the combined volume of cell suspension and lysis buffer was 20μl, the PCR 
reaction volume need to be adjusted to approximately 50μl.  Each reaction 
contained:- 25μl 2x Taqman reaction mix, 1μl POL forward primer (10μM), 1μl 
POL reverse primer (10μM), 1μl POL probe (10μM), 1μl β2M forward primer 
(4μM), 1μl β2M reverse primer (4μM) and 1μl β2M probe (5μM) (see above for 
primer sequences).  10μl Namalwa standard samples (described above) mixed 
with 10μl PCR-grade water were also included as controls.  Finally, 30ul of PCR 
mastermix was added to each sample, the wells were sealed with lid strips, and 
the plate centrifuged at 1000rpm for 1 minute.  The PCR conditions were 
identical to those used for total EBV POL (described above).   
For analysis of limiting dilution qPCR assays, each well was scored positive or 
negative for a detectable POL signal (above the set threshold).  The number of 
positive wells at each dilution, together with the number of replicates (8), and 
the cell input number was used to estimate the frequency of EBV positive cells 
by Poisson distribution.  The calculation was carried out using software based 
on (Hu and Smyth, 2009), provided by WEHI Bioinformatics at the following 
webpage: http://bioinf.wehi.edu.au/software/elda/index.html. 
2.14 Taqman qPCR to Measure AID Transcripts 
In order to study the expression of three AID variants AID-FL, AID-ΔE4 and 
AID-ΔE3E4 (Figure 10), qPCR assays were designed for each.  qPCR can also 
be used for measuring cellular gene expression with an additional reverse 
transcription (RT) step (Lossos et al., 2003, Bustin et al., 2005).  RT qPCR 
shares many of the benefits of qPCR (see previous section), however extra 
attention must be paid when designing primers to avoid amplification of 
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genomic DNA.  Primers that target DNA sequences crossing exon boundaries 
are less likely to anneal to intronic sequences.  The endogenous reference 
gene used for normalisation must also be carefully selected; human GAPDH 
RNA was chosen for this study.  The multiplex PCR was optimised to prevent 
the depletion of the reaction by GAPDH amplification, thus minimising 
interference of detection of the target gene (Bell et al., 2006). 
In order to design qPCR assays for the expression of AID-FL, AID-ΔE4 and 
AID-ΔE3E4, the following steps were taken:- (i) Cloning of the variant 
transcripts from Akata-BL cells using nested PCR, (ii) ligation of AID variant 
PCR products into a pGEMT vector and validation of PCR products by 
sequencing, (iii) design of qPCR primers and probes for each variant and (iv) 
calculation of copy numbers of AID variant plasmid standards. 
2.14.1 Conventional RT-PCR to amplify AID Transcripts in Akata-
BL 
cDNA Synthesis 
RNA extraction from cells was carried out using the Nucleospin kit and protocol.  
RNA was eluted in 70ul PCR-grade water.  RNA concentration was calculated 
using a nanodrop spectrophotometer, and each sample diluted to 100ng/ul with 
PCR-grade water. 
cDNA reagents were added to a thin-walled PCR tube.  A 20ul reaction 
contained; 5ul RNA at 100ng/ul, 4ul 5x reaction buffer (Roche), 2ul dNTPs at 
2mM (Roche), 2ul random hexamers at 50ng/ul (Promega), 6.5ul PCR-grade 
water and 0.5ul AMV enzyme (Roche).  The mix was incubated for 5 minutes at 
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room temperature, before being placed in a thermocycler for 60 minutes at 
42°C, followed by 5 minutes at 90°C.  The cDNA samples were stored at -20°C. 
 
PCR to Amplify AID Variant Transcripts  
Amplification of AID transcripts AID-FL, AID-ΔE4 and AID-ΔE3E4 from Akata-
BL cells was carried out using a nested RT-PCR method (Wu et al., 2008).  
Both the first and second rounds of the PCR were carried out using primers 
targeting exon 1 and exon 5 in order to amplifying each of the 3 AID variant 
transcripts.  For the first round PCR, the following primers were used; forward 
5'-AGG CAA GAA GAC ACT CTG GAC ACC -3' and reverse 5'-GTG ACA TTC 
CTG GAA GTT GC -3'.  Each PCR reaction contained a final concentration of 
1x Expand High Fidelity reaction buffer (with 1.5mM MgCl2), (Roche), 3.5 units 
of Expand High Fidelity enzyme mix (Roche), 200µM each of dATP, dGTP, 
dTTP and dCTP, and 1µM of each primer.  The second round PCR was 
performed using 2µl of the first round PCR product, with the following primers:- 
forward 5'-GAC AGC CTC TTG ATG AAC CGG-3' and reverse 5'-TCA AAG 
TCC CAA AGT ACG AAA TGC-3'.  The PCR reactions were performed using 
an Eppendorf™ Thermocycler with the following PCR conditions:- 35 cycles of 
95°C for 30 seconds (denaturation), 55°C for 30 seconds (annealing) and 72°C 
for 30 seconds (extension).  To visualise the nested PCR products, 
electrophoresis was carried out on an acrylamide gel to provide maximal band 
resolution, and a 1kb ladder was run alongside the samples in order to 
determine the size of the PCR products. 
2.14.2 Sequencing of AID variant transcripts 
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AID variant PCR products from Akata-BL were cut from an acrylamide gel.  The 
products were cloned and sequenced as described above.  Briefly, each PCR 
product was extracted and ligated into a pGEMT vector.  The vector was cloned 
into competent DH5α and grown on indicator ampicillin agar plates.  Five 
colonies corresponding to each product were picked and sequenced using the 
plasmid to profile facility at the Functional Genomics Laboratory, University of 
Birmgham, UK.  AID variant AID-FL, AID-ΔE4 and AID-ΔE3E4 sequences were 
confirmed using nucleotide blast database. 
2.14.3 AID Variant qPCR primer design 
The Primer Express program (ABI) was used to design primers and probes to 
use in Taqman PCR assays to measure AID-FL, AID-ΔE4 and AID-ΔE3E4 
transcripts (Figure 12 and Table 2).  For the AID-FL assay, a forward primer 
targeting exon3, a reverse primer targeting exon4, and a Taqman probe 
targetted to anneal across the exon3-exon4 boundary were designed.  For the 
AID-ΔE4 assay, a forward primer targeting exon3, a reverse primer targeting 
exon5, and a Taqman probe targetted to anneal across the exon3-exon5 
boundary were designed, and for the AID-ΔE3E4 assay, a forward primer 
targeting exon2, a reverse primer targeting exon5, and a Taqman probe 
targetted to anneal across the exon2-exon5 boundary were designed. 
2.14.4 AID Variant Plasmid Standards 
As expression levels of the three AID variants varied significantly, plasmid 
standards were used to generate standard curves in the qPCR assays (the 
same plasmids that were generated in order to sequence the nested variant 
PCR products were used).  The advantage of using plasmid standards rather 
E1 Exon2 Exon3 Exon4 Exon5AID-FL
E1 Exon2 Exon3 Exon5AID-ΔE4
E1 Exon2 Exon5AID-ΔE3E4
F
F
F
R
R
R
P
P
P
Figure 12 . Taqman primers and probe targets in AID variant qPCRs
AID-FL:  the forward primers targets exon3, while the reverse primer targets exon4.  The probe was 
designed to overlap the boundary of exons3 and 4.
AID-ΔE4:  forward primer targets exon3, while the reverse primers targets exon5.  The probe overlaps 
the exon3 – exon5 boundary.
AID-ΔE3E4:  forward primer targets exon2, while the reverse primers targets exon5.  The probe 
overlaps the exon2 – exon5 boundary.
AID-FL
forward 5'-CGC CGG GGT GCA AAT AG-3' exon3
reverse 5'-GCC GAA GCT GTC TGG AGA GA-3' exon4
probe
5'-TAMRA-CAT CAT GAC CTT CAA AGA TTA TTT TTA CTG CTG GAA-
FAM-3'
exon3-exon4
AID-ΔE4
forward 5'-CTG AGC CCG AGG GGC T-3' exon3
reverse 5'-CTA TCA AAG TCC CAA AGT ACG AAA TG-3' exon5
probe 5'-TAMRA-CAT GAC CTT CAA AGC CCC TGT ATG AGG TTG-FAM-3' exon3-exon5
AID-ΔE3E4
forward 5'-TAC GTA GTG AAG AGG CGT GAC AGT-3' exon2
reverse 5'-TGC TAT CAA AGT CCC AAA GTA CGA-3' exon5
probe 5‘-TAMRA-TCT TCG CAA TAA GCC CCT GTA TGA GGT TG-FAM-3' exon2-exon5
Table 2.  AID-FL, AID-ΔE4 and AID-ΔE3E4 qPCR assay primers
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than cDNA generated from cell lines is that known plasmid concentrations can 
be used to calculate gene copy number. 
DNA concentrations in each plasmid sample were calculated using a nanodrop 
spectrophotometer.  From the stock concentration, each plasmid was diluted to 
5ng/μl using PCR-grade water.  From the concentration, the number of plasmid 
molecules per μl was calculated: 
  (Plasmid + insert bp) x (330 Da X 2 nucleotide/bp) = g/mol 
 Eg. (3646bp) x (660) = 2.4x106 g/mol 
 (g/mol)/Avogadro’s number (6 x 1023) = g/molecule 
 Eg/ (2.4x106 g/mol)/( 6 x 1023) = 4 x 10-18g/molecule 
 Concentration (g/μl)/(g/molecule) = molecules/μl (i.e. copy number) 
 Eg. (5 x 10-9g/μl)/ 4 x 10-18g/molecule = 1.2 x 109 molecules/μl 
Based on these calculations, the copy numbers of each plasmid at 5ng/μl were: 
AID-FL; 1.2 x 109. 
AID--ΔE4; 1.3 x 109. 
AID-ΔE3E4; 1.4 x 109. 
10-fold serial dilutions were then carried out for each plasmid, using PCR-grade 
water, generating five concentrations for the each standard.  Each diluted 
plasmid was divided into 20ul aliquots and stored at -20°C. 
GAPDH qPCR Standards 
cDNA prepared from X50-7 cells (see above) was used to generate standard 
curves for the GAPDH internal control.  As described in the cDNA synthesis 
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section above, 5μl of 100ng/μl RNA was used in each reaction.  The cDNA was 
then diluted in a 5-fold serial dilution using PCR-grade water.  Aliquots from 
each concentration in the series were made and stored at -20°C. 
2.14.5 AID variant qPCR Assays 
The Taqman assay used for quantifying AID variant transcripts was based on 
the same principle as that described above for EBV POL quantification.  The 
housekeeping gene GAPDH used as an internal control for RNA input.  As 
previously discussed, plasmids containing the relevant AID variant sequences 
were used as standards, whereas X50-7 cDNA was used as the GAPDH 
standard.  Each reaction was carried out in duplicate, in a 96-well PCR plate.  
The reaction mix was assembled and added to the plate in a designated PCR 
set-up area, as were the cDNA samples.  Plasmids were added at the last step 
in a separate area in order to avoid contamination of the designated PCR area.  
For each AID variant assay, the following 25μl reaction mix was used; 12.5μl 2x 
Taqman reaction mix, 2.5μl forward primer at 10μM, 2.5μl reverse primer at 
10μM, 1μl probe at 5μM, 0.5μl GAPDH primer mix (ready made), 1μl PCR-
grade water and 5μl cDNA sample.  Following addition of samples to each row 
of the plate, the wells were sealed with optical cap lids.  When all samples had 
been loaded, the plate was briefly spun at 1000rpm to ensure all reagents were 
in the bottom of the wells.  The PCR was carried out using an ABI 7500 system, 
using Sequences Detection System 1.4 Software Prism.  Results were 
normalised to GAPDH expression values. 
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2.15 Taqman qPCR to Measure UNG and Polη Transcripts 
Taqman qPCR assays to measure uracil DNA glycosylase (UNG) and 
polymerase-eta (Polη) were obtained from.  The reagents from each assay 
included forward and reverse primers, and a FAM-labelled Taqman probe.   The 
housekeeping gene GAPDH used as an internal control for RNA input.  Serially 
diluted Ramos cDNA was used as a standard for UNG, Polη and GAPDH.  
Each reaction was carried out in duplicate, in a 96-well PCR plate.  For each  
assay, the following 25μl reaction mix was used; 12.5μl 2x Taqman reaction 
mix, 1.25μl appropriate ready-made primer mix, 0.5μl GAPDH primer mix (ready 
made), 10.75μl PCR-grade water and 5μl cDNA sample.  The PCR plate and 
PCR reaction was performed as described above.  The results were normalised 
to GAPDH, and values calculated as relative to UNG or Polη expression in the 
immortalized T cell line, Jurkat. 
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3 Ex Vivo Studies of EBV Colonisation within 
Distinct B cell Subsets 
Both the ex vivo and in vitro sections of this PhD project involved work that 
formed a part of ongoing studies carried out within the B cell group.  The focus 
of the ex vivo chapter therefore is a continuation of the PhD project previously 
carried out by Dr Sridhar Chaganti, and as such the initial part of the 
investigation was carried out in collaboration between myself and Dr Chaganti, 
and was subsequently published (Chaganti et al., 2009). 
In this work, the subject of EBV persistence within the B cell compartment was 
addressed, with a view to increasing the understanding of the initial cell targets 
of the virus during primary infection.  As discussed previously in the 
Introduction, the route by which EBV establishes persistence is still a matter of 
debate.  There is evidence suggesting preferential infection and expansion of 
the switched memory subset, and conversely, other evidence supporting the 
initial infection of a naive B cell followed by differentiation to a memory B cell via 
the germinal centre route.  The aim of this chapter therefore, is to investigate 
the distribution of the virus within distinct B cell populations in the peripheral 
blood (PB) of healthy EBV carriers and the tonsils of chronic carriers and IM 
patients. 
3.1 Isolation of Peripheral Blood B cell Subsets  
B cells were routinely isolated from the PB of healthy donors supplied by the 
National Blood Service (NBS), either in the form of buffy coats or leukocyte 
cones.  The standard method for isolating B cells using magnetic CD19 
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Dynabeads yielded consistently pure populations based on CD20 surface 
staining, two typical examples of which can be seen in Figure 13. 
Purified B cells were further sorted by FACS into three different subgroups 
based on IgD and CD27 expression.  Using this staining protocol, the three 
different subsets, naive (IgD+CD27-), switched memory (IgD-CD27+) and non-
switched memory (IgD+CD27+), are distinguishable within the B cell population 
(Figure 14).  In order to minimise contamination from adjacent populations, 
appropriately sized sort gates were drawn around the target population, often 
sacrificing cell numbers for high purity.  In each case sorted populations were 
re-analysed in order to confirm their purity (data from 13 PB sorts is 
summarised in Table 3).  The naive B cell yield was invariably the most pure, in 
most instances achieving >99% purity and switched memory populations were 
96%-100% pure.  Since the ease by which the non-switched memory cells 
could be distinguished from the other two populations often varied between 
sorts, the purity of this subset was less consistent, but was usually >93% (mean 
= 92%).  Potential contamination of the non-switched memory fraction usually 
came from the naive B cell population, and specifically in the two sorts (PB6 
and PB7) yielding non-switched memory cells of <90% purity, no contamination 
from the switched memory B cell subset occurred (data not shown).  Any source 
of contamination within the naive or memory B cell subset usually came from 
the non-switched memory population, but in most cases these levels were <1%. 
3.2 Isolation of Tonsillar B cell Populations 
Tonsillar UMs were obtained from tonsillar material by Ficoll density gradient 
centrifugation, and B cells isolated by either positive selection using CD19 
94%
Peripheral blood donor 1
97%
Peripheral blood donor 3
Figure 13.  CD20 staining of CD19-selected peripheral blood B cells
Two  representative CD19-selected B cell populations stained for surface CD20 expression.  
CD20+ cells are represented by the pink outlined histogram, whereas the isotype control is 
represented by the black outlined histogram.  
Figure 14.  Isolation of peripheral blood B cell subsets
Using  IgD-PE and CD27-FITC staining, peripheral blood B cells were sorted into three separate 
populations; naive (IgD+CD27-), switched memory (IgD-CD27+) and non-switched memory 
(IgD+CD27+). Three distinct populations can clearly be seen, together with the gates used to select 
the cells targeted for collection.  The three lower panels show reanalysis of each sorted population 
and the corresponding purities based on analysis of approximately 2000 events. This sort was used 
to provide cells for experiment 7.  Note: the gates drawn around the reanalysed populations are 
consistently larger than the initial gates due to a shift in fluorescence intensity following sorting.
Subset purity (%)
naive NSM SM
PB donor (IgD+CD27-) (IgD+CD27+) (IgD-CD27+)
PB 1 99 98 99
PB 2 99 95 99
PB 3 99 91 99
PB 4 99 99 99
PB 5 98 92 97
PB 6 98 85 98
PB 7 92 81 90
PB 8* n/d n/d n/d
PB 9* 99 98 99
PB 10* 99 87 95
PB 11* 99 97 99
PB 12* 99 95 99
PB 13* 99 91 92
Table 3 .  Summary of peripheral blood FACS-sorted B cell populations for virus load 
assays
Summary of re-analysis of peripheral blood (PB) B cell populations sorted by FACS into 
IgD+CD27- naive, IgD+CD27+  non-switched memory (NSM) and IgD-CD27+ switched memory 
(SM).   n/d = not determined.  *B cells used for limiting dilution assays. 
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Dynabeads, or negative selection using CD3 Dynabeads.  B cells were further 
sorted by FACS based on CD38, IgD and CD27 expression (FACS data from a 
representative healthy carrier is shown in (Figure 15).  In order to separate GC 
B cells from those outside GCs, the CD38+ and CD38- cell gates were drawn 
around the two distinct populations.  The CD38+ GC B cell subset was collected 
separately, and the CD38- B cells were divided into three further populations; 
IgD+CD27- naive, IgD-CD27+ switched memory and IgD+CD27+ non-switched 
memory.  As with the PB B cell isolation, sorted populations were re-analysed in 
order to confirm their purity (summarised in Table 4).  The naive and switched 
memory B cells were >98% pure in most sorts, and although the non-switched 
memory populations were less abundant in the tonsil than in blood, it was still 
possible to sort these cells to between 93-97% purity where analysis was 
carried out (note, in cases where very small numbers of cells were collected, 
reanalysis was not possible). 
3.3 Total EBV Genome Load in B cell Populations 
3.3.1 Healthy Carrier Peripheral Blood B cell Populations  
Sorted B cells from the peripheral blood of 13 healthy carriers were examined 
by qPCR for EBV genome load.  Virus loads, expressed as genome number per 
106 cells, from naive (IgD+CD27-), non-switched memory (IgD+CD27+) and 
switched memory (IgD-CD27+) B cell populations are shown in Table 5.  The 
chart depicted in Figure 16 summarises the data from the 13 donors, and shows 
the median EBV load in each population.  The data show that there is 
considerable variation in EBV load between different donors.  The distribution of 
virus load between the three B cell populations is consistent with published data 
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Figure 15.  Isolation of tonsillar B cell subsets
A representative sort (tonsil 1) is shown.  B cells were first gated according to CD38 expression.  
CD38+ GC B cells were then collected separately, and CD38- B cells were further divided into 
switched memory (SM),  naive (N) and non-switched memory (NSM).  
98%
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Subset purity (%)
naive NS memory S memory GC
tonsil CD38-IgD+CD27- CD38-IgD+CD27+ CD38-IgD-CD27+ CD38+
T1 99 97 98 97
T2 97 97 99 n/d
T3 n/d n/d 98 n/d
T4 99 n/d n/a 98
T5 98 93 90 98
T6 99 94 99 98
IMT3 98 n/d 98 95
IMT5 99 n/d 98 97
IMT6 99 n/d 99 97
Table 4 .  Summary of FACS-sorted tonsillar B cell populations for virus load assays
Summary of reanalysis of tonsillar B cells from chronic carriers (T) and IM patients (IMT) sorted by FACS 
into; CD38-IgD+CD27- naive, CD38-IgD+CD27+ non-switched memory (NSM), CD38-IgD-CD27+ switched 
memory (SM), and  (CD38+) GC B cells.  n/d = not determined.
naive NSM SM
PB1 193 1260 770
PB2 0 730 2816
PB3 22 202 2160
PB4 0 15562 4211
PB5 15 55 731
PB6 273 1299 18330
PB7 9 499 1206
PB8 200 1350 5000
PB9 30 1700 28000
PB10 0 250 1000
PB11 44 350 6500
PB12 110 1700 11600
PB13 260 310 6200
Table 5. EBV load distribution in peripheral blood B cell subsets
EBV loads from PB naive, non-switched memory (NSM) and switched memory B cell subsets 
derived from 13 donors is shown.  Values are expressed as EBV genomes per million cells.  
Figure 16. EBV load distribution in peripheral blood B cell subsets
EBV loads from PB naive, non-switched memory (NSM) and switched memory B cell 
subsets derived from 13 donors is shown.  Values are expressed as EBV genomes per 
million cells.  Horizontal lines within data from each subset show the median value.
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(Babcock et al., 1998, Chaganti et al., 2009), with the highest viral load (median 
= 4,210 EBV genomes/106 cells) observed within the switched memory B cell 
subset, and only minimal levels (median = 15 EBV genomes/106 cells) 
detectable in the naive B cell population.  In addition, the non-switched memory 
population in all 13 donors contained significant levels of viral DNA (median = 
730 EBV genomes/106 cells) that was only ~3-fold lower than that detected in 
switched memory B cells, and substantially higher than in naive B cells.  Note 
than in 2 out of the 13 donors, the detected load was actually higher in the non-
switched memory than in the switched memory B cell subset. 
3.3.2 Healthy Carrier Tonsillar B cell Populations 
In parallel experiments, sorted tonsillar B cell subsets from 6 healthy carrier 
individuals were examined for EBV load by qPCR.  EBV loads from naive 
(CD38-IgD+CD27-), non-switched memory (CD38-IgD+CD27+), switched 
memory (CD38-IgD-CD27+) and GC (CD38+) B cell populations from each 
tonsil are shown in Table 6 and all the data, together with median values are 
summarised in Figure 17.  In most cases both the naive B cell and GC B cell 
subsets contained low EBV loads.  However, the non-switched and switched 
memory B cell values consistently gave higher but more varied results.  
Collectively the data show that the virus was distributed primarily within the 
switched memory B cell fraction (median = 5,690 EBV genomes/106 cells), with 
minimal loads in both the CD38+ GC (median = 380 EBV genomes/106 cells) 
and naive (median = 210 EBV genomes/106 cells) B cell subsets.  As seen in 
the blood, substantial levels of virus were also detected within the non-switched 
memory B cell population (median = 3,150 EBV genomes/106 cells).  This 
median viral load was approximately 15–fold higher than in naive, 8-fold higher 
GC naive NSM SM
Tonsil 1 706 268 1938 843
Tonsil 2 320 2240 6171 13675
Tonsil 3 213 184 4892 10540
Tonsil 4 2651 12 3143 22747
Tonsil 5 444 0 473 618
Tonsil 6 146 232 3162 673
IMT3 1132607 0 n/t 1659062
IMT5 450900 85067 n/t 77079
IMT6 393132 4413 n/t 222165
Table 6.  EBV load in tonsillar B cell subsets
EBV load in chronic carrier tonsillar CD38+ germinal centre (GC), naive, non-switched memory 
(NSM) and switched memory (SM) populations was estimated using qPCR targetting the EBV 
pol gene.  The results were normalised against beta-2-microglobin (β2M), and values expressed 
as number of EBV genomes per million cells.  Tonsils derived from IM patients are designated 
“IM”.   n/t = not tested.
Figure 17 . EBV load distribution in healthy carrier tonsillar B cell subsets
EBV loads from chronic carrier tonsillar germinal centre (GC) naive, non-switched memory 
(NSM) and switched memory B cell subsets derived from 6 donors.  Values are expressed as 
EBV genomes per million cells.  Horizontal lines within data from each subset show the 
median value.
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than in CD38+ GC and only 2–fold lower than in switched memory B cells.  In 
one instance (T6), the load detected in the non-switched memory subset was 
~5–fold higher than that in switched memory. 
3.3.3 Infectious Mononucleosis Tonsillar B cell Populations  
To examine whether a similar distribution of EBV was observed during primary 
infection, tonsillar B cells from 3 individuals with IM were sorted by FACS into 
naive (CD38-IgD+CD27-), switched memory (CD38-IgD-CD27+) and GC 
(CD38+) B cell populations.  Note that the non-switched memory (CD38-
IgD+CD27+) B cell population was barely detectable from each of these donors 
and therefore these cells were not available for collection (data not shown). 
The results from each tonsil are shown separately in Table 6, and summarised 
together with median values in Figure 18.  The data emphasise that the EBV 
loads are dramatically higher in IM tonsils compared to chronic carrier tonsils or 
peripheral blood.  The relative distribution of EBV load between the naive and 
switched memory populations was consistent with previous findings, with the 
highest load in the memory B cell subset (median = 220,000 EBV genomes/106 
cells) and lowest in the naive B cell fraction (median = 4,000 EBV genomes/106 
cells).  In contrast to chronic carrier tonsils, a substantial load was also detected 
in the CD38+ GC B cell fraction (median = 450,000 EBV genomes/106 cells).  
However, in addition to its expression by GC B cells, CD38 is considered to be 
a marker of activated B cells during IM.  The finding of EBV in CD38+ “GC” B 
cells is therefore open to question (see Discussion). 
Figure 18 . EBV load distribution in IM tonsillar B cell subsets
EBV loads from IM tonsillar germinal centre (GC) naive and switched memory B cell subsets 
derived from 3 donors.  Values are expressed as EBV genomes per million cells.  Horizontal 
lines within data from each subset show the median value.
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3.4 Frequency of EBV-Infected cells 
The above method to examine EBV loads in different B cell subsets provides an 
absolute value of virus genomes within each cell population, but provides no 
information about the frequency of virus-infected cells.  Therefore, it cannot be 
used to ascertain whether high loads within a cell population reflect increased 
numbers of infected cells, or higher numbers of EBV genomes per infected cell, 
or a combination of the two.  In order to answer these questions, a limiting 
dilution PCR approach, based on that first described by Thorley-Lawson and 
colleagues, was employed to estimate the frequency of infected cells (Khan et 
al., 1996).  Using this limiting dilution method for the analysis of EBV-infected 
cells, the principle aims were to examine (i) the frequency of infected cells 
within different B cells subsets from the peripheral blood and tonsil, and (ii) to 
estimate the number of EBV genomes carried by each infected cell.  Data 
produced using this method therefore supplements the EBV total load data 
described above. 
3.4.1 Validation of the Limiting Dilution Method Using Namalwa-
BL Cell Line 
Before ex vivo samples were used, the limiting dilution method was first 
validated in a control experiment using the EBV-positive cell line Namalwa-BL 
(illustrated in Figure 19).  EBV+ cells were added to an EBV-negative cell 
population (DG75) at a known frequency of 1 EBV+ cell to 4,000 EBV- cells.  
The starting sample, containing a known quantity of cells (eg. 50,000 cells per 
50μl), was serially diluted 2-fold until 8 dilutions containing known quantities of 
cells were acquired.  Subsequently 8 replicates from each of the dilutions were 
Figure 19 .  Validation of limiting dilution analysis using the Namalwa-BL cell line
Cells from the EBV-positive Namalwa-BL cell line were added to an EBV-negative DG75 cell population at 
a frequency of 1 EBV+ cell per 4000 EBV- cells.  A. Starting with 50,000 cells per 50μl at the highest 
concentration, the cell sample was serially diluted 1:2 to the lowest concentration (391 cells per 50ul).  
50μl of each dilution was then added to 8 wells of a 96-well plate, the cells lysed and a qPCR assay for 
EBV pol carried out.  B. The number of wells containing an EBV pol positive signal was scored at each 
dilution (total score from the 8 replicates is indicated to the right of the table).  C. Summary of the data 
used to calculate the cell frequency.  These values are added to the data entry box at the WEHI limiting 
dilution analysis webpage.  The calculation provides an estimated frequency (in this instance 1 positive 
cell in 4426) together with upper and lower confidence intervals (2799 to 7000).  In this control 
experiment, where a known frequency of 1 EBV+ cell to 4000 EBV- cells was used, the limiting dilution 
method was validated.
AB
C
Figure 19.  Validation of limiting dilution analysis using the Namalwa-BL cell 
line
A. Example of cell input in serial dilution series.  B. Result of qPCR to detect EBV 
genomes.  C. Summary of data.  (A full description is provided on the opposite page).
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placed into a 96-well PCR plate (Figure 19a).  The replicate samples were then 
lysed and subjected to the same EBV load qPCR as described above, and the 
number of positive wells in each dilution was scored (Figure 19b).  Typically all 
wells containing the highest cell inputs in the series were positive, whilst those 
at the bottom of the dilution, containing the lowest cell numbers, were negative.  
The cell input at each dilution, number of replicates and fraction of positive wells 
were used to estimate the frequency of infected cells (Figure 19c) by a simple 
Poisson distribution method using software provided by WEHI Institute of 
Medical Research, Australia (Hu and Smyth, 2009). 
In the example shown in Figure 19, the estimated frequency of EBV-infected 
cells was 1 cell in 4,426 (with confidence intervals of 2,799-7,000).  This value 
is close to the known frequency of 1 cell in 4,000, and therefore validates the 
limiting dilution method.  Note that using this value, the number of genomes per 
infected cell can also be estimated by dividing the number of genomes per 106 
cells by the number of infected cells per 106 cells (see below). 
3.4.2 Frequency of Infected Cells in Peripheral Blood B cell 
Subsets Derived from Healthy Carrier Donors  
In the first experiment, limiting dilution analysis was carried out on naive, non-
switched memory and switched memory B cells from the peripheral blood of 6 
healthy carrier donors (shown in Table 7 and Figure 20).  In support of the 
previous section, these results confirm that the highest viral loads were found in 
switched memory (median = 6,350 EBV genomes/106 cells), followed by non-
switched memory (median = 850 EBV genomes/106 cells), with minimal loads 
detected in naive B cells (median = 110 EBV genomes/106 cells) (Figure 20a).  
Figure 20 . EBV distribution in sorted peripheral blood B cell populations 
from healthy carriers
Summary of EBV load and frequency data from naive, non-switched memory (NSM) 
and switched memory (SM) B cell subsets derived from the peripheral blood of 
healthy carriers. Shown are median values from 6 donors.  A. EBV load (EBV 
genomes/106 cells). B. Frequency of EBV-infected cells (EBV+ cells/106 cells).  C.
Number of EBV genomes/cell.  
A.
B.
C.
EBV load per 106 cells
Frequency of EBV-infected cells
EBV genomes per cell
Frequency of EBV+ cells EBV+ cells/106 EBV genomes/106 cells EBV genomes/cell (mean)
PB8 naive 1 in 112000 (28000-450000) 8 200 25
NSM 1 in 36000  (19000-68000) 28 1350 48
SM 1 in 12000  (7400-19000) 83 5000 60
PB9 naive 1 in 560000  (n/d) 2 30 15
NSM 1 in 21000  (10000-42000) 48 1700 35
SM 1 in 730  (450-1200) 1370 28000 20
PB10 naive nd nd nd nd
NSM 1 in 44000  (14000-138000) 23 250 11
SM 1 in 25000  (14000-44000) 40 1000 25
PB11 naive 1 in <90000  (n/d) <10 44 nd
NSM 1 in 132000  (43000-405000) 8 350 44
SM 1 in 6300  (3900-9900) 160 6500 41
PB12 naive 1 in 550000 (n/d) 2 110 55
NSM 1 in 43000  (19000-95000) 24 1700 71
SM 1 in 3600 (1400-4100) 410 11600 28
PB13 naive 1 in 54000  (32000-91000) 18 260 14
NSM n/d n/d 310 n/d
SM 1 in 5800  (3300-10000) 170 6200 36
Table 7.  EBV distribution in sorted peripheral blood B cell populations from healthy carriers
Summary of limiting dilution data from naive, non-switched memory (NSM) and switched memory (SM) B 
cells from the peripheral blood (PB) 6 healthy EBV carrier donors (PB donors 8-13). Also shown are the 
estimated values for (a)  frequency of infected (EBV+) cells calculated using limiting dilution qPCR assay, (b) 
number of EBV+ cells/106 cells, (c)  EBV genomes/106 cells calculated using standard EBV load qPCR assay, 
with values normalised against β2M, and (d) mean number of EBV genomes/cell.  In cases where too few 
cells were available, or the virus load was undetectable, values could not be determined (n/d).
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Similarly, the frequencies followed the same pattern, with the highest number of 
EBV-infected cells detected in switched memory (median = 165 EBV+ cells/106 
cells), followed by non-switched memory (median = 24 EBV+ cells/106 cells), 
and naive B cells (median = 8 EBV+ cells/106 cells) (Figure 20b). 
Once the the total EBV load (genomes/106 cells) and the frequency (by limiting 
dilution) of EBV-positive cells is known, these data can be used to estimate (a) 
the number of EBV-positive cells per 106 cells, and (b) the number of genomes 
per cell.  An example of these calculations, using data from the switched 
memory population of PB8, is described below: 
Frequency of EBV+ cells = 1 in 12,000  
EBV+ cells per 106 cells = 1,000,000 ÷ 12,000 = 83 
EBV genomes/106 = 5,000 
Mean number of genomes per cell = 5,000 ÷ 83 = 60 
Interestingly, no marked difference in number of EBV genome copies per 
infected cell were observed in any B cell population (non-switched memory cells 
median = 44 EBV genomes/cell, switched memory median = 32 EBV 
genomes/cell and naive median = 20 EBV genomes/cell) (Figure 20c). 
3.4.3 Frequency of Infected Cells in Ex Vivo IM Tonsillar B cells 
In the next experiment, the limiting dilution technique was used to analyse total 
CD19-selected B cells derived from IM tonsils.  These cells were chosen for 
their higher overall EBV load, and because they were readily available.  The 
frequency of infected tonsillar B cells within the 4 individuals ranged from 6,400 
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EBV+cells/106 cells to 32,300  EBV+cells/106 cells, with the estimated mean 
number of EBV genomes per cell ranging from 46 to 343 (median = 128).  A 
summary of the results from 4 IM tonsils (IMT2, IMT3, IMT6 and IMT7) can be 
seen in Table 8.  Due to the small numbers of cells available from these donors, 
it was not possible to examine specific B cell subsets using the limiting dilution 
PCR method. 
3.4.4 Genome Copies in Lytic and Latent AKBM Cells  
From the above experiments an average number of genomes per infected cell 
can be estimated.  However, if the population should contain a small number of 
lytic cells, the average value may be skewed.  In order to estimate how many 
EBV copies are present in a productively infected cell, the AKBM cell line was 
used.  AKBM is a cell line derived from Akata-BL, which has been stably 
transfected with a GFP reporter under the control of the lytic BMFR1 promoter.  
AKBM cells can be induced into lytic cycle following cross-linking with anti-IgG 
antibody (Ressing et al., 2005), leading to expression of the GFP reporter, 
which enables the separation of lytically infected cells from latently infected cells 
by FACS sorting. 
Three separate experiments were carried out whereby AKBM cells were 
induced to undergo lytic replication.  In each case, GFP-negative (latent) and 
GFP-positive (lytic) cells were sorted by FACS (data not shown) directly to 
individual wells of 96-well PCR plates and viral loads in individual cells were 
determined by qPCR (data shown in Figure 21 and summarised in Table 9).  
The results show that in each separate occasion when AKBM cells were 
induced to go into lytic cycle, individual GFP+ cells appeared to carry 100-fold 
Table 8.  Frequency of infected cells in unfractionated B cells derived from 4 IM tonsils
Summary of limiting dilution data from 4 IM tonsillar B cell samples.  Rows A-H represent limiting dilution 
qPCR plates, including cell input (cells/well), number of replicate qPCRs (8) and the number wells 
containing EBV pol amplification (+ve wells).  Displayed underneath are the calculated values for (a) EBV 
genomes/106 cells calculated using standard EBV load qPCR assay, with values normalised against β2M, 
(b)  frequency of infected (EBV+) cells calculated using limiting dilution qPCR assay, (c) number of EBV+ 
cells/106 cells, and (d) number of EBV genomes/cell.  Numbers in brackets represent lower and upper 
confidence intervals.
IMT3 IMT2 IMT6 IMT7
row cells/well replicates +ve wells cells/well replicates +ve wells cells/well replicates +ve wells cells/well replicates +ve wells
A 250 8 8 32 8 6 250 8 7 250 8 4
B 125 8 8 16 8 3 125 8 7 125 8 5
C 63 8 8 8 8 0 63 8 6 63 8 4
D 31 8 6 4 8 1 31 8 2 31 8 2
E 16 8 2 2 8 1 16 8 2 16 8 2
F 8 8 1 1 8 0 8 8 5 8 8 1
G 4 8 0 0.5 8 0 4 8 1 4 8 0
H 2 8 0 0.25 8 0 2 8 0 2 8 0
EBV genomes/106 cells 1.5 x 106 4.3 x 106 2.0 x 106 2.2 x 106
Frequency of EBV+ cells
1 in 31
(19-48)
1 in 34
(19-61)
1 in 58
(37-92)
1 in 157
(94-260)
EBV+ cells/106 cells 32,300 29,400 17,200 6,400
EBV genomes/cell 46 145 110 343
Table 8. Frequency of infected cells in unfractionated B cells derived from 4 IM tonsils
GFP+ AKBM Cells GFP- AKBM Cells
experiment number 1 2 3 1 2 3
no. of PCR reactions 68 61 44 82 40 70
median no. EBV genomes per cell 24394 13245 2906 161 36 97
Table 9.  EBV genome copies in individual GFP+ and GFP- AKBM cells
Populations of AKBM cells where induced to go into lytic cycle on 3 separate occasions.  
Single GFP+ (lytic) and GFP- (latent) cells were then sorted directly into 96-well PCR plates 
and EBV pol qPCR carried out.  In most instances levels of the β2M were undetectable, 
therefore EBV pol values were not normalised a cellular gene.  Median numbers of EBV 
genome copy number per cell from each sort are shown.
Figure 21.  EBV genome copies in individual GFP+ and GFP- AKBM cells
All qPCR values (EBV genome copy number per cell) from single GFP+ and GFP- cells from 
each of the 3 experiments are shown.   The majority of GFP- cells are latently infected, 
whereas the majority of GFP+ cells were induced into lytic cycle. Median vaules from each 
population are highlighted by horizontal lines.  The  data are presented using a log scale.
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higher (median = 9770) numbers of EBV genomes than GFP- cells (median = 
109).  These values, based on the number of genomes per latently infected 
AKBM cell, are similar to those seen in infected B cells ex vivo. 
3.5 Discussion 
EBV establishes persistence in the human host by long-term latent infection of 
circulating memory B cells.  Since it has been reported that both naive and 
memory B cells appear equally infectable in vitro (Ehlin-Henriksson et al., 
2003), the mechanism by which the virus selectively colonises memory B cells 
in vivo remains unclear.  Two models have been suggested to explain this 
process; the initial targeting of naive B cells during infection, which drives them 
to differentiate into memory B cells via a physiological GC reaction (Thorley-
Lawson, 2001), or the GC-independent targeting of both cell types, followed by 
the preferential outgrowth of infected memory B cells due to an as yet 
unidentified survival advantage (Kuppers, 2003).  In light of these hypotheses, 
we proposed that the central question arising from this debate is whether or not 
GC transit is a prerequisite for the colonisation of the memory B cell 
compartment by EBV.  To address this issue, the current study aimed to 
examine EBV colonisation of PB B cell subsets from chronic carrier individuals, 
and in tonsillar B cell subsets from both chronic carriers and IM patients by 
sorting ex vivo cell suspensions, followed by qPCR assays to determine EBV 
load in each population.  Two subsets in particular were focussed upon; (i) non-
switched memory B cells, which as suggested by several studies (see 
Introduction for alternative developmental pathways) develop in a GC-
independent manner, and (ii) germinal centre B cells. 
108 
 
3.5.1 EBV Colonisation of Non-Switched Memory B cells 
Three major B cell subsets are found in the peripheral blood of healthy 
individuals (Klein et al., 1998); naive (IgD+CD27-), switched memory (IgD-
CD27+) and non-switched memory (IgD+CD27+).  Whilst convincing evidence 
has been put forward for the preferential colonisation of EBV within the switched 
memory B cell population of chronic carriers (Babcock et al., 1998, Joseph et 
al., 2000b), prior to the current study, EBV infection of the non-switched 
memory B cell fraction was not well documented in healthy individuals.  EBV 
colonisation of the non-switched memory subset has, however, been described 
in the context of immunodeficiency (Chaganti et al., 2008).  Specifically, 
Chaganti et al. showed that in XLP patients, who due to an inherited deficiency 
that prevents GC formation, lack switched memory B cells (Ma et al., 2006, Ma 
et al., 2007), but who still possess a circulating non-switched memory B cell 
population (Ma et al., 2006), EBV is able to establish persistence within the 
latter cell type.  In order to explore whether this subset could also harbour EBV 
in immunocompetent individuals, B cell subsets were sorted from the peripheral 
blood of 13 healthy carrier donors and from 6 chronic carrier tonsils. 
We first confirmed published findings (Babcock et al., 1998), showing that in 
healthy carriers a much higher viral load can be found in switched memory than 
in naive B cells.  In addition however, a substantial EBV load was detected in 
the non-switched memory B cell fraction in all 13 donors, which although in 
most cases was not as high as that in switched memory, was notably higher 
than in the naive B cells.  It is unlikely that this result is the product of 
contamination with infected switched memory B cells since the non-switched 
memory B cell populations were sorted to high purity (mean = 92%), with 
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contaminating cells being of a naive (IgD+CD27-) phenotype, rather than of a 
switched memory (IgD-CD27+) phenotype.  Indeed given the switched memory 
B cell population median value (4200 genomes per 106 cells), 10% 
contamination with this subset would produce a value of ~420 genomes per 106 
cells, which is almost 2-fold lower than the median EBV load from the non-
switched memory population (730 genomes per 106 cells).  Interestingly, in 2 of 
the 13 donors, higher loads were detected in the non-switched memory than in 
the switched memory fraction.  Whereas this is an unexpected result, a similar 
finding was also observed in the published portion of this study (data generated 
by Dr Chaganti), where 1 out of 9 donors tested possessed detectable virus 
exclusively in the non-switched memory population (Chaganti et al., 2009).  
Following the examination of three B cell populations within peripheral blood, 
the larger range of phenotypically distinct subsets in tonsillar B cell preparations 
was then examined.  In agreement with a separate study (Babcock et al., 2000), 
the viral load detected in the switched memory B cell population was 
substantially higher than in either the naive (CD38-IgD+CD27-) subset or the 
CD38+ GC subset, both of which contained either undetectable or extremely 
low levels of virus.  Although the non-switched memory (CD38-IgD+CD27+) B 
cell subset was less abundant in tonsil populations than in the blood, it was still 
possible to sort these cells to high purity (mean = 95%).  In 4 of 6 donors, a 
robust load was detected in the non-switched memory subset, with an overall 
median value which was only 2-fold lower than that of the switched memory B 
cell population.  In one case (T6), the load in the non-switched memory 
population was markedly higher (~5-fold) than in the isotype-switched 
population.  As before, these results are unlikely to represent contaminating 
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switched memory cells within the non-switched memory B cell populations since 
the latter cells were sorted to high purity. 
Taken together, the results from both the healthy carrier peripheral blood and 
chronic carrier tonsil donors indicate that EBV can colonise the non-switched 
memory B cell subset in a substantial number of individuals, albeit not as 
efficiently as the switched memory B cell population.  This observation is in 
agreement with data from a larger cohort of donors that was generated by Dr 
Chaganti and subsequently published (Chaganti et al., 2009).  Our findings, 
however, contradict several other studies.  One earlier study reported no 
evidence of EBV infection within peripheral blood IgD+CD27+ B cells from 
healthy carriers, although only 3 donors were examined (Joseph et al., 2000b).  
Since 2 of 9 donors were found to have no detectable virus load in our 
published work (Chaganti et al., 2009), it is not unfeasible that by chance three 
such individuals were tested in the study by Joseph et al.  The original study, 
which first suggested selective colonisation of the switched memory subset 
(Babcock et al., 1998), compared EBV infection in CD27+ B cells to CD27- B 
cells from IM patients.  The author reported that the virus was concentrated 
primarily within the CD27+ subset, which includes both IgD-CD27+ switched 
memory and IgD+CD27+ non-switched memory B cells.  In the same 
investigation, IgD+ and IgD- B cells were also compared.  Whilst virus was 
found primarily within the IgD- subset, rather than in the IgD+ population, it is 
possible that infection of the non-switched memory population may have been 
masked by IgD+ naive cells, which constitute a much larger proportion of the 
blood B cell compartment (Klein et al., 1998).  More recent studies have used 
RT-PCR single cell analysis of EBV-infected cells within sorted B cell 
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populations of blood from IM patients (Souza et al., 2005, Souza et al., 2007).  
In one such study, each of the small number of cells examined per patient 
carried mutated Ig genes (Souza et al., 2005).  However, whilst most of these 
cells expressed either Igγ or α transcripts (corresponding to IgG and IgA, 
respectively), cells expressing mutated Igμ (IgM) transcripts were detected in 3 
out of the 6 donors examined.  In a similar investigation, EBER-positive cells 
expressing Igμ were also detected within CD27+ populations (Souza et al., 
2007). 
If IgD+CD27+ non-switched memory B cell development is GC-independent, 
our findings suggest that EBV is able to establish persistence in at least one 
memory B cell subset without the obligation to drive the cell through a GC 
reaction. 
3.5.2 EBV Colonisation of Germinal Centre B cells  
One popular model describing selective EBV colonisation of switched memory 
B cells is based on GC transit of the infected cell (Thorley-Lawson, 2001, 
Thorley-Lawson and Allday, 2008, Thorley-Lawson and Gross, 2004).  It is 
proposed that following initial infection of naive B cells, the virus mimics 
physiologic antigen-driven B cell activation via expression of Latency III 
antigens, LMP1 and LMP2.  Using this mechanism, the virus then drives the 
infected cell to form and participate in a GC reaction, thereby differentiating into 
a switched memory B cell, in which viral proteins are no longer expressed.  
Although this theory is supported by evidence of Latency III expression in 
tonsillar naive B cells (Babcock et al., 2000, Joseph et al., 2000a), up until 
recently little evidence for EBV infection of GC B cells has been presented.  The 
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second aim of these experiments therefore was to find out whether EBV 
infection could be detected in GC B cells from chronic carrier and IM tonsils.  
Examination of sorted B cell subsets from 6 carrier tonsils revealed that B cells 
expressing the GC marker CD38 consistently contained extremely low levels of 
detectable virus, which were comparable to those found in the non-GC naive B 
cell population.  These findings were in agreement with results previously 
generated by our laboratory (Chaganti et al., 2009). 
The examination of IM tonsillar B cell subsets revealed firstly that, as expected, 
viral loads were up to 100-fold higher in IM tonsils than in chronic carriers.  
Secondly, we noted a different distribution of EBV load between the chronic and 
IM tonsil suspensions.  While higher loads were found in the switched memory 
than in the naive B cell populations in both situations, high viral loads were also 
detected within the CD38+ B cells from IM tonsils and were similar, overall, to 
the loads seen in switched memory.  Whilst only 3 IM donors were included in 
the current study, these findings are consistent with published data using a 
larger panel of material (Chaganti et al., 2009). 
To address this difference in virus distribution, Chaganti et al. adopted a 
different B cell staining strategy to sort CD77+ centroblasts and CD10+ 
centrocytes, together with two subsets of CD77-CD10- (non-GC) cells; IgD+ 
(mainly naive) and IgD- (mainly switched memory).  Using this technique, the 
virus was found to be concentrated within the non-GC, primarily IgD- B cell 
populations.  This latter result raises doubt as to whether in an IM setting EBV is 
genuinely found in the GC cell fraction.  Indeed, although CD38 is considered to 
be a useful marker of GC B cells in the setting of non-IM tonsils (Pascual et al., 
1994, Klein et al., 2003), there is evidence to suggest that in vitro transformation 
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of B cells by EBV induces upregulation of this molecule (Rochford et al., 1993, 
O'Nions and Allday, 2004).  It is possible, therefore, that in the context of 
primary EBV infection, where the latency III program may be expressed in 
newly infected cells, CD38 is primarily a marker for EBV-driven activation of 
infected cells, rather than of GC B cells. 
Our findings contradict work that has recently been published.  In one study 
EBV infection was analysed in chronic carrier tonsillar B cells which were co-
stained for CD10 expression together with classical GC B cell markers Bcl6 or 
AID.  The similar frequency of EBV-infected cells in tonsillar B cells before and 
after separation based on GC markers was put forward as evidence of GC B 
cell colonisation by EBV.  Furthermore the expression of AID and Bcl6 in 
CD10+ B cell populations that contained EBV-positive cells (detected by PCR) 
was taken as proof that the EBV-infected cells were undergoing a GC reaction 
(Roughan and Thorley-Lawson, 2009).  In a very recent investigation by the 
same authors, only ~45% of GCs in chronic carrier tonsils were found to contain 
EBV-infected cells, which were present in very small numbers (~3-4 cells per 
GC) (Roughan et al., 2010).  Although these studies claim to provide 
confirmation of the existence of EBV-infected GC B cells, immunohistochemical 
examination of tonsil sections in many other studies has failed to find convincing 
evidence that EBV-infected cells are situated in the GC (Anagnostopoulos et al., 
1995, Niedobitek et al., 1997, Kurth et al., 2000, Kurth et al., 2003).  Whilst very 
small numbers of EBER-positive GC cells were detected in these investigations, 
Ig gene analysis of such rare cells suggested it was unlikely that they were 
participating in the local germinal centre reaction, but instead represented 
members of stable memory B cell clones derived from adjacent lymphoid tissue 
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(Kurth et al., 2003).  In conclusion, therefore our results are consistent with 
these latter observations that EBV colonisation is not strictly dependent on GC 
transit. 
3.5.3 Frequency of EBV-Infected Cells and Genome Copies in 
Individual Cells 
In a series of parallel experiments, the frequency of infected cells was estimated 
via limiting dilution PCR in order to verify that virus loads reflected absolute 
numbers of infected cells in the different B cell subsets (rather than being 
skewed by differences in mean genome load per infected cell). 
In agreement with earlier data, the virus load values were primarily 
concentrated within the switched memory B cell population, which also yielded 
the highest frequency of infected cells, while the lowest loads and frequencies 
were consistently detected in the naive B cell subset.  We noted that the load 
and frequency values from the non-switched population were substantially 
higher than naive values.  Importantly, no consistent difference in average EBV 
genome copies per infected cell was identified between the 3 distinct B cell 
subsets.  These results therefore confirmed that EBV load values reflected the 
frequency of infected cells in each B cell population, rather than being skewed 
by differences in the number of genomes per cell between the 3 subsets. 
One limitation of the qPCR method used to estimate the number of EBV 
genomes per cell in the ex vivo populations is that these values are an average 
calculated from the whole population, rather than an absolute value from each 
individual cell.  Such information would be particularly useful in order to rule out 
the possibility that lytically infected cells, carrying high numbers of genomes, 
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may exist within the sample and skew the average value.  Although this remains 
a possibility, it is highly unlikely that lytically infected cells were present in our 
data since (i) the high genomes numbers in lytically infected AKBM cells 
(median genomes = >9000 per cell) suggest that even if 1% of the population 
were lytic, the apparent average values may be substantially increased, (ii) lytic 
replication has been shown to be absent from peripheral blood B cells 
(Miyashita et al., 1995), and (iii) examination of lytic cycle transcripts in tonsillar 
B cells in our own laboratory revealed that only trace signals of immediate early 
transcripts and no late signal transcripts were detected (Chaganti et al., 2009). 
Our estimates of average genomes per cell in latently infected PB B cell 
populations derived from healthy carriers (non-switched memory median = 44, 
switched memory median = 32) are consistent with those reported by others in 
both in vitro and ex vivo studies.  In vitro analyses of genome copies in 
individual latently infected cells have shown that a range of values exist, 
depending on the cell line and the methods used.  Early studies measuring viral 
DNA using non-PCR methods such as DNA reassociation kinetics have 
reported that the cell line Raji reportedly carries 50 to 60 EBV genomes per cell 
(Pritchett et al., 1976, Nonoyama and Pagano, 1973), whereas LCLs may carry 
5-800 genomes per individual cell (Sugden et al., 1979).  More recently, 
however, the LCL X50-7 was found to carry a median of 7 (range 2-18) EBV 
genomes per cell using fluorescent in situ hybridisation (FISH) targetting EBV 
DNA (Calattini et al., 2010).  FISH has also been used to investigate genome 
copies in individual ex vivo B cells derived from PTLD patients (Rose et al., 
2002).  In this study, analysis of infected cells from both low load (1-20 EBV 
genomes/106 cells) and high load (>20 EBV genomes/106 cells) patients 
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revealed that both carrier types harboured cells containing 1-2 genomes per 
cell, but that an additional subset of cells carrying 20-50 genomes per cell was 
also detected in high load carriers.  In a separate, very recent study, EBV 
genomes in individual ex vivo B cells were examined using peripheral blood 
derived from patients with high EBV loads.  Individuals included in the study 
suffered from a range of disorders including HIV, IM, PTLD and severe primary 
EBV infection.  Remarkably, the numbers of EBV genomes in single B cells 
from each patient were similar, with an overall median of 13.9 (range 1-40).  
Although the subject material and techniques used in both these recent studies 
differed from the current qPCR-based work, which focussed on fractionated B 
cell populations from healthy carriers, the values are comparable to our own 
estimations.  Furthermore, in agreement with our findings, Calattini et al. also 
show that total EBV loads did not correlate with numbers of genomes in 
individual cells. 
These results raise the question of how genome amplification within infected 
cells occurs.  Particularly in light of the early study carried out by Sugden et al., 
which showed that following the infection of peripheral blood lymphocytes in 
vitro with only ~1 EBV particle per cell, after 30 generations in cell culture the 
number of EBV genomes had amplified 15-20-fold.  Exactly how, and at what 
stage this amplification occurs both in vitro, and potentially in vivo is unclear, 
however, and may prove to be an interesting matter for future research. 
In conclusion, we therefore propose that EBV is able to establish persistence in 
at least one memory B cell subset in vivo in a GC-independent manner.  This 
hypothesis is explored further in the next chapter, where the ability of EBV 
infection to impose GC-associated genotypic and phenotypic changes to naive 
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B cells in vitro, and therefore outside a germinal centre environment, is 
examined in depth. 
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4 EBV Infection of B cell Subsets in vitro: Effects 
on IgH Genotype and Cellular Phenotype 
The work presented in this chapter builds upon previous studies carried out by 
two former PhD students in the B Cell Group; Dr Sridhar Chaganti, and Dr 
Noelia Begue Pastor, in which peripheral blood B cells were sorted into naïve 
(IgD+CD27-), switched memory (IgD-CD27+) and non-switched memory 
(IgD+CD27+) subpopulations and then infected with EBV in vitro.  In this EBV 
infection procedure, a limiting dilution technique was employed in order to 
generate predominantly monoclonal or biclonal LCL cultures.  The effect of EBV 
infection upon cell genotype, specifically mutations in the IgH variable region, 
and phenotype, focusing on immunoglobulin (Ig) isotype expression, were then 
examined.  The results from these experiments showed that approximately one 
quarter of LCL cultures derived from naive B cells had acquired Ig variable 
region mutations by approximately 10 weeks post-infection.  However, naïve 
LCLs did not isotype-switch and remained IgD+IgM+ regardless of whether they 
had accrued mutations.  These findings imply a role for EBV in the induction of 
somatic hypermutation in vitro. 
The potential to confer a mutated IgH genotype, typically associated with a 
memory B cell, upon a naive B cell in the absence of germinal centre transit is 
an important finding, which is relevant to current theories surrounding EBV 
persistence in vivo.  Although a widely accepted hypothesis suggests EBV 
drives infected naive B cells to differentiate into memory B cells via a germinal 
centre reaction, in the previous chapter we challenged the necessity of germinal 
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centre involvement in EBV persistence.  Furthermore the ability of EBV to 
induce mutation processes which inflict genomic instability upon the cell could 
have important implications to the oncogenic potential of the virus. 
The initial stages of my own project extended these earlier studies.  A very 
small number of these experiments were collaborations between myself and Dr 
Chaganti (highlighted where appropriate in this chapter).  The aim of my 
investigation was to examine further the phenomenon of in vitro somatic 
hypermutation in naïve LCLs following EBV infection.  In addition to carrying out 
EBV transformation experiments under limiting dilution conditions using small 
numbers of naive B cells, bulk LCL cultures were also produced by infecting 
larger numbers of cells.  Whereas limiting dilution assays tended to generate 
monoclonal cultures that needed to be expanded for ten weeks before enough 
cells were available for analysis, the establishment of bulk LCLs provided the 
opportunity to harvest cells at multiple time points.  This had the advantage that 
the appearance of IgH mutations could be followed over time in the culture.  
Following on from earlier genotypic and phenotypic analyses, several other 
investigations were also carried out including; (i) transformation efficiency 
assays comparing transformability of naive B cells and non-switched memory B 
cells, (ii) measuring the relative amounts of three distinct AID transcripts by 
qPCR, (iii) experiments using in vitro cytokine stimulation of naive LCLs in order 
to ascertain whether naive B cells were capable of CSR following EBV-driven 
transformation. 
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4.1 Isolation of Peripheral Blood B cell Subsets  
Highly pure populations of peripheral blood B cell subsets were collected by 
FACS after staining for IgD and CD27, as described in the previous chapter.  
Re-analysis data of naive, non-switched and switched memory B cell purities 
from 11 sorts are summarised in Table 10.  Note that although all three subsets 
were collected in each sort, only naïve B cells were used from sorts 1-6, 
whereas naïve B cells plus non-switched memory B cells were used from sorts 
7-11. 
4.2 Establishment and Analysis of EBV-Infected Naive LCLs and 
CD40L/IL-4 B Blasts 
4.2.1 Experimental Outline 
Although previous findings by Dr Chaganti suggested a link between EBV 
infection of naïve B cells and the accrual of somatic hypermutations in naive 
LCLs, the possibility that this phenomenon was an artifact of in vitro cell culture, 
rather than a direct effect of EBV infection, had not been excluded.  Therefore in 
the first series of experiments we looked for evidence of IgH mutations in naive 
B blasts activated to proliferate in vitro, in the absence of EBV.  To this end, 
bulk populations of naïve B cells were stimulated with CD40 ligand (CD40L) and 
IL-4, and maintained as CD40 blasts (BN-blasts) for up to nine weeks after 
establishment.  In parallel, resting naïve B cells from different donors (except in 
the case of donor 4 where a CD40 blast and an LCL were produced from the 
same starting population) were infected with EBV to produce bulk naïve LCLs 
Subset purity (%)
naive NS memory S memory
sort (IgD+CD27-) (IgD+CD27+) (IgD-CD27+) alias experiment summary
1 99 94 98 BN-blast 1 CD40L/IL-4 stimulation
2 99 94 96 BN-blast 2 CD40L/IL-4 stimulation
3 99 97 98 BN-LCL 1 bulk infection
4 99 80 99 BN-blast 3 + BN-LCL 3 bulk infection + CD40L/IL-4 stimulation
5 99 93 99 BN-LCL 4a, b and c bulk infection
6 99 95 99 BN-LCL5 + CN-LCL5 limiting dilution + bulk infection
7 99 98 99 BN-LCL6 + CN-LCL6 + TA-1
limiting dilution + bulk infection + transformation assay + isotype switch 
experiment
8 99 98 99 TA-2 transformation assay
9 99 98 99 TA-3 transformation assay
10 99 95 99 BN-LCL7 + TA-4 transformation assay + isotype switch experiment
11 99 97 99 TA-5 transformation assay + isotype switch experiment
Table 10.  Summary of peripheral blood FACS–sorted B cell populations used in in vitro experiments
Naive B cells were consistently the most pure sorted populations (>99%).  Switched memory sorted populations were also highly pure 
(96-100%), whereas the purity of sorted non-switched memory  cells varied between experiments from 80% to 98%.  BN-blast = bulk 
naive blast, BN-LCL = bulk naive LCL, CN-LCL clonal naive LCL (established by limiting dilution), TA = transformation assay.  In experiments 
1-6, all 3 populations were sorted, but only naive were used, whereas in experiments 7-11 naive and non-switched memory were used.
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(BN-LCLs).  Cells were harvested for analysis at regular time points from both 
BN-blasts and BN-LCLs. 
In order to examine IgVH sequences, genomic DNA was extracted from cell 
pellets, and PCR carried out to amplify the target VDJ sequences.  The PCR 
products were then inserted into pGEMT vectors, and transformed into 
competent E.coli.  Each E.coli colony represented a cloned IgH product, which 
in turn represented a single cell within the culture; therefore, each sequence 
shown in the following results represents the IgH sequence derived from a 
single B cell.  Colonies were picked and grown up into small cultures, plasmid 
DNA extracted using standard methods and the PCR-generated inserts were 
sequenced.  The IgH mutations were identified by aligning the sequences to 
published V, D and J germline segments using Vbase (Retter et al., 2005), and 
where appropriate confirmed using IGMT/V-QUEST (Giudicelli et al., 1998) (see 
Appendix for correlated V, D and J nomenclature).  Mutations were defined as 
individual nucleotide changes compared to the nearest matched germline 
sequence.  Sequences carrying more than two mutations were classified as 
“mutated”, whereas those with two or fewer mutations were deemed to be 
“unmutated”.  A schematic outline of these experiments is shown in Figure 22. 
For each sequence analysed, several characteristics were recorded.  As an 
example of how individual sequences will be presented in this chapter, two 
representative sequences (1 and 12) from the BN-blast1 resting cell data are 
shown in Figure 23.  The following features are highlighted;  (i) the germline 
sequence on the top row, (ii) the locations of the V region up to codon 94,(iii) 
the first ten amino acids of the VDJ junction translation as provided by Vbase, 
typically including the last 3 codons of the V region sequence and the first 7 
Figure 22.  Generation of bulk naive CD40 blasts and LCLs
B cells were isolated from peripheral blood using anti-CD19 Dynabeads.  IgD+CD27- Naïve B cells 
were then sorted by FACS.  Naïve B cells were either infected with EBV to produce a naïve LCL (N-
LCL), or cultured with CD40L+ mouse L-cells and IL-4 to generate naïve CD40 B blasts (N-blasts).  
At various time points, cell pellets were collected and IgH PCR carried out on extracted genomic 
DNA.  IgH PCR products were then cloned into competent E.coli and colonies (representing 
individual cell sequences) were picked to undergo DNA sequencing.  The VDJ and CDR3 sequences 
in each sample were identified using V base, a database containing published germline VDJ 
segments.  Nucleotide differences to published germline sequence were classed as mutations, and 
any sequence with >2 mutations was considered mutated.  
Peripheral Blood
CD19 selection using magnetic beads
B cells
IgD+CD27- naïve B cell selection by FACS
IgD+CD27- naïve B cells
+ CD40 ligand
+ IL-4
Naïve CD40 blasts
+ EBV
Naïve LCLs
IgH PCR 
PCR products cloned into competent E.coli
IgH sequences compared to germline using Vbase
Figure 22.  Generation of bulk naive CD40 blasts and LCLs
Unmutated sequence
2
1
CDR1
DP-71/3d197d+ CCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGG
0wk(S1)       .....................................................................................
CDR2
DP-71/3d197d+ ATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACAGTGGGAGCACCAACTACAACCCCTCCCTCAAGA
0wk(S1)       .....................................................................................
DP-71/3d197d+ GTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTA
0wk(S1)       .....................................................................................
CDR3
DP-71/3d197d+ TTACTGTGCGAGAGA
0wk(S1)       ....C..........ACATATTAAGGGGTACTTCGATCTCTGGGGCCGTGGC
V
V
V
V
RAREHIKGYF
Mutated sequence
CDR1
DP-51+ GGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGG
0wk(S12)   .......C....CA.......................................................................
CDR2
DP-51+     GTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTAGTACCATATACTACGCAGACTCTGTGA
0wk(S12)   .....................................................................................
DP-51+ AGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGACGAGGACACGGCTGT
0wk(S12)   .....................................................................................
DP-51+ GTATTACTGTGCGAGT CDR3
0wk(S12)   ...............GGACGAAGGCTACAACTCCTGGTACTTCGATCTCTGGGGCCGTGGC
V
V
V
V
CARDEGYNSW
3
3
3
3
3
5
13
4
Legend
1. V region location.  
2. The first 30 bases, corresponding to the first 10 amino acids of the VDJ junction translation provided by 
Vbase, which also includes the first 7 amino acids of the CDR3 (the sequence between codon 94 and a 
conserved Trp residue in the J region was deemed to constitute the CDR3 region).   
3. Mutations, which are identifiable as nucleotide changes from the germline sequence.  
4. Where specific mutation locations are referred to in the text, the codon position may also be indicated.
5. Total number of mutations in the sequence may be shown if multiple mutated sequences are presented 
together.
Note: sequences shown exclude the FR1c and JH primers sequences since they may not reflect the true sequence of the 
IgH allele.  The V region alignment therefore begins at codon 9.  
Figure 23.  Examples of mutated and unmutated IgH sequences
Data shown are sequences 1 and 12 from BN-blast 1 (0 week) experiment.
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codons of the CDR3 sequence (highlighted by a lilac box), (iv) sequence 
changes relative to the germline sequence, (v) where relevant, the codon 
locations of specific mutations, (vi) where more than one clonal sequence is 
shown, the individual sequence identity plus number of mutations are 
highlighted to the left of the figure.  CDR1, CDR2 and CDR3 IgH sequences are 
highlighted in blue text.  The CDR3 region was estimated to be between codon 
94 (in the V segment) and a conserved Trptophan (Trp) residue in the J 
segment at approximately codon 102 (Raaphorst et al., 1997). 
Since it was not feasible to display all sequence data individually, most of the 
results are presented as summary tables showing the identification of V, D and 
J segments and the total number of V region mutations between codons 9 and 
91 for each sequence.  As individual B cells harbour unique CDR3 region 
sequences, clonally related cells were identified by the first 10 translated amino 
acids of the VDJ junction. 
4.2.2 IgH Analysis of Bulk Naive CD40 Blasts 
In this first experiment, two bulk naive cultures of CD40L/IL-4-stimulated blasts 
(BN-blasts 1 and 2) were established using PB naive B cells from separate 
donors.  IgH sequences from the starting naïve B cell populations were 
examined, together with sequences amplified from the bulk cultures at six and 
nine weeks post-stimulation (Table 11 and Table 12). 
The resting naive B cell sorted population used to generate BN-blast1 was 
estimated to be 99% pure (Table 10).  Examination of IgVH sequences from this 
starting population revealed 11 out of 12 sequences analysed were unmutated 
(based on the assumption that 0-2 mutations are classified as germline), 
sequence V D J junction translation mutations
1 DP-71/3d197d…+ D3 JH2 RAREHIKGYF 0
2 DP-10/hv1051…+ D3-10/DXP'1 JH6b RAITYYYGSG 0
3 DP-54/V3-7...+ D4 JH6c CARPRHLGLG 0
4 DP-71/3d197d…+ Not found JH6c CARTEEGYDS 0
5 DP-73/V5-51…+ D2-21 JH4b CARSYCGGDC 0
6 DP-49/1.9III…+ D1-26 JH6c CAKDKKAALG 0
7 DP-75/VI-2…+ D4 JH6b CARAFRPGY 0
8 DP-15/VI-8+ D1-26 JH6c CARGGRVTIF 0
9 DP-73/V5-51…+ D7-27/DHQ52 JH4b CARLGSSVGG 1
10 DP-14/VI-18+ D2-8/DLR1 JH6b CARGMHYGMD 1
11 V3-48/hv3d1…+ D7-27/DHQ52 JH6b CAKDWGYGMD 2
12 DP-51+ D5-24 JH2 CARDEGYNSW 3
sequence V D J junction translation mutations
1 DP-71/3d197d…+ D5-5/DK4 JH5b CARSPRGYSY 0
2 DP-73/V5-51…+ not found JH4b CARAGRDDFL 0
3 DP-71/3d197d…+ D6-19 JH6b CARDQGGIAV 0
4 VI-4.1b+ not found JH5b CARDRSKRDR 0
5 DP-15/V1-8+ D4 JH6c CARGGYCSST 0
6 DP-71/3d197d…+ D1-7/DM1 JH3b CAREKNDIPG 0
7 DP-71/3d197d…+ D2-15/D2 JH6c CASRFVGYCS 0
8 DP-15/V1-8+ D5-12/DK1 JH6b CARGVVDIVA 0
9 VIV-4/4.35+ D2-15/D2 JH2 CARDPGYCSS 0
10 DP-35/V3-11…+ D6-13/DN1 JH4b CARDHSIAAA 0
11 DP-78/3d230d…+ D2-15/D2 JH4b CASSAYCSGG 0
12 DP-54/V3-7…+ D7-27/DHQ52 JH4b CARTTGEFIP 0
13 DP-47/V3-23…+ D4 JH4b CAKGGLAGGL 0
14 DP-66/V71-2…+ D3-3/DXP4 JH4b CARVDVDFWS 1
15 DP-10/hv1051…+ D6-19 JH4b CARSSYSGGW 1
16 DP-71/3d197d…+ D6-19 JH4b CARLRGWGIA 1
17 DP-79/4d154...+ D4-17 JH6c CARHPHIEND 1
18 DP-75/VI-2…+ D1-7/DM1 JH5b CARKEIVELG 1
19 DP-75/VI-2…+ D1-26 JH4b CASFFWEGVS 1
20 VIV-4/4.35+ D5-12/DK1 JH6c CARVAYRRYY 1
21 VI-4.1b+ D3-10/DXP'1 JH6c CARVWAPLLW 1
22 VHGL1.2 D2-15/D2 JH3b CAREEDIVVV 2
sequence V D J junction translation mutations
1 DP-2/V71-5+ D3-3/DXP4 JH6b CAAEHDFWSG 0
2 DP-65/3d75d…+ D5-24 JH6c CARSLGDYHY 0
3 DP-71/3d197d…+ D6-13/DN1 JH6c CARSVVYANT 0
4 DP-79/4d154…+ D1-7/DM1 JH6c CARLPNWNYV 0
5 DP-10/hv1051…+ not found JH6c CARSLIDYVP 0
6 DP-77/WHG16+ D6-13/DN1 JH5a CAAVYIQQVK 0
7 DP-10/hv1051…+ not found JH3b CARGGGAFDI 0
8 DP-48/13-2+ not found JH6b CARESRGGGG 0
9 DP-14/V1-18+ D3-10/DXP'1 JH4b CARDRILWFR 0
10 DP-15/V1-8+ D5-5/DK4 JH2 CARELWSLNW 1
Resting naive B cells
6 weeks
9 weeks
Table 11.  BN-blast 1
Table summarises the matched V, D and J alignments for each IgH sequence analysed at 0, 6 
and 9 weeks post-establishment, the first 10 amino acids of the VDJ junction translation, and 
the number of mutations detected in the V region.
sequence V D J junction translation mutations
1 DP-35/V3-11…+ D1-26 JH4b CARDLVGGPT 0
2 V3-53+ D5-5/DK4 JH2 CARDRRDTAI 0
3 DP-49/1.9III…+ D5-5/DK4 JH4b CAKNHVDTAM 0
4 DP-31/V3-9P…+ D4-17 JH2 CAKVGTVTTL 0
5 DP-2/V71-5+ D5-24 JH6b CAADYLTGIR 0
6 DP-79/4d154…+ D7-27/DHQ52 JH4b CARRWLTGDL 0
7 DP-49/1.9III…+ D4-17 JH4b CAKDLGTTVT 0
8 DP-49/1.9III…+ D1-26 JH1 CASTASSSLE 0
9 DP-10/hv1051…+ D7-27/DHQ52 JH5b CARGGGPYGD 0
10 DP-73/V5-51…+ D6-13/DN1 JH6b CARRYSSSWY 0
11 3d279d+ D1-1 JH4b CAREVWNDFS 0
12 YAC-5+ D6-13/DN1 JH4b CARATGIAAA 0
13 DP-65/3d75d…+ D2-15/D2 JH4b CARAGFGYCS 0
14 DP-14/V1-18+ D2-2 JH5b CARGLGHCSS 0
15 DP-77/WHG16+ D4-11/DA1 JH6b CARLRTTVTD 0
16 DP-65/3d75d…+ D6-13/DN1 JH6b CARFWGSSPL 1
17 DP-54/V3-7…+ D6-19 JH4b CAKTGEVAVA 2
sequence V D J junction translation mutations
1 DP-65/3d76d…+ D6-6/DN4 JH4b CAREASSFGG 0
2 DP-46/3d216…+ D6-13/DN1 JH6b CARDSYFPGI 0
3 DP-54/V3-7…+ D5-5/DK4 JH6b CARGFSYPYY 0
4 DP-47/V3-23…+ D6-19 JH6b CAKDPGVAGT 0
5 DP-31/V3-9P…+ D1-7/DM1 JH6b CAKEFGLRYS 0
6 DP-35/V3-11…+ D5-24 JH6b CARVLVEMAT 0
7 DP-79/4d154…+ D2-2 JH5b CASTKVPAAI 0
8 DP-14/VI-18+ D4 JH6b CARVYGYCSS 0
9 DP-79/4d154…+ D1-7/DM1 JH4b CASFRPFLIT 0
10 DP-79/4d154…+ not found JH4b CARQIGRGxE 0
11 DP-54/V3-7…+ D5-12/DK1 JH4b CARPVPTVQA 0
12 DP-7/21-2…+ D4-11/DA1 JH6b CARENYSIHY 0
13 DP-35/V3-11…+ D6-19 JH2 CARNLAVADY 1
14 DP-75/VI-2…+ D3-10/DXP'1 JH5b CAREEGNIGD 1
15 DP-10/hv1051…+ D24-23 JH6b CARGILSTVV 1
16 DP-46/3d216…+ D4-17 JH6b CARDPPYGDS 1
17 DP-25/VI-3b+ D3-16 JH4b CARDGSVITF 1
18 DP-63/VH4.21…+ D3-16 JH6b CxREISGWGP 2
sequence V D J junction translation mutations
1 DP-70/4d68…+ D3 JH4b CARDLVVIAR 0
2 DP-77/WHG16+ D6-19 JH6b CARATGAVAG 0
3 DP-10/hv1051…+ D3-3/DXP4 JH4b CARSPDYDFW 0
4 DP-46/3d216…+ D6-13/DN1 JH4b CAVGGPEQQL 0
5 DP-10/hv1051…+ D6-6/DN4 JH6b CARASWDSSS 0
6 V3-53+ not found JH6b CARQKSSYYY 0
7 DP-54/V3-7…+ D4 JH6b CARENCISTS 0
8 DP-49/1.9III…+ D6-6/DN4 JH4b CARRKQLAEI 0
9 DP-15/V1-8+ D4-11/DA1 JH4b CARGVGAVTN 0
10 DP-48/13-2+ not found JH6b CARGGGGFWS 0
11 DP-35/V3-11…+ D6-19 JH2 CARGIGYSSG 0
12 DP-75/VI-2…+ D2-15/D2 JH4b CARGRSMLVV 1
13 COS-6/DA-8…+ D4 JH4b CARGLRLVPA 1
14 DP-54/V3-7…+ D6-6/DN4 JH4b CARARRGWSA 1
15 DP-71/3d197d…+ D2-15/D2 JH4b CARIVGEYCS 2
16 DP-78/3d230d…+ D3-16 JH4b CARHGDRRLM 2
17 DP-46/3d216…+ D3 JH3b CARDPPSAVW 3
18 DP-47/V3-23…+ D6-19 JH6b CAKDGSSGW* 4
Resting naive B cells
6 weeks
9 weeks
Table 12.  BN-blast 2
The table summarises the matched V, D and J alignments for each IgH sequence analysed at 
0, 6 and 9 weeks post-establishment, the first 10 amino acids of the VDJ junction translation, 
and the number of mutations detected in the V region.
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confirming the purity of the isolated naive B cells (Table 11).  As expected the 
VDJ rearrangment of each sequence, together with the junction translation, was 
unique, indicating that each sequence represented a different unrelated B cell. 
When the same BN-blast 1 culture was screened after six weeks in culture, 22 
of 22 sequences analysed were unmutated.  Similar to the resting cells, the IgH 
sequences contained unrelated VDJ rearrangements and junction translations, 
signifying a polyclonal culture.  Likewise IgH analysis of BN-blast 1 at nine 
weeks yielded 10 out of 10 unmutated and clonally independent sequences 
(Table 11). 
To confirm these observations, the analysis was repeated with a second CD40 
blast culture (BN-blast 2).  The results from BN-blast 2 were comparable to 
those from BN-blast1.  All 17 IgH sequences obtained from the isolated naive B 
cells and all 18 sequences examined in the six week old culture were scored as 
unmutated (Table 12).  Nine weeks after establishment, two mutated IgH 
sequences out of 18 were identified (sequence 17 and sequence 18, Table 12), 
accounting for 11% of the total sequences at this time point.  The VDJ 
rearrangements and junction translation combinations of each sequence 
revealed a polyclonal population of cells prior to stimulation, which remained 
polyclonal at six and nine weeks (Table 12). 
Taken together the results from BN-blast 1 and BN-blast 2 suggest that naive B 
cell cultures stimulated with CD40L and IL-4 in vitro remain polyclonal and show 
no evidence of SHM for up to nine weeks in culture. 
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4.2.3 IgH Analysis of Bulk Naive LCL1 
In the next experiment, the effect of EBV infection on IgH genotype was 
determined following transformation of naive B cells in vitro.  The starting naive 
B cell population was processed and sorted as before to a purity of 99%.  Each 
of 16 IgH sequences examined in the starting population was unique, based on 
VDJ analysis and CDR3 sequences, reflecting a polyclonal population.  Fifteen 
of 16 IgH sequences analysed were unmutated.  The single mutated IgH 
sequence carried 12 mutations, and may represent a contaminating memory B 
cell. 
Resting naive B cells were then infected with EBV in vitro and expanded in 
culture, with cells harvested for analysis at six, nine and twelve weeks post-
infection.  In contrast to the B blast cultures, clonally related IgH sequences 
were detected in the BN-LCL 1 culture at six weeks post-infection.  These 
sequences (which will be referred to as clonal families) share VDJ 
rearrangements, junction translations and CDR3 sequences.  As shown in 
Table 13, in order to make the families easily distinguishable, the IgH 
sequences are grouped together and highlighted in a specific colour (e.g. 
family1 in each experiment is always yellow).  IgH sequences only detected 
once within a set of data are not colour highlighted and are displayed 
underneath any clonal families in ascending order according to number of 
mutations. 
By six weeks post-infection, 16 out of 20 sequences were clonally related 
(referred to as family 1), and the remaining 4 were all unique.  At nine weeks, a 
small proportion of individual sequences were still present, but family 1 still 
sequence V D J junction translation mutations
1 DP-88/hv1051K….+ D6-13/DN1 JH4b CARGYSSSWH 0
2 DP-32/V3-20+ not found JH6b CARDSWWGGN 0
3 DP-73/V5-51…+ D4 JH5b CARGAIVVVP 0
4 DP-10/hv1051…+ D4-17 JH4b CAKMGGGYGQ 0
5 DP-79/4d154…+ D2-21 JH2 CARTAMTWYF 0
6 DP-70/4d68…+ D6-13/DN1 JH4b CARHSGIAAV 0
7 DP-47/V3-23…+ D4-11/DA1 JH6b CAKQYSNYDY 0
8 DP-8+ D6-6/DN4 JH6b CARVL*VGQL 0
9 DP-88/hv1051K….+ D3-10/DXP'1 JH6b CARGLGNYYY 0
10 DP-71/3d197d…+ D2-15/D2 JH6b CARYHCSGGS 0
11 DP-47/V3-23…+ not found JH3b CAKAGYLDGQ 0
12 DP-49/1.9III…+ D3-22/D21-9 JH6b CAKVGGIAKV 1
13 7A.4 not found JH6b TVWTSGAKGP 1
14 VHVCW/COS-24+ D5-12/DK1 JH4b CARSGYSGYV 1
15 V3-48/hv3d1…+ not found JH4b CARVARxxFD 2
16 DP-8+ D3 JH6b CARESHSRPY 12
sequence V D J junction translation mutations
1 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
2 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
3 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
4 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
5 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
6 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
7 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
8 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
9 DP-88/hv1051K…+ D5-12/DK2 JH6b CARSERSGWE 0
10 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
11 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
12 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
13 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
14 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
15 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
16 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 4
17 DP-78/3d230d…+ D6-25 JH4b CARGAEDSSG 0
18 DP-10/hv1051…+ D4 JH6b CARAGGYCSS 1
19 DP-65/3d75d…+ D1-26 JH4b CARVKGIGGD 5
20 COS-16+ D2-8/DLR1 JH4b CAKVVHTAPA 21
Resting naive B cells
6 weeks
Table 13.  BN-LCL1
Table summarises the matched V, D and J alignments for each IgH sequence analysed at 0 
and 6 weeks post-establishment (9 and 12 weeks shown on next page), the first 10 amino 
acids of VDJ junction translation, and the number of mutations detected in the V region.
IgH sequences identified as clonal family 1 are highlighted in yellow, family 2 highlighted in 
blue and IgH sequences only detected once are not colour-highlighted.
Family 1
Family 2
sequence V D J junction translation mutations
1 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
2 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
3 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
4 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
5 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 0
6 DP-10/hv1051…+ D5-12/DK1 JH6b CATSERSGWE 0
7 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
8 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
9 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
10 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
11 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
12 DP-88/hv1051K…+ D5-12/DK1 JH6b CVRSERSGWE 1
13 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
14 DP-88/hv1051K…+ D3 JH6b CARSERSGWE 1
15 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 1
16 DP-88/hv1051K…+ D5-12/DK1 JH6b CARSERSGWE 3
17 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 0
18 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 1
19 DP-88/hv1051K…+ not found JH6b CARDSRVWLL 1
20 DP-70/4d68…+ not found JH6b CAAFNTGFGT 3
21 DP-49/1.9III…+ D2-2 JH4b CARTRGATHP 3
sequence V D J junction translation mutations
1 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 0
2 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 0
3 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 0
4 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 0
5 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 0
6 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 0
7 DP-88/hv1051k…+ D3 JH6b CARSERSGRE 0
8 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 1
9 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 1
10 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 1
11 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 1
12 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 1
13 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 1
14 DP-88/hv1051k…+ D5-12/DK1 JH6b CARSERSGWE 2
15 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLVYCS 0
16 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 0
17 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 0
18 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 0
19 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 0
20 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 0
21 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 0
22 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 1
23 DP-65/3d75d…+ D2-15/D2 JH5b CARDQLAYCS 4
24 DP-49/1.9III…+ D6-25 JH4b YARTRGATHP 1
9 weeks
12 weeks
Family 1
Family 2
Table 13.  BN-LCL1
The table summarises the matched V, D and J alignments for each IgH sequence analysed at 
9 and 12 weeks post-establishment (0 and 6 weeks shown on the previous page), the first 10 
amino acids of the VDJ junction translation, and the number of mutations detected in the V 
region.  IgH sequences identified as clonal family 1 are highlighted in yellow, family 2 
highlighted in blue and IgH sequences only detected once are not colour-highlighted.
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dominated the culture with 16 out of 21 related sequences.  At this time point, 
two sequences from a second clone (family 2) were also detected.  Finally, at 
twelve weeks post-infection, the culture consisted mainly of family 1 and family 
2, with only 1 unique sequence.  Interestingly the culture contained an 
increasing proportion of family 2 sequences over time, suggesting initial 
outgrowth of clones belonging to this family was slower than family 1. 
Although a few instances of mutated IgH sequences arose in the BN-LCL1 
culture, the majority of IgH sequences obtained were unmutated, regardless of 
time following infection.  Examples of germline sequences from family 1 are 
shown in Figure 24.  Where IgH mutations were identified in either family, they 
were for the most part situated at distinct V region locations; however, there 
was one example of a single mutation at codon 32 that was shared by several 
sequences in family 1 (Figure 25).  The recurrence of this mutation within the 
data suggests it is the result of a genuine mutation event, rather than the 
product of PCR error.  Furthermore, the isolation of a sequence (6wk(s16)) 
harbouring 3 mutations in addition to the common one, is suggestive of ongoing 
SHM within this cell clone. 
4.2.4 IgH Analysis of Bulk CD40 Blast and Bulk LCL Cultures 
Established from a Single Donor 
The first three experiments clearly showed preferential outgrowth of clonal cell 
lines following EBV transformation, whereas BN-blasts remained polyclonal.  
Since all three cultures were generated from different B cell preparations, it is 
possible that these differences were a result of variation between individual 
donors.  In order to resolve this issue, a BN-blast (BN-blast 3) and a BN-LCL 
CDR1
DP-88/hv1051K+ GGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGG
6wk(S1)        .....................................................................................
9wk(S1)        .....................................................................................
12wk(S1)       .....................................................................................
CDR2
DP-88/hv1051K+ GTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACGCACAGAAGTTCC
6wk(S1)        .....................................................................................
9wk(S1)        .....................................................................................
12wk(S1)       .....................................................................................
DP-88/hv1051K+ AGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGT
6wk(S1)        .....................................................................................
9wk(S1)        .....................................................................................
12wk(S1)       .....................................................................................
DP-88/hv1051K+ GTATTACTGTGCGAGA CDR3
6wk(S1)        ................TCAGAACGCAGTGGCTGGGAGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
9wk(S1)        ................TCAGAACGCAGTGGCTGGGAGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
12wk(S1)       ................TCAGAACGCAGTGGCTGGGAGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
V
V
V
V
Figure 24.  BN-LCL1 family 1 germline sequences were detected at 6, 9 and 12 weeks
BN-LCL1 family 1 sequences are aligned relative to the matched germline V region sequence (top row).  
The location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue text.  A box is 
drawn around the first 30 nucleotides of the VDJ junction translation.
Examples of unmutated IgH sequences from family 1.  No changes from the germline IgH sequence (top 
line) were detected in the V region.  Identical CDR3 sequences signify the clonal relationship between the 
sequences.
CDR1
DP-88/hv1051K+ GGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGG                                                                                                 
9wk(S7)        .....................................................................T...............
12wk(S9)       .....................................................................T...............
12wk(S10)      .....................................................................T...............
6wk(S16)       ........................G.....................A.....................AT...............
12wk(S14)      ................T...............................................................A....
9wk(S16)       .....................................................................................
CDR2
DP-88/hv1051K+ GTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACGCACAGAAGTTCC 
9wk(S7)        .....................................................................................
12wk(S9)       .....................................................................................
12wk(S10)      .....................................................................................
6wk(S16)       .....................................................................................
12wk(S14)      .....................................................................................
9wk(S16)       ...........................A..............................C..........................
DP-88/hv1051K+ AGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGT
9wk(S7)        .....................................................................................
12wk(S9)       .....................................................................................
12wk(S10)      .....................................................................................
6wk(S16)       .....................................................................................
12wk(S14)      .....................................................................................
9wk(S16)       ...................T.................................................................
DP-88/hv1051K+ GTATTACTGTGCGAGA CDR3
9wk(S7)        ................TCAGAACGCAGTGGCTGGGAGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
12wk(S9)       ................TCAGAACGCAGTGGCTGGGAGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
12wk(S10)      ................TCAGAACGCAGTGGCTGGGAGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S16)       ................TCAGAACGCAGTGGCTGGGAGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
12wk(S14)      ................TCAGAACGCAGTGGCTGGGAATACTACTACGGTATGGACGTCTGGGGCCAAGGG
9wk(S16)       ................TCAGAACGCAGTGGCTGGGAGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
V
V
V
V
Figure 25.  BN-LCL1 family 1 related and unrelated mutations
BN-LCL1 family 1 sequences are aligned relative to the matched germline V region sequence (top 
row).  The location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue 
text.  A box is drawn around the first 30 nucleotides of the VDJ junction translation.
Shared: 4 clonally related IgH sequences shared a common C→T  mutation.  Sequence 6wk(S16) 
carries an additional 3 changes.
Separate: 2 clonally related IgH sequences with distinct V region mutations.    
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(BN-LCL3) were established in parallel from sorted resting naive B cells derived 
from the same donor.  The two cultures were established and grown in parallel, 
and IgVH sequences from both were studied after for up to twelve weeks. 
The IgH sequences amplified from sorted naive B cells from donor 3 showed a 
polyclonal population of cells, with 17 out of 18 unmutated IgH sequences 
tested, indicating good sort purity (Table 14).  Consistent with previous data, the 
sequencing results from BN-blast 3 at six and nine weeks revealed minimal IgH 
changes compared to the resting cells, and the culture was polyclonal at all 
three time points.  Two of 23 IgH sequences were mutated at six weeks, 
however the absence of mutated IgH sequences at nine weeks suggests there 
was no accumulation of such sequences over time (Table 15).  BN-blast 3 
stopped proliferating after this point and no further time points were analysed. 
The BN-LCL3 sequence data was clearly different to the BN-blast 3 data, most 
notably due to the outgrowth of clonally related families in the LCL culture.  
Whereas BN-blast 3 remained polyclonal at all time points, BN-LCL3 contained 
5 clonally related families by six weeks, 4 of which were also found at nine and 
twelve weeks (Table 16). 
In order to confirm these observations, CDR3 spectratyping was also carried 
out on the same samples.  This method, similar to IgH sequencing, involves the 
PCR amplification of the IgH region, generating products of varying sizes due to 
differences in the lengths of CDR3 regions.  Consequently, a polyclonal 
population will produce a spectratype with a broad range of peaks 
corresponding to different sizes of amplified IgH products, whereas a 
monoclonal population yields only one peak.  Figure 26 shows the CDR3 
sequence V D J junction translation mutations
1 DP-49/1.9III…+ D6-6/DN4 JH3b CAKDRAHCTV 0
2 V3-48/hv3d1…+ D1-26 JH6b CARARHRWFG 0
3 VH32Sanz+ D6-19 JH4b CARPDPGAAA 0
4 DP-77/WHG16+ D3-10/DXP'1 JH6b CARDPTVWFG 0
5 DP-47/V3-23…+ D2-15/D2 JH3b CAKDRGYCSG 0
6 DP-71/3d197d…+ D2-21 JH4b CARGGAGYFD 0
7 DP-73/V5-51…+ not found JH6b CARHFTTGYY 0
8 DP-5/VI-24P+ not found JH6b CATPWGWGIF 0
9 DP-73/V5-51…+ D5-24 JH4b CARHASIVDY 0
10 DP-73/V5-51…+ not found JH4b CARAGRDDFL 0
11 DP-47/V3-23…+ D3-3/DXP4 JH4b CANLGAYDFW 0
12 DP-71/3d197d…+ D3-22/D21-9 JH5a CARASSGYYR 0
13 DP-79/4d154…+ D3-22/D21-9 JH4b CARHQDYYVC 0
14 DP-51+ D4 JH6b CASKVVPAAI 0
15 DP-65/3d75d…+ D5-12/DK1 JH6b CARGLWWLQY 0
16 DP-54/V3-7…+ D2-15/D2 JH6b CARDDAGMGC 1
17 DP-65/3d75d…+ D4-17 JH5b CASSSTVTMG 1
18 VH3-8 D6-19 JH6b CARDLRVDSS 4
Table 14.  Resting naive B cells used for BN-blast 3 and BN-LCL3
The table summarises the matched V, D and J alignments for each IgH sequence analysed at in 
the resting naive B cells used to generate both BN-blast 3 and BN-LCL3, the first 10 amino 
acids of the VDJ junction translation, and the number of mutations detected in the V region.  
Resting naive B cells
sequence V D J junction translation mutations
1 DP-47/V3-23…+ D3-22/D21-9 JH4b CEGWLLLHRV 0
2 DP-79/4d154…+ D2-21 JH4b CARLLSGYHS 0
3 DP-77/WHG16+ D6-6/DN4 JH4b CARDKGHIAA 0
4 DP-75/VI-2…+ D5-5/DK4 JH6b CARDQKYRYS 0
5 DP-10/hv1051…+ D5-5/DK4 JH4b CARSLSGYSY 0
6 DP-65/3d75d…+ D5-5/DK4 JH4b CAREGDSAMV 0
7 DP-79/4d154…+ D4-23 JH3b CARRPMTTVV 0
8 DP-10/hv1051…+ D3-22/D21-9 JH5b CAIMYYYDSS 0
9 DP-77/WHG16+ D6-6/DN4 JH6b CARGHSSSSH 0
10 DP-77/WHG16+ D1-26 JH6b CARASISDYY 0
11 DP-10/hv1051…+ D2-8/DLR1 JH4b CARVLLSTAV 0
12 DP-75/VI-2…+ D3-10/DXP'1 JH5b CARDQYYGLG 0
13 DP-79/4d154…+ D6-19 JH4b CARSGYSSGW 0
14 YAC-9/COS-27…+ D4 JH5b CTRLSWFDPW 0
15 DP-47/V3-23…+ not found JH4b CAKDYFTKRM 0
16 V3-53+ D6-19 JH6b CARESRQWLV 1
17 DP-75/VI-2…+ not found JH4b CARDQSWLDF 1
18 DP-79/4d154…+ D6-19 JH1 CARHVLAVAV 1
19 DP-54/V3-7…+ D4 JH6b CARVAIPAAI 1
20 DP-48/13-2+ D2-2 JH2 CARSPSYCSS 1
21 DP-54/V3-7…+ D1-26 JH6b CASRYRKPTD 2
22 DP-79/4d154…+ D4-23 JH4b CARQFVGYYL 5
23 H9 D3-10/DXP'1 JH4b CARVGRRGYY 5
sequence V D J junction translation mutations
1 LSG6.1 D1-26 JH6b CTTEGKPVAA 0
2 DP-7/21-2…+ D1-26 JH6b CAGSTLVGAP 0
3 DP-65/3d76d…+ D2-21 JH5b CARGYCGGDC 0
4 DP-47/V3-23…+ D4-23 JH4b CAKEEWTTVV 0
5 VH32Sanz+ D6-19 JH4b CARPPKNSIA 0
6 DP-77/WHG16+ D5-5/DK4 JH6b CARDRAIDTA 0
7 DP-65/3d76d…+ D5-24 JH2 CARDGNQWET 0
8 V3-53+ D2-8/DLR1 JH6b CARAGVGHYY 0
9 DP-75/VI-2…+ D1-26 JH5b CARDLEWEPR 0
10 DP-77/WHG16+ D4-17 JH4b CARDQGDYVV 0
11 DP-77/WHG16+ D3-22/D21-9 JH4b CARDPGQPKN 0
12 DP-74/VH-VI…+ D6-6/DN4 JH4b CASSFGVGLD 0
13 DP-66/V71-2…+ D3-22/D21-9 JH5b CASLSITMIV 1
14 DP-47/V3-23…+ D3-22/D21-9 JH4b CAKVGGKRIT 1
15 LSG6.1 D6-13/DN1 JH6b CTRPPSGMDV 1
16 VIV-4/4.35+ D2-15/D2 JH6b CVGEVVVVAA 1
17 DP-65/3d76d…+ D5-24 JH5b CARDGVEMAT 1
18 4M28 D5-5/DK4 JH6b CARPPGGGAR 1
19 DP-47/V3-23…+ D3-16 JH4b CAKDPPPPAM 1
6 weeks
9 weeks
Table 15. BN-blast 3
The table summarises the matched V, D and J alignments for each IgH sequence 
analysed at 6 and 9 weeks post-establishment, the first 10 amino acids of the VDJ 
junction translation, and the number of mutations detected in the V region.
sequence V D J junction translation mutations
1 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
2 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
3 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
4 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
5 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
6 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
7 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
8 DP-75/V1-2…+ D3-3/DXP4 JH4b CASSRVLRFL 0
9 DP-75/V1-2…+ D3-3/DXP4 JH4b CASSRVLRFL 1
10 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 0
11 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 0
12 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 0
13 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 0
14 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 0
15 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 1
16 DP-54/V3-7…+ D6-13/DN1 JH4b CALRIAAAGT 3
17 DP-54/V3-7…+ D6-13/DN1 JH4b CALRIAAAGT 3
18 VIV-4/4.35+ D3-22/D21-9 JH4b CARASQGYDS 3
19 VIV-4/4.35+ D3-22/D21-9 JH4b CARASQGYDS 3
20 YAC-9/COS-27…+ D2-8/DLR1 JH6b CTVYVYYYYG 0
21 DP-50/hv3019b9…+ D3-3/DXP4 JH4b CAREWLLDYW 1
sequence V D J junction translation mutations
1 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
2 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
3 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
4 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
5 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
6 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
7 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
8 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
9 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
10 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
11 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
12 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
13 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 1
14 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 0
15 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 0
16 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 0
17 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL** 1
18 DP-54/V3-7…+ D6-13/DN1 JH4b CALRIAAAGT 4
19 VIV-4/4.35+ D3-22/D21-9 JH4b CARASQGYDS 3
20 VIV-4/4.35+ D3-22/D21-9 JH4b CARASQGYDS 4
21 DP-65/3d75d…+ D6-19 JH5b CARVRPRIAV 0
sequence V D J junction translation mutations
1 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
2 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
3 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
4 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
5 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
6 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
7 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
8 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
9 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
10 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
11 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
12 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
13 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL*** 0
14 DP-79/4d154…+ D3-22/D21-9 JH3b CARPIVLL*** 0
15 DP-54/V3-7…+ D6-13/DN1 JH4b CALRIAAAGT 3
16 DP-54/V3-7…+ D6-13/DN1 JH4b CALRIAAAGT 4
17 DP-54/V3-7…+ D6-13/DN1 JH4b CALRIAAAGT 4
18 VIV-4/4.35+ D3-22/D21-9 JH4b CARASQGYDS 3
19 VIV-4/4.35+ D3-22/D21-9 JH4b CARASQGYDS 3
20 DP-49/1.9III…+ D5-24 JH4b CAKTPRVATI 5
6 weeks
9 weeks
12 weeks
Table 16.  BN-LCL3
Summary of matched V, D and J alignments for each IgH sequence analysed at 9 and 12 weeks post-
establishment (0 and 6 weeks shown on the previous page), the first 10 amino acids of VDJ junction 
translation, and the number of mutations detected in the V region.  Clonally related IgH sequences are 
colour highlighted (see legend). Note; family 3 sequences reflect a non-functional Ig rearrangement.
Family 1
Family 2
Family 3
Family 4
Family 5
Legend
resting 
naive B 
cells
BN-blast3 
6 weeks
BN-blast3 
9 weeks
BN-LCL3 
6 weeks
BN-LCL3 
9 weeks
Figure 26.  CDR3 spectratyping analysis of BN-blast 3 and BN-LCL3 
In-frame rearranged VDJ gene fragments of various sizes are represented by blue peaks.  The 
top axis represents a size ladder in base pairs.   The red peaks represent a control sample 
containing template sequences of known size.
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spectratypes from the resting naive B cells and from both BN-blast 3 and BN-
LCL3 cultures at six and nine weeks.  This data clearly shows that the B blast 
culture remained polyclonal at six and nine weeks post-establishment, with a 
spectratype which was unchanged from the resting population.  In contrast, the 
limited number of peaks in the LCL data reflects a cell culture that was 
oligoclonal at these time points.  Taken together these results confirm that 
expansion of EBV-transformed naive B cells in vitro yields selective outgrowth 
of a limited number of B cell clones, whereas induction of the same cells to 
proliferate in vitro in the absence of EBV does not cause this effect. 
Closer inspection of the IgH data from BN-LCL3 showed that three families 
contained germline IgH sequences, whereas two families harboured mutated 
IgH sequences (Table 16).  In Family 1, which was the dominant clonal family 
within the culture at six, nine and twelve weeks post-infection, unmutated IgH 
sequences were consistently detected at each time point post-infection.  
Similarly the two related IgH sequences at week six that made up family 2 were 
both germline.  Although family 3 was also detected at six, nine and twelve 
weeks, it is worth noting that these sequences carry stop codons (represented 
by asterisks) within their CDR3 regions, and as such are not able to express 
functional BCRs.  It is unknown how this family of cells was able to persist for 
up to twelve weeks in culture, but it is possible that the sequences represent 
PCR amplification of a non-functional allele which was dismissed prior to 
successful rearrangement of the alternative allele during allelic exclusion (see 
Introduction).  For the purposes of scoring IgH mutations, however, such non-
functional sequences were disregarded.  By contrast, IgH sequences from 
families 4 and 5 were detected at six, nine and twelve weeks post-infection, and 
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were all mutated.  In family 4, each sequence harboured 3 identical V region 
mutations at codons 31, 60 and 88 (Figure 27).  In addition to these shared 
mutations, three sequences (6wk(18), 12wk(16) and 12wk(17)) had each 
acquired an additional independent mutation, which could reflect ongoing SHM.  
Similarly, the IgH sequences analysed from family 5 also shared 3 mutations, at 
codons 60, 71 and 91 (Figure 28). 
In summary, the analysis of IgH sequences in this experiment has revealed the 
presence of multiple mutated sequences from six weeks onwards within the BN-
LCL3 culture.  This is in contrast to the almost exclusively germline sequences 
found in the BN-blast 3 culture.  These findings thus strengthen the correlation 
between EBV infection and the accumulation of IgV mutations within cells seen 
in earlier experiments. 
4.2.5 Detailed Studies of Clonal Evolution in Three LCLs 
Established from a Single Donor 
The above results suggest differences between the evolution of CD40L/IL-4 – 
stimulated B blasts and EBV-infected LCLs in terms of clonality and appearance 
of IgH mutations.  To further study this phenomenon, a more detailed 
experiment was carried out in which three separate BN-LCLs were established 
from a single donor. 
In this experiment, an outline of which is shown in Figure 29, B cells were FACS 
sorted and naive B cells were collected as previously described.  Approximately 
0.5 x 106 naive B cells were infected with EBV, and the following day the culture 
was split evenly into three separate wells of a 96 well plate.  The cells were 
CDR1
DP-54/V3-7+ GGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGG
6wk(S14)    ....................................................................A................
6wk(S15)    ....................................................................A................
12wk(S15)   ....................................................................A................
12wk(S16)   ....................................................................A................
12wk(S17)   ....................................................................A................
9wk(S18)    ............................................T.......................A................
CDR2
DP-54/V3-7+ GTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTATGTGGACTCTGTGA
6wk(S14)    ........................................................................T............
6wk(S15)    ........................................................................T............
12wk(S15)   ........................................................................T............
12wk(S16)   ........................................................................T............
12wk(S17)   ..........................................G.............................T............
9wk(S19)    ........................................................................T............
DP-54/V3-7+ AGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGT
6wk(S14)    ..................................................................................C..
6wk(S15)    ..................................................................................C..
12wk(S15)   ..................................................................................C..
12wk(S16)   ...............C..................................................................C..
12wk(S17)   ..................................................................................C..
9wk(S19)    ..................................................................................C..
DP-54/V3-7+ GTATTACTGTGCG CDR3
6wk(S14)    .............CTTCGTATAGCAGCAGCTGGTACGAGAGCCCTGCCTTTTGACTACTGGGGCCAGGGA
6wk(S15)    .............CTTCGTATAGCAGCAGCTGGTACGAGAGCCCTGCCTTTTGACTACTGGGGCCAGGGA
12wk(S15)   .............CTTCGTATAGCAGCAGCTGGTACGAGAGCCCTGCCTTTTGACTACTGGGGCCAGGGA
12wk(S16)   .............CTTCGTATAGCAGCAGCTGGTACGAGAGCCCTGCCTTTTGACTACTGGGGCCAGGGA
12wk(S17)   .............CTTCGTATAGCAGCAGCTGGTACGAGAGCCCTGCCTTTTGACTACTGGGGCCAGGGA
9wk(S18)    .............CTTCGTATAGCAGCAGCTGGTACGAGAGCCCTGCCTTTTGACTACTGGGGCCAGGGA
V
V
V
V
Figure 27.  BN-LCL3  family 4         
BN-LCL3 family 4 sequences are aligned relative to the matched germline V region sequence (top row).  
The location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue text.  A box is 
drawn around the first 30 nucleotides of the VDJ junction translation.
5 sequences harboured 3 identical mutations.  Extra mutations acquired by sequences “12wks(16)”, 
“12wks(17)” and “9wks(18)” were distinct from one another. 
3
4
3
4
3
4
3
4
31
60
88
CDR1
VIV-4/4.35+ CCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGG
6wk(S16)    .....................................................................................
6wk(S17)    .....................................................................................
9wk(S20)    .....................................................................................
12wk(S18)   .....................................................................................
12wk(S19)   .....................................................................................
9wk(S21)    ...........................................................T.........................
CDR2
VIV-4/4.35+ ATCCGGCAGCCCGCCGGGAAGGGACTGGAGTGGATTGGGCGTATCTATACCAGTGGGAGCACCAACTACAACCCCTCCCTCAAGA
6wk(S16)    .......................................................................T.............
6wk(S17)    .......................................................................T.............
9wk(S20)    .......................................................................T.............
12wk(S18)   .......................................................................T.............
12wk(S19)   .......................................................................T.............
9wk(S21)    .......................................................................T.............
VIV-4/4.35+ GTCGAGTCACCATGTCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTA
6wk(S16)    .................A...................................................................
6wk(S17)    .................A...................................................................
9wk(S20)    .................A...................................................................
12wk(S18)   .................A...................................................................
12wk(S19)   .................A...................................................................
9wk(S21)    .................A...................................................................
VIV-4/4.35+ TTACTGTGCG CDR3
6wk(S16)     ...T......AGAGCCAGTCAGGGCTATGATAGTAGTGGTTATTACTCGTACTTCTTTGACTACTGGGGCCAGGGA
6wk(S17)     ...T......AGAGCCAGTCAGGGCTATGATAGTAGTGGTTATTACTCGTACTTCTTTGACTACTGGGGCCAGGGA
9wk(S20)     ...T......AGAGCCAGTCAGGGCTATGATAGTAGTGGTTATTACTCGTACTTCTTTGACTACTGGGGCCAGGGA
12wk(S18)    ...T......AGAGCCAGTCAGGGCTATGATAGTAGTGGTTATTACTCGTACTTCTTTGACTACTGGGGCCAGGGA
12wk(S19)    ...T......AGAGCCAGTCAGGGCTATGATAGTAGTGGTTATTACTCGTACTTCTTTGACTACTGGGGCCAGGGA
9wk(S21)     ...T......AGAGCCAGTCAGGGCTATGATAGTAGTGGTTATTACTCGTACTTCTTTGACTACTGGGGCCAGGGA
V
V
V
V
Figure 28.  BN-LCL3 family 5    
BN-LCL3 family 5 sequences are aligned relative to the matched germline V region sequence (top 
row).  The location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue text.  
A box is drawn around the first 30 nucleotides of the VDJ junction translation.
6 sequences harboured 3 identical mutations.  An extra mutation was acquired by sequences 
“9wks(20)”. 
3
4
3
4
3
4
3
4
60
71
91
IgD+CD27- naïve B cells
+ EBV (1 hour)
EBV infection
24 hours
cells split into 3 wells
2 weeks
3 separate culture split and waste 
pooled for a single pellet
3 cultures kept  separate as distinct LCLs derived from a single donor
IgH sequences compared to germline using Vbase
IgH PCR of cell pellets 
and E.coli
transformation
IgH PCR of cell pellets 
and  E.coli
transformation
Figure 29.  Establishment of three separate LCLs from one donor (BN-LCL4a, b and c)
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thereafter cultured and expanded separately and three distinct BN-LCLs (BN-
LCL4a, BN-LCL4b and BN-LCL4c) were established. 
Since all the naive B cells collected during the cell sort were used to generate 
the BN-LCL cultures, the first time point analysed was at two weeks post-
infection, when a cell sample was obtained by pooling aliquots from each of the 
three BN-LCLs.  Analysis of 33 sequences generated at this two week time 
point revealed that the cultures were typical of resting naive B cells, containing 
a polyclonal mixture, of which all 33 sequences were unmutated (Table 17).  
Cells continued to be harvested from each LCL at regular time points up until 
twelve weeks post-infection and IgH sequences examined as before. 
Clonal Dynamics of BN-LCL4 Cultures 
As early as four weeks post-infection, distinct clonal families were identified in 
the BN-LCL4a culture (Table 18).  At this time there was still a significant 
proportion of clonally independent IgH sequences (9 out of 32), but from six 
weeks onwards this proportion continued to diminish.  Interestingly, whilst family 
2 was clearly the predominant clone at four and six weeks post-infection, 
member of this family vastly declined by week nine, and at week twelve no 
sequences belonging to this clone were detected.  Conversely, only 2 IgH 
sequences (at week four) from family 1 were observed prior to twelve weeks, at 
which point this clone not only reappeared in the culture, but became the 
dominant clonal family.  A similar pattern was observed in family 3, in which 
substantial numbers of IgH sequences were not detected until nine weeks post-
infection when they made up the largest proportion of clonally related 
sequences in the culture.  Taken together, these results highlight the shifts in 
sequence V D J junction translation mutations
1 DP-71/3d197d D3-10/DXP'1 JH6b CARHSGITM 0
2 DP-7/21-2 D1-26 JH4b CARDGGFVGA 0
3 DP-14/V1-18+ D3-9/DXP1 JH4b CARSTGGYDI 0
4 DP-2/V71-5+ D4 JH6b CAAQNDIVVV 0
5 DP-66/V71-2 D3-22/D21-9 JH5b CARYEYYYDS 0
6 DP-71/3d197d D1-26 JH1 CARETIVGAT 0
7 DP-10/hv1051 D3-22/D21-9 JH2 CASSSGYPDW 0
8 VH32sanz+ D6-19 JH4b CARLSGWYSE 0
9 LSG6.1 D6-19 JH4b CTTGIRIAVA 0
10 DP-65/3d75d D1-26 JH4b CARENNEGSP 0
11 3d277d+ D4-17 JH4b CARSPRLRGP 0
12 DP-14/V1-18+ D3-3/DXP4 JH6b CARGSYDFWS 0
13 DP-7/21-2 D3-22/D21-9 JH5b CVTDSSGFHW 0
14 DP-73/V5-51 D5-5/DK4 JH4b CARHVTAMAD 0
15 DP-58/hv3d1EG D4 JH6b CARDGVPAAM 0
16 hv3005/b1..m..+ D2-8/DLR1 JH6b CARDPGVTYY 0
17 DP-47/V3-23 D3-10/DXP'1 JH4b CAKLFHR*ED 0
18 DP-65/3d75d not found not found CARQVAAAVD 0
19 DP-25/VI-3b+ not found JH4b CARGPTDYWG 0
20 COS-6/DA-8 D2-15/D2 JH6b CARRGGSDIY 0
21 DP-8+ D7-27 JH3b CARDGNLGRG 0
22 DP-58/hv3d1EG D4-11/DA1 JH6b CARDYSNYDY 0
23 DP-47/V3-23 D3-22/D21-9 JH4b CAKSSNYYDS 0
24 DP-17/3d197d D1-26 JH4b CARSPPGLNN 0
25 DP-73/V5-51 D3-10/DXP'1 JH6b CARLYYGSGP 0
26 DP-49/1.9III D6-13/DN1 JH6b CARAGTRYYY 0
27 DP-70/4d68 D2-15/D2 JH3b CARDMGKDIV 1
28 DP-17/3d197d D2-8/DLR1 JH4b CAKKRxLY*W 1
29 DP-88/hv1051K D2-2 JH6b CASSNTVLGG 1
30 DP-73/V5-51 D5-5/DK4 JH6b CARLGAAMVF 1
31 DP-79/4d154 D3-9/DXP1 JH5b CARPRHDITM 1
32 DP-5/V1-24P+ D3-10/DXP'1 JH6b CACCSRSEDY 2
33 DP-5/V1-24P+ not found not found CATVEF 2
2 weeks
Table 17.  Two week IgH data from BN-LCL4a, b and c
Summary table of IgH sequences from cells harvested and pooled from all three 
LCLs (BN-LCL2a, b and c)  at 2 weeks post-EBV infection.  Data contain matched 
V, D and J alignments for each IgH sequence, the first 10 amino acids of the VDJ 
junction translation, and the number of mutations detected in the V region.
4 weeks 
6 weeks 
sequence V D J junction translation mutations
1 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 1
2 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 3
3 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 0
4 DP-71/3d197d…+ D1-7/DM1 JH6 CASGTTVRYY 1
5 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 2
6 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 3
7 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
8 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
9 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
10 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
11 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
12 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
13 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
14 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
15 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
16 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
17 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
18 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
19 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
20 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
21 DP-71/3d197d…+ D1-7/DM2 JH6b CASGTTVRYY 5
22 DP-7/21-2…+ D6-6/DN4 JH4b CAREYSGSSN 13
23 DP-7/21-2…+ D6-6/DN4 JH4b CAREYSGSSN 14
24 DP-73/V5-51…+ D6-13/DN1 JH4b CARPYRDSSS 0
25 DP-58/hv3d1EG not found JH4b xAxDLDYWGQ 1
26 hv3005/b1…m…+ D6-13/DN1 JH4b CARALIAAAG 3
27 DP-73/V5-51…+ D4-17 JH4b CARRTDYGDY 3
28 DP-10/hv1051…+ D4 JH4b CAKGYCSSTS 4
29 DP-65/3d75d…+ D1-14/DM2 JH4b CARVSRYSDD 6
30 DP-88/hv1051K…+ D6-6/DN4 JH4b CARDGGIAAL 7
31 DP-8+ D6-6/DN4 JH5b CARASPYSSS 12
32 DP-7/21-2…+ D1-1 JH5b CARVVGRRFD 13
sequence V D J junction translation mutations
1 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 2
2 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 2
3 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
4 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
5 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
6 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
7 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
8 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
9 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
10 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
11 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
12 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
13 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
14 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
15 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
16 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
17 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
18 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 5
19 DP-71/3d197d…+ D1-7/DM1 JH6b CTSGTTVRYY 6
20 DP-7/21-2…+ D6-6/DN4 JH4b CAREYSGSSN 13
Family 1
Family 2
Family 3
Family 4
Family 5
Legend
Family 6
Table 18.  BN-LCL4a
Summary of matched V, D and J alignments for each IgH sequence analysed at 4 and 
6 weeks post-establishment (9 and 12 weeks shown on the next page), the first 10 
amino acids of the VDJ junction translation, and the number of mutations detected 
in the V region.  Clonally related IgH sequences are colour highlighted (see legend). 
9 weeks 
12 weeks 
sequence V D J junction translation mutations
1 DP-71/3d197d…+ D3-22/D21-9 JH6b CARGRDDSSG 0
2 DP-71/3d197d…+ D3-22/D21-9 JH6b CARGRDDSSG 2
3 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 1
4 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 3
5 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 3
6 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
7 DP-71/3d197d…+ D1-7/DM1 JH6b CASGTTVRYY 4
8 DP-70/4d68…+ D6-6/DN4 JH4b CARLEAMTSF 5
9 hv3005/b1..m…+ D3-10/DXP' JH6b CARDFIHDYY 8
10 hv3005/b1..m…+ D3-10/DXP' JH6b CARDFIHDYY 9
11 DP-7/21-2…+ D6-6/DN4 JH4b CAREYSGSSN 13
12 DP-7/21-2…+ D6-6/DN4 JH4b CAREYSGSSN 13
13 DP-7/21-2…+ D6-6/DN4 JH4b CAREYSGSSN 13
14 DP-7/21-2…+ D6-6/DN4 JH4b CAREYSGSSN 13
15 DP-7/21-2…+ D6-6/DN4 JH4b CATEYSGSSN 14
16 DP-7/21-2…+ D6-6/DN4 JH4b CAREYSGSSN 15
17 hv3005/b1..m…+ D1-20 JH6b CAREVVREGS 3
18 DP-71/3d197d…+ D5-12/DK1 JH6b CARGGFRGYE 4
19 hv3005/b1..m…+ D5-5/DK4 JH5a CARDQQTWIQ 9
sequence V D J junction translation mutations
1 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 3
2 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 3
3 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 3
4 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 3
5 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 3
6 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 4
7 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 4
8 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 6
9 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 6
10 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 7
11 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARRWFGELW 7
12 DP-70/4d68…+ D6-6/DN4 JH4b CARLEAMTSF 4
13 DP-70/4d68…+ D6-6/DN4 JH4b CARLEAMTSF 4
14 hv3005/b1..m…+ D3-10/DXP'1 JH6b CARDFIHDYY 8
15 DP-73/V5-51…+ D3-10/DXP'1 JH4b CARTSTLLRG 10
16 DP-49/1.9III…+ D3-22/D21-9 JH4b CAKDSHSSA 12
Family 1
Family 2
Family 3
Family 4
Family 5
Legend
Family 6
Table 18.  BN-LCL4a
Summary of matched V, D and J alignments for each IgH sequence analysed at 9 
and 12 weeks post-establishment (4 and 6 weeks shown on the previous page), the 
first 10 amino acids of the VDJ junction translation, and the number of mutations 
detected in the V region.  Clonally related IgH sequences are colour highlighted 
(see legend).
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the dynamics of clonal dominance within the BN-LCL4a culture, suggesting 
variability in the relative capacity of each family to thrive or compete as the 
culture progressed.  It is possible that although IgH sequences such as those 
from family 1 were not detected at six and nine weeks, they were in fact still 
present in small numbers. 
In contrast to BN-LCL4a, the IgH sequencing data from BN-LCL4b reflected a 
culture that was polyclonal at four weeks post-infection (Table 19).  However, by 
six weeks post-infection three clonally related families (1, 2 and 3) were 
detected, although half the amplified IgH sequences were still clonally unique.  
After nine weeks the culture was dominated by two clonal families, with the 
largest proportion of sequences belonging to family 3.  At twelve weeks post-
infection, 11 of 11 IgH sequences analysed were derived from family 3 (Table 
19). 
In the case of LCL4b, the CDR3 spectratyping technique was also used to 
confirm the evolution of dominant clones in the culture.  Figure 30 shows the 
spectratypes from BN-LCL4b at four, six, nine and twelve weeks post-infection.  
These data confirm that whilst the culture was still polyclonal at four weeks, 
fewer peaks were seen at six weeks reflecting an oligoclonal culture, and only 2 
peaks were seen at nine weeks.  These peaks presumably correspond to the 2 
clonal families detected in the IgH sequencing data.  A single peak was 
observed at twelve weeks, in agreement with the IgH data from that time point. 
From previous data it was apparent that in some instances clonal families 
dominating the culture at twelve weeks were detectable in smaller proportions 
as early as four weeks post-infection.  We therefore investigated whether B cell 
sequence V D J junction translation mutations
1 DP-47/V3-23…+ D6-19 JH4b CARFSSGWWG 2
2 DP-66/V71-2….+ D6-6/DN4 JH4b CARDSSAARP 0
3 DP-79/4d154…+ not found JH3b CARAGGKLVA 0
4 DP-71/3d197d…+ D7-27/DHQ52 JH5b CARSGQVRFG 0
5 DP-10/hv1051…+ D6-13/DN1 JH6b CARAGGRDPP 0
6 DP-71/3d197d…+ D3-22/D21-9 JH4b CARAVGGPPF 0
7 DP-65/3d75d…+ D3 JH4b CARDGYGLDY 0
8 DP-73/V5-51…+ D1-26 JH4b CARLQDSPPD 0
9 DP-7/21-2…+ D5-5/DK4 JH4b CAREAVRYSY 0
10 DP-3+ D4-b JH4b CATARSTGYL 0
11 DP-73/V5-51…+ D1-26 JH6b CARYGSYPYY 0
12 DP-54/V3-7…+ D1-1 JH3b CARDTNWNGA 1
13 DP-77/WHG16+ D6-13/DN1 JH6b CARDVGSSSW 1
14 b54../hv3005f3…+ D3-22/D21-9 JH4b CAKSRYYYDS 2
15 DP-79/4d154…+ D1-26 JH4b CARAASGSLD 2
16 DP-88/hv1051K…+ not found not found CARVARYDIL 2
17 DP-71/3d197d…+ D3-3/DXP4 JH4b CARVRLSGWY 3
18 DP-70/4d68…+ D1-26 JH4b CARDQGSYYG 5
19 DP-67/VH4-4B+ D1-14/DM2 JH4b CARVSLEAVx 5
20 DP-7/21-2…+ D6-19 JH6b CARDSSGWYS 6
sequence V D J junction translation mutations
1 DP-47/V3…+ D6-19 JH4b CARGSSGWWG 2
2 DP-47/V3-23…+ D6-19 JH4b CARGSSGWWG 5
3 DP-51+ not found JH6b CARVRGWTTY 2
4 DP-51+ not found JH6b CARVRGWTTY 5
5 DP-51+ not found JH6b CARVRGWTTY 5
6 DP-51+ not found JH6b CARVRGWTTY 6
7 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 2
8 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
9 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
10 DP-47/V3-23…+ D3-D10/DXP'1 JH6b CAKDRGFGEL 7
11 DP-10/hv1051…+ not found JH6b CARESTGDYY 0
12 DP-65/3d75d…+ D5-24 JH6b CARELKRWLQ 0
13 VHSP/VH4.2…+ not found JH6b CARDTYYDSN 0
14 DP-71/3d197d…+ D1-26 JH5b CARDLGSQWE 0
15 DP-73/V5-51…+ D4-23 JH6b CARHGGGNSR 0
16 DP-79/4d154….+ D3-10/DXP'1 JH3b CLGGNDAFDI 1
17 DP-73/V5-51…+ D3-22/D21-9 JH4b CARQTDDSSG 1
18 DP-71/3d197d…+ D6-19 JH6b CASMPSIAVA 1
19 p1 D3-D21-9 JH6b CVKEGSSYYY 2
4 weeks
6 weeks 
Table 19.  BN-LCL4b
Summary of matched V, D and J alignments for each IgH sequence analysed at 4 
and 6 weeks post-establishment (9 and 12 weeks shown on the next page), the 
first 10 amino acids of the VDJ junction translation, and the number of mutations 
detected in the V region.  Clonally related IgH sequences are colour highlighted 
(see legend).
family 1
family 2
family 3
sequence V D J junction translation mutations
1 DP-47/V3-23…+ D6-19 JH4b CARGSSGWWG 2
2 DP-47/V3-23…+ D6-19 JH4b CARGSSGWWG 2
3 DP-47/V3-23…+ D6-19 JH4b CARGSSGWWG 3
4 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
5 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
6 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
7 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
8 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
9 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
10 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
11 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
12 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
13 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
14 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
15 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
16 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 8
17 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 8
18 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 8
19 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 8
sequence V D J junction translation mutations
1 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 4
2 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
3 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
4 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
5 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
6 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
7 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
8 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
9 DP-47/V3-23…+ D3-10/DXP'2 JH6b CAKDRGFGEL 7
10 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 7
11 DP-47/V3-23…+ D3-10/DXP'1 JH6b CAKDRGFGEL 8
9 weeks 
12 weeks 
Table 19.  BN-LCL4b
Summary of matched V, D and J alignments for each IgH sequence analysed at 9 
and 12 weeks post-establishment (4 and 6 weeks shown on the previous page), 
the first 10 amino acids of the VDJ junction translation, and the number of 
mutations detected in the V region.  Clonally related IgH sequences are colour 
highlighted (see legend). 
family 1
family 2
family 3
4 weeks
6 weeks
9 weeks
12 weeks
Figure 30.  CDR3 spectratyping analysis of BN-LCL4b
In-frame rearranged VDJ  gene fragments of various sizes are represented by blue 
peaks.  The top axis represents a size ladder in base pairs.   The red peaks represent 
a control sample containing template sequences of known size.  BN-LCL4b was still 
polyclonal at 4 weeks, but fewer clones were detected over time until one clone 
dominated the culture at 12 weeks post-infection.
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clones from family 3, detectable at six, nine and twelve weeks by sequencing of 
the bulk IgH PCR products could also be detected at 4 weeks.  To address this 
issue, an Ig V region-alignment/CDR3-specific PCR technique was employed to 
probe the BN-LCL4b four week DNA sample.  Using this approach, 12 
sequences from family 3 were isolated, indicating that expansion was clearly 
occurring at this early stage albeit not to a degree significant enough to be 
detected by the global IgH PCR method (data not shown). 
In the third LCL (BN-LCL4c) established from this donor, IgH sequences at six 
weeks post-infection reflected an almost monoclonal culture (Table 20).  Family 
1 was by far the predominant clonal group at six weeks, comprising 13 of 15 
IgH sequences amplified.  Similar results were found at weeks nine and twelve, 
reflecting that family 1 largely dominated the culture (Table 20). 
During the analysis of BN-LCL4c, no viable sequencing data could be obtained 
from the four week time point using the standard IgH PCR method.  Therefore 
family 1 CDR3-specific primers were used to amplify DNA from this timepoint.  
As shown in Table 20, B cells carrying this same CDR3 sequence were present 
at four weeks, but it is not known if they represented the dominant clone at this 
time (data not shown). 
Somatic Hypermutation within BN-LCL4 Cultures 
Having examined the clonal relationships within the BN-LCL4a, -b and –c 
cultures, we next looked in detail at the patterns of SHM seen in some of the 
clones.  Within all three cultures, most clonal families showed evidence of 
mutated IgH sequences from four weeks post-infection.  Closer examination 
revealed that IgH sequences in some clonal families shared identical mutation 
sequence V D J junction translation mutations
1 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
2 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
3 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
4 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
5 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
6 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
7 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
8 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
9 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
10 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
11 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
12 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 12
13 DP-88/hv1051k…+ D6-19 JH5b CARGIAVPGG 1
14 DP-88/hv1051k…+ D6-19 JH5b CARGIAVPGG 1
15 DP-79/4d154…+ D6-25 JH4b CARQVAAAVD 3
6 weeks 
sequence V D J junction translation mutations
1 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
2 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
3 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
4 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
5 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
6 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
7 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
8 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
9 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
10 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
11 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
12 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
13 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
14 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
15 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
16 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
17 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 6
18 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 6
19 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 6
20 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 7
21 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 8
22 DP-51+ D7-27/DHQ52 JH4b CARDPGRPQQ 3
sequence V D J junction translation mutations
1 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
2 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
3 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
4 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
5 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
6 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
7 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
8 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
9 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
10 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
11 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
12 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
13 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
14 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
15 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
16 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
17 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 5
18 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 6
19 DP-47/V3-23…+ not found JH4b CAKGCGGVKT 6
20 DP-51+ D7-27/DHQ52 JH4b CARDPGRPQQ 3
21 DP-51+ D7-27/DHQ52 JH4b CARDPGRPQQ 3
9 weeks 
12 weeks 
Family 1
Family 2
Family 3
Legend
Table 20.  BN-LCL4c
Summary of matched V, D and J alignments for each IgH sequence analysed at 6, 
9 and 12 weeks post-establishment , the first 10 amino acids of the VDJ junction 
translation, and the number of mutations detected in the V region.  Clonally 
related IgH sequences are colour highlighted (see legend). 
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patterns (BN-LCL 4a/family 3 and BN-LCL4c/family 3) with little or no deviation 
detected between sequences.  On the other hand, several families contained 
IgH sequences which although related to one another, varied significantly in the 
number and location of mutations.  Generally, such clonal families contained a 
mixture of (i) multiple sequences harbouring a pattern of shared, family-specific 
mutations, (ii) sequences containing the family-specific mutation pattern, plus 
additional mutations, which may represent ongoing mutation in the culture, (iii) 
sequences containing some but not all of the shared mutation pattern, possibly 
representing ancestors, (iv) sequences carrying mutations that were not shared 
by any other sequence.  Indeed in several of these clonal families, detailed 
analysis of the IgH mutations revealed complex relationships between the 
sequences, in which mutations appeared to accumulate in a successive fashion 
in consecutive generations of cell progeny.  As these mutations were 
suggestive of “clonal evolution” within the families, hypothetical family trees 
were constructed based on the relationships between IgH sequences identified 
within the cultures. 
The first LCL clonal family tree presented in this thesis will be discussed in the 
greatest detail in order to illustrate how the data was interpreted. 
BN-LCL 4a/Family 2 
Using the sequence information (summarised in Table 18), a family tree was 
drawn to show the relationship between members of the clonally related family 
2 from BN-LCL4a.  Cell clones are represented by a circle, inside which is 
shown the number of IgH mutations.  Ancestor cell clones are positioned on the 
top row, with arrows leading to descendents on the row below, and so on.  
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Specific IgH sequences representing cells/clones in which the mutations were 
identified are indicated underneath the circles.  Where multiple sequences 
harbouring the same mutations were found, the identity of an example 
sequence is provided, and the number of identical sequences detected is 
shown in brackets inside the circle.  Circles with dashed lines represent putative 
intermediates that were not identified within the cultures.  Divergent branches of 
the family trees are indicated where appropriate, and IgH sequence alignments 
from distinct branches are presented in separate figures. 
Multiple sequences carrying the same 4 mutations (at codons 29, 35, 62 and 
70) were identified in family 2; therefore this mutation pattern could be 
described as family-specific.  Importantly, a germline sequence with the same 
CDR3 region, but carrying 0 mutations was also identified, confirming that the 
common ancestor in this case was a naive B cell.  Several distinct progeny cell 
lineages can be seen, with additional mutations arising along successive 
generations (Figure 31).  The most striking example of this can be seen in 
branch 1, where a germline clone with 0 mutations gave rise to a cell that 
acquired 1 mutation (at codon 70), which was succeeded by a cell acquiring a 
further mutation (at codon 29), followed by a clone acquiring 2 additional 
mutations (at codons 35 and 62).  Subsequent multiple progeny presumably 
then went on to acquire additional mutations independently of one another 
(Figure 32). 
Similar lines of succession can be seen in branch 2 (Figure 33) and branch 3 
(Figure 34). 
 
Figure 31.  BN-LCL4a family 2 tree
Cell clones are represented by a circle, inside which is shown the number of IgH mutations.  
Ancestor cell clones are positioned on the top row, with arrows leading to descendents on the 
row below. Specific IgH sequences representing cells/clones in which the mutations were 
identified are indicated underneath the circles.  Where multiple sequences harbouring the 
same mutations were found, the identity of an example sequence is provided, and the number 
of identical sequences detected is shown in brackets inside the circle.  Circles with dashed lines 
represent intermediates that were not identified within the cultures.  Arrows signify the 
proposed order of mutation accumulation.  Different trees branches are indicated where 
appropriate.
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Figure 31.  BN-LCL4a family 2 tree
4wk(S3)
4wk(S4)
4wk(S5)
9wk(S3)
6wk(S1)
4wk(S6)
4wk(S20)
6wk(S14)
Branch 1
Branch 2
Branch 3
CDR1
DP-71/3d197d+ CCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGG
4wk(S3)       .....................................................................................
9wk(S3)       .....................................................................................
6wk(S1)       ...............................................................T.....................
4wk(S6)       ...............................................................T.................T...
6wk(S15)      ...............................................................T.................T...
6wk(S16)      ...............................................................T.................T...
6wk(S17)      ...............................................................T.................T...
6wk(S18)      ...............................................................T.................T...
4wk(S18)      ...............................................................T.................T...
4wk(S19)      ...............................................................T......C..........T...
6wk(S19)      ........................................................A......T.................T...
CDR2
DP-71/3d197d+ ATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACAGTGGGAGCACCAACTACAACCCCTCCCTCAAGA
4wk(S3)       .....................................................................................
9wk(S3)       .....................................................................................
6wk(S1)       .....................................................................................
4wk(S6)       ..............................................T......................................
6wk(S15)      ..............................................T......................................
6wk(S16)      ............................................T.T......................................
6wk(S17)      .............................A................T......................................
6wk(S18)      ..............................................T......................................
4wk(S18)      ..............................................T......................G...............
4wk(S19)      ..............................................T......................................
6wk(S19)      ..............................................T............................C.........
DP-71/3d197d+ GTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTA
4wk(S3)       .....................................................................................
9wk(S3)       ..............G......................................................................
6wk(S1)       ..............G......................................................................
4wk(S6)       ..............G......................................................................
6wk(S15)      ..............G............................T.........................................
6wk(S16)      ..............G......................................................................
6wk(S17)      ..............G......................................................................
6wk(S18)      ..............G.........................................................G............
4wk(S18)      ..............G......................................................................
4wk(S19)      ..............G......................................................................
6wk(S19)      ..............G......................................................................
DP-71/3d197d+ TTACTGTGCGAGA CDR3
4wk(S3)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
9wk(S3)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S1)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
4wk(S6)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S15)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S16)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S17)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S18)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
4wk(S18)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
4wk(S19)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S19)      .......A....TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
V
V
V
V
Figure 32.  BN-LCL4a family 2 – branch 1
BN-LCL4a family 2 sequences are aligned relative to the matched germline V region sequence (top row).  
The location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue text.  A box is 
drawn around the first 30 nucleotides of the VDJ junction translation.
The ancestral cell carrying 0 mutations gave rise to progeny harbouring a single mutation at codon 70, 
followed by a daughter cell which gained an extra mutation at codon 29 and so on.  The branch of the family 
2 tree shown in this alignment highlights the accumulation of mutations in a stepwise fashion, along with 
successive generations of cell progeny. 
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CDR1
DP-71/3d197d+ CCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGG
4wk(S3)       .....................................................................................
4wk(S4)       ...............................................................T.................T...
6wk(S2)       ...............................................................T.................T...
4wk(S5)       ...............................................................T.................T...
9wk(S4)       ...............................................................T.................T...
9wk(S9)       ...............................................................T.................T...
CDR2
DP-71/3d197d+ ATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACAGTGGGAGCACCAACTACAACCCCTCCCTCAAGA
4wk(S3)       .....................................................................................
4wk(S4)       .....................................................................................
6wk(S2)       .....................................................................................
4wk(S5)       ..............................................T......................................
9wk(S4)       ..............................................T......................................
9wk(S9)       ..............................................T......................................
DP-71/3d197d+ GTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTA
4wk(S3)       .....................................................................................
4wk(S4)       .....................................................................................
6wk(S2)       .....................................................................................
4wk(S5)       .....................................................................................
9wk(S4)       .....................................................................................
9wk(S9)       .....................................................................................
DP-71/3d197d+ TTACTGTGCGAGA CDR3
4wk(S3)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
4wk(S4)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S2)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
4wk(S5)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
9wk(S4)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
9wk(S9)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
Figure 33.  BN-LCL4a  family 2 – branch 2
BN-LCL4a family 2 sequences are aligned relative to the matched germline V region sequence (top 
row).  The location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue text.  
A box is drawn around the first 30 nucleotides of the VDJ junction translation.
Two IgH sequences (4wk(S4) and 6wk(S2)) carry 2 identical mutations at codons 29 and 35.  Three 
sequences (4wk(S5), 9wk(S4) and 9wk(S9)) carrying an additional third mutation at codon 52 were 
also detected.
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CDR1
DP-71/3d197d+ CCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGG
4wk(S3)       .....................................................................................
9wk(S3)       .....................................................................................
4wk(S20)      .................................................................................T...
6wk(S14)      ...............................................................T.................T...
4wk(S18)      ...............................................................T.................T...
CDR2
DP-71/3d197d+ ATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACAGTGGGAGCACCAACTACAACCCCTCCCTCAAGA
4wk(S3)       .....................................................................................
9wk(S3)       .....................................................................................
4wk(S20)      ..............................................T......................................
6wk(S14)      ..............................................T......................................
4wk(S18)      ..............................................T......................................
DP-71/3d197d+ GTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTA
4wk(S3)       .....................................................................................
9wk(S3)       ..............G......................................................................
4wk(S20)      ..............G...............................................G....C.................
6wk(S14)      ..............G....................................................C.................
4wk(S18)      ..............G....................................................C.................
DP-71/3d197d+ TTACTGTGCGAGA CDR3
4wk(S3)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
9wk(S3)       ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
4wk(S20)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
6wk(S14)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
4wk(S18)      ............TGGGACTACGGTCAGGTACTACTACGGTATGGACGTCTGGGGCCAAGGG
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Figure 34 - BN-LCL4a family 2 – branch 3
BN-LCL4a family 2 sequences are aligned relative to the matched germline V region sequence (top 
row).  The location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue text.  
A box is drawn around the first 30 nucleotides of the VDJ junction translation.
Three IgH sequences were identified carrying 5 mutations.  Of these, 4 identical mutations at codons
35, 62, 70 and 84 were shared by each IgH sequence.  The fifth mutations in sequences 6wk(S14) 
and 4wk(S18) are identical (at codon 29), whereas the fifth mutation in 4wk(S20) is unique.  
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BN-LCL 4b/Family 3 
The tree constructed for family 3 (Figure 35) contains one main branch (branch 
1), plus a subsidiary branch (branch 2) in which only one IgH sequence 
(“12wk(S1)”) was detected, harbouring the same 2 mutations (at codons 56 and 
81) carried by all sequences belonging to branch 1.  Indeed an IgH sequence 
carrying just these 2 mutations was also present in the data, which not only 
represents the common ancestor between the two branches, but by the criteria 
used in this study is also genotypically a naive cell (Figure 36). 
As with the BN-LCL4a/family 2 tree, branch 1 is a good example of successive 
accumulation of mutations within a clonal family.  The detection of multiple 
sequences carrying the family-specific set of 7 mutations at codons 29, 30, 31 
(x2), 35, 56 and 81 is particularly interesting as this suggests preferential 
expansion of the clone at this stage.  This analysis strongly suggests that 
mutated IgH sequences arise from naive B cell infection, rather than PCR error 
or contamination with memory B cells. 
4.2.6 Analysis of IgH Mutations in Bulk LCLs and LCLs 
Established by Limiting Dilution 
In work performed by Dr Sridhar Chaganti prior to the current study, the effect of 
EBV infection and transformation on naive B cells was studied using LCLs 
established under the conditions of limiting dilution.  Such experiments mainly 
yielded monoclonal cultures, of which approximately one quarter contained 
mutated IgH sequences after ten-twelve weeks of growth.  Since this method 
involved the infection of small numbers of B cells (typically 50-200 per well), 
sufficient cell numbers were not available to harvest until approximately10 
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Figure 35.  BN-LCL4b family 3 tree
Cell clones are represented by a circle, inside which is shown the number of IgH mutations.  
Ancestor cell clones are positioned on the top row, with arrows leading to descendents on 
the row below. Specific IgH sequences representing cells/clones in which the mutations 
were identified are indicated underneath the circles.  Where multiple sequences 
harbouring the same mutations were found, the identity of an example sequence is 
provided, and the number of identical sequences detected is shown in brackets inside the 
circle.  Arrows signify the proposed order of mutation accumulation.  Separate lineage 
branches are indicated.
6wk(S7)
12wk(S1)
4wk(S1)F3
6wk(S8)
Branch 1 Branch 2
Figure 36.  BN-LCL4b family 3 
BN-LCL4b family 3 sequences are aligned relative to the matched germline V region sequence (top row).  The 
location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue text.  A box is drawn 
around the first 30 nucleotides of the VDJ junction translation.
An IgH sequence from a genotypically naive common ancestor was detected, carrying 2 mutations at codons 56 
and 81.  These 2 mutations were subsequently identified in all clonally related IgH sequences.  Sequence 
4wk(S1)F3 carried an additional 4 mutations at codons 28, 30 and 31.  Sequence 6wk(S8), which carried a 7th
mutation at codon 35, is one example of the 34 IgH sequences detected that carried the family-specific 
mutation pattern of 7 mutations.  Following on from this, 6 sequences were discovered carrying these 7 
mutations plus an extra (unrelated) 1, and 1 sequence carried an additional 3 (4wk (S13) F3).  Sequence 
12wk(S1) carried the 2 common mutations at codons 56 and 81, plus two unrelated mutations, suggesting it had 
descended along a separate branch from it’s relatives.
CDR1
DP-47/V3-23+ GGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGG
6wk(S7)      .....................................................................................
4wk(S1)F3    ...........................................................T......T.AT...............
6wk(S8)      ...........................................................T......T.AT..........A....
9wk(S17)     ...........................................................T......T.AT..........A....
9wk(S19)     ...........................................................T......T.AT..........A....
12wk(S11)    ...........................................................T......T.AT..........A....
9wk(S16)     ..........C................................................T......T.AT..........A....
9wk(S18)     ..........C................................................T......T.AT..........A....
4wk(S13)F3   .............................................G........G....T......T.AT..........A....
12wk(S1)     ..........................................................................G..........
CDR2
DP-47/V3-23+ GTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGA
6wk(S7)      ............................................................G........................
4wk(S1)F3    ............................................................G........................
6wk(S8)      ............................................................G........................
9wk(S17)     ...........................................................CG........................
9wk(S19)     ..................................................C.........G........................
12wk(S11)    .....................................T......................G........................
9wk(S16)     ............................................................G........................
9wk(S18)     ............................................................G........................
4wk(S13)F3   ............................................................G........................
12wk(S1)     ..................................................C.........G........................
DP-47/V3-23+ AGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGT
6wk(S7)      ...................................................G.................................
4wk(S1)F3    ...................................................G.................................
6wk(S8)      ...................................................G.................................
9wk(S17)     ...................................................G.................................
9wk(S19)     ...................................................G.................................
12wk(S11)    ...................................................G.................................
9wk(S16)     ...................................................G.................................
9wk(S18)     ...................................................G.................................
4wk(S13)F3   .................C.................................G.................................
12wk(S1)     ...................................................G.................................
DP-47/V3-23+ ATATTACTGTGCG CDR3
6wk(S7)      .............AAAGACCGGGGGTTCGGGGAGTTACACGGTATGGACGTCTGGGGCCAAGGG
4wk(S1)F3    .............AAAGACCGGGGGTTCGGGGAGTTACACGGTA..A.T---C.AATT.-----
6wk(S8)      .............AAAGACCGGGGGTTCGGGGAGTTACACGGTATGGACGTCTGGGGCCAAGGG
9wk(S17)     .............AAAGACCGGGGGTTCGGGGAGTTACACGGTATGGACGTCTGGGGCCAAGGG
9wk(S19)     .............AAAGACCGGGGGTTCGGGGAGTTACACGGTATGGACGTCTGGGGCCAAGGG
12wk(S11)    .............AAAGACCGGGGGTTCGGGGAGTTACACGGTATGGACGTCTGGGGCCAAGGG
9wk(S16)     .............AAAGACCGGGGGTTCGGGGAGTTACACGGTATGGACGTCTGGGGCCAAGGG
9wk(S18)     .............AAAGACCGGGGGTTCGGGGAGTTACACGGTATGGACGTCTGGGGCCAAGGG
4wk(S13)F3   .............AAAGACCGGGGGTTCGGGGAGTTACACGGTAK.A.T---C.AATT.-----
12wk(S1)     .............AAAGACCGGGGGTTCGGGGAGTTACACGGTATGGACGTCTGGGGCCAAGGG
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weeks post-infection, thus preventing analysis of the cultures at earlier time 
points.  We therefore aimed to compare this limiting dilution method with the 
bulk LCL method used in the current work, in order to examine whether both 
techniques could generate LCLs with mutated IgH genes.  To this end, we 
carried out two experiments in which we established both limiting dilution clonal 
cultures and a bulk LCL from the same population of purified naive B cells, 
originating from a single donor (Figure 37). 
Naive B cells from a single peripheral blood donor were purified as previously 
described, and exposed in vitro to EBV supernatant taken from a single batch.  
Cells were seeded into three separate 96-well plates at densities of 1000, 500 
or 200 cells per well to generate limiting dilution clones, or into a single well of a 
96-well plate at a density of 0.5 x 106 to produce a bulk LCL.  The bulk naive 
LCLs (BN-LCL5 and BN-LCL6), were harvested at six, nine and twelve weeks 
post-infection.  The corresponding clonal naive LCL cultures (CN-LCL5 and CN-
LCL6) were expanded and harvested at twelve weeks post infection. 
IgH Analysis of Bulk Naive LCL5 
The pre-infection IgH sequencing data for both BN-LCL5 and CN-LCL5, 
reflected a polyclonal population of naive B cells, with all 14 IgH sequences 
tested being unmutated (Table 21).  Consistent with previous results, clonal 
outgrowth was observed at six weeks post-infection, and thereafter variations in 
clonal dominance could be seen (Table 21).  The proportion of family 1, which 
was dominant at six weeks (11 out of 18 IgH sequences) declined by twelve 
weeks (4 out of 26 IgH sequences).  By contrast, family 2, which was barely 
0.5 x 106 cells + EBV
limiting dilution clone cultures
1000/500/200 cells 
per well + EBV
bulk LCL culture
IgD+CD27- naïve B cells
Figure 38.  Establishment of limiting dilution naive LCL clones and bulk naive LCLs from one 
donor
IgH PCR of cell pellets 
+ E.coli
transformation
IgH PCR of cell pellets 
+ E.coli
transformation
IgH sequences compared to germline using Vbase IgH sequences compared to germline using Vbase
6 weeks
9 weeks
12 weeks
12 weeks
sequence V D J junction translation mutations
1 DP-79/4d154…+ D3-22/D21-9 JH3b CARLYYYDSS 0
2 DP-75/V1-2…+ not found JH4b CARLEEEAVT 0
3 V3-53+ D1-7/DM1 JH6b CARSPRVGDG 0
4 DP-31/V3-9P…+ D2-15/D2 JH6c CAKDGGGSSY 0
5 DP-31/V3-9P…+ D2-2 JH6c CAKDSS*YCS 0
6 DP-66/V71-2…+ D4-23 JH5b CARESGGGWY 0
7 DP-47/V3-23…+ D5-5/DK4 JH6b CARGVGEIQL 0
8 DP-73/V5-51…+ D1-26 JH3b CARHGMYSGS 1
9 DP-10/Hv1051…+ D6-6/DN4 JH4b RALSEARSWY 1
10 DP-75/V1-2…+ D6-13/DN1 JH6b CARGSQEYSS 1
11 DP-31/V3-9P…+ D4-17 JH4b CAKDRLPYGD 1
12 DP-7/21-2…+ D3-22/D21-9 JH4b CARIPTYYDSS 1
13 DP-73/V5-51…+ D5-24 JH6c CARHGAGYMA 1
14 V3-49+ not found JH6b CTRELSWVPR 2
sequence V D J junction translation mutations
1 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
2 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
3 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
4 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
5 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
6 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
7 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
8 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
9 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
10 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
11 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 3
12 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 21
13 DP-31/V3 D4-17 JH4b CAVGYGDYHS 0
14 DP-31/V3-9P…+ D3-22/D21-9 JH5b CAKGMMAMYY 0
15 DP-50/hv3019b9…+ D3-22/D21-9 JH3b CAREGYYYDS 0
16 DP-47/V3-23…+ not found JH4b CAKEMRLGSR 0
17 DP-58/hv3d1EG not found JH5b CASVRWLTLW 1
18 DP-31/V3-9P…+ D4-11/DA1 JH6b CAKDSPPLYG 3
pre-infection
6 weeks
Table 21.  BN-LCL5
Summary of matched V, D and J alignments for each IgH sequence analysed at 0 
and 6 weeks post-establishment (9 and 12 weeks shown on next page), the first 
10 amino acids of the VDJ junction translation, and the number of mutations 
detected in the V region.  Clonally related IgH sequences are colour highlighted 
(see legend).
Family 1
Family 2
Family 3
Family 4
Legend
sequence V D J junction translation mutations
1 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
2 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
3 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
4 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
5 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
6 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
7 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
8 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
9 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
10 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 5
11 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
12 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 21
13 VIV-4/4.35+ not found JH4b CARDSSVGWD 11
14 DP-47/V3-23…+ not found JH5b CARDRSGNWF 0
15 DP-38/9-1…+ D3-22/D21-9 JH4b CTSPL*KRIT 0
16 DP-88/hv1051K…+ D1-26 JH4b CARDSAAIVG 1
sequence V D J junction translation mutations
1 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 0
2 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 1
3 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 2
4 DP-65/3d75d…+ D6-6/DN4 JH6b CARVRLAGPL 3
5 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
6 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
7 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
8 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
9 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
10 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
11 DP-38/9-1…+ D1-14/DM3 JH6b CTTYNRIRGS 20
12 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
13 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 20
14 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 21
15 DP-38/9-1…+ D1-14/DM2 JH6b CTTYNRIRGS 21
16 VIV-4/4.35+ not found JH4b CARDSSVGWD 11
17 VIV-4/4.35+ not found JH4b CARDSSVGWD 11
18 VI-4.1b+ D5-5/DK4 JH5a CARATQLWTP 6
19 VI-4.1b+ D5-5/DK4 JH5a CARATQLWTP 6
20 VI-4.1b+ D5-5/DK4 JH5a CARATQLWTP 6
21 DP-73/V5-51...+ not found JH6c CARCYSMFYY 2
22 DP-71/3d197d...+ D6-25 JH5b CARSLAAAGW 2
23 DP-32/V3-20+ D2-15/D2 JH6b CARDRRFCRG 2
24 DP-65/3d75d…+ D5-12/DK1 JH5b CARDLVATSFW 3
25 DP-77/WHG16+ D6-6/DN4 JH4b CARDKGHVAA 15
26 DP-48/13-2+ D4-17 JH6b CARVRGGHEY 12
9 weeks
12 weeks
Family 1
Family 2
Family 3
Family 4
Legend
Table 21.  BN-LCL5
Summary of matched V, D and J alignments for each IgH sequence analysed at 9 
and 12 weeks post-establishment (0 and 6weeks shown on previous page), the 
first 10 amino acids of the VDJ junction translation, and the number of mutations 
detected in the V region.  Clonally related IgH sequences are colour highlighted 
(see legend).
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detectable at six weeks (1 out of 18 IgH sequences) became the dominant 
clone at later time points. 
Three out of four families (families 2, 3 and 4) in BN-LCL5 contained mutated 
IgH sequences.  Further analysis revealed that IgH sequences within each of 
these families shared family-specific mutations.  IgH sequences within family 1 
carried between 0 and 5 mutations, which was suggestive of in vitro mutation, 
although insufficient sequences were obtained to construct a family tree. 
IgH Analysis of Limiting Dilution LCL5 Naive Clones  
In parallel to the bulk culture of BN-LCL5, a total of 32 cultures were established 
by limiting dilution, arising from 1000, 500 or 200 cells per well.  DNA was 
isolated from each culture, subjected to IgH DNA amplification and the PCR 
products cloned.  Up to 5 sequences from each of the cultures were then 
examined.  A summary of the IgH sequencing results is displayed in Table 22. 
Of the 32 cultures analysed, 24 yielded a single amplified IgH and were deemed 
to be monoclonal.  In cultures where more than one IgH sequence was 
detected, the dominant one was designated representative of the culture.  For 
example, culture 31 containing 4 unmutated, clonally related sequences plus a 
unique sequence carrying 10 mutations, was scored as unmutated.  In 
monoclonal cultures where members of the same clonal family carried different 
numbers of mutations, the mean numbers of mutations per IgH sequences was 
calculated in order to decide whether to classify the culture as mutated or 
unmutated.  Based on these criteria, 25% of the CN-LCL5 cultures were 
classified as mutated.  Taking into account the inclusion of biclonal and 
seeding culture sequence V D J junction translation mutations
200 cells/well 1 1 V3-53+ not found JH6b CARDSDYGFE 0
2 V3-53+ not found JH6b CARDSDYGFE 0
2 1 DP-70/4d68…+ D6-19 JH4b CARGGAVAGP 1
2 DP-70/4d68…+ D6-19 JH4b CARGGAVAGP 1
3 1 DP-31/V3-9P…+ D1-26 JH4b CAKGxGLRLD 0
2 DP-31/V3-9P…+ D1-26 JH4b CAKGVGLRLD 0
4 1 DP-7/21-2…+ D6-19 JH4b CARVGGSSGY 0
2 DP-7/21-2…+ D6-19 JH4b CARVGGSSGY 0
3 DP-7/21-2…+ D6-19 JH4b CARVGGSSGY 1
500 cells/well 5 1 DP-65/3d75d…+ D4 JH4b CARTPNYWGQ 2
2 DP-65/3d75d…+ D4 JH4b CARTPNYWGQ 2
3 DP-65/3d75d…+ D4 JH4b CARTPNYWGQ 3
6 1 DP-47/V3-23…+ D5-24 JH4b CAKVSVEMAT 2
2 DP-47/V3-23…+ D5-24 JH4b CAKVSVEMAT 2
3 DP-47/V3-23…+ D5-24 JH4b CAKVSVEMAT 2
7 1 DP-14/V1-18+ D2-21 JH3b CARDLVVVTA 1
8 1 DP-79/4d154…+ D3-10/DXP'1 JH5b CARRNDYVWS 0
2 DP-79/4d154…+ D3-10/DXP'1 JH5b CARRNDYVWS 0
3 DP-79/4d154…+ D3-10/DXP'1 JH5b CARRNDYVWS 0
9 1 DP-75/VI-2…+ D2-15/D2 JH6b CARGGCGGGR 4
2 DP-75/VI-2…+ D2-15/D2 JH6b CARGGCGGGR 4
1000 cells/well 10 1 V3-48/hv3d1…+ D2-15/D2 JH5b CARGAPRYCS 0
2 V3-48/hv3d1…+ D2-15/D2 JH5b CARGAPRYCS 0
3 V3-48/hv3d1…+ D2-15/D2 JH5b CARGAPRYCS 1
11 1 DP-47/V3-23…+ D3-10/DXP-1 JH1 CAKDPVLLWF 0
2 DP-47/V3-23…+ D3-10/DXP-1 JH1 CAKDPVLLWF 0
3 DP-47/V3-23…+ D3-10/DXP-1 JH1 CAKDPVLLWF 0
12 1 DP-79/4d154…+ D2-8/DLR1 JH4b CARRATIPYF 0
2 DP-49/I.9III…+ D3-22/D21-9 JH4b CAKDHYDSSG 0
13 1 DP-54/V3-7…+ D2-21 JH6c CTRDNTCDGD 12
2 DP-54/V3-7…+ D2-21 JH6c CTRDNTCDGD 12
14 1 DP-77/WHG16+ not found JH5b CARDLTYGDY 0
2 DP-57/hv3003…+ not found JH4b CSSGASVLEG 0
15 1 DP-79/4d154…+ not found JH4b CARQDDYGEG 0
2 DP-79/4d154…+ not found JH4b CARQDDYGEG 0
3 DP-79/4d154…+ D4-17 JH4b CARQDDYGEG 0
4 DP-79/4d154…+ D4-17 JH4b CARQDDYGEG 0
5 DP-75/VI-2…+ not found JH4b CARDSWVYSS 1
16 1 DP-49/I.9111…+ not found JH4b CAKDVGKGRG 5
2 DP-49/I.9111…+ not found JH4b CAKDVGKGRG 5
3 DP-49/I.9111…+ not found JH4b CAKDVGKGRG 6
17 1 DP-7/21-2…+ not found JH4b CAMPTTVTTG 0
2 DP-7/21-2…+ not found JH4b CAMPTTVTTG 1
3 DP-71/3d197d…+ not found JH5b CARFGTEQLL 0
Table 22.  Naive LCL5 limiting dilution cultures
Blocks shaded grey represent unmutated cultures.  Blocks shaded green represent mutated 
cultures.  Green frames around grey blocks highlight instances where cultures contain 
umutated and mutated sequences of the same CDR3 clonotype. Cultures were deemed 
mutated if the majority of sequences contained >2 mutations.  Where cultures contained 
more than one distinct CDR3 clonotype, the mutation status of the family comprising the 
highest proportion of the culture is represented in the table.
seeding culture sequence V D J junction translation mutations
1000 cells/well 18 1 DP-79/4d154…+ not found JH5b CARRSPGAAY 1
2 DP-79/4d154…+ not found JH5b CARRSPGAAY 1
19 1 DP-49/I.9111…+ not found JH4b CANSYSSSWY 4
2 DP-49/I.9111…+ not found JH4b CANSYSSSWY 4
3 DP-49/I.9111…+ not found JH4b CANSYSSSWY 5
20 1 DP-31/V3-9P not found JH4b CAKDVSRKDY 0
2 DP-31/V3-9P not found JH4b CAKDVSRKDY 0
3 DP-31/V3-9P D3-22/D21-9 JH4b CAKDVSRKDY 0
4 DP-31/V3-9P D3-22/D21-9 JH4b CAKDVSRKDY 0
21 1 DP-66/V71-2…+ D5-5/DK4 JH6b CARLKGTALV 3
2 DP-66/V71-2…+ D5-5/DK4 JH6b CARLKGTALV 3
3 DP-66/V71-2…+ D5-5/DK4 JH6b CARLKGTALV 4
22 1 DP-7/21-2…+ D3-22/D21-9 JH6c CARAPTLYYD 0
2 DP-7/21-2…+ D3-22/D21-10 JH6c CARAPTLYYD 0
3 DP-7/21-2…+ D3-22/D21-9 JH6c CARAPTLYYD 1
23 1 DP-77/WHG16+ D6-13/DN1 JH4b CARDREWEQ 0
2 DP-77/WHG16+ D6-13/DN1 JH4b CARDREWEQ 1
3 DP-77/WHG16+ D6-13/DN1 JH4b CARDREWEQ 1
24 1 DP-77/WHG16+ D2-8/DLR1 JH3b CARGGPEKYC 0
25 1 DP-35/V3-11…+ D5-24 JH4b CARVVPRGWL 6
2 DP-35/V3-11…+ D5-24 JH4b CARVxPRGWL 6
3 DP-35/V3-11…+ D5-24 JH4b CARVVPRGWL 6
26 1 DP-63/VH4.21…+ D3-9/DXP1… JH4b CAKSDILTGY 9
27 1 DP-15/V1-8+ D7-27/DHQ52 JH6c CARGEWGALR 9
2 DP-15/V1-8+ D7-27/DHQ52 JH6c CARGEWGALR 9
3 DP-15/V1-8+ D7-27/DHQ52 JH6c CARGEWGALR 9
28 1 DP-5/V1-24P+ D3-10/DXP'1 JH4b CAPRFGELSR 0
2 DP-5/V1-24P+ D3-10/DXP'1 JH4b CAPRFGELSR 1
29 1 DP-71/3d197d…+ D6-19 JH5b CARDAPGGSY 0
2 DP-71/3d197d…+ D6-19 JH5b CARDAPGGSY 0
3 DP-47/V3-23…+ not found JH6c CASNKVGSYM 0
4 DP-74/VH-VI…+ D6-6/DN4 JH3b WTGSHREPRI 0
30 1 DP-49/1.9III…+ not found JH2 CAKDPTYMKD 0
2 DP-49/1.9III…+ not found JH2 CAKDPTYMKD 0
3 V3-64/YAC-6+ D3-16 JH1 CARGTLL*LRL 2
31 1 DP-77/WHG16+ not found JH6c CARGGSDYYY 10
2 DP-75/VI-2…+ D5-5/DK4 JH6b CASRPRHTAM 1
3 DP-75/VI-2…+ D5-5/DK4 JH6b CASRPRHTAM 1
4 DP-75/VI-2…+ D5-5/DK4 JH6b CASRPRHTAM 1
5 DP-75/VI-2…+ D5-5/DK4 JH6b CASRPRHTAM 1
32 1 DP-78/3d230d…+ D3-22/D21-9 JH6c CARGGYYDSSG 0
2 DP-10/hv1051…+ D3-10/DXP'1 JH4b CASxRVVRGV 0
Table 22.  Naive LCL5 limiting dilution cultures
Blocks shaded grey represent unmutated cultures.  Blocks shaded green represent mutated 
cultures.  Green frames around grey blocks highlight instances where cultures contain 
umutated and mutated sequences of the same CDR3 clonotype. Cultures were deemed 
mutated if the majority of sequences contained >2 mutations.  Where cultures contained more 
than one distinct CDR3 clonotype, the mutation status of the family comprising the highest 
proportion of the culture is represented in the table.
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oligoclonal cultures, the proportion of total mutated families within the 
experiment as a whole was also calculated at 23%. 
Whether considering mutation frequency in terms of either total cultures (25%) 
or total clonal families (23%), the results show that by twelve weeks post-
infection, mutated IgH sequences were present in significant proportions 
compared to the resting naive B cell pre-infection data (0%).  Interestingly, in 
culture 5, a monoclonal LCL where only 1 clonal family was identified, 
unmutated sequences were detected alongside a sequence carrying 3 
mutations (Figure 38). 
IgH Analysis of Bulk Naive LCL6 
IgH sequence analysis data derived from the resting naive B cell population 
prior to EBV infection and on the BN-LCL population twelve weeks post-
infection are shown in Table 23.  The resting naive B cells were polyclonal, with 
13 out of 14 unmutated IgH sequences confirming the purity of the starting 
population.  As seen previously, the LCL culture had become oligoclonal by 
twelve weeks, with two families (1 and 2) dominating approximately half of the 
culture.  Interestingly, at this time point, the majority of IgH sequences were 
mutated including those from both clonal families, and 6 out of 9 of the unique 
IgH sequences. 
IgH Analysis of Limiting Dilution LCL6 Naive Clones  
As in the previous experiment, LCL cultures were established in parallel by 
limiting dilution and expanded for analysis.  Table 24 shows the IgH sequence 
data from 25 such LCL cultures.  Overall these cultures were very similar to 
CDR1
DP-65/3d75d+ CCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTACTGG
culture5(S1)   .....................................................................................
culture5(S2)   .....................................................................................
culture5(S3)   ...........................................................................C.........
CDR2 
DP-65/3d75d+  AGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATTACAGTGGGAGCACCTACTACAACCCGTCCC
culture5(S1)   ..................................................T..................................
culture5(S2)   ..................................................T..................................
culture5(S3)   ..................................................T..................................
DP-65/3d75d+  TCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCCGCGGACACGGC
culture5(S1)   .............C.......................................................................
culture5(S2)   .............C.......................................................................
culture5(S3)   .............C.......................................................................
CDR3
DP-65/3d75d+  CGTGTATTACTGTGCGAGAACTACTTTGACTACTGGGGCCAGGGA
culture5(S1)   ......................C.C--A.................
culture5(S2)   ......................C.C--A.................
culture5(S3)   ......................C.C--A.................
V
V
V
V
Figure 39.  CN-LCL5 culture 5
CN-LCL5/c23 sequences are aligned relative to the matched germline V region sequence (top row).  The 
location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue text.  A box is drawn 
around the first 30 nucleotides of the VDJ junction translation.
CN-LCL5/c23 is an example of a culture containing both unmutated and mutated sequences.  Since 2 out 
of 3 isolated sequences harbour <3 mutations, the culture was deemed unmutated, despite sequence 3 
carrying 3 mutations.
2
3
2
3
2
3
2
3
sequence V D J junction translation mutations
1 3d277d+ D5-5/DK4 JH4b CAxDPDGYxP 0
2 DP-88/hv1051K...+ D4-17 JH6b CARSPPGRVT 0
3 DP-58/hv3d1EG D5-12/DK1 JH4b CAREETVAGV 0
4 DP-71/3d197d...+ D4-17 JH4b CARAIQKDYG 0
5 DP-73/V5-51...+ D7-27/DHQ52 JH6c CARWGPIWYY 0
6 3-09 DP31/V3-9p not found JH4b 0
7 3-74 COS6 not found JH6b 0
8 V3-49 not found JH1 0
9 DP-65/3d75d...+ D5-24 JH6b CARDRGGPNY 1
10 DP-50/hv3019b9 D4-17 JH2 CASNNDYGHH 1
11 DP-14/V1-18+ D6-19 JH3b CARDSHPDSS 1
12 4-31 DP65/3d75d not found JH6b 1
13 5-51 DP73/V5-51 not found JH6b 1
14 b54../hv3005b54 D3-16 JH4b CARYREGVGA 5
sequence V D J junction translation mutations
1 4-b DP67 not found JH5b CATSGWYDAK 8
2 4-b DP67 not found JH5b CATSGWYDAK 8
3 4-b DP67 not found JH5b CATSGWYDAK 8
4 4-b DP67 not found JH5b CATSGWYDAK 9
5 4-b DP67 not found JH5b CATSGWYDAK 9
6 3-53 V3-53+ not found JH4b CARTGEFSFG 7
7 3-33 DP50 not found JH4b CARTGEFSFG 8
8 3-33 DP50 not found JH4b CARTGEFSFG 8
9 3-33 DP50 not found JH4b CARTGEFSFG 8
10 6-01 DP74 not found JH6b CARERLSSGW 0
11 3-33 DP50 not found JH3b CARDLERYYD 1
12 3-74 COS-6 not found JH6c CATNLVGVYY 2
13 4-59 DP71 not found JH6b CAREAELRQL 4
14 3-21 DP77 not found JH4b CARAQDDSSG 6
15 3-21 DP77 not found JH4b CARAAGDYAH 8
16 4-59 DP71 not found JH3b CARGRITMVR 8
17 4-61 DP66 not found JH6b CARETHTVVV 9
18 3-21 DP77 not found JH5b CARGRVPAAN 10
pre-infection
12 weeks
Table 23.  BN-LCL6
Summary of matched V, D and J alignments for each IgH sequence analysed at 9 and 
12 weeks post-establishment (0 and 6weeks shown on previous page), the first 10 
amino acids of the VDJ junction translation, and the number of mutations detected in 
the V region.  Clonally related IgH sequences are colour highlighted (see legend).
seeding culture sequence V D J junction translation mutations
1000 cells/well 1 1 3-11 DP35 not found JH6b CAREWGGYKP 0
2 3-11 DP35 not found JH6b CAREWGGYKP 0
2 1 3-23 DP47 D6-19 JH4b CAKDRLAVAV 0
2 3-23 DP47 D6-19 JH4b CAKDRLAVAV 0
3 3-23 DP47 not found JH4b CAKDRLAVAV 0
4 3-23 DP47 not found JH4b CAKDRLAVAV 0
3 1 4-59 DP71 not found JH4b CASGSSGWLY 7
2 4-59 DP71 D5-12 JH4b CASGSSGWLY 7
3 4-59 DP71 D5-12 JH4b CASGSSGWLY 7
4 1 4-04 DP70 not found JH3b CARSITIFGV 0
2 4-04DP70 not found JH3b CARSITIFGV 0
3 4-04 DP70 not found JH3b CARSITIFGV 1
5 1 1-08 DP15 D1-26 JH4b CARGGYYEGF 0
2 1-08 DP15 D4-17 JH4b CARGGYYEGF 0
3 1-08 DP15 D4-17 JH4b CARGGYYEGF 1
6 1 1-69 DP10 not found JH4b CASASRDSSS 0
2 1-69 DP10 not found JH4b CASASRDSSS 1
7 1 3-30 COS-8 D4-23 JH4b CAREATEVPF 3
2 3-30 COS-8 D4-23 JH4b CAREATEVPF 3
3 3-30 COS-8 D4-23 JH4b CAREATEVPF 3
8 1 DP58 not found JH4b CARDQGGVTT 0
2 DP58 not found JH4b CARDQGGVTT 0
3 DP58 not found JH4b CARDQGGVTT 0
4 DP58 not found JH4b CARDQGGVTT 2
9 1 3-15 DP38 not found JH4b CTTDQWLSWE 0
2 3-15 DP38 not found JH4b CTTDQWLSWE 0
3 1e DP88 not found JH4b CARDSSSSWY 1
10 1 3-23 DP47 not found JH6c CAKEWVGSGS 0
2 3-23 DP47 not found JH6c CAKEWVGSGS 0
3 3-23 DP47 not found JH6c CAKEWVGSGS 0
4 3-23 DP47 not found JH6c CAKEWVGSGS 0
11 1 1-58 DP2 not found JH5b CAVELWFGDI 5
2 1-58 DP2 not found JH5b CAVELWFGDI 5
3 1-58 DP2 not found JH5b CAVELWFGDI 5
12 1 DP67 not found JH4b CARTLVVVDWG 0
2 DP67 not found JH4b CARTLVVVDWG 0
3 DP67 not found JH4b CARTLVVVDWG 0
Table 24.  Naive LCL6 limiting dilution cultures
Blocks shaded grey represent unmutated cultures.  Blocks shaded green represent mutated 
cultures.  Green frames around grey blocks highlight instances where cultures contain 
umutated and mutated sequences of the same CDR3 clonotype. Cultures were deemed 
mutated if the majority of sequences contained >2 mutations.  Where cultures contained 
more than one distinct CDR3 clonotype, the mutation status of the family comprising the 
highest proportion of the culture is represented in the table.
seeding culture sequence V D J junction translation mutations
1000 cells/well 13 1 1-08 DP15 not found JH4b CARGGDYEGF 0
2 1-08 DP15 not found JH4b CARGGDYEGF 1
14 1 3-74 COS6 not found JH4b CARTRITIFG 0
2 3-74 COS6 not found JH4b CARTRITIFG 0
3 3-74 COS6 not found JH4b CARTRITIFG 0
16 1 5-51 DP73 not found JH4b CARQSFGSYY 1
2 5-51 DP73 not found JH4b CARQSFGSYY 2
17 1 4-30 DP65 D2-21 JH6b CARVRLAGPL 1
2 5-51 DP73 D6-19 JH5b CARHEEAGEV 1
18 1 DP58 D5-5 JH4b CARDRSRDTA 0
2 DP58 D5-5 JH4b CARDRSRDTA 0
19 1 3-21 DP77 D3-3 JH4b CARMTTVTRL 0
2 3-21 DP77 D4-17 JH6b CVRAPWSGDY 5
20 1 3-21 DP77 D1-26 JH4b CAREELRGYWG 0
2 1-69 DP10 D3-22 JH4b CARNQDTSGS 3
21 1 3-11 DP35 D4-17 JH6b CARDYGDYGA 0
2 1-08 DP15 D5-12 JH4b CARVCVGNAA 0
22 1 3-21 DP77 D5-12 JH4b CARGDRGDTL 0
2 3-21 DP77 D5-12 JH4b CARGDRGDTL 3
23 1 4-59 DP71 not found JH4b CARAPAITMV 0
2 4-59 DP71 not found JH4b CARAPAITMV 0
3 4-59 DP71 not found JH4b CARAPAITMV 1
24 1 DP58 not found JH4b CAVLGSEYSD 9
2 3-13 DP48 not found JH6b CARDNSRGDC 15
3 3-13 DP48 not found JH6b CARDNSRGDC 15
4 3-13 DP48 not found JH6b CARDNSRGDC 16
25 1 4-04 DP70 not found JH4b CARGRFEEDY 4
2 4-04 DP70 not found JH4b CARGRFEEDY 4
3 4-04 DP70 not found JH4b CARGRFEEDY 6
Table 24.  Naive LCL6 limiting dilution cultures
Blocks shaded grey represent unmutated cultures.  Blocks shaded green represent mutated 
cultures.  Green frames around grey blocks highlight instances where cultures contain 
umutated and mutated sequences of the same CDR3 clonotype. Cultures were deemed 
mutated if the majority of sequences contained >2 mutations.  Where cultures contained 
more than one distinct CDR3 clonotype, the mutation status of the family comprising the 
highest proportion of the culture is represented in the table.
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those generated in the first limiting dilution experiment (CN-LCL5 cultures), both 
in terms of clonality and proportion of mutated cultures and/or clonal families. 
Of the 25 cultures examined (Table 24), 19 were monoclonal and the remaining 
6 were presumably biclonal.  24% of the cultures were scored as having 
mutated IgH sequences.  When accounting for the two families detected in the 
biclonal cultures, it was calculated that 26% of the total number of distinct clonal 
families identified in the experiment were mutated.  In those families that were 
comprised of mutated IgH sequences, the mutations were shared and “family-
specific”.  Two instances where 2 or more mutations had been acquired by an 
IgH sequence in addition to the family-specific mutation pattern were observed 
in cultures 22 and 25 (data not shown), suggesting ongoing SHM within the 
culture. 
Taken together, the analysis of the limiting dilution LCL cultures from both 
experiments have confirmed the earlier findings of Dr Pastor and Dr Chaganti 
that approximately one quarter of established cultures are mutated at twelve 
weeks post-infection.  Furthermore, this observation of IgH mutation in naive B 
cells is seen in both bulk LCLs and LCLs established by limiting dilution. 
4.2.7 Phenotype of Naive LCLs 
The data presented so far from the IgH sequence analysis of both bulk and 
limiting dilution LCL cultures revealed that a substantial proportion of IgH 
sequences were mutated as early as six weeks post-infection.  These results 
demonstrate that EBV-driven transformation of naive B cells in vitro has the 
capacity to induce a memory IgH genotype within a fraction of the infected cells.  
In order to find out whether EBV transformation could also induce a memory 
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phenotype via class switching, selected clonal and bulk LCLs were examined 
for Ig isotype expression by flow cytometry.  Expression of IgM, IgD, IgG, and 
IgA, together with expression of the memory B cell marker CD27 was analysed. 
The staining procedure was first validated using CD19-selected PB B cells 
(Figure 39a).  Using the FIX & PERM® (CALTAG) protocol for intracellular and 
surface Ig staining, 63% of the B cells were IgD+ and 68% were IgM+, 
consistent with a naive or non-switched memory B cell phenotype.  16% of the 
B cells were IgG+ and 10% were IgA+, both of which represent switched 
memory B cells.  Whereas these percentages are consistent with the expected 
proportions of B cell subsets within the PB B cell compartments, only 12% of 
the total B cells stained positive for the memory marker CD27, a result that 
could reflect weak staining with the anti-CD27 antibody.  Ig isotype analysis of 7 
bulk naive LCL cultures (BN-LCL1, BN-LCL3, BN-LCL4a-c, BN-LCL5 and BN-
LCL6) revealed dual expression of IgD and IgM, with the absence of IgG or IgA, 
indicating that the cells had not undergone CSR.  Two examples (BN-LCL3 and 
BN-LCL5) of flow cytometry staining analysis can be seen in Figure 39b and c, 
and results from all 7 bulk LCLs are summarised in Table 25. 
We then went on to analyse Ig isotype expression in a selection of limiting 
dilution LCL cultures with either unmutated or mutated IgH sequences (obtained 
from CN-LCL5 and CN-LCL6 experiments).  As with the bulk cultures, all 37 
LCLs tested expressed IgD and IgM in the absence of the memory markers IgG 
or IgA.  CD27 was expressed in either very low cell numbers (1%) or not at all.  
Staining of representative mutated (CN-LCL5/c13) and unmutated (CN-
LCL5/c20) LCL cultures are shown in Figure 40, and all the results are 
summarised in Table 26. 
Figure 39.  Phenotypic analysis of  BN-LCL3 and BN-LCL5
A. A control for the FIX & PERM®  intracellular staining protocol was carried out using CD19-
selected PB B cells.  63% of the B cells were IgD+ and 68% were IgM+, consistent with a naive or 
non-switched memory B cell phenotype.  16% were IgG+ and 10% were IgA+, consistent with a 
switched memory phenotype.  Only 3% of cells were CD27+ using this protocol.  B. and C. Using 
intracellular staining, both LCLs expressed IgM and IgD, in the absence of IgG, IgA or CD27.  Note: 
for each of the cell populations shown in A, B and C, distinct isotype controls (black outline), using 
cells from the relevant culture were used to draw gates.
B. BN-LCL3
IgD
IgM
IgG
IgA
CD27
C. BN-LCL5
18%
89%
0%
0%
0%
17%
68%
0%
0%
1%
63%
68%
16%
10%
A. CD19+ PB B cells
3%
Figure 39.   Phenotypic analysis of  BN-LCL3 and BN-LCL5
Figure 40.  Phenotypic analysis of two representative CN-LCL5 cultures
Shown are examples of fix and perm staining for IgM, IgD, IgG, IgA and CD27 
carried out on the CN-LCL5/c13 culture, which carried mutated IgH sequences and 
the CN-LCL5/c20 culture, which carried unmutated IgH sequences.  Both LCL 
cultures expressed both IgM and IgD in the absence of IgG or IgA.  CD27 was 
expressed by a small percentage of cells.
20%
36%
0%
1%
0%
CN-LCL5/c13
(mutated)
19%
35%
0%
0%
1%
CN-LCL5/c20
(unmutated)
IgD
IgM
IgG
IgA
CD27
LCL Phenotype
IgM IgD IgG IgA CD27
BN-LCL1 + + ‒ ‒ ‒
BN-LCL3 + + ‒ ‒ ‒
BN-LCL4a + + ‒ ‒ ‒
BN-LCL4b + + ‒ ‒ ‒
BN-LCL4c + + ‒ ‒ ‒
BN-LCL5 + + ‒ ‒ ‒
BN-LCL6 + + ‒ ‒ ‒
Table 25.  Summary of Ig phenotype s of PB bulk naive LCLs
All bulk naive LCLs remained IgM+IgD+IgG-IgA-CD27-, consistent with a 
naive B cell phenotype. 
IgM IgD IgA IgG CD27
umutated LCL cultures 26 26 0 0 0
mutated LCL cultures 11 11 0 0 0
Table 26.  Summary of Ig phenotype of PB limiting dilution naive 
LCLs
All LCL cultures generated by limiting dilution infection remained 
IgM+IgD+IgG-IgA-CD27-, consistent with a naive B cell phenotype. 
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Together these findings indicate that although EBV infection of naive B cells in 
vitro can confer genotypic changes consistent with differentiation to memory, no 
CSR was observed since the cells remained phenotypically naive. 
4.3 Transformation Assays Comparing EBV Infection of 
Peripheral Blood B cell Subsets 
Experiments from the previous section strongly suggest that a proportion of 
naive B cells infected with EBV in vitro can acquire IgH mutations in culture.  
Since mutated IgH genotypes are typically associated with switched or non-
switched memory B cells in vivo, it was imperative to show that these results did 
not simply reflect the preferential transformation of small numbers of 
contaminating memory cells within the initial naive B cell preparations. 
The earlier Ig isotype staining data showed that all LCLs derived from naive B 
cells co-expressed IgM/IgD, consistent with a naive B cell origin.  If any of these 
LCLs had been derived from a switched memory B cell, this would have been 
identifiable by detection of IgG or IgA expression in the culture.  It does, 
however, remain possible that these mutated IgH sequences were derived from 
IgM+IgD+ non-switched memory B cells carrying pre-mutated IgH sequences, 
which grew out preferentially in vitro during the transformation.  To address this 
possibility, transformation assays were used to compare the transformation 
efficiency of naive B cells and non-switched memory B cells in vitro.  Both 
subpopulations were sorted to high purity, infected with B95-8 supernatant at 
various MOIs, and seeded into 96-well plates in equal numbers (800-1000 cells 
per well).  The number of wells showing LCL outgrowth were then counted after 
six weeks. 
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Results from five experiments using B cells from different donors are shown in 
Figure 41.  Note that in each transformation assay a range of MOIs was used 
(between 50 and 1).  From this figure, a number of conclusions can be drawn.  
The most notable observation is that the transformation efficiency of the cells 
varied greatly between each donor.  This can be seen by focussing on the 
percentage of transformed wells at an MOI of 12.5 in each assay.  TA-3 shows 
the highest proportion of transformed wells (82%), whereas values for the other 
donors range from 2% to 67%.  This large range of values most likely 
represents variation between different individuals.  Nonetheless there were no 
reproducible differences in transformation efficiency between the two B cell 
subsets in any of the five donors tested.  The most pronounced difference 
between the two B cell subsets can be seen in TA-1, where the percentage of 
transformed wells containing naive B cells was more than twice that that of non-
switched memory B cells at each MOI tested.  In the other donors, however, 
differences in transformation efficiency were less than two-fold (Figure 41). 
4.4 Tonsillar Naïve B Cell Transformation 
All previous transformation experiments presented so far have used naive B 
cells isolated from PB.  The next two experiments aimed to determine whether 
similar observations could be found when using B cells from two other sources, 
namely tonsil and cord blood (see below).  First a bulk tonsillar naive B cell 
infection (BTN-LCL1) was carried out using IgD+CD27- tonsillar B cells purified 
by FACS using the same method as previously described for the ex vivo EBV 
load experiments (Figure 15). 
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Figure 41.  Transformation assays using different B cell subsets
MOI values are shown on the x axis, and the percentage of transformed wells 
are shown on the y axis (n/t = not tested).  Results from 5 separate donors 
show no consistent difference between naive B cells and non-switched 
memory B cells in terms of transformation efficiency in vitro.
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Twenty-four out of 26 IgH sequences analysed from the resting naive B cell 
sample were unmutated, confirming the purity of the sorted population.  All 
sequences contained individual VDJ recombinations and CDR3 regions, 
indicating the cell population was polyclonal (Table 27).  At six weeks post-
infection, most IgH sequences analysed remained clonally unique, although 2 
sequences from the same clonal family were detected.  At nine and twelve 
weeks post-infection, small numbers of IgH sequence from multiple clonal 
families were detected, but the clonally independent sequences persisted in the 
culture in significant numbers (6 out of 14 IgH sequences at nine weeks, and 7 
out of 21 at twelve weeks) (Table 27). 
When examining the mutation levels of the IgH sequences generated from the 
BTN-LCL1 culture, three observations were noted: (i) all sequences isolated 
from families 1, 3, 4, 7, 8, and 9 were unmutated regardless of time post-
infection, (ii) families 5 and 6 were comprised of mutated IgH sequences 
carrying identical, family-specific mutations, (iii) all sequences identified from 
family 2 were mutated, carrying 3 family-specific mutations (Figure 42).  In 
addition, increasing numbers of mutated IgH sequences were identified within 
the clonally unique populations as the culture aged. 
The proportion of mutated and non-mutated clonal families detected at each 
time point is shown in Figure 43.  An increase in mutated IgH sequences from 
8% prior to infection, to 23% at 6 weeks post-infection, 27% at nine weeks and 
37% at twelve weeks was observed.  Together these results present a similar 
scenario to that seen in bulk peripheral blood naive B cell infections, i.e. the 
outgrowth of clonal families, and an increase in proportion of mutated IgH 
sequences from six weeks post-infection onwards. 
sequence V D J junction translation mutations
1 DP-2/V71-5+ D4-b JH5b CARDVDIVVV 0
2 DP-10/hv1051…+ D1-1 JH6c CARRSPGTTS 0
3 DP-14/V1-18+ D5-5/DK4 JH6c CARGPQGYAH 0
4 DP-78/3d230d…+ D5-12/DK1 JH4b CARWTGYSGY 0
5 DP-31/V3-9P…+ D3-10/DXP'1 JH4b CAKTYYYGSG 0
6 DP-65/3d75d...+ D4 JH6b CARVVGCIST 0
7 DP-46/3d216...+ D3-22/D21-9 JH6b CARDYDSSGR 0
8 DP-71/3d197d...+ D5-12/DK1 JH5b CARADGYLGN 0
9 DP-47/V3-23...+ D2-8/DLR1 JH6c CAKTPYYMDV 0
10 DP-35/V3-11...+ D2-21 JH6b CACDWNPHYG 0
11 DP-73/V5-51...+ not found JH6c CARRHYYYYM 0
12 DP-46/3d216...+ D3-10/DXP'1 JH4b CAREALWFGE 0
13 DP-54/V3-7...+ D4-17 JH3b CAKDGPHFGG 0
14 DP-78/3d230d…+ D6-6/DN4 JH2 CAREYSSSEF 0
15 DP-48/13-2+ D1-7/DM1 JH2 CARAIRGTNW 0
16 DP-48/13-2+ D6-6/DN4 JH2 CARVKWLGYF 0
17 DP-46/3d216...+ D5-12/DK1 JH3a CARGGAILVW 0
18 DP-46/3d216...+ not found JH6c CARVTGHYYY 0
19 DP-79/4d154…+ D3-3/DXP4 JH5b CARRFELNYD 1
20 DP-46/3d216...+ D6-19 JH6b CAKDQRAAAY 1
21 DP-31/V3-9P…+ not found JH6c CSCDMDVWGK 1
22 4.3 D6-19 JH5b CARDLAVAGV 1
23 DP-70/4d68...+ D6-25 JH4b CARHLAGGSW 1
24 DP-49/1.9III…+ D5-24 JH4b CARDRRWLQL 2
25 DP-79/4d154…+ D4-11/DA1 JH5b CARGDNSNYG 4
26 DP-65/3d75d...+ D4-17 JH6c CARARQYGDH 15
resting tonsillar naive B cells
6 weeks
sequence V D J junction translation mutations
1 DP-46/3d216…+ D4-11/DA1 JH4b CATDFDWSYY 0
2 DP-46/3d216…+ D4-11/DA1 JH4b CATDFDWSYY 0
3 DP-79/4d154…+ D5-24 JH4b CARHTRMATI 3
4 DP-71/3d197d…+ D2-15/D2 JH5b CARERCSGGS 0
5 DP-73/V5-51…+ D3-22/D21-9 JH3b CARPYYDSTV 0
6 DP-78/3d230d…+ D3-22/D21-9 JH6b CARDGKxYYG 0
7 DP-73/V5-51…+ not found JH6b CARRGAESNY 0
8 DP-71/3d197d…+ D1-26 JH4b CASYSGSYYY 0
9 DP-7/21-2…+ D7-27/DHQ52 JH6b CARSERRGIS 0
10 DP-73/V5-51…+ D6-6/DN4 JH4b CARREPYSSS 0
11 DP-46/3d216…+ D2-21 JH6c CARALTTHSV 2
12 DP-65/3d75d…+ D5-5/DK4 JH2 CASRYNYGYG 2
13 DP-70/4d68…+ D2-15/D2 JH4b CARFDCSGGS 6
14 DP-77/WHG16+ D1-26 JH6b CARDRGSHTK 7
family 1
family 2
family 3
family 4
family 5
family 6
family 7
family 8
family 9
Table 27.  BTN-LCL1
Summary of matched V, D and J alignments for each IgH sequence analysed 
at 0 and 6 weeks post-establishment (9 and 12 weeks shown on previous 
page), the first 10 amino acids of the VDJ junction translation, and the 
number of mutations detected in the V region.  Clonally related IgH
sequences are colour highlighted (see legend).
sequence V D J junction translation mutations
1 DP-46/3d216...+ D4-11/DA1 JH4b CATDFDWSYY 0
2 DP-46/3d216...+ D4-11/DA1 JH4b CATDFDWSYY 0
3 DP50/hv3019b9...+ D3-22/D21-9...+ JH4b CARDYYDSSG 1
4 DP-50/hv3019b9...+ D3-22/D21-9...+ JH4b CARDYYDSSG 1
5 DP-50/hv3019b9...+ D3-22/D21-9...+ JH4b CARDYYDSSG 1
6 DP-78/3d230d...+ D2-2 JH5b CARGELGYCI 2
7 DP-51+ D6-19 JH2 CAREIGAVAA 6
8 DP-79/4d154...+ D1-7/DM1 JH1 CASSMGRPSI 8
9 DP-31/V3-9P...+ D6-6/DN4 JH4b CTKARSRTYF 0
10 DP-73/V5-51...+ D2-15/D2 JH4b CARLGTPDIV 0
11 DP-15/V1-8+ not found JH6c CARGHRLLVE 0
12 DP-2/V71-5+ D3-16 JH6b CAADFTFGGV 0
13 DP-77/WHG16+ D6-19 JH6b CASSGWYVRY 1
14 b13../hv3019b13 D3-10/DXP'1 JH6c CAKDGYGSGS 8
9 weeks
sequence V D J junction translation mutations
1 DP-10/hv1051...+ D3-22/D21-9...+ JH5b CAIMYYYDSS 0
2 DP-10/hv1051...+ D3-22/D21-9...+ JH5b CAIMYYYDSS 0
3 DP-71/3d197d...+ not found JH4b CASTRWGVTP 1
4 DP-71/3d197d...+ not found JH4b CASTRWGVTP 1
5 DP-64/3d216d+ D6-19 JH2 CARGQAVAGS 1
6 DP-64/3d216d+ D6-19 JH2 CARGQAVAGS 1
7 DP-50/hv3019b9...+ D3-22/D21-9...+ JH4b CARDYYDSSG 1
8 DP-78/3d230d...+ D2-2 JH5b CARGELGYCI 2
9 DP-78/3d230d...+ D2-2 JH5b CARGELGYCI 2
10 DP-79/4d154...+ D5-24 JH4b CARHTRMATI 3
11 DP-79/4d154...+ D5-24 JH4b CARHTRMATI 3
12 DP-51+ D6-19 JH2 CAREIGAVAA 6
13 DP-79/4d154...+ D1-7/DM1 JH1 CTSSMGRPSI 8
14 DP-79/4d154...+ D1-7/DM1 JH1 CASSMGRPSI 8
15 DP-79/4d154...+ D6-19 JH4b CASRGYSSGW 0
16 DP-73/V5-51...+ not found JH6b CARAYGDYDY 0
17 DP-54/V3-7...+ D4 JH4b CARGYCISTS 0
18 DP-46/3d216...+ not found JH4b CARDRPSRTL 2
19 DP-78/3d230d...+ D2-21 JH3b CARHLYYYDA 3
20 DP-51+ D3-10/DXP'1 JH4b CARVSFNNYG 4
21 DP-46/3d216...+ D6-19 JH4b CARASSGWYD 5
12 weeks
family 1
family 2
family 3
family 4
family 5
family 6
family 7
family 8
family 9
Table 27.  BTN-LCL1
Summary of matched V, D and J alignments for each IgH sequence analysed at 9 
and 12 weeks post-establishment (0 and 6 weeks shown on previous page), the 
first 10 amino acids of the VDJ junction translation, and the number of mutations 
detected in the V region.  Clonally related IgH sequences are colour highlighted 
(see legend).
CDR1
DP-79/4d154+ CCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTAGTTACTACTGG
12wk(S10)    .....................................................................................
12wk(S11)    .....................................................................................
6wk(S3)      .....................................................................................
CDR2
DP-79/4d154+ GGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGAGCACCTACTACAACCCGTCCC
12wk(S10)    .............................A...............GC......................................
12wk(S11)    .............................A...............GC......................................
6wk(S3)      .............................A...............GC......................................
DP-79/4d154+ TCAAGAGTCGAGTCACCATATCCGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCAGACACGGC
12wk(S10)    .....................................................................................
12wk(S11)    .....................................................................................
6wk(S3)      .....................................................................................
DP-79/4d154+ TGTGTATTACTGTGCGAGA CDR3
12wk(S10)    ...................CATACCAGGATGGCTACAATTGAATTTGACTACTGGGGCCAGGGA
12wk(S11)    ...................CATACCAGGATGGCTACAATTGAATTTGACTACTGGGGCCAGGGA
6wk(S3)      ...................CATACCAGGATGGCTACAATTGAATTTGACTACTGGGGCCAGGGA
3
Figure 42.  BTN-LCL1 family 2 mutation distribution   
BTN-LCL1 family 2 sequences aligned relative to the matched germline V region sequence (top 
row).  The location of the V region is indicated and the CDRs (1, 2 and 3) are highlighted in blue 
text.  A box is drawn around the first 30 nucleotides of the VDJ junction translation.
All sequences isolated from family 2 carried 3 identical mutations; 1 at codon 44 and 2 at codon
50.  
5044
V
V
V
V
3
3
3
Figure 43.  Percentage of mutated and unmutated clonal families in tonsillar naive LCLs over 
time
The pie charts show the proportion of clonal families yielding predominantly mutated IgH sequences 
(pink segment) compared to the proportion of clonal families yielding predominantly unmutated IgH
sequences (blue segments).  Percentage values are indicated within the segments.  Data from 0, 6, 9 and 
12 weeks are shown.  Together these results show an increase in the proportion of clonal families 
containing IgH mutations over time.
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4.4.1 Phenotype of the Bulk Tonsillar Naive LCL  
As with the peripheral blood naive LCLs, the LCLs generated from naive 
tonsillar B cells contained a proportion of IgH sequences (up to 37%) exhibiting 
a mutated IgV genotype consistent with memory B cells.  In order to determine 
whether EBV infection resulted in Ig class switching, the Ig isotype of the BTN-
LCL1 culture was determined using fluorochrome-conjugated antibodies against 
IgM, IgD, IgG, IgA and CD27.  Figure 44 shows that BTN-LCL1 expressed IgM 
and IgD, but not IgG, IgA or CD27, consistent with a naive B cell phenotype.  
This data indicates that in vitro infection of tonsillar naive B cells with EBV did 
not induce CSR in the cells, and supports the view that the IgH sequencing 
results reflect naive B cells that have acquired IgH mutations in vitro. 
4.5 Umbilical Cord B cell Transformation 
In order to examine the effects of in vitro EBV transformation in a non-adult B 
cell population (presumed to contain almost exclusively naive B cells), a final 
series of transformation experiments, cord blood LCLs (BCB-LCL1 and BCB-
LCL2) were established by infecting total cord blood lymphocytes.  In this 
cases, cyclosporine A was added to the culture in order to prevent T cell-
mediated B cell killing.  Following EBV infection, cells were harvested at various 
time points for IgH analysis. 
4.5.1 Bulk Cord Blood LCL1 
Twelve out of 14 IgH sequences generated from the uninfected cord blood 
lymphocytes were unmutated, and as expected each sequence was clonally 
unique.  Interestingly, 2 mutated IgH sequences were also detected in the 
resting cell population.  It has recently been reported that the majority of CB B 
80%
92%
0%
IgD
IgM
0%
0%
IgG
IgA
CD27
Figure 44.  BTN-LCL1  phenotype
Intracellular staining for IgM, IgD, IgG, IgA and CD27 was carried out on BTN-LCL1.  
The culture expressed both IgM and IgD in the absence of IgG, IgA or CD27.
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cells are phenotypically naive (Ha et al., 2008), however in one study a low 
proportion of CD27+ B cells was described (Ha et al., 2008), and other studies 
have shown the existence of rare non-switched memory B cells carrying 
mutated Ig genes (Weill et al., 2009, Scheeren et al., 2008).  It is therefore 
feasible that the 2 mutated IgH sequences are examples of this small proportion 
of cells.  At two weeks post-infection, 2 of 17 IgH sequences were mutated, but 
the cultures remained polyclonal.  At ten weeks, 4 distinct clonal families were 
detected, yet 16 out of 26 sequences were still unique.  All sequences at this 
last time point were unmutated (Table 28). 
4.5.2 Bulk Cord Blood LCL2 
The pre-infection data showed that 22 out of 23 IgH sequences analysed were 
unmutated, and the population was polyclonal (Table 29).  By six weeks post-
infection, 6 clonal families were detected, and only 3 of 20 IgH sequences were 
clonally unique.  At this time point, all sequences were unmutated except for 
those identified as family 4, each of which carried the same 3 mutations.  At 
fourteen weeks post-infection, small numbers of sequences from multiple clonal 
families were identified.  The dominant families detected at six weeks (families 
1-6) had largely been replaced by different families (7-9), suggesting a shift in 
outgrowth of distinct clonal families occurred between six and fourteen weeks 
post-infection.  All IgH sequences analysed from the fourteen week time point 
were unmutated. 
Taken together, the data from BCB-LCL1 and BCB-LCL2 show preferential 
clonal outgrowth within the culture occurring by six weeks post-infection.  These 
results are consistent with EBV infection of both peripheral blood naive B cells 
sequence V D J junction translation mutations
1 DP-74/VH-V1…+ not found JH6c GLLLLLHGRL 0
2 DP-74/VH-VI….+ not found not found CAREF 0
3 DP-47 D4 JH6c not found 0
4 DP-47/V3-23…+ D3-3/DXP4 JH4b CAKGSDYDFW 0
5 DP-47/V3-23….+ D6-19 JH6c CAKGQSGYSS 0
6 DP-65/3d75d D3-10/DXP'1 JH5b CARVKWFGEL 0
7 DP-47/V3-3…+ JH6b CAKGRLLNHG 0
8 DP-35/V3-11….+ D7-27/DHQ52 JH6b CAREPLSGSS 1
9 DP-25/VI-3b+ D3-10/DXP'1 JH3b CATGSGSYYD 1
10 DP-71/3d197d….+ D4 JH6b CARALGYCSS 1
11 p1 D4 JH3b not found 2
12 DP-48/13-2+ D6-13/DN1 JH4b CARDSWF*QQ 2
13 DP-15/V1-8+ D4-23 JH2 CARGREGGNS 3
14 DP-58/hv3d1EG D4 JH4b CARDWGSSSW 4
sequence V D J junction translation mutations
1 DP-10/V1 D6-6 JH6c CAKAQLLSKI 0
2 DP-7/V1 D6-13 JH5b CARAGPDMGW 0
3 DP-38/V3 not found not found CTTVAARGYW 0
4 hv3005/V3 D4-17 JH3b CARESFGDYA 0
5 V1-4/V7 D1-26 JH6c CARASTVNYY 0
6 DP-10/V1 D1-26 JH6b CARDPTVIVG 0
7 DP-71/V4 D6-6 JH4b CARSLSSSSN 0
8 DP-47/V3 D4-11 JH6b CAKDVWSVTY 1
9 DP-71/V4 D5-5 JH4b CARVPRPTGW 1
10 DP-75/V1 D7-27 JH6c CARGKGPTRG 1
11 VH5 D3-10 JH5b CARLGVVQGV 1
12 DP-75/V1 D6-6 JH4b CARDSSSSFD 1
13 DP-2/V1 not found JH3b CAASPQTYKE 1
14 DP-25/V1 D4-17 JH3b CARAGSSETT 1
15 DP-31/V3 D1-26 JH3b CAKVRGRGHH 1
16 DP-15 D1-26 JH2 CARDLGASNW 2
17 V3-48 D3-22 JH2 CAKDGYYDSS 3
resting CB 
lymphocytes
2 weeks
10 weeks sequence V D J junction translation mutations
1 DP-58/hv3d1EG D6-13 JH6c CARVSAAGHY 0
2 DP-58/hv3d1EG D6-13 JH6c CARVSAAGHY 0
3 DP-58 D6-13 JH6c CARVSAAGHY 0
4 V3-53+ D3-3 JH3b CARSRRGYYA 0
5 V3-53+ D3-3 JH3b CARSRRGYYA 0
6 COS-6/DA-8…..+ D6-6/DN4 JH5a CARVARSSFD 0
7 COS-6/DA-8…..+ D6-6/DN4 JH4b CARVARSSFD 0
8 COS-6/DA-8…..+ D6-6/DN4 JH4b CARVARSSFD 1
9 V3-49+ D7-27/DHQ52 JH4b CTRDTDPVGI 1
10 V3-49+ D7-27/DHQ52 JH4b CTRDTDPVGI 1
11 DP-77/WHG16+ D3-22/D21-9 JH6b CARDHPYDSS 0
12 DP-77/WHG16+ not found JH1 not found 0
13 DP-10/Hv1051…+ D3-3/DXP4 JH4b CATGGNITIF 0
14 COS-6/DA-8…..+ D4 JH4b CARDGRGIL* 0
15 DP-77/WHG16+ not found not found CARDPVVPAA 0
16 DP-25/VI-3b+ D3-3/DXP4 JH5b CARVSGEDYD 0
17 DP-71/3d197d….+ D4 JH6c CARYLNEDIV 0
18 V3-53+ D4-b JH6c AVREFFLH** 0
19 DP-71/V4 D6-19 JH2 CARDLHSSGW 0
20 VH32Sanz+ D3-9 JH6c CARVSEAAMT 0
21 DP-71/V4 D4 JH3b CARDLGYCSS 0
22 V3-21+ JH6c CARGGSDYYY 0
23 YAC-9/V3 D7-27 JH4b CTSRILTGDS 0
24 VI-4.1b+ D7-27 JH6c CARLPLLNWG 0
25 DP-73/V5 D6-19 Jh4b CARLEEAVAG 1
26 DP-15/V1 D2-8 JH4b CARGLGDFDY 2
Table 28.  BCB-LCL1
Summary of matched V, D and J alignments for each IgH sequence analysed at 0, 
2 and 10 weeks post-establishment, the first 10 amino acids of the VDJ junction 
translation, and the number of mutations detected in the V region.  Clonally 
related IgH sequences are colour highlighted (see legend). 
family 1
family 2
family 3
family 4
sequence V D J junction translation mutations
1 DP-79/4d154…+ D1-26 JH4b CARRRSGSYF 0
2 DP-10/hv1051…+ D5-5/DK4 JH4b CAGGQSGYSY 0
3 DP-73/V5-51...+ D3-22/D21-9 JH4b CARNDSSGYY 0
4 DP-58/hv3d1EG D2-15/D2 JH6c CARDDSSGPY 0
5 DP-71/3d197d...+ D6-6/DN4 JH4b CARDGGSSFD 0
6 VH32Sanz+ D4 JH3a CARRPVVPAA 0
7 DP-77/WHG16+ D7-27/DHQ52 JH4b CARGGSFLRG 0
8 DP-38/9-1...+ D6-13/DN1 JH6b CTTDPNSSSW 0
9 DP-71/3d197d...+ D7-27/DHQ52 JH2 CARSTGVYWY 0
10 DP-75/VI-2..+ not found JH4b CARGPITYPE 0
11 12M28 D1-26 JH6c CARAGWELLL 0
12 DP-49/1.9III...+ D1-14 JH6b CAKDRGDHYY 0
13 DP-75/VI-2..+ D5-5/DK4 JH4b CARDSGRRGY 0
14 VH32Sanz+ D5-5/DK4 JH6c CARGGGWAAM 0
15 DP-75/VI-2..+ D3-9/DXP1... JH4b CALRPEYYDI 0
16 DP-66/V71-2...+ not found JH4b CAGGPGVPFD 1
17 DP-75/VI-2..+ D6-25 JH4b CARDSWYSSS 1
18 DP-71/3d197d...+ D5-12/DK1 JH2 CARGHPGDGY 1
19 VH32Sanz+ D6-25 JH6b CATPGIAAWY 1
20 DP-71/3d197d...+ D6-6/DN4 JH2 CARHGIAARP 2
21 DP-71/3d197d...+ D1-26 JH4b CARRDRSSYY 2
22 DP-71/3d197d...+ D6-6/DN4 JH6c CARLLAGTWY 2
23 p1 D3-3/DXP4 JH4b CVNGGLV*IT 3
sequence V D J junction translation mutations
1 DP-10/hv1051...+ D7-27/DHQ52 JH4b CAREVPATGD 0
2 DP-10/hv1051...+ D7-27/DHQ52 JH4b CAREVPATGD 0
3 DP-10/hv1051...+ D7-27/DHQ52 JH4b CAREVPATGD 0
4 DP-10/hv1051...+ D7-27/DHQ52 JH4b CAREVPATGD 1
5 DP-10/hv1051...+ D7-27/DHQ52 JH4b CAREVPATGD 1
6 DP-74/VH-VI...+ D6-19 JH4b CARDRSRGWY 0
7 DP-74/VH-VI...+ D6-19 JH4b CARDRSRGWY 0
8 DP-74/VH-VI...+ D6-19 JH4b CARDRSRGWY 0
9 DP-74/VH-VI...+ D6-19 JH4b CARDRSRGWY 0
10 V3-53+ D2-21 JH4b CARASGDFDY 3
11 V3-53+ D2-21 JH4b CARASGDFDY 3
12 V3-53+ D2-21 JH4b CARASGDFDY 3
13 12M28 D3-22/D21-9 JH2 CATTYDSSGY 0
14 12M28 D3-22/D21-9 JH2 CATTYDSSGY 1
15 4M28 D3-22/D21-9 JH2 CATTYDSSGY 1
16 DP-79/4d154...+ D1-14/DM2 JH4b CARHQRSYPD 0
17 DP-49/1.9III...+ D6-13/DN1 JH4b CAKVPHSSSW 0
18 DP-71/3d197d...+ D7-27/DHQ52 JH2 CAREDPTGDW 0
19 DP-47/V3-23...+ D6-25 JH4b CAKDLTAAPD 0
20 DP-58/hv3d1EG D7-27/DHQ52 JH3b CARDQMTGDR 0
sequence V D J junction translation mutations
1 DP-10/hv1051...+ D7-27/DHQ52 JH4b CAREVPATGD 0
2 DP-74/VH-VI...+ D6-19 JH4b CARDRSRGWY 0
3 12M28 D3-22/D21-9 JH2 CATTYDSSGY 0
4 12M28 D3-22/D21-9 JH2 CATTYDSSGY 1
5 DP-79/4d154...+ D1-14/DM2 JH4b CARHQRSYPD 0
6 DP-49/1.9III...+ D6-13/DN1 JH4b CAKVPHSSSW 0
7 4-04 VIV4 not found JH6c CARDETLVSS 0
8 4-04 VIV4 not found JH6c CARDETLVSS 0
9 4-04 VIV4 not found JH6c CARDETLVSS 1
10 4-30.1 DP65 not found JH3b CASEFNDPSY 0
11 4-30.1 DP65 not found JH3b CASEFNDPSY 0
12 4-59 DP71 not found JH2 CARQDNWNYW 2
13 4-59 DP71 not found JH2 CARQDNWNYW 2
14 4-59 DP71 not found JH2 CARQDNWNYW 2
15 3-30 COS8 not found JH4b CARGGSSYYF 0
16 5-51 DP73 not found JH5a CARRGGGGYS 0
17 3-30 DP49 not found JH3b CAKGGYGSGS 0
18 4-59 DP71 not found JH3b CARHITGTAF 2
14 weeks
6 weeks
family 1
family 2
family 3
family 4
family 5
family 6
family 7
family 8
family 9
resting CB 
lymphocytes
Table 29.  BCB-LCL2
Summary of matched V, D and J alignments for each IgH sequence analysed at 0, 
2 and 10 weeks post-establishment, the first 10 amino acids of the VDJ junction 
translation, and the number of mutations detected in the V region.  Clonally 
related IgH sequences are colour highlighted (see legend).
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and tonsillar naive B cells.  However, in contrast to PB or tonsillar B cells, little 
evidence of SHM was observed in the cord blood LCLs, suggesting that EBV 
transformation of cord blood lymphocytes in vitro does not induce SHM. 
As with the LCL cultures derived from PB and tonsillar naive B cells, the cord 
blood LCLs were examined for Ig isotype expression.  Flow cytomety analysis 
of Ig and CD27 expression in BCB-LCL1 and BCB-LCL2 revealed that both 
LCLs expressed IgD and IgM without IgG, IgA or CD27, consistent with a naive 
B cell phenotype (data not shown). 
4.6 N-LCLs Can be Induced to Undergo Isotype-Switching in 
Vitro 
Evidence of IgH mutation following EBV transformation of PB and tonsillar naive 
B cells, suggests the virus is able to induce one of the key processes of an in 
vivo GC reaction in an in vitro setting.  Although a proportion of the infected 
naive B cells had acquired memory B cell genotypes, analysis of Ig isotype 
expression revealed that EBV infection in vitro was not able to induce a second 
hallmark of a GC reaction, CSR.  In order to examine whether EBV-transformed 
naive B cells were capable of undergoing CSR when provided with appropriate 
B cell-activating signals, a number of experiments were carried out.  Based on 
methods published by others, a combination of CD40L, IL-4 and IL-21 was 
employed to induce CSR (Avery et al., 2008).  A range of LCLs generated from 
PB naive B cells were used, including recently established (BN-LCLs 6 and 7) 
and long-established (BN-LCL5) cultures.  In addition, a tonsillar naive LCL 
(BTN-LCL1) and a cord blood LCL (BCB-LCL2), both of which were long-
established, were also examined. 
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For the first experiment (BN-LCL5), purified naive B cells were infected with 
EBV and cultured for 14 days before being divided into three cultures; the first 
was left untreated, the second treated with CD40L and IL-4, and the third with 
CD40L, IL-4 and IL-21.  The three cultures were grown for 7 days before being 
stained for IgD, IgG, IgA and CD27, and analysed by flow cytometry.  The 
results of the three culture conditions are shown in Figure 45.  The untreated 
culture expressed IgD in the absence of IgG, IgA or CD27.  The culture treated 
with CD40L and IL-4 alone showed a slight increase in IgG and IgA expression, 
with little change in IgD.  Exposure to CD40L, IL-4 and Il-21 caused a significant 
upregulation of IgG and IgA together with a decrease in IgD expression.  These 
findings confirm that EBV infected naive B cells retain their capacity to isotype-
switch. 
Since the use of CD40L, IL-4 and IL-21 together produced the most potent 
effect in the first experiment, all three were used in combination for subsequent 
experiments (summarised in Table 30).  A further PB N-LCL (BN-LCL7) was 
split into two cultures at day 14 post-infection, and either treated with CD40L/IL-
4/IL-21, or left untreated.  In BN-LCL7, expression of IgG and IgA was 
upregulated in the CD40L/IL-4/IL-21-treated, but not the untreated culture.  The 
same experiment was carried using the long-established (>12 weeks) BN-LCL5.  
In this case, IgG expression was upregulated as a result of stimulation, but only 
a small increase in IgA expression was observed.  Similarly examination of a 
well-established tonsillar naive LCL (BTN-LCL1) and cord blood LCL (BCB-
LCL2) revealed selective upregulation of IgG following CD40L/IL-4/IL-21 
treatment. 
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Figure 45.  BN-LCL treated with CD40L, IL-4 and IL-21
14 days following in vitro infection, naive B cells were either cultured as before without treatment 
(A), treated with CD40L and IL-4 (B), or treated with CD40L, IL-4 and IL-21 (C) for 7 days.  
Intracellular staining for IgD, IgG, IgA and CD27 was then carried out.  The isotype control is shown 
in black outline, whereas the specific staining is shown in coloured outline (note, the same isotype
controls and gates were used in A and B, whereas a separate isotype control and gate was for the 
staining shown in C.).
A. The untreated LCL culture expressed both IgM and IgD in the absence of IgG, IgA or CD27.  B.
Whilst the majority of cells still expressed IgD, small cells numbers in the CD40L/IL-4-treated LCL  
switched to IgG or IgA expression.  C. A decrease in the number of cells expressing IgD was 
observed in the CD40L/IL-4/IL-21-treated LCL, together with a substantial increase in the number 
of cells expressing either IgG or IgA.  Upregulation of CD27 was not observed in either of the 
treated cultures.   
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BN-LCL6
(14 days)
IgD 84 85 35
IgG 0 3 14
IgA 0 4 43
CD27 0 0 0
BN-LCL7
(14 days)
IgD 45
n/t
49
IgG 0 53
IgA 0 15
CD27 0 0
BN-LCL5
(>12 weeks)
IgD 85
n/t
58
IgG 0 42
IgA 0 2
CD27 0 0
to
n
si
l BTN-LCL1
(>12 weeks)
IgD 83
n/t
49
IgG 0 22
IgA 0 1
CD27 0 0
co
rd
 b
lo
o
d
BCB-LCL2
(>12 weeks)
IgD 75
n/t
62
IgG 0 52
IgA 0 2
CD27 0 0
Table 30.  Summary of isotype-switching experiments
Summary of isotype expression in a range of LCLs treated with CD40L/IL-4/IL-21. All 
untreated LCLs expressed IgD in the absence of IgG, IgA or CD27.  In PB naive B cells 
treated with CD40L/IL-4/IL-21 at 14 days post-infection, a substantial proportion of 
cells within both cultures switched to IgG or IgA.  In long-established LCLs derived 
from PB, tonsil and CB, however, whilst class-switching to IgG was clearly observed, 
only small numbers of cells switched to IgA.  CD27 was not upregulated in any of the 
LCLs treated with CD40L/IL-4/IL-21.   
147 
 
These results show that EBV-transformed naive B cells from PB, tonsil and cord 
blood are capable of CSR in vitro.  Whereas each LCL culture retained the 
capacity to switch to IgG, only those recently established switched to IgA. 
4.7 AID Variant Expression in Peripheral Blood B cell Cultures 
Activation-induced cytidine deaminase (AID) is essential for the process of both 
isotype-switching and somatic hypermutation in vivo (Muramatsu et al., 2000).  
In addition to the most abundantly expressed full length AID mRNA transcript, 
several variants also occur (Figure 10).  Significantly, certain AID variants 
generated by alternative splicing are reportedly deficient in either somatic 
hypermutation activity (AID-ΔE3E4) or class-switch recombination activity (AID-
ΔE4) (Wu et al., 2008).  Since EBV infection reportedly upregulates expression 
of AID in vitro (He et al., 2003, Gil et al., 2007, Epeldegui et al., 2007), we 
designed qPCR assays to determine the relative levels of the full length 
transcript (AID-FL), the transcript missing exon 4 (AID-ΔE4) and the transcript 
missing exons 3 and 4 (AID-ΔE3E4).  These assays were then used to 
investigate AID expression in EBV-blasts and CD40-blasts. 
Using a nested reverse transcription (RT) PCR approach, we first isolated 
variant AID cDNA products derived from the Akata-BL cell line by agarose gel 
electrophoresis (data not shown).  These different AID cDNA products were 
then excised from the gel and cloned into a pGEMT vector system.  Following 
sequence analysis to confirm the identity of the variants, the plasmids were 
subsequently used as standards in the qPCR reactions. 
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4.7.1 Validation of AID qPCR Assays 
Individual qPCR assays were designed to detect each of the three AID 
isoforms.  Each assay was then validated using serial dilutions of each AID 
variant (Figure 46-a, b and c).  The three assays showed similar sensitivities 
and PCR amplification efficiencies.  In addition, each assay was tested against 
the two other AID variant targets, but no cross-reactivity was detected (data not 
shown).  In conclusion, therefore, these assays were both sensitive and 
specific. 
4.7.2 AID Upregulation in Peripheral Blood B cells Following EBV 
Infection in Vitro 
In order to confirm the upregulation of AID expression in B cells following EBV 
infection, PB B cells were infected with B95.8 virus.  In parallel, B cells from the 
same donor were stimulated with CD40L and IL-4 to generate B blasts.  Cells 
were collected prior to treatment and at various time points up to 35 days 
following either infection or stimulation.  Following RNA isolation and cDNA 
synthesis, the levels of each AID transcript were then determined by qPCR 
(Figure 47).  Whilst no AID expression was detected in the resting B cells, 
upregulation of AID-FL and to a lesser degree AID-ΔE4 was detected following 
both EBV infection and CD40L/IL-4 treatment.  A markedly higher level (~ 10-
fold) of AID-FL and AID-ΔE4 transcripts was detected in the blast cultures than 
in the LCL cultures.  AID-FL was the most abundantly expressed transcript in 
both cultures, followed by AID-ΔE4 which was ~10-fold lower; levels of AID-
ΔE3E4 were extremely low. 
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AID-FL standard curve 
AID-FL plasmid serial dilution qPCR amplification plots
Legend
1.2 x 106 plasmid copies4
1.2 x 105 plasmid copies5
1.2 x 107 plasmid copies3
1.2 x 108 plasmid copies2
1.2 x 109 plasmid copies1
Figure 46a.  AID-FL plasmid standards
The plasmid vector containing the AID-FL inserted sequence was serially 
diluted 1:10 to generate 5 values for a standard curve.  Duplicate samples 
from each concentration were amplified in an AID-FL specific qPCR assay.
The upper panel shows a representative AID-FL qPCR standard curve (see 
legend for plasmid copy numbers).  The lower panel shows the corresponding 
qPCR amplification curves for each point of the standard curve.
AID-ΔE4 standard curve 
AID-ΔE4 plasmid serial dilution qPCR amplification plots
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Figure 46b. AID-ΔE4 plasmid standards
The plasmid vector containing the AID-ΔE4 inserted sequence was serially 
diluted 1:10 to generate 5 values for a standard curve.  Duplicate samples 
from each concentration were amplified in an AID-ΔE4 specific qPCR assay.
The upper panel shows a representative AID-ΔE4 qPCR standard curve (see 
legend for plasmid copy numbers).  The lower panel shows the corresponding 
qPCR amplification curves for each point of the standard curve.
AID- ΔE3ΔE4 standard curve 
AID-ΔE3ΔE4 plasmid serial dilution qPCR amplification plots
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Figure 46c. AID-ΔE3E4 plasmid standards
The plasmid vector containing the AID-ΔE3E4 inserted sequence was serially 
diluted 1:10 to generate 5 values for a standard curve.  Duplicate samples 
from each concentration were amplified in an AID-ΔE3E4 specific qPCR assay.
The upper panel shows a representative AID-ΔE3E4 qPCR standard curve (see 
legend for plasmid copy numbers).  The lower panel shows the corresponding 
qPCR amplification curves for each point of the standard curve.
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Figure 47.  AID upregulation in PB B cells following EBV infection or CD40L/IL-4 
stimulation
In order to confirm the induction of AID variant transcription, CD19-selected B cells from a 
single donor were either infected with EBV, or treated with CD40L/IL-4.  Cells were then 
harvested at various time points, RNA was isolated and expression of AID-FL, AID-ΔE4 and 
AID-ΔE3E4 measured by qPCR.  AID transcript copy numbers were estimated by comparison 
to plasmid standard curves, and the RNA input was normalised against GAPDH.  The values 
presented are therefore semi-quantitative transcript copy numbers.   
Marked upregulation of AID expression was detected at ~21 days post-infection in the LCL , 
and ~7 days post-establishment of the CD40 blast.    Higher levels of all expressed AID 
transcripts were detected in the CD40 blast than in the LCL.  In both cultures, however, AID-FL 
was expressed ~ 10-fold higher than AID-ΔE4 and AID-ΔE3E4 was expressed in extremely low 
levels.
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4.7.3 AID Expression in Tonsillar B cells 
In order to assess whether the levels of AID expression in an LCL were 
comparable to physiological levels, we compared the levels of AID in the LCL 
used in the previous experiment, together with ex vivo tonsillar B cells and the 
Ramos-BL cell line, which is known to undergo continuous SHM (Sale and 
Neuberger, 1998).  The primary tonsillar B cells expressed both AID-FL and 
AID-ΔE4 at similar levels to the LCL and Ramos cells; again levels of AID-
ΔE3E4 were extremely low or undetectable (Figure 48).  The AID-FL transcript 
was the most abundantly expressed in each sample, whereas AID-ΔE4 
expression was approximately 7-fold lower.  The AID-ΔE3E4 transcript 
expression was a further 10-fold lower, and as such was barely detectable by 
the assay. 
4.7.4 AID expression in Naive LCLs and CD40 blasts 
A selection of BN-blast cultures and LCL cultures yielding either predominantly 
mutated or unmutated IgH sequences were examined for AID variant 
expression (Figure 49).  Consistent with the above findings, all three blast 
cultures expressed AID transcripts at levels over 10-fold higher than the LCLs, 
with AID-FL being the most abundantly expressed transcript.  Whereas AID-FL 
and AID-ΔE4 transcripts were detectable in all BN-blast and LCL cultures, the 
AID-ΔE3E4 was barely detectable (data not shown).  No obvious differences in 
AID transcript expression were detected in the LCLs containing mutated IgH 
sequences (BN-LCLs3, 4b and 5) compared to those that did not (BN-LCL1 and 
BCB-LCL1). 
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Figure 48.  AID expression in tonsillar B cells
AID expression in an LCL derived from PB CD19-selected B cells was compared to 
that in ex vivo tonsillar B cells and the Ramos-BL cell line using qPCR assays.   AID 
transcript copy numbers were estimated by comparison to plasmid standard 
curves, and the RNA input was normalised against GAPDH.  The values presented 
are therefore semi-quantitative transcript copy numbers.  Similar levels of AID-FL 
and AID-ΔE4 were observed in all 3 cell types, with AID-FL more highly expressed 
than AID-ΔE4.  AID-ΔE3E4 expression was not detected in any of the samples (not 
shown).
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Figure 49.  AID expression in established naive LCLs and CD40 blasts
AID variant expression from several of the established LCL and BN-blast cultures featured in 
this study was evaluated using qPCR.  Both AID-FL and AID-ΔE4 were expressed ~10-fold higher 
in the BN-blasts than in the LCL cultures, however in both cultures AID-FL was expressed more 
highly than AID-ΔE4.  No consistent difference in expression of either AID transcript was 
observed between LCLs yielding predominantly mutated IgH sequences, and LCLs yielding 
predominantly unmutated IgH sequences.
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4.7.5 Expression of SHM molecules Polymerase-η and Uracil DNA 
Glycosylase 
In the next series of experiments, expression of two further enzymes involved in 
the SHM process, polymerase-η and uracil DNA glycosylase (UNG) (Peled et 
al., 2008) were also examined by qRT-PCR.  These assays were used to 
screen a selection of LCLs derived from PB naive B cells (BN-LCL3, BN-LCL4b 
and BN-LCL5), tonsillar naive B cells (BTN-LCL1) and cord blood (BCB-LCL1), 
together with two CD40 blasts (BN-blast1 and BN-blast3) (Figure 50).  The 
results show that expression of both Pol-η and UNG was upregulated in all the 
LCL and CD40 blasts examined, albeit at lower levels than the reference cell 
line Jurkat.  All cultures expressed similar levels of either Pol-η or UNG, with no 
considerable difference in expression between LCLs or CD40 blasts.  As 
expected, expression of neither Pol-η nor UNG was detected in resting PB B 
cells (data not shown). 
These data confirm that in addition to AID variants AID-FL and AID-ΔE4, 
expression of two additional components of the SHM process, Pol-η and UNG, 
were also upregulated in both LCLs of different origin and in CD40-blasts. 
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Figure 50. pol-η and UNG expression in established LCLs and CD40 blasts
Relative expression of pol-η and UNG in several established LCL and BN-blast cultures  
was examined by qPCR.  Results were normalised against GAPDH values to control for 
RNA input.  Normalised values are presented relative to the leukemic cell line, Jurkat.  The 
results show that expression of both pol-η and UNG was upregulated in BN-LCLs, BTN-
LCL1, BCB-LCL1 and BN-blasts, with no notable difference in expression levels identifiable 
between the different cultures.
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4.8 Discussion 
4.8.1 EBV Infection of Naive B cells Induces IgH Mutations in 
Vitro 
Previous work carried out by Dr Begue Pastor and Dr Chaganti suggested that 
in vitro transformation of naive B cell populations from PB could yield LCL 
cultures carrying mutated IgH genes.  In the current project, purified naive B 
cells of PB, tonsil and cord blood B cells were used to generate both bulk and 
limiting dilution LCL cultures, which were subsequently analysed by IgH 
sequencing at various time points (up to twelve weeks) post-infection.  The 
present results confirm that following EBV infection of adult PB and tonsillar 
naive B cells in vitro, a subset of cells carrying mutated IgH sequences were 
detectable from approximately six weeks post-infection, with some evidence of 
ongoing SHM in some instances.  We suggest that these findings do not reflect 
artifacts of in vitro culture or PCR-induced error, since similar results were 
observed using two different transformation techniques (bulk culture and limiting 
dilution infections), and from naive B cells derived from both peripheral blood 
and tonsil. 
The simplest explanation for the appearance of LCLs carrying mutated IgH 
sequences is that the initial naive B cell products were contaminated with 
memory B cells.  However, IgD+CD27- naive B cells derived from adult PB or 
tonsil were sorted to high purity (~99%) as shown in the reanalysis data 
summarised in Table 10.  In addition, IgH sequence analysis of starting 
populations from PB or tonsillar naive B cells, and cord blood B cells confirmed 
that over >95% of the cells carried unmutated IgH genes, confirming the cells 
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were genotypically naive (summarised inFigure 51).  The high purity of the 
starting populations implies that the vast majority of transformed cells growing 
out in the LCL cultures should therefore be of naive B cell origin.  This was 
further confirmed by examination of Ig isotype expression in established LCLs, 
which showed that each culture retained an IgM+IgD+ phenotype, eliminating 
the possibility that mutated IgH sequences were derived from small numbers of 
contaminating switched memory B cells.  However, such sequences could have 
arisen from IgM+IgD+CD27+ non-switched memory B cells, which were the 
most likely source of contamination during FACS sorting.  Regarding this issue, 
expression of the memory marker CD27, which can be used to distinguish 
IgM+IgD+CD27- naive B cells from IgM+IgD+CD27+ non-switched memory B 
cells, was consistently undetectable in any of the LCLs, further suggesting that 
the cultures examined in this study reflected bone fide transformed naive B 
cells.  However, the lack of CD27 expression in our established LCLs 
contradicts a recent report describing upregulation of CD27 in naive LCLs 
(Siemer et al., 2008). 
In order to determine whether non-switched memory B cells were able to 
transform more efficiently than naive B cells, and therefore may potentially grow 
out preferentially in vitro, we directly compared the transformation efficiency of 
naive and non-switched memory B cell populations from five separate PB 
donors.  Although a considerable level of variation in transformation efficiency 
between B cells from separate PB donors was noted, no reproducible difference 
between the two B cell subsets was detected in these experiments. 
The successive accumulation of IgH mutations is a hallmark of SHM within 
clonal expansions.  In order to examine in further detail the development of 
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Figure 51.  Frequency of mutations in resting B cell populations
IgH mutation frequencies in the resting cell populations used to generate PB N-LCLs, tonsillar
N-LCLs and CB-LCLs.  IgH analysis revealed >90% of the cells were unmutated.
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SHM patterns within IgH genes of EBV-infected cells, three BN-LCLs (BN-
LCL4a, -b and-c) were established from a single donor.  From mutations 
identified in IgH sequences within these cultures, clonal family trees were 
constructed which highlighted the sequential accumulation of mutations along 
successive generations of cells.  Genealogical trees generated by other 
investigators have described a similar stepwise accumulation of small numbers 
of mutations in vitro, namely in a rheumatoid factor (RF) – producing LCL 
(Chezar et al., 2008) and in the Ramos BL cell line (Sale and Neuberger, 1998). 
In several instances in the current study, cells carrying mutated IgH sequences 
could be traced back to genotypically naive, germline IgH sequences from the 
same clone, present within the same culture.  Co-existence within the cultures 
of clonally related cells, each harbouring distinct IgH mutation patterns reflecting 
different stages of the stepwise accrual of mutations, strongly suggests that this 
process took place in vitro, following EBV infection.  Furthermore, it is highly 
unlikely that these clonal expansions had occurred in vivo and were 
subsequently collected during cell sorting since (i) the cells were derived from 
PB rather than from lymphoid tissue, (ii) IgH analysis of resting cells in each 
case revealed polyclonal populations of unmutated cells, and (iii) clonal families 
containing IgH mutations were not detected until approximately six weeks after 
infection, suggesting the mutation process occured over time in culture.  
Together these observations suggest that EBV infection of naive B cells can 
induce IgH mutations in at least a proportion of cells in vitro, and support the 
argument that such sequences do not reflect outgrowth of contaminating 
memory cells. 
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EBV Infection of Cord Blood B cells does not Induce IgH Mutation  
In contrast to the results seen in transformed naive B cells derived from PB and 
tonsils, analysis of IgH sequences from two cord blood-derived LCLs did not 
provide any evidence of IgH mutation.  The reason why SHM is induced in adult 
B cells, but not cord blood B cells is not obvious from these experiments since 
AID, UNG and Pol-η were also upregulated in the CB-LCL examined.  
Nevertheless both phenotypic and functional differences between cord blood 
and adult PB B cells have been documented.  A recent study showed a 
markedly higher proportional of immature, transitional B cells in cord blood 
compared to adult PB, together with a deficiency in signaling molecules 
associated with cell activation such as ERK, p38 and MAP kinases following 
CD40 stimulation (Ha et al., 2008).  Whether or not these discrepancies account 
for the lack of mutation in the CB-LCLs is unclear, however it is feasible that 
further unidentified differences exist between cord blood and adult B cells, 
which render the former subset less susceptible to SHM. 
4.8.2 AID is Upregulated Following EBV Infection in Vitro 
The enzyme AID, whose natural function is to introduce lesions into IgH genes, 
is critical for the processes of both CSR and SHM (Muramatsu et al., 2000, 
Revy et al., 2000).  Although AID activity is classically refined to the IgH locus, 
AID is also known to target a range of non-Ig genes within the human genome 
(Wang et al., 2004), including proto-oncogenes (Liu et al., 2008, Pasqualucci et 
al., 1998, Shen et al., 1998).  Furthermore, ectopic expression of AID is 
involved in chromosomal translocations (Ramiro et al., 2004, Dorsett et al., 
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2007), and has been implicated in malignant transformation of B cells (Okazaki 
et al., 2007). 
Examination of the location of IgH mutations in the PB naive LCLs included in 
this study revealed a concentration of nucleotide changes at AID hotspots 
(Dorner et al., 1998) (summarised in Figure 52).  Although evidence that this 
pattern of IgH mutations occurred in vitro may be circumstantial, it confirms 
firstly that the mutations identified in these cultures were AID-mediated, and 
secondly that PCR error was not responsible.  Subsequently, it was also 
confirmed that whereas no AID expression could be detected in circulating B 
cells, expression of AID transcripts was upregulated by EBV infection and by 
CD40L/IL-4 stimulation of B cells in vitro, each of which has been reported 
previously (Pasqualucci et al., 2004, He et al., 2003, Gil et al., 2007, Epeldegui 
et al., 2007).  Although both processes result in the upregulation of AID 
expression, the means by which this is achieved in CD40 blasts and LCLs is 
likely to be different.  CD40L and IL-4 treatment provides mitogen activation to 
B cells in vitro, similar to those signals provided during T-dependent activation 
of B cells in vivo.  In the case of EBV infection, however, components of the 
latency III program are likely to induce AID expression.  Specifically, LMP1 
expression has been linked to the upregulation of AID in ex vivo PB B cells (He 
et al., 2003); an observation which is not surprising given the ability of LMP1 to 
mimic CD40 signalling (Uchida et al., 1999).  In the current study, AID 
expression was detected in all LCL cultures examined by RT-PCR, but SHM 
was only detected in a fraction of cells.  It is unclear why AID expression in 
some instances lead to SHM, but in others appeared to be inhibited.  Studies of 
AID expression in cases of B cell chronic lymphocytic leukemia B-CLL have 
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Figure 52.  High numbers of mutations in naive LCL cultures accumulate in AID hotspots
The chart shows a summary of mutations identified in each N-LCL culture derived from PB.  Identical mutations in clonal families were only counted once. 
Solid blue bars with above numbered codons represent AID hotspots and asterisks next to numbered codons represent AID coldspots (described by Dorner et 
al., 1998).
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shown that the enzyme is only upregulated in a subset of cells within B-CLL 
clonal expansions in vivo (Albesiano et al., 2003).  In the same investigation no 
differences in levels of overall AID expression were identified when comparing 
mutated and non-mutated clones.  If a similar situation were to take place in 
vitro, whereby only a subset of cells within one population upregulated AID 
expression, this could lead to SHM within only a fraction of cells in LCL cultures.  
Indeed, such a phenomenon would be undetectable by RT-PCR, which 
provides an average expression value across a whole population of cells.  This 
explanation does not, however, account for the finding that no SHM at all was 
detected in the either the BN-blasts or the BCB-LCLs where AID was clearly 
expressed by some, if not all, of the cells in these cultures.  A more likely 
explanation, therefore, may be that although AID is expressed in each case, in 
instances where no IgH mutations were found, its capacity to induce SHM was 
somehow inhibited. 
4.8.3 SHM was detected in BN-LCLs but not BN-blasts 
In order to carry out EBV-negative control experiments for the in vitro activation 
and cell culture of B cells, three BN-blasts were established using PB naive B 
cells.  Unlike the BN-LCLs, no increase in mutated IgH sequences was detected 
in any of the BN-blasts after six or nine weeks in culture (the percentage of 
mutated IgH sequences from all BN-LCLs and BN-blasts at 0, 6 and 9 weeks 
post-establishment is summarised in Figure 53).  To rule out the possibility that 
these differences merely reflect variations between the naive B cell populations 
used to generate the separate cultures, a BN-blast (BN-blast 3) and a BN-LCL 
(BN-LCL3) were established in parallel, using the same collection of naive B 
cells derived from a single donor.  IgH sequence analysis of this experiment 
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Figure 53.  Mutation frequencies in PB BN-blast and BN-LCL cultures over time
IgH sequence data pooled from all BN-blast and BN-LCL cultures.  The frequency of IgH mutations in 
the BN-blasts remained comparable to that of resting naive B cells up to 9 weeks post-establishment.  
In the BN-LCLs, however, an increase in IgH mutation frequency was observed from 6 weeks post-
infection.
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revealed that while BN-LCL3 yielded a substantial number of mutated IgH 
sequences from six weeks onwards, very few IgH sequences from BN-blast 3 
were mutated. 
The BN-blast IgH data also served to confirm that mutations identified within 
IgH sequences derived from the LCLs were not merely a reflection of PCR 
error, since if this were the case, mutations would be expected to arise in IgH 
sequences from both cultures.  Taken together these findings verify that the 
mutated IgH sequences identified in N-LCL cultures are a result of EBV-driven 
transformation of naive B cells, rather than an artifact of in vitro cell culture or 
IgH analysis techniques.  In order to explore why SHM was detected in a 
proportion of LCL cultures, but not in BN-blasts, we examined the expression of 
functionally distinct AID isoforms and of other proteins involved in SHM (UNG 
and pol-η). 
Expression of AID Isoforms 
In addition to the fully competent, most abundantly expressed full length AID 
isoform (AID-FL), AID is known to exist as several other isoforms generated by 
alternative splicing of the full length transcript.  In a recent study, two isoforms in 
particular were associated with impaired AID function, namely AID-ΔE4, 
reportedly deficient in CSR, and AID-ΔE3E4, reportedly deficient in both CSR 
and SHM (Wu et al., 2008).  Wu and colleagues further demonstrated that 
single cells derived from B-CLL were only able to express one given AID 
isoform, and suggested therefore that the function of the enzyme is regulated by 
alternative splicing to produce different variants, some of which may be 
functionally restricted. 
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Based on the possibility that differentially expressed AID isoforms may be 
responsible for the presence or absence of mutated IgH sequences, or indeed 
the lack of CSR observed in cultures included in the present study, qPCR 
assays were designed to examine the expression of three isoform transcripts in 
the LCL and BN-blast cultures.  The results from these assays showed no 
preferential expression of AID splice variants associated with CSR or SHM 
deficiency (AID-ΔE4 or AID-ΔE3E4) in any of the LCLs or BN-blasts.  Although 
upregulation of AID-ΔE4 was detected in most instances, levels of the fully 
competent AID-FL isoform were consistently approximately 10-fold higher.  The 
lack of SHM observed in the BN-blasts, cord blood LCLs and a proportion of 
adult LCLs was therefore unlikely to be a result of preferential expression of a 
functionally defective AID splice variant. 
Both AID-FL and AID-ΔE4 transcripts were expressed at consistently higher 
levels in the BN-blasts than in LCLs, with substantial transcript levels detected 
at earlier timepoints in the former (~ 3 days) than in the latter (7-14 days).  
These discrepancies could be a result of the EBNA2-driven inhibitory effect on 
AID expression that has been described elsewhere (Tobollik et al., 2006).  In 
this study although EBNA2 alone was able to reduce AID expression, 
subsequent upregulation of other components of the latency III program 
including LMP1, was able to counterbalance the effects of EBNA2 to a certain 
degree.  Although AID expression was not completely ablated by EBNA2-
mediated inhibition, it is possible that the balance between this effect and the 
LMP1-induced upregulation of AID (He et al., 2003, Tobollik et al., 2006) may 
contribute to the relatively low levels of AID expression seen in BN-LCLs 
compared to BN-blasts. 
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Accessory factors involved in SHM 
In normal circumstances, damage introduced to the genome is repaired by high 
fidelity enzymes, in an error-free manner.  During a GC reaction, however, AID-
induced DNA damage is repaired in an error-prone fashion, ensuring the 
accumulation of mutations within the IgH variable region (Peled et al., 2008).  
Two molecules involved in the repair of AID-mediated damage include; UNG, 
which is primarily responsible for initiating base excision repair of IgH genes in 
GC B cells in vivo (Di Noia and Neuberger, 2002, Imai et al., 2003), and Pol-η, 
an error-prone polymerase that has been implicated in the generation of 
mutations in IgH genes (Kunkel et al., 2003).  The present results revealed that 
both UNG and pol-η were expressed in BN-blasts and LCLs, with no 
discernable difference in expression levels detected in any particular culture. 
Thus the expression of these accessory factors is unlikely to account for the 
lack of SHM seen in a proportion of LCLs and in all BN-blasts. 
Regulation of AID Activity 
Although we were able to demonstrate that AID transcripts were expressed in 
LCLs and BN-blasts, it is possible that post-transcriptional modifications of the 
AID protein may regulate its activity.  Due to its potential to induce DNA 
damage, the expression and function of AID is tightly controlled within healthy 
individuals.  Much research is currently being carried out to decipher the 
extensive mechanisms that are in place to regulate the activity of the enzyme 
(Lee-Theilen and Chaudhuri, 2010).  Expression of AID has been shown to be 
regulated by microRNAs such as mir-155 and mir-181b (Teng et al., 2008, 
Dorsett et al., 2008, de Yebenes et al., 2008), and recent work has also found 
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evidence that transcription is actively repressed in inactivated B cells and non-B 
cells by silencer elements which are overcome following activation by CD40L, 
IL-4 and transforming growth factor-B in vitro (Tran et al., 2010). 
Post-translational modifications of the AID protein also serve to regulate its 
activity.  Since disruption of phosphorylation sites (such as serine 38) in knock-
in mice results in defective CSR and SHM (McBride et al., 2008, Cheng et al., 
2009), it has been suggested that phosphorylation of different residues within 
the AID protein may distinguish between CSR and SHM activity (Delker et al., 
2009).  Additionally, the subcellular localisation of the AID protein determines 
the extent to which it is able to come into contact with the genome, and 
therefore dictates its function.  It is known that AID shuttles back and forth 
between the cytoplasm and nucleus (Ito et al., 2004, McBride et al., 2004, Brar 
et al., 2004).  However whilst it was previously believed that the protein was 
able to diffuse passively from the one to the other, recent evidence suggests 
that AID is retained in the cytoplasm or imported to the nucleus in an active 
manner (McBride et al., 2004, Brar et al., 2004). 
Although none of the specific regulatory mechanisms described above can 
conclusively provide an explanation for the lack of SHM found in some cultures 
examined in this study, given the myriad of systems in place to regulate AID 
function, it is not surprising that its activity may be dysregulated in the non-
physiological setting of in vitro cell culture.  Future studies could focus on any 
one of these regulatory systems in order to determine the discrepancy in SHM 
activity observed between adult N-LCLs, BCB-LCLs and BN-blasts. 
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Intriguingly, other viruses including hepatitis C virus (HCV) and Abelson murine 
leukemia virus (Ab-MLV) have also been shown to upregulate AID expression, 
together with SHM activity (Sale and Neuberger, 1998, Gourzi et al., 2006, 
Machida et al., 2004).  AID has even been implicated in the host response 
against Ab-MLV infection since AID-expressing infected cells displayed reduced 
proliferation with simultaneous upregulation of the immune recognition molecule 
NKG2DL (Gourzi et al., 2006).  Indeed other deaminating enzymes have been 
shown to act in the defence against retroviral infection by inflicting DNA damage 
upon the single stranded DNA viral genome.  Although any link between EBV-
induced AID expression in vivo and the host defence against EBV infection 
remains to be established, it is interesting to speculate that AID may contribute 
to the elimination of infected cells by instigating genome-wide DNA damage and 
subsequent cell death. 
4.8.4 EBV Infection does not Induce Isotype-Switching in Vitro 
The question of whether in vitro EBV infection of B cells is able to induce CSR 
is controversial.  While one study described LMP1-induced isotype-switching to 
IgG (He et al., 2003), others have shown that infection of IgD+ PB B cells was 
unable to induce CSR (Miyawaki et al., 1991).  Phenotypic analysis of the LCLs 
generated in the current study revealed that EBV-transformed PB N-LCLs, 
tonsillar N-LCLs and cord blood LCLs retained expression of IgM and IgD, and 
therefore EBV infection in vitro did not induce CSR. 
In order to determine whether EBV-transformed N-LCLs of PB, tonsil and cord 
blood origin retained the capacity to undergo CSR, a selection of cultures were 
provided with various signals known to induce isotype switching ex vivo.  These 
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experiments were based on a recent study where PB naive B cells and cord 
blood B cells were induced to switch to IgG and IgA following the provision of 
two signals; CD40 ligation and cytokine stimulation (Avery et al., 2008).  These 
authors show that while CD40L plus either IL-4 or IL-21 induced istoype 
switching to IgG in a proportion of cells, CD40L plus IL-4 with IL-21 produced a 
synergistic effect, increasing IgG expression 2-fold compared to either cytokine 
alone.  Although IgA expression was induced by treatment with CD40L and IL-
21, cells treated with CD40L plus IL-4 with IL-21 did not upregulate IgA 
expression.  Similarly, CD40L with IL-4 alone did not induce isotype-switching to 
IgA. 
Consistent with Avery et al. we found that CD40L treatment with both cytokines 
(IL-4 and IL-21) had a synergistic effect on the frequency of cells switching to 
IgG; showing a 5-fold increase compared to CD40L with IL-4 alone.  In conflict 
with Avery et al., however, CD40L/IL-4/IL-21 treatment resulted in a marked 
increase in IgA+ cells in recently-transformed (~2 weeks) PB N-LCL cultures.  
Long-established (>3 months) N-LCL cultures derived from PB, tonsil and cord 
blood, however, were able to switch to IgG, but not IgA.  The time spent in 
culture may therefore have an effect on the capacity to switch to this isotype. 
Taken together the results from these experiments suggest that although EBV 
infection alone is not capable of inducing CSR of B cells in vitro, the cells do 
retain their capacity to switch when provided with the appropriate signals. 
4.8.5 LCLs are Characterised by Outgrowth of Dominant Clones 
In bulk LCLs examined in the current study, clonal outgrowth was observed 
primarily by IgH sequence analysis, and confirmed by CDR3 spectratyping.  
163 
 
The tendency of LCL cultures to become monoclonal over time has also been 
documented by other researchers (Kataoka et al., 1997, Ryan et al., 2006, 
Lacoste et al., 2010).  Such clonal expansions were identified within our LCLs 
between four and six weeks post-infection, and although the time scale of the 
progression towards monoclonality varied from culture to culture, dominant 
families were clearly present in each, with most being either monoclonal or 
biclonal by twelve weeks post-infection.  By this time, each LCL culture had 
been passaged approximately the same number of times (data not shown), and 
therefore the variation in time post-infection at which monoclonality was 
achieved was unlikely to be entirely attributable to proliferation rate.  These 
findings are in agreement with those described by others, whose LCL cultures 
also reached monoclonality between 8 to 12 weeks post-infection (Ryan et al., 
2006, Lacoste et al., 2010).  Furthermore, in the study carried out by Ryan et al. 
the time taken for individual LCL cultures to become monoclonal did not 
correlate with the rate of cell proliferation. 
Clonal Selection in LCL Cultures  
In several of the LCLs studied in this investigation the most frequently detected 
clonal family at early time points was often replaced by a separate clone later 
on.  This switch in dominant clones over time, which was also reported by 
Lacoste et al, suggests either that a minority of clonally related cells harbour 
growth advantages enabling their positive selection in the culture, or that the 
majority of cells are unable to survive due to certain disadvantages, and are 
essentially negatively selected.  Such advantages or disadvantages are unlikely 
to be a result of IgH mutation since dominant clones carrying unmutated IgH 
genes were identified in at least one of the LCL cultures.  However, while AID is 
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known to target the IgH locus primarily, its ectopic expression is associated with 
SHM of non-IgH genes that are undergoing active transcription (Muramatsu et 
al., 1999, Epeldegui et al., 2007, Liu and Schatz, 2009).  There exists, 
therefore, a possibility that regardless of mutations in the IgH region, AID-
induced mutations may have accumulated elsewhere in the genome, and 
conferred growth advantages to certain cell clones which were positively 
selected in the culture.  This theory may explain the fact that although a broad 
range of related cells representing various stages of successive SHM were 
detected within clonal families, multiple IgH sequences derived from dominant 
families often carried identical, family-specific patterns of mutation.  This 
suggests that during a particular round of SHM, a growth advantage was 
simultaneously provided to the cell, allowing subsequent clonal expansion in the 
culture.  Although such an advantage is unlikely to be provided by the IgH 
mutation itself, the introduction of a favourable mutation elsewhere in the 
genome is a possibility. 
Alternatively, Lacoste et al. propose a negative selection process based on 
evidence that EBV induces genomic instability (in the form of aberrations in 
chromosome structure) as early as four weeks post-infection.  The highest 
frequency of EBV-induced DNA damage took place at four weeks post-
infection, but thereafter declined until six months when the LCL cultures 
comprised single clones possessing stable karyotypes.  The authors therefore 
suggest that those cells subjected to the most extensive EBV-induced damage 
died off early on, allowing only healthy cell clones to thrive within the culture. 
Taking into consideration the possibility of positive selection via advantageous 
AID-mediated mutations, or negative selection due to extensive AID-mediated 
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DNA damage, it is tempting to suggest that either or both of these processes 
contribute to the outgrowth of certain clones identified within the LCL cultures of 
this study. 
Relevance of EBV-induced Clonal Outgrowth in Vivo 
Although clonal outgrowth within EBV-transformed cultures in vitro was an 
interesting observation, it may have little significance to the issue of EBV 
persistence in vivo, since the virus is predominantly found in polyclonal 
populations of memory B cells in healthy individuals (Souza et al., 2005).  The 
possibility that EBV-induced mutations may confer growth advantages to some 
cells, resulting in clonal expansion, may be more relevant in post-transplant 
lymphoproliferations (PTLs).  Indeed both PTL tumours and LCLs express the 
latency III program, and several studies have shown that the majority of EBV-
driven post-transplant lymphomas are monoclonal (Gulley et al., 1992, 
Chadburn et al., 1997, Locker and Nalesnik, 1989).  Furthermore, in an in vitro 
examination of LCL cultures generated from total PBMCs, clonal outgrowth 
correlated with decreasing numbers of T cells in the cultures, the time scale of 
which, corresponded to the earliest diagnoses of PTL,(Ryan et al., 2006). 
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5 Conclusions and Future Work 
It has long been acknowledged that EBV persistently infects circulating IgD-
CD27+ switched memory B cells for life in immunocompetent hosts (Babcock et 
al., 1998).  The processes by which this persistence is established during 
primary infection, however, remain the subject of debate; the central issue of 
which hinges on whether or not GC-transit of infected cells is necessary.  In one 
model (shown in Figure 54), the virus first targets naive B cells in the 
oropharyngeal lymphoid tissue, whereby expression of Latency III proteins 
essentially mimics antigen-driven stimulation of the infected cell, driving it to 
participate in a GC reaction.  After undergoing SHM and CSR, the virus 
downregulates expression of all viral antigens in order to avoid immune 
detection and persist in the differentiated memory B cell (Thorley-Lawson, 
2001).  An alternative model (shown in Figure 54b) challenges the involvement 
of the GC in this selective colonisation and instead proposes that oropharyngeal 
memory B cells are either preferentially infected by EBV, or both naive and 
memory cells are targetted, with the latter cell type possessing a growth 
advantage following infection (Kurth et al., 2000). 
In order to explore this issue in further detail, we carried out a series of ex vivo 
and in vitro experiments.  In our ex vivo investigation, we showed firstly that 
EBV is capable of colonising a B cell subset (IgD+CD27+ non-switched 
memory) that most likely develops independently of the GC, and secondly that 
the virus was rarely detected in CD38+ GC B cells from healthy carrier tonsils.  
In our in vitro infection experiments, we found that in a non-GC environment 
EBV infection of naive B cells alone is capable of conferring a mutated IgH 
Figure 54.  Proposed models of selective EBV colonisation of the memory B cell 
reservoir
A. Shows the current GC-dependent model of EBV persistence in the switched (S) memory B 
cell compartment (Thorley-Lawson et al., 2001).  The virus initially infects naive B cells where 
Latency III antigens such as LMP1 and LMP2 mimic antigen-driven B cell activation to drive the 
cell through a GC reaction.  The infected cell undergoes SHM and CSR to differentiate into a S 
memory B cell, whereupon expression of viral antigens are downregulated.  B. In a second 
model, which challenges the involvement of GC transit, memory B cells are preferentially 
infected, or possess a survival advantage post-infection (Kurth et al., 2000).  C. Depiction of an 
alternative model of GC-independent memory B cell colonisation based on the in vitro results 
generated in the current study.  EBV infection of naive B cells is followed by expression of 
Latency III antigens and upregulation of AID.  EBV infection alone may induce SHM, whereas 
infection together with the receipt of CSR-inducing signals (CD40-ligation plus cytokines), may 
induce isotype-switching, producing an infected cell harbouring the genoytpic and phenotypic 
characteristics of a S memory B cell.  Our ex vivo results show that EBV is able to colonise the 
NS memory B cell population.  Whether this occurs as a result of direct infection, or reflects 
EBV-induced SHM of infected naive B cells without CSR remains to be resolved.  Adapted from 
Rowe et al. 2009.
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memory B cell genotype upon a fraction of cells.  We further showed that when 
provided with appropriate stimulation, these EBV-infected cells could be 
induced to isotype-switch to a memory B cell phenotype.  Although these 
findings were observed in an in vitro setting, they raise the possibility that a 
similar phenomenon may occur in vivo.  Taken together therefore, these results 
suggest that EBV is able to establish persistence of both switched and non-
switched B cells in a germinal centre-independent manner.  A simple 
diagrammatic depiction of the current models describing selective colonisation 
of the memory B cell compartment, together with an alternative hypothesis 
based on the findings of this study is shown in Figure 54. 
Future investigations could concentrate on whether EBV directly infects specific 
tonsillar B cell populations (naive, switched memory and non-switched 
memory).  In light of our observations, it would be particularly useful to examine 
whether EBV-infected circulating non-switched memory B cells are the result of 
direct infection, or rather represent naive B cells that have acquired mutated Ig 
genes, together with CD27 expression, as a result of EBV infection.  Further ex 
vivo studies may seek to find evidence of SHM in EBV-positive phenotypically 
naive tonsillar B cells.  To this end, EBER-positive cells could be isolated from 
both the tonsil and peripheral blood, followed by single cell IgH RT-PCR.  It may 
also be informative to analyse viral load and distribution in individuals who have 
recently undergone B cell-depleting therapies such as rituximab (Roll et al., 
2006, Dorner and Burmester, 2008).  Here the central aim would be to follow 
the re-population of the B cell compartment and in parallel determine the EBV 
load.  A key question would be whether detectable EBV is only seen after 
memory cells have emerged or whether EBV can colonise the circulating 
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immature or naive B cells in the absence of switched memory B cells in these 
patients. 
Regarding the in vitro study, it is unclear why SHM is seen only in a fraction of 
EBV-infected cells and not at all in CD40 blasts, despite the observed 
upregulation of AID in these cultures.  Analysis of AID within single cells from 
LCLs or CD40 blasts may reveal differences in the regulation of AID activity, for 
example in cellular localisation of the protein, which may be examined 
microscopically using a fluorescence-labeled antibody for AID.  The relationship 
between EBV infection, AID expression and the emergence of dominant clones 
within LCL cultures also deserves further investigation, in the context of virus-
driven PTLD lesions.  Assuming that the functional capacity of AID is 
comparable in each EBV-infected cell in vitro, sequencing the entire genome in 
representative cells from LCL clonal families may identify other non-IgH genes 
targeted by AID as a result of EBV transformation.  Indeed if such cellular 
mutations were identified, their potential to confer growth advantages or 
disadvantages could be explored. 
In conclusion, the observations made in this project are important in terms of 
the controversy surrounding the initial events during EBV primary infection and 
establishment of persistence.  The finding that EBV is capable of inducing SHM 
via the ectopic expression of AID in infected naive B cells may prove to be of 
further importance to the oncogenic potential of the virus. 
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Vbase IMGT Vbase IMGT Vbase IMGT
1 1-1+ IGHV1-2*03 41 7A.10 IGHV7-40*03 81 COS-3/BHGH1+ IGHV3-30*02  
2 1--17 IGHV3-9*01                   42 7A.16 IGHV7-40*03 82 COS-30 IGHV3-15*02                  
3 1--19 IGHV3-20*01                  43 7A.18 IGHV7-40*03 83 COS-4 IGHV1-3*01                   
4 1--36 IGHV3-23*01                  44 7A.4 IGHV7-4-1*03                 84 COS-5+ IGHV1-45*03
5 >1-52 IGHV3-9*01                   45 7E.2 IGHV7-40*03 85 COS-6/DA-8...+ IGHV3-74*02                  
6 1-v/CLL-27...+ IGHV5-78*01 46 7R.9 IGHV7-40*03 86
COS-
8/hv3005f3...+ IGHV3-30*04                  
7 12M28 IGHV1-69*10                  47 8-1B+ IGHV3-66*01                  87 DA-1+ IGHV1-f*02                   
8 15-1/HC16-3 IGHV1-2*02                   48 8M27 IGHV1-69*08                  88 DA-2+ IGHV1-69*07                  
9 1d101/DP-18+ IGHV7-40*03 49 b1..e IGHV3-30*05                  89 DA-3+ IGHV3-72*01                  
10 >2-2 IGHV3-43*01                  50 b13../hv3019b13 IGHV3-30*19                  90 DA-4+ IGHV3-49*05                
11 2--20 IGHV3-43*01                  51 b18../hv3019b18 IGHV3-30*06                  91 DA-5+ IGHV3-h*01
12 2.9II/VH4-MC8...+ IGHV4-55*02 52 b25 IGHV3-30*10                  92 DP-1/HC15-1 IGHV1-2*02                   
13 2.9III+ IGHV3-54*02 53 b26 IGHV3-30*12                  93 DP-10/hv1051...+ IGHV1-69*01                  
14 22-1+ IGHV1-2*01                   54 b28e IGHV3-33*05                  94 DP-11/8-2+ IGHV1-46*01                  
15 2M27/11M27... IGHV1-69*12    55 b28m IGHV3-33*01                95 DP-12 IGHV1-46*01                  
16 >3-17 IGHV3-20*01                  56 b29e IGHV3-30*13                  96 DP-13+ IGHV7-81*01
17 >3-36 IGHV3-20*01                  57 b29m IGHV3-30*05                  97 DP-14/V1-18+ IGHV1-18*01                  
18 3-49RBe IGHV3-49*04                58 b30 IGHV3-33*04                  98 DP-15/V1-8+ IGHV1-8*01                   
19 3-49RBm IGHV3-49*03                59 b32e/b36m IGHV3-30*14                  99 DP-17/HC16-1 IGHV1-46*01                  
20 3d277d+ IGHV4-31*01                  60 b32m IGHV3-30*05                  100 DP-19/HC15-3 IGHV1-3*01                   
21 3d279d+ IGHV4-61*02                  61 b37 IGHV3-30*15                  101 DP-2/V71-5+ IGHV1-58*01                  
22 >4-32 IGHV3-20*01                  62 b43 IGHV3-30*16                  102 DP-21/4d275a+ IGHV7-4-1*01                 
23 4.3 IGHV4-39*06                  63 b48 IGHV3-30*17                  103 DP-22/HC15-2 IGHV1-18*03                
24 4.31 IGHV4-30-2*03                64 b52 IGHV3-30*11                  104 DP-23/HC15-4 IGHV1-2*02                   
25 4.32 IGHV4-31*10                  65 b54../hv3005b54 IGHV3-30*07                  105 DP-24 IGHV1-f*02                   
26 4.34.2 IGHV4-30-4*02                66 COS-10+ IGHV3-7*01                   106 DP-25/VI-3b+ IGHV1-3*01                   
27 4.36 IGHV4-34*09                  67 COS-12+ IGHV3-d*01                   107
DP-28/VH2-
MC1...+ IGHV2-70*04                  
28 4.37 IGHV4-34*10 68 COS-13/HC16-14 IGHV3-74*02                  108 DP-29/12-2+ IGHV3-72*01                  
29 4.38 IGHV4-59*10                  69 COS-14/HC15-5 IGHV1-46*01                  109 DP-3+ IGHV1-f*01                   
30 4.39 IGHV4-61*03                  70 COS-15+ IGHV3-47*01 110 DP-30 IGHV3-72*01                  
31 4.42/VH4.13... IGHV4-28*01                  71 COS-16+ IGHV3-43*02                  111 DP-31/V3-9P...+ IGHV3-9*01                   
32 4.43.4 IGHV4-55*09 72 COS-18/HC15-6 IGHV1-24*01                  112 DP-32/V3-20+ IGHV3-20*01                  
33 4.43/VH4-MC8... IGHV4-55*02 73 COS-19+ IGHV1-c*01 113 DP-33/V3-43+ IGHV3-43*01                  
34 4.44 IGHV4-34*04                  74 COS-2+ IGHV3-52*02 114 DP-34/DA-10+ IGHV3-71*01
35 4.44.3 IGHV4-34*05                  75 COS-20 IGHV3-15*03                  115 DP-35/V3-11...+ IGHV3-11*01                  
36 4M28 IGHV1-69*09                  76 COS-21/DA-12+ IGHV3-30*19                  116 DP-36/HC16-6... IGHV3-15*08                  
37 65-1/DP-20... IGHV1-46*01                  77 COS-22+ IGHV3-54*02 117 DP-37/HC16-7 IGHV3-15*03                  
38 65-3/COS-11... IGHV1-2*02                   78 COS-23+ IGHV3-38*02 118 DP-38/9-1...+ IGHV3-15*01                  
39 6M27 IGHV1-69*11                  79 COS-25+ IGHV5-51*05                  119 DP-39/HC16-8... IGHV3-11*03                  
40 7-2+ IGHV1-45*01                  80 COS-28+ IGHV3-62*01 120 DP-4+ IGHV1-45*02                
Appendix 
V region nomenclature (Vbase and IMGT correlation) 
Vbase IMGT Vbase IMGT Vbase IMGT
121 DP-40/HC16-9... IGHV3-11*03                  161 DP-76+ IGHV2-5*10                   201 hv4005/3d24d+ IGHV4-28*02                  
122 DP-41+ IGHV3-21*04                162 DP-77/WHG16+ IGHV3-21*01 202 LSG11.1 IGHV3-15*08                  
123 DP-42+ IGHV3-53*02 163 DP-78/3d230d...+ IGHV4-30-4*01                203 LSG12.1 IGHV3-49*02                  
124 DP-43/V3-52P...+ IGHV3-52*01 164 DP-79/4d154...+ IGHV4-39*01                204 LSG2.1 IGHV3-15*04  
125 DP-44/HC16-10... IGHV3-13*01                  165 DP-8+ IGHV1-2*04                   205 LSG3.1 IGHV3-15*05
126 DP-45 IGHV3-13*01                  166 DP-81+ IGHV3-63*02 206 LSG4.1 IGHV3-15*06                  
127 DP-46/3d216...+ IGHV3-30-3*01                167 DP-84/HC16-12 IGHV3-11*01                  207 LSG6.1 IGHV3-15*07                  
128 DP-47/V3-23...+ IGHV3-23*01                  168 DP-85/HC16-11 IGHV3-13*01                  208 LSG8.1/LSG9.1... IGHV3-15*03                  
129 DP-48/13-2+ IGHV3-13*01                  169 DP-86/DA-9+ IGHV3-66*03   209 MTGLa IGHV3-66*01                  
130 DP-49/1.9III...+ IGHV3-30*03                  170 DP-87/HC16-13 IGHV3-74*02                  210 p1 IGHV3-64*05                  
131 DP-5/V1-24P+ IGHV1-24*01                  171 DP-88/hv1051K...+ IGHV1-69*06 211 p2 IGHV3-30-3*02 
132
DP-
50/hv3019b9...+ IGHV3-33*01                172 DP-9/V1-27P...+ IGHV7-4-1*04               212 p6 IGHV3-33*03                  
133 DP-51+ IGHV3-48*02                173 E IGHV3-9*01                   213 p9e IGHV3-30*03 
134 DP-52+ IGHV3-47*02 174 F IGHV3-20*01   214 PS421 IGHV4-34*01 
135 DP-53/hvm148...+ IGHV3-74*01                  175 f1m/f2e IGHV3-64*03                  215 psiRC IGHV3-15*08                  
136 DP-54/V3-7...+ IGHV3-7*01                   176 f2m IGHV3-64*03                  216 RR.VH1.1e IGHV1-69*02                  
137 DP-55+ IGHV3-25*02 177 f3..e IGHV3-64*04 217 RR.VH1.2 IGHV1-69*05                  
138 DP-56+ IGHV3-25*03 178 f7 IGHV3-30*09                  218 S12-1 IGHV2-70*09    
139 DP-57/hv3003...+ IGHV3-22*02 179 GL-SJ2e IGHV3-30*08                  219 S12-10 IGHV2-70*12                  
140 DP-58/hv3d1EG IGHV3-48*03                  180 H10 IGHV4-31*04                  220 S12-12 IGHV2-5*08                   
141 DP-59/V3-35...+ IGHV3-35*01 181 H11Rechavi+ IGHV3-74*03                  221 S12-14 IGHV2-5*09                   
142 DP-6+ IGHV1-NL1*01 182 H11vanEs IGHV4-31*05                  222 S12-2 IGHV2-5*04                   
143 DP-60/V3-6P+ IGHV3-21*02                  183 H12 IGHV4-30-2*02                223 S12-4 IGHV2-5*05                   
144 DP-61+ IGHV3-64*02                184 H16BR+ IGHV3-52*03 224 S12-5 IGHV2-70*10                  
145 DP-63/VH4.21...+ IGHV4-34*01                185 H3 IGHV4-34*08                  225 S12-6 IGHV2-5*06                   
146 DP-64/3d216d+ IGHV4-30-2*01                186 H4 IGHV4-59*03 226 S12-7 IGHV2-70*11                  
147 DP-65/3d75d...+ IGHV4-31*03                  187 H6 IGHV4-39*05                  227 S12-8 IGHV2-5*04                   
148 DP-66/V71-2...+ IGHV4-61*01                  188 H7 IGHV4-59*04                  228 S12-9/DP-27...+ IGHV2-70*01                  
149 DP-67/VH4-4B+ IGHV4-b*01                   189 H8 IGHV4-59*05                  229 Tou-VH4.21 IGHV4-34*12                  
150 DP-68/1.9II...+ IGHV4-28*01                  190 H9 IGHV4-59*06                  230 V1-12P+ IGHV1-2*02                   
151 DP-69/4d255... IGHV4-4*02                   191 HA2 IGHV1-3*01                   231 V1-14P/DP-16+ IGHV1-46*01                  
152 DP-7/21-2...+ IGHV1-46*01                  192 HC15-7 IGHV3-72*01                  232 V1-17P+ IGHV1-NL1*01
153 DP-70/4d68...+ IGHV4-4*02                   193 HC16-15/VHGL3.4 IGHV3-16*02 233 V1-40P+ IGHV7-4-1*04               
154 DP-71/3d197d...+ IGHV4-59*01                194 HC16-16/DP-82 IGHV3-16*02 234 V1-45+ IGHV1-45*01                  
155 DP-71RBe IGHV4-59*08 195 HG3+ IGHV1-46*02                  235 V1-46+ IGHV1-46*01                  
156 DP-71RBm IGHV4-59*08                196 HHG4 IGHV3-21*01                236 V11 IGHV4-4*02                   
157 DP-72/V4-55P...+ IGHV4-55*01 197 hv1263/3M28... IGHV1-69*04                  237 V13C IGHV1-46*01 
158 DP-73/V5-51...+ IGHV5-51*01                  198 hv1f10t IGHV1-46*01                  238 V2-1+ IGHV4-39*02                  
159 DP-74/VH-VI...+ IGHV6-1*01                   199 hv3.3+ IGHV3-11*01                  239 V2-10P/COS-1+ IGHV2-10*01
160 DP-75/VI-2...+ IGHV1-2*02                   200 hv3005/b1..m...+ IGHV3-30*01 240 V2-26/DP-26+ IGHV2-26*01     
Appendix 
V region nomenclature (Vbase and IMGT correlation) 
Vbase IMGT Vbase IMGT Vbase IMGT
241 V201 IGHV1-NL1*01 281 V79/VIV-4b...+ IGHV4-4*01 321 VHD26 IGHV3-72*01 
242 V3-13+ IGHV3-13*02      282 VF2-26/HC16-5... IGHV2-26*01 322 VHGL1.2 IGHV1-2*02
243 V3-15+ IGHV3-15*02                  283 VF3-16P/YAC-2 IGHV3-16*02 323 VHGL1.8 IGHV1-69*13
244 V3-16P+ IGHV3-16*01 284 VH15+ IGHV5-78*01 324 VHGL1.9 IGHV1-69*13
245 V3-19P/COS-26+ IGHV3-19*01 285 VH1GRR IGHV1-18*02 325 VHGL3.5/DP-82 IGHV3-16*02
246 V3-21+ IGHV3-21*02  286 VH2-MC1a IGHV2-70*06 326 VHGL3.6 IGHV3-16*02
247 V3-22P+ IGHV3-22*01 287 VH2-MC2b IGHV2-70*07 327 VHGL3.7/DP-82 IGHV3-16*02
248 V3-25P+ IGHV3-25*01 288 VH2-MC2d IGHV2-70*08 328 VHGL3.8 IGHV3-23*03
249 V3-30+ IGHV3-30*03                  289 VH20 IGHV1-46*01 329 VHGL3.9 IGHV3-16*02
250 V3-32P+ IGHV3-32*01 290 VH251Shen+ IGHV5-51*02 330 VHSP/VH4.22...+ IGHV4-b*02 
251 V3-33+ IGHV3-33*02                  291 VH26Rabbitts+ IGHV3-23*02 331 VHVBLK32 IGHV5-a*04
252 V3-36P/DP-83+ IGHV3-h*01 292 VH26-3.7 IGHV3-23*03 332 VHVCW/COS-24+ IGHV5-51*03 
253 V3-37P+ IGHV3-48*03                  293 VH3-11 IGHV3-7*02 333 VHVJB IGHV5-51*04 
254 V3-38P+ IGHV3-38*01 294 VH3-8 IGHV3-11*03 334 VHVMW/VHVRG IGHV5-a*03
255 V3-41P+ IGHV3-7*01                   295 VH32Humphries+ IGHV5-a*02 335 VI-3+ IGHV1-3*02
256 V3-42P+ IGHV3-72*01                  296 VH32Sanz+ IGHV5-a*01 336 VI-4.1b+ IGHV7-4-1*02
257 V3-44P+ IGHV3-73*01                  297 VH4-MC3a IGHV4-61*01 337 VII-5+ IGHV2-5*01
258 V3-47P+ IGHV3-47*03 298 VH4-MC4a IGHV4-4*04 338 VII-5b+ IGHV2-5*10 
259 V3-48/hv3d1...+ IGHV3-48*01                  299 VH4-MC4b IGHV4-4*05 339 VIV-4/4.35+ IGHV4-4*07 
260 V3-49+ IGHV3-49*01                  300 VH4-MC5a IGHV4-34*06 340 WAD4GL IGHV2-5*03 
261 V3-50P+ IGHV3-11*01                  301 VH4-MC5c IGHV4-34*07 341 YAC-10/1d37+ IGHV7-81*01
262 V3-53+ IGHV3-53*01                  302 VH4-MC7 IGHV4-28*05 342 YAC-11/COS-29+ IGHV3-74*01
263 V3-54P+ IGHV3-54*01 303 VH4-MC8b IGHV4-55*03 343 YAC-12/V3-29P+ IGHV3-32*01
264 V3-63P+ IGHV3-63*01 304 VH4-MC8d IGHV4-55*04 344 YAC-3+ IGHV2-70*05 
265 V3-64/YAC-6+ IGHV3-64*01                  305 VH4-MC8e IGHV4-55*05 345 YAC-4+ IGHV3-49*05
266 V35/VI-2b+ IGHV1-2*01                   306 VH4-MC8f IGHV4-55*06 346 YAC-5+ IGHV3-66*02 
267 V3e IGHV3-11*03                  307 VH4-MC8g IGHV4-55*07 347 YAC-7/10M28...+ IGHV1-69*02
268 V3m IGHV3-71*02 308 VH4-MC9a IGHV4-31*06 348 YAC-8+ IGHV1-46*01
269 V4-31+ IGHV4-31*02                  309 VH4-MC9b IGHV4-31*07 349 YAC-9/COS-27...+ IGHV3-73*01
270 V4-34+ IGHV4-34*02                  310 VH4-MC9c IGHV4-31*08
271 V54 IGHV1-18*03                311 VH4-MC9d IGHV4-31*09
272 V58 IGHV4-34*11                  312 VH4-MC9e IGHV4-30-4*03
273 V71-1e+ IGHV3-62*01 313 VH4-MC9f IGHV4-30-4*04
274 V71-1m/DP-62+ IGHV3-62*01 314 VH4.12 IGHV4-61*05
275 V71-3e+ IGHV3-62*01 315 VH4.14 IGHV4-28*04
276 V71-3m/COS-9+ IGHV3-62*01 316 VH4.15m IGHV4-59*01
277 V71-4+ IGHV4-59*02                  317 VH4.16 IGHV4-59*07
278 V71-6e+ IGHV3-21*03 318 VH4/COS-7+ IGHV3-21*01
279 V71-6m+ IGHV3-13*01 319 VH5/4d76...+ IGHV4-34*01  
280 V71-7+ IGHV7-81*01 320 VHBam+ IGHV3-72*01
Appendix 
V region nomenclature (Vbase and IMGT correlation) 
Vbase IMGT Vbase IMGT Vbase IMGT
1 D1 IGHD2-8*02 13 D3-16 IGHD3-16*02 25 D5-24 IGHD5-24*01
2 D1-1 IGHD1-1*01 14 D3-22/D21-9 IGHD3-22*01 26 D5-5/DK4 IGHD5-5*01
3 D1-14/DM2 IGHD1-14*01 15 D3-3/DXP4 IGHD3-3*01 27 D6-13/DN1 IGHD6-13*01
4 D1-20 IGHD1-20*01 16 D3-9/DXP1... IGHD3-9*01 28 D6-19 IGHD6-19*01
5 D1-26 IGHD1-26*01 17 D4 IGHD2-2*01 29 D6-25 IGHD6-25*01
6 D1-7/DM1 IGHD1-7*01 18 D4-11/DA1 IGHD4-11*01 30 D6-6/DN4 IGHD6-6*01
7 D2-15/D2 IGHD2-15*01 19 D4-17 IGHD4-17*01 31 D7-27/DHQ52 IGHD7-27*01
8 D2-2 IGHD2-2*02 20 D4-23 IGHD4-23*01
9 D2-21 IGHD2-21*02 21 D4-4/DA4 IGHD4-4*01
10 D2-8/DLR1 IGHD2-8*01 22 D4-b IGHD2-2*03
11 D3 IGHD2-21*01 23 D5-12/DK1 IGHD5-12*01
12 D3-10/DXP'1 IGHD3-10*01 24 D5-18 IGHD5-18*01
Appendix 
Vbase IMGT Vbase IMGT Vbase IMGT
1 JH1 IGHJ1*01 13 JHpsi1 IGHJ1P*01
2 JH2 IGHJ2*01 14 JHpsi3 IGHJ3P*01
3 JH3a IGHJ3*01
4 JH3b IGHJ3*02
5 JH4a IGHJ4*01
6 JH4b IGHJ4*02
7 JH4d IGHJ4*03
8 JH5a IGHJ5*01
9 JH5b IGHJ5*02
10 JH6a IGHJ6*01
11 JH6b IGHJ6*02
12 JH6c IGHJ6*03
D region nomenclature (Vbase and IMGT correlation) 
J region nomenclature (Vbase and IMGT correlation) 
